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1 Abstract 
Nesrin Mohamed Elhatab 
The Community Pharmacists’ Role Enhancing Medicines Management for 
Type II Diabetes in Tripoli, Libya 
A Randomised Controlled Trial in Community Pharmacy to Investigate 
Knowledge and Practice in Relation To Type II Diabetes and Glycaemic Control 
Key words: Type II diabetes, diabetes knowledge, self-management, diabetes 
attitudes, fasting plasma glucose, HbA1c, pharmaceutical services, 
pharmaceutical care, medicine management 
Aim/Objectives: There were two aims; improving type II diabetes glycaemic 
control; and enhancing the role of community pharmacists by engaging them in 
type II diabetes medicine management. 
Methods: This quantitative study collected data from both community 
pharmacists and patients. In a premises survey, 426 self-administered 
questionnaires were distributed to community pharmacies. In a knowledge 
survey, 125 questionnaires were distributed to community pharmacists. In a 
clinical trial, 40 community pharmacies were randomly assigned to be control 
(18) and intervention (22) premises. Each pharmacy recruited 4 or 5 patients 
with type II diabetes. 225 patients were recruited and assigned to receive usual 
pharmacist care (n=100) or a pre-defined pharmacist intervention (n=125). 
Results: Community pharmacists had good knowledge of diabetes with 
average scores 21/29 (±3.18). The differences between control and intervention 
groups in patients' HbA1c and FPG changes were not significant. In the 
intervention group patients' diabetes knowledge was significantly improved 
(p=0.031). In the intervention group HbA1c and FPG improved significantly and 
in the control group FPG improved significantly and HbA1c did not. Patients' 
self-reported self-management activities improved significantly around blood 
glucose measurements (p<0.001) and physical exercising (p=0.001). Attitudes 
around the value of tight control of diabetes improved (p<0.001). 
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Conclusion: The findings suggest that community pharmacists in Libya may 
have the ability to improve type II diabetes care. The primary outcomes were 
not improved in intervention versus control. The before/after analysis showed 
significant improvement in primary outcomes in the intervention group and also 
in one of the primary outcomes in the control group. Patients' self-reported self-
care activities and attitudes improved significantly in the intervention group. 
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1. Introduction 
The thesis is structured into eight chapters. Chapter One describes the health 
care system and diabetes care in Libya and summarises effective management 
of type II diabetes. Chapter Two provides the reader with the essential 
literature review.  The aims and objectives of the thesis are outlined in Chapter 
Three. The structure of community pharmacy premises and pharmaceutical 
services in Tripoli, Libya are described in Chapter Four. Community 
pharmacists’ knowledge and practice with respect to type II diabetes are 
explored in Chapter Five. Steps taken to enhance community pharmacists’ 
diabetes knowledge (i.e. training) are outlined in Chapter Six. A randomized 
controlled trial of community pharmacy intervention to improve glycemic control 
for patients with type II diabetes is described in Chapter Seven. The discussion 
and conclusion along with suggestions for future studies are provided in 
Chapter Eight. 
Chapter One is divided into five sections. A brief description of geography, 
demographics and diabetes care in Libya is provided in Section 1.1.The 
pathophysiology of type II diabetes along with incidence and prevalence are 
outlined in Section 1.2. The general management of type II diabetes is 
described in Section 1.3. Diabetes medicine management is outlined in 
Section 1.4 and the chapter summary is provided in Section 1.5. 
From the outset, it is important to define key terms related to clinical and self-
management of patients with type II diabetes. Among the terms used in this 
document are: (medical) pathophysiological, incidence and prevalence terms; 
behavioural terms related to self-management; and medicines management 
including medicine adherence, patient counselling and health education. 
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1.1. Brief description of geography, demographics in Libya 
In this section, important geographical information concerning Libya will be 
provided as this study concerns the improvement of medicines management for 
type II diabetes in Libya. It is important to explain to the reader where Libya is, 
and provide its demographic profile, because the number of Libyan people 
affected by diabetes is considered to be high. The most important information 
concerning the Libyan health care system will also be discussed. This context 
will help the reader to understand the research. 
1.1.1. Geographic profile 
Libya is an upper middle income North African nation located on the coast of 
the Mediterranean Sea. The country borders Algeria, Chad, Egypt, Niger, 
Sudan and Tunisia. Libya has a Mediterranean climate along the coast, which 
comprises four seasons, which are mainly dry and hot in summer and warm and 
rainy in winter, whilst the south of Libya has a semi-desert climate. The main 
cities are concentrated in the northern part of the country along the coastal 
area. Figure 1.1 shows the geographic location of Libya (WHO, 2007). 
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Figure  1.1: Geographical locations of Libya 
Source: MAP XL copied from electronic source 
http://www.mapsofworld.com/libya/ 2002-2016 
1.1.2. Population size 
The total population of Libya in 2015 was 6,278,000 (WHO, 2017). It has one of 
the lowest (overall) population density rates in the world due to its large 
geographical area of 1,775,500 square kilometres. Most of the population lives 
in urban areas with about 85% concentrated in two main cities Tripoli and 
Benghazi and 15% living in rural areas (WHO, 2007). 
1.1.3. Diabetes care in Libya 
The incidence of diabetes has been increasing in recent years in Libya. There 
are some activities and interventions to reduce the cost of treatment. The 
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Libyan Association for Diabetes and Endocrinology (LADE) has different 
activities, has held conferences and publishes information to educate people 
with diabetes. The first publication of the Libyan Diabetes Care Guidelines 
(LDCG) was launched in 2010 and this guideline was launched at a conference 
held in Dat ElImad in Tripoli. Bishya (2010) stated that LADE was responsible 
for disseminating these guidelines amongst the front line workers as the first 
step towards implementation. It is noteworthy that most of the local nursing staff 
have a limited command of English; translation to Arabic will obviously enhance 
their involvement in implementing these guidelines. This process may even help 
patients understand “what care to expect”. This is an important advocacy role 
and highly appropriate for LADE to undertake. However, auditing of this 
guideline has still not emerged, and there is no on-going study to review this 
guideline.  
A workshop titled Living with Diabetes was held in Sabratha Hall on April 2012. 
Sabratha is located on the Mediterranean coast about 66km west of Tripoli and 
it is famous for its historical heritage. The workshop was about improving self-
management of diabetes for people with diabetes. In a two day programme, the 
first day consisted lectures given to physicians working in primary care and the 
second day comprised lectures about awareness and knowledge of diabetes 
especially for people with diabetes (LADE, 2012). 
1.1.4. Diabetes pathway in Tripoli/Libya  
The pathway begins when a patient describes symptoms of diabetes to their 
doctor. Next, blood samples are taken to the laboratory for analysis.  The 
patient collects his/her results from the laboratory and returns back to the 
physician. The diagnostic criteria for diabetes are highlighted in Table 1.1. The 
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medicines prescribed for the patients are dispensed by either the hospital 
pharmacist or community pharmacist. There is one special hospital for diabetes 
in Tripoli named National Centre for Diabetes & Endocrinology (NCDE). NCDE 
provides diabetes follow-up services at its outpatient clinics to patients with 
diabetes (Ashur et al., 2016). To have free of charge medicine patients with 
diabetes have to bring with them a diabetic card and receive their medicine from 
the NCDE hospital. The card holds personal information, type of diabetes, 
medicine information, and recommendations about self-management. The card 
is used to record medical follow-up (Ashur et al., 2015). The card is also used to 
identify that the patient has diabetes, if for instance the patient collapsed then 
people are better able to help the patient. 
The management of diabetes has been highlighted in the LDCG (NDCGAB, 
2010) by stating that patients with diabetes should be educated and supported 
therapeutically to control blood glucose. Table 1.2 also describes the goals of 
blood glucose control to prevent microvascular complications. 
The diabetes care plan has been explained in the LDCG by dividing it into initial 
visit and follow up care plan. In the initial visit the physician will take the medical 
history of patient including: symptoms of disease, eating habit, smoking status, 
lifestyle, any acute or chronic complications, and cardiovascular risk factors 
inherited, hypertension and dyslipidaemia, diabetes family history. Afterwards, a 
physical examination includes: height, weight, BMI, and waist circumference; 
blood pressure measurements systolic and diastolic; oral examination; 
cardiovascular evaluation; abdominal examination, including liver size; foot 
examination, for oedema, ulcer, deformities and footwear; neurological 
examination including vibration, reflexes, touch, monofilament and motor 
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system. Next, the diagnostic tests are performed for blood glucose and HbA1c, 
serum creatinine and eGFR, lipid profile (total-, LDL-, HDL-cholesterol and 
triglycerides), urinalysis (microscopy, proteinuria, and microalbuminuria), thyroid 
stimulating hormone (for people with type I diabetes). Later, the treatment plan 
is discussed between patient and doctor in order to control blood glucose by 
lifestyle changes or by both taking medicine and lifestyle modification. In 
everyday practice referral of patients to a diabetes educator, dietician, foot care 
examination, eye examination, cardiologist, psychological assessment or family 
planning (for female in reproductive age) is uncommon. In an editorial, Benamer 
(2007) said he was shocked to see a Libyan patient come to the UK for 
treatment based on advice from his Libyan doctor. The patient did not carry with 
him any referral letter. He was just carrying with him different medications and 
some emptied containers of other medicines used. 
For the follow up care plan, it has been recommended by LDCG that every visit 
should evaluate blood pressure, weight, blood glucose, medication review, 
smoking status, physical activity, diet review and foot care. In addition, HbA1c 
and lipid profile should be assessed every three to six months. As well as 
annual: fundus examination, feet examination including peripheral pulses 
sensation and feet inspection, cardiac symptoms, lipid profile, creatinine and 
eGFR, microalbuminuria, inspection of injection sites and oral examination, 
including gums (NDCGAB, 2010). 
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Table  1.1: Diagnostic criteria of diabetes 
Source: (National Diabetes Care Guidelines Advisory Board, 2010). 
 Normal 
Impaired 
fasting 
glycaemia 
Impaired 
glucose 
tolerance 
Diabetes 
Fasting 
plasma 
glucose 
(mg/dl 
<110 
110-125 <126 
≥126 
2-H plasma 
glucose 
(mg/dl) 
<140 
_ 140-199 
>200 
Random 
plasma 
glucose 
(mg/dl) 
_ 
_  >200 (plus 
symptoms) 
An HbA1C greater than 6.5 % can be used to support diagnosis 
 
Table  1.2: Indicators used to manage hyperglycaemia  
Indicator  Normal  Target  Action required  
Plasma glucose 
values (mg/dl) 
Pre- meal and 
(fasting) glucose  
Post- meal 
glucose  
 
 
<110 
 
<120 
 
 
90-130 
 
110-150 
 
 
<90 or >150 
 
<110 or >180 
HbA1c% <6,0 6.5-7.0 >7.0 
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1.1.5. Structure of the health care system in Libya 
The Libyan government provides free health care to all citizens. The public 
sector is the main health service provider. Health care including preventive, 
curative and rehabilitation services are provided to all citizens free of charge by 
the public sector. Almost all levels of health services are decentralized. In Libya, 
there is a mixed system of public and private health care, rather than a purely 
state-run model. Health care is delivered through a series of primary health care 
units, centres, polyclinics, rehabilitation centres, general hospitals in urban and 
rural areas and tertiary care specialised hospitals (WHO, 2007). The health care 
delivery system operates on three levels. The first level comprises: the primary 
health care units (which provide curative and preventive services for 5.000 to 
10.000 citizens); primary health care centres (serve from 10,000 to 26,000 
citizens); and polyclinics, staffed by specialised physicians and containing 
laboratories as well as radiological services and a pharmacy. These polyclinics 
serve approximately 50,000 to 60,000 citizens. At the second level, there are 
general hospitals in rural and urban areas where care is provided to those 
referred from the first level. The third level comprises tertiary care specialized 
hospitals see Figure 1.2. 
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Figure  1.2: The levels of health care system delivery Source: WHO (2007) 
1.1.6. Recent developments 
Libya’s health care system has deteriorated to the point of collapse and 
struggles to deal with casualties from the conflict. Serious illness and disease 
are rising. In conflict areas, over 60% of hospitals have been inaccessible or 
closed in the last six months, especially in the east and south (WHO, 2016). 
Hospitals are overcrowded, and their capacities have been severely reduced by 
a large scale exodus of foreign health workers (WHO, 2016). There is also a 
shortage of essential medicines and supplies. An estimated 1.9 million people 
need assistance to meet their basic health-care needs (WHO, 2016). 
1.1.7. Human resources in the health sector 
Human resource assessment, production and management are a high priority 
for the health sector. There are no clear plans to match needs with the number 
and categories of health personnel. The lack of an accreditation system, weak 
inter-sectional collaboration, lack of links between continuous medical education 
Specialised hospitals (21) 
Rural hospitals (26) 
General hospitals (36) 
Polyclinics (39) 
Communicable disease centres (23) 
Primary health care units& centres (1165) 
Second Level health care  
First level health care  
Third Level health care 
10 
 
programmes and career development, and inadequate training in management 
are other factors that hinder health care delivery. In 2010 there were 19 
physicians, 6 dentists, 3.6 pharmacists and 68 nurses and midwives per 10,000 
population, see Figure 1.3 for international comparisons. 
 
Figure  1.3: International comparison of Libyan healthcare staffing (staff per 
10,000 Population) Source: WHO (2011) 
1.1.8. Communication in health 
Information and communication technology (ICT) is increasingly recognised as 
an essential element to support health care services. ICT activities are isolated 
and uncoordinated, without adequate communication and consultation between 
the different on-going programmes (WHO, 2007). Awareness on ICT issues 
among staff is not optimal. This is largely the result of inadequate computer 
literacy among health professionals, many of whom have not had training or 
orientation in this field. In summary, health care informatics expertise is 
inadequate (WHO, 2007). The information and telecommunication infrastructure 
in health care institutions is weak (WHO, 2007). Most hospitals, primary health 
11 
 
care centres, medical colleges and other health facilities do not have the 
necessary infrastructure to benefit from electronic-health solutions. For 
example, hospital and health facility records and information are not 
computerized (WHO, 2007). 
1.1.9. Pharmaceutical structure 
The basic structure of the pharmaceutical sector is predominantly public, 
with the Government aiming to provide medicines to all citizens. 
However, recently this may have changed because of the collapse of the 
health care system in the public sector. According to WHO (2007), the 
National Pharmaceutical and Medical Supplies Company are responsible 
for providing pharmaceutical supplies, centrally to both the public and 
private sectors. In addition, Libyan professionals are permitted to have 
agencies for the international pharmaceutical companies and are also 
able to bring medicines and supplies of international quality to both the 
public and private health sectors. There is no recent document 
describing the structure of the Libyan pharmaceutical services. El Oakley 
et al. (2013) highlighted the current inadequacy of the Libyan 
pharmaceutical sector and its deficient quality assurance systems. Drug 
legislation and regulation is inadequate, and there is no stable or 
functioning drug regulatory authority with adequate resources and 
infrastructure. It has been recommended that there is a need to 
implement modern legislation and regulation to circumvent the current 
supply difficulties and acute shortages (El Oakley et al., 2013). 
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1.2. Pathophysiology, incidence and prevalence of type II diabetes 
This section discusses the pathophysiology, aetiology and prevalence of 
type II diabetes globally and in Libya. It aims to provide reader with 
background information about the scale of diabetes issues worldwide 
and projected growth in patient numbers. 
1.2.1. What is type II diabetes? 
Type II diabetes is a complex metabolic disorder that is characterized by 
hyperglycaemia and associated with a high risk of cardiovascular, 
microvascular, and other complications (Diabetes Care, 2015; 
International Diabetes Federation, 2015). Although glycaemic control is 
associated with reductions in the risk of microvascular complications, the 
macrovascular benefits of glycaemic control are less certain. 
Furthermore, concern has been raised about the cardiovascular safety of 
anti-hyperglycaemic therapies (Holman et al., 2014).  
The imbalance between energy intake and expenditure is the most 
important underlying pathology and is regulated by complex interaction 
between multiple genes and environmental factors (Thomas & Vasan, 
2016). The disease is most often suspected to be due to defects both at 
the level of insulin resistance and insulin secretion (Thomas & Vasan, 
2016). 
Two terms requiring definition are: glycosylated haemoglobin (HbA1c) 
and Fasting Plasma Glucose (FPG). In the term HbA1c, “glycation refers 
to non-enzymatic addition of sugar residue to an amino group of a 
protein” (Thomas & Vasan, 2016, p.25). HbA1c gives a retrospective 
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index of integrated plasma glucose values over a 6 to 8 week period and 
is not subject to wide fluctuations in plasma levels. HbA1c serves as a 
reliable indicator of diabetes control during the past 90 days, effectivness 
of treatment and risk of development of acute or long-term complications. 
Hence, HbA1c should be performed routinely in all patients with 
diabetes, to assess the degree of glyceamic control at initial visit and 
then as a part of continuing visits every three months to assess 
metabolic control (Thomas & Vasan, 2016). 
FPG is defined by the American Diabetes Assocaition (2016a) as the test 
checks on a person’s fasting blood glucose levels. Fasting means not 
having had anything to eat or drink (except water) for at least 8 hours 
before the test. This test is usually done first thing in the morning, before 
breakfast. Diabetes is diagnosed at FPG of greater than or equal to 126 
mg/dlmilligrams. The concordance between the FPG and 2-hour plasma 
gluscose (PG) tests is imperfect, as is the concordance between A1c and 
either glucose-based test. National Health and Nutrition Examination 
Survey (NHANES) data indicate that an A1c cut off point of ≥6.5% 
identifies one-third fewer cases of undiagnosed diabetes than a fasting 
glucose cut off point of ≥126 mg/dL (7.0 mmol/L) (Picón et al., 2012). 
Numerous studies have confirmed that, compared with these A1c and 
FPG cut off points, the 2-hour  PG  value diagnoses more people with 
diabetes. Of note, the lower sensitivity of A1c at the designated cut off 
point may be offset by the test’s ease of use and facilitation of more 
widespread testing (American Diabetes Association, 2016a). 
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Unless there is a clear clinical diagnosis (e.g. a patient in a 
hyperglycaemic crisis or with classic symptoms of hyperglycaemia and a 
random plasma glucose ≥200 mg/dL), it is recommended that the same 
test be repeated immediately using a new blood sample for confirmation 
because there will be a greater likelihood of concurrence. For example, if 
the A1c is 7.0% and a repeat result is 6.8%, the diagnosis of diabetes is 
confirmed. If two different tests (such as A1c and FPG) are both above 
the diagnostic threshold, this also confirms the diagnosis. On the other 
hand, if a patient has discordant results from two different tests, then the 
test result that is above the diagnostic cut off point should be repeated. 
The diagnosis is made on the basis of the confirmed test. For example, if 
a patient meets the diabetes criterion of the A1c (two results ≥6.5%), but 
not FPG (<126 mg/dL [7.0 mmol/L]), that person should nevertheless be 
considered to have diabetes (American Diabetes Association, 2016a). 
1.2.2. Complication of type II diabetes 
Uncontrolled type II diabetes has serious health implications other than 
chronic hyperglycaemia, such as heart disease, stroke, retinopathy, 
neuropathy, and nephropathy (Matricciani and Jones, 2015). The 
complications do not end there; lower extremity amputations comprise 
over 60% of non-traumatic amputations in the United States (Neder and 
Nadash, 2003). Type II diabetes related lower extremity amputations 
have critical implications for individuals, family members, and caretakers 
in terms of psychosocial, physical, functional, and financial implications 
(Scollan-Koliopoulos, 2004). Type II diabetes related complications 
account for a death risk that is two times higher than that of someone 
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that does not have type II diabetes (Centres for Disease Control and 
Prevention, 2011). However the development of such complications can 
be prevented and reduced through the implementation of comprehensive 
programs focused on foot care, which have been shown to greatly 
reduce amputation rates (Neder and Nadash, 2003).  
Type II diabetes foot complications, which more often affect older adults, 
have the capacity to diminish a person's quality of life (Matricciani and 
Jones, 2015). Foot self-care behaviours, including daily inspection of 
feet, professional treatment, hygiene, and proper footwear help minimize 
the risk of foot complications (Matricciani and Jones, 2015). Type II 
diabetes is multifaceted and requires a multidisciplinary approach to the 
treatment of the condition and prevention of associated complications 
(Wu et al., 2007). 
1.2.3. Risk factors of type II diabetes 
Type II diabetes is caused by a combination of genetic and lifestyle factors 
(Kaprio et al., 1992). Beyond the genetic predisposition and increasing age as 
non-modifiable conditions, several somatic and behavioural risk factors have 
been identified in the development of type II diabetes mellitus, including obesity 
(Eckel et al., 2011), low physical activity (Sigal et al., 2006), smoking (Kowall et 
al., 2010) and hypertension (Meisinger et al., 2005). In addition, research has 
made great efforts to investigate whether psychosocial factors are related to the 
onset of type II diabetes. Recent studies found that depression (Knol et al., 
2006, Mezuk et al., 2008) and post-traumatic stress disorders (Lukaschek et al., 
2013) as well as burnout (Melamed et al., 2006), high job-strain (Norberg et al., 
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2007), sleep disorders (Frank and Durden, 2017) and perceived mental stress 
(Kato et al., 2009) are associated with an increased risk of type II diabetes. 
There is also some preliminary evidence suggesting that social support has an 
impact on the subsequent development of type II diabetes. Studies showed that 
single indicators of social support such as low emotional support in women 
(Norberg et al., 2007) and living alone in men (Meisinger et al., 2009) are 
associated with an increased risk of type II diabetes. Social support refers to a 
coping resource provided by relationships with significant others including family 
members, friends, co-workers and club members. Two dimensions of social 
support should be distinguished, namely functional and structural support. 
Functional support refers to the aid and encouragement provided to the 
individual by the social network, whereas structural support describes the 
characteristics of the network of people surrounding an individual and his/her 
interactions within this network (Altevers et al., 2016). 
Several dietary practices are linked to unhealthy body weight and/or type II 
diabetes risks, including high intake of saturated fatty acids, high total fat intake 
and inadequate consumption of dietary fibre (WHO, 2014). High intake of sugar-
sweetened beverages, which contain considerable amounts of free sugars, 
increases the likelihood of being overweight or obese, particularly among 
children (Singh et al., 2013, Jeon and Murray, 2008). Recent evidence further 
suggests an association between high consumption of sugar-sweetened 
beverages and increased risk of type II diabetes (WHO, 2014, Lu et al., 2014, 
WHO, 2015). 
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1.2.4. Prevalence of type II diabetes  
The number of people with diabetes is increasing due to: population growth; 
aging; urbanisation; and the increasing prevalence of both obesity and physical 
inactivity. In 2015, the number of people with diabetes reached 415 million 
adults and by 2040 the number will increase to 642 million people worldwide 
(International Diabetes Federation, 2015). The prevalence of diabetes in the 
Middle East and Northern African countries reached approximately 35.4 (24.3–
47.4) million people, or 9.1% (6.3–12.2%) of adults aged 20-79. Over 40.6% of 
these are undiagnosed. Although only 54.9% of all adults in the region live in 
urban areas, 67.0% of people with diabetes live in urban environments. The 
vast majority (83.9%) of the people with diabetes in the region are living in low 
or middle income countries (International Diabetes Federation, 2015). 
The International Diabetes Federation (2015) estimated that the 
prevalence of diabetes in Libya accounts for 9.2% of the population with 
uncertainty in the range 6.4% to 11.9%. However, it is expected that the 
true incidence is higher than that suggested by the statistics. In 2009 the 
survey done on 3625 participants by using the STEPwise accounted that 
16.4% from the participants have diabetes (Beshyah, 2010). 
It has been defined by WHO (2016, p: 1) as “a simple, standardized method for 
collecting, analysing and disseminating data in WHO member countries”.  Then 
the surveyed data was compared with the (other) Middle Eastern and North 
African countries (see Table 1.3) (Beshyah, 2010). 
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Table  1.3: Comparison of STEP wise survey data generated from 10 Middle Eastern and South African countries to show the frequency of 
non-communicable diseases. Source: (Beshyah, 2010). 
Country Year 
Diabetes 
% 
Hyper-
tension 
(%) 
Overweight 
& Obesity 
(%) 
Hyper- 
cholesterolemia 
(%) 
Smoking 
(%) 
Low Physical activity 
(%) 
Low intake of 
fresh fruits& 
vegetables (%) 
  
FBG≥7 
mmol/dl 
BP≥140/90 
mmHg 
BMI≥25 
Cholesterol 
level≥5.2mmol/dl 
Current daily 
smokers 
Daily activity≥10min ≤5 serving /day 
Syria 2003 20.5 28.4 56.3 34 24.7 31.15 95.7 
Iraq 2005 10.4 40.4 66.9 37.5 21.6 56.7 91.4 
Kuwait 2006 12.4 20.5 75.4 38.6 20.6 64.7 81 
Sudan 2005 19.2 23.6 53.9 19.8 12 86.8  
Iran 2005 10.3 14.8 42.8 43.6 13 67.5  
Egypt 
2005-
2006 
15.8 26.7 66 19.4 18 70.4 79 
Jordan 2007 12 26 57 46 25 51 84 
Saudi 
Arabia 
2007 18.3 21.3 68.8 19.15 11 67.7 93.45 
Libya 2009 16.4 40.6 63.5 20.9 49.6 43.9 34 
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1.2.5. Diagnosis of type II diabetes  
Diagnosis of diabetes is based upon plasma glucose levels. Three ways to test 
diabetes are possible and each, in the absence of unequivocal hyperglycaemia, 
must be confirmed, on a subsequent day (Thomas & Vasan, 2016). The 75 g 
oral glucose tolerance test (OGTT) is more sensitive and modestly more 
specific than fasting plasma glucose (FPG) in the diagnosis of diabetes, but is 
poorly reproducible (Thomas & Vasan, 2016). Because of its ease, patient 
acceptability and lower cost, measurement of FPG is the preferred diagnostic 
test (Thomas & Vasan, 2016). The use of the glycosylated haemoglobin 
(HbA1c) for the diagnosis of diabetes was previously not recommended due to 
lack of global standardisation and uncertainty about diagnostic thresholds 
(Thomas & Vasan, 2016). Presently, because of a worldwide move towards a 
standardized assay and with increasing evidence about the prognostic 
significance of HbA1c it is being more widely used (Thomas & Vasan, 2016).  
Approximately one-quarter of people with diabetes in the U.S. and nearly half of 
Asian and Hispanic Americans with diabetes are undiagnosed (Menke et al., 
2015). Although screening of asymptomatic individuals to identify those with 
prediabetes or diabetes might seem reasonable, rigorous clinical trials to prove 
the effectiveness of such screening have not been conducted and are unlikely 
to occur (American Diabetes Association, 2016a). A large European 
randomized controlled trial compared the impact of screening for diabetes and 
intensive multifactorial intervention with that of screening and routine care 
(Griffin et al., 2011). General practice patients between the ages of 40–69 years 
were screened for diabetes and randomly assigned by practice to intensive 
treatment of multiple risk factors or routine diabetes care. After 5.3 years of 
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follow-up, cardiovascular disease (CVD) risk factors were modestly but 
significantly improved with intensive treatment compared with routine care, but 
the incidence of first CVD events or mortality was not significantly different 
between the groups (Griffin et al., 2011). The excellent care provided to patients 
in the routine care group and the lack of an unscreened control arm limited the 
authors’ ability to prove that screening and early intensive treatment impact 
outcomes (American Diabetes Association, 2016a). 
1.2.6. Screening of diabetes 
There is a major distinction between diagnostic testing and screening. When an 
individual exhibits symptoms or signs of the disease, diagnostic tests are 
performed and such tests do not represent screening (Engelgau et al., 2000). 
Screening may use a variety of methods (e.g. risk assessment questionnaires, 
portable capillary blood assessments, and laboratory-based assessments) and 
various thresholds or cut off points. In general, though, a screening test is not 
part of the diagnostic test. Ideally, screening tests are rapid, simple, and safe 
(Engelgau et al., 2000) A positive screening test only means the subject is more 
likely to have the disease than a subject with a negative screening test 
(Engelgau et al., 2000) . Separate diagnostic tests using standard criteria are 
required after positive screening tests to establish a definitive diagnosis  (Gavin 
III et al., 1997). 
Another screening method used in Finland is called the Finnish diabetes risk 
score (FINDRISC) and has proven its value in the national type II diabetes 
prevention programme in Finland, which was developed based on prospective 
data on the incidence of type II diabetes in a population-based cohort (Saaristo 
et al., 2007). The risk score consists of eight non-invasive variables, which can 
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be self-reported. The FINDRISC questionnaire is the most widely used and 
tested diabetes risk score and has been validated in several European 
countries including Sweden, the Netherlands, Greece, Spain, Hungary and 
Germany (Alssema et al., 2008; Hellgren et al., 2012; Li et al.,2009; Makrilakis 
et al., 2011; Soriguer et al., 2012; Winkler et al., 2013). Although people who 
are obese or overweight are at great risk of developing type II diabetes, not 
every subject develops diabetes (Meijnikman et al., 2016). 
1.3. General diabetes management 
The current study focuses on two aspects of diabetes management: self-
management (i.e. how people manage everyday life in terms of diet, exercise, 
feet care, eye care) and medicines management (i.e. oral hypoglycaemic 
adherence). In the long term, diabetes cannot be managed by medicine or diet 
alone, but when first diagnosed type II diabetes can be managed by diet and 
exercise. However, older people have to take oral hypoglycaemic tablets to 
control blood glucose levels, and may progress to management with insulin. 
Keenan (2010) highlighted that recently diagnosed type II diabetes is initially 
managed by a combination of: restricted energy and carbohydrate intake; and 
an increase in physical activity. This should be incorporated into a structured 
education programme that is tailored to the patient’s particular needs and 
preferences. Funnell et al (2009:87) agree and stated that: “Diabetes self-
management education (DSME) is a critical element of care for all people with 
diabetes and is necessary in order to improve patient outcomes.” Mehuys et al 
(2008) stated that community pharmacists can play a valuable role in the 
education of patients with diabetes, as they have the advantages of the ease of 
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patient access (near homes and workplaces) and frequent patient contact due 
to collection of repeat prescriptions. I strongly agree that the pharmacist is 
easily accessible. 
1.3.1. Diabetes Self-management 
Self-management has become a popular term for behavioural interventions as 
well as for healthy behaviours (Lorig and Holman, 2003). This is especially true 
for the management of chronic conditions (Lorig and Holman, 2003). 
Diabetes self-management is defined by Diabetes UK (2009: 3) as: 
“Self-management means that people have to make choices 
and decisions about how to manage their life and their diabetes. 
Through good self-management, people with diabetes can 
improve their quality of life and reduce the risk of developing 
complications. It can also help to prevent hospital admissions, 
or make those times when they do need to go into hospital, for 
whatever reason, a better experience, with a reduced length of 
stay.” 
Anderson & Funnel (2005:13) stated that: 
“The cornerstone of the empowerment approach is recognizing 
that the person with diabetes is completely responsible for 
managing his or her illness. The patient’s responsibility is non-
negotiable, indivisible, and inescapable. Although that 
statement may sound strong, we believe it is a straight forwards 
description of the reality of diabetes care. The patient’s 
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complete responsibility rests on three characteristics of the 
disease – choices, control, and consequences.” 
This is particularly true when the self-management plan has been designed to 
fit patients’ diabetes, but has not been tailored to fit their priorities, goals, 
resources, culture, and lifestyle. 
To manage diabetes successfully, patients must be able to set goals and make 
frequent daily decisions that are both effective and fit their values and lifestyles, 
while taking into account multiple physiological and personal psychosocial 
factors. Intervention strategies that enable patients to make decisions about 
goals, therapeutic options, and self-care behaviours and to assume 
responsibility for daily diabetes care are effective in helping patients care for 
themselves (Funnel & Anderson, 2004). There are some identified essential 
elements of diabetes self-management that people with diabetes need to be 
able to access and a minimum service level that needs to be in place to ensure 
that people are supported to self-manage (Funnel & Anderson, 2004). 
Diabetes self-management includes eating healthy meals, exercising, 
monitoring blood glucose levels, taking medications, understanding 
psychological aspects of living with diabetes, using problem-solving skills to 
manage diabetes-related self-care challenges, and lessening risks of 
complications (Haas et al., 2013). Literature suggests lessening barriers is 
essential to diabetes self-management (Jones et al., 2014). Major barriers 
include an inadequate health system and communication interfaces, difficulty 
coping with diabetes, and managing diabetes within current social roles and 
context (Grant and Steadman, 2016). 
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Individuals also report experiencing a variety of emotional responses to a 
diagnosis of type II diabetes, including denial and fear of diabetes and resulting 
complications (Jones et al., 2014). Clients who reject their diagnoses of 
diabetes may feel “betrayed” by their own bodies and lose confidence in their 
abilities to implement therapeutic self-care behaviours. This fear and inability to 
accept diabetes is significant, commonly resulting in clients ignoring health care 
providers’ suggestions regarding how to successfully manage type II diabetes 
(Majeed-Ariss et al., 2015). These feelings are also influenced by depression 
and other negative emotions. In a cross-sectional survey of 160 rural African 
American women with type II diabetes, 70% had scores suggestive of 
significant depressive symptomatology (Miller, 2011). An open-ended survey 
and thematic qualitative analysis of data from 7,228 individuals with type II 
diabetes, of whom 1,050 lived in rural areas, almost 500 respondents reported 
emotional reactions such as not accepting the diagnosis of diabetes, anxiety, 
fear, and depression (Stuckey et al., 2014). 
1.3.2. Lifestyle management 
A healthy lifestyle has been defined by the National Institute for Health and 
Care Excellence (NICE 2015a) as one which involves being active, losing 
weight if one is overweight, getting enough exercise, having a healthy diet, not 
smoking and controlling alcohol intake. A doctor or nurse can provide people at 
risk with more information about a healthy lifestyle and what steps can be taken 
to keep type II diabetes under control (for example, having a healthy diet, taking 
more exercise and losing weight). 
The components of lifestyle management were categorized by the Scottish 
Intercollegiate Guidelines Network (SIGN, 2013) into: 
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 Delivery of lifestyle interventions,  
 Structured education, 
 Self-monitoring of glycaemic control, and,  
o Smoking,  
o Obesity,  
o Physical activity,  
o Healthy eating 
1.3.2.1. Diet management  
It has been recommended by NICE (2015a) that having a healthy diet is an 
important part of living with type II diabetes. Eating healthily and losing weight, if 
the patient is overweight, help to manage diabetes better. If the patient is 
overweight, he or she will be encouraged to lose weight and agree on a target 
weight loss. It recommended by NICE (2015a) that the weight-loss target 
should be to lose 5% to 10% of body weight. Any weight loss will help, although 
the nearer the patient gets to a healthy body weight, the better it will be for the 
diabetic patient’s long-term health. In recent decades, men and women around 
the globe have gained weight, largely due to changes in dietary patterns and 
decreased physical activity levels (Ezzati and Riboli, 2013). Excess adiposity 
reflected by higher body mass index (BMI) is the strongest risk factor for 
diabetes, and Asians tend to develop diabetes at a much lower BMI than those 
of European ethnicity (Hu, 2008). 
Worldwide, an unhealthy lifestyle is one of the leading causes of preventable 
death (Lopez et al., 2006). Inactive lifestyle and obesity are highly associated 
with the risk of developing type II diabetes and the complications associated 
with this disease (American Diabetes Association, 2002, Mokdad et al., 2003). 
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Many programmes to improve physical activity and dietary behaviour have been 
investigated. Randomised controlled trials have shown positive effects of 
combined lifestyle interventions on the development of type II diabetes in 
patients with impaired glucose tolerance (Gillies et al., 2007).  
In patients who already have type II diabetes, combined lifestyle interventions 
improved weight loss, diabetes control and lowering cardiovascular risk factors  
have proven to be effective (Espeland, 2007). The translation of these 
combined lifestyle interventions in community and primary care settings has 
been shown to be promising, yet challenging (Absetz et al., 2007) (Laatikainen 
et al., 2007). In addition, the effects of exercise-only programmes for patients 
with type II diabetes were small, even in randomised trial settings (Boulé et al., 
2001, Thomas et al., 2006). Furthermore, when investigated in primary care, 
lifestyle counselling interventions had marginal effects on cardiovascular risk 
(Fleming and Godwin, 2008), exercise-referral schemes showed a small 
increase in physical activity in adults (Williams et al., 2007) and group education 
for patients with type II diabetes had modest effects on weight loss and smoking 
cessation (Davies et al., 2008). 
1.3.2.2. Exercising and physical activity  
Exercise is defined by SIGN (2013, p: 17) as “a subset of physical activity which 
is done with the goal of enhancing or maintaining an aspect of fitness (e.g. 
aerobic, strength, flexibility, balance). It is often supervised (e.g. in a class). 
Systematic and regular exercising is encouraged (e.g. jogging, swimming, 
attending exercise classes)”. However, physical activity is defined “as any 
skeletal muscle movement which expends energy beyond resting level (e.g. 
walking, gardening, stair climbing)” (SIGN, 2013, p: 17).  
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There are three general types of exercise: aerobic, resistance and flexibility. 
Aerobic exercise involves repeated and continuous movement of large muscle 
groups (Department of Health and Human Services, 2008). Activities such as 
walking, cycling, jogging, and swimming rely primarily on aerobic energy-
producing systems. Resistance (strength) training includes exercises with free 
weights, weight machines, body weight, or elastic resistance bands. Flexibility 
exercises improve the range of motion around joints (Herriott et al., 2004). 
Balance exercises benefit gait and prevent falls (Morrison et al., 2010). 
Activities like tai chi and yoga combine flexibility, balance, and resistance 
activities (Colberg et al., 2016). 
For many years, exercise along with diet and medication has been considered 
one of three cornerstones of diabetes therapy (Joslin et al., 1959). Regular 
physical activity is recommended for patients with type II diabetes since it may 
have beneficial effects on metabolic risk factors for the development of diabetic 
complications (ADA, 2002, ADA, 1997). The low-cost, non-pharmacological 
nature of physical activity further enhances its therapeutic appeal (Boulé et al., 
2001). 
The adoption and maintenance of physical activity are critical foci for blood 
glucose management and overall health in individuals with diabetes and 
prediabetes (Colberg et al., 2016). Physical activity includes all movement that 
increases energy use, whereas exercise is planned, structured physical activity. 
Exercise improves blood glucose control in type II diabetes, reduces 
cardiovascular risk factors, contributes to weight loss, and improves well-being 
(Chen et al., 2015, Lin et al., 2015).  Regular exercise may prevent or delay the 
onset of type II diabetes development (Schellenberg et al., 2013). Regular 
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exercise also has considerable health benefits for people with type I diabetes 
(e.g., improved cardiovascular fitness, muscle strength, insulin sensitivity, etc.) 
(Yardley et al., 2014). The challenges related to blood glucose management 
vary with diabetes type, activity type, and presence of diabetes-related 
complications (American Diabetes Association, 2016b, American Diabetes 
Association, 2016c). Physical activity and exercise recommendations, therefore, 
should be tailored to meet the specific needs of each individual (Colberg et al., 
2016). 
1.3.2.3. Structured education 
Diabetes education courses provide information on how to manage diabetes 
through diet, physical activity and medication. They are run by health 
professionals – usually a diabetes specialist nurse or dietitian often in a group 
setting (NHS, 2015a). Structured education programmes for people with type II 
diabetes are an effective and cost efficient way of improving outcomes and are 
a key part of diabetes self-management when linked with collaborative care 
planning, screening and medications (NHS, 2015a, Deakin et al., 2006).  
Acting early to prevent complications limits the impact on the person’s life and 
saves the NHS money (Deakin et al., 2006). However access to structured 
education is very poor and there is an unacceptable variation in some areas, for 
example South London (Gadsby and Young, 2013). When people are 
diagnosed with diabetes, providers, referrers and commissioners work 
collaboratively so that real change can happen allowing education to reach a 
greater number of the population, as has been demonstrated by Bexley, 
Southwark and Lambeth (Cotter and Grumitt, 2011; Diabetes Modernisation 
Initiative, 2014). NICE states that structured education should be offered to 
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every person with diabetes and/or their carer around the time of diagnosis, with 
annual reinforcement and opportunities taken to repeat education as necessary 
(NICE, 2011). It is vital to record and report those who are not attending the 
structured education offered (usually DESMOND or X-PERT) and provide a 
suitable alternative that meets their individual needs (NHS, 2015a; Department 
of Health and Diabetes UK, 2005). High quality alternative education 
programmes do exist for harder to reach groups and innovative ways should be 
sought to allow people with diabetes to access different types of learning (NHS, 
2015b). 
1.3.3. Pharmacological management 
To treat type II diabetes, the commonly used oral therapeutics include 
sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinedione, which 
often failed to protect the pancreas or control the disease progression 
accompanied by serious side effects (Minshall et al., 2008). Although the 
majority of patients with type II diabetes requiring insulin therapy can be 
successfully treated with basal insulin alone, some, because of progressive 
diminution in their insulin secretory capacity, will require prandial insulin therapy 
with shorter-acting insulins (Inzucchi et al., 2012). This is typically provided in 
the form of the rapid insulin analogues, insulin lispro (B28Lys,B29Pro human 
insulin), insulin as part (B28Asp human insulin) or insulin glulisine (B3Lys, 
B29Glu human insulin), which may be dosed just before the meal (Inzucchi et 
al., 2012). They result in better postprandial glucose control than the less costly 
human regular insulin, whose pharmacokinetic profile makes it less attractive in 
this setting. Ideally, an insulin treatment programme should be designed 
specifically for an individual patient, to match the supply of insulin to his or her 
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dietary/exercise habits and prevailing glucose trends, as revealed through self-
monitoring (Inzucchi et al., 2012). Since currently available medications cannot 
completely meet the clinical needs of type II diabetes treatment, scientists have 
been committed to the discovery and development of novel antidiabetic 
therapeutics (Hu et al., 2016). 
The immediate purpose of lowering blood glucose is to provide relief from 
symptoms (thirst, polyuria, nocturia, and blurred vision). Thereafter, the aim is 
to prevent microvascular complications: loss of vision (retinopathy), renal failure 
(nephropathy), and foot ulceration (neuropathy). High blood glucose 
(hyperglycaemia) is also one of the features of diabetes – with raised blood 
pressure and cholesterol associated with macrovascular complications 
(myocardial infarction, stroke, and peripheral arterial disease). The effects of 
glucose-lowering therapies on cardiovascular morbidity and mortality are 
therefore of major importance and not necessarily related to glucose-lowering 
(SIGN, 20103). 
It has been recommended that in the therapeutic management of 
hyperglycaemia when HbA1c >6.5% antidiabetic drugs are commenced and the 
therapy should be intensified if HbA1c > 7.5%. These targets are generalised 
and may be altered depending on individual circumstances (Keenan, 2010). 
1.4. Diabetes medicine management 
There is no widely accepted definition of medicines management, although the 
term is widely used. The National Prescribing Centre in England defines it as ‘a 
system of processes and behaviours that determines how medicines are used 
by patients and by the NHS’ (NHS, 2016). When first described in 2002, 
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medicines management encompassed clinical assessment, monitoring and 
review in individual patients, medicines delivery services, review of repeat 
prescribing systems, clinical audit, health education, risk assessment, disease 
prevention and formularies and guidelines (Krska and Godman, 2011). Recent 
developments in the UK have resulted in considerable changes in the ways 
medicines are used; hence medicines management has also changed (Krska & 
Godman, 2011). These important developments include non-medical 
prescribing, increasing clinical roles of community pharmacists, changes in the 
way that GPs and pharmacists are remunerated for their NHS work, electronic 
prescribing, early discharge from hospital, hospital at home services, minor 
ailments services, pharmacy public health services and more standards for care 
quality (Krska & Godman, 2011) 
The US Food and Drug Administration (FDA) reported in 1987 that 12,000 
deaths and 15.000 hospitalizations were due to adverse drug reactions (ADRs) 
(Manasse, 1989a, Manasse, 1989b). The philosophy of Hepler and Strand 
(1990: 533) states that: 
“Drug related morbidity often preventable and pharmaceutical 
services can reduce the number of ADRs, the length of hospital 
stays, and the cost of care. Pharmacists must abandon 
factionalism and adopt patient-centred pharmaceutical care as 
their philosophy of practice.”  
This philosophy faces a variety of problems with its application but leads to 
development (in conjunction with other practitioners) of a practice of 
pharmaceutical care. 
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There is a debate about whether the terms pharmaceutical care or medicines 
management is the more appropriate term to use. Some British pharmacists 
argue that pharmaceutical care is used to describe only a particular model of 
practice so they are unhappy to use the term more generally.  The term 
medicines management is widely used in NHS documents and has also gained 
favour in the UK among pharmacy managers. Medicines management 
encompasses all the activities that contribute to safe and rational medicine use, 
including strategic functions such as purchasing, formulary policy, risk 
management and many other roles of pharmacists and pharmacy technicians 
(Sexton et al., 2006). 
1.4.1. Health education 
Health education is defined by WHO (1998: 4) as: 
“Health education comprises consciously constructed 
opportunities for learning involving some form of communication 
designed to improve health literacy, including improving 
knowledge, and developing life skills which are conducive to 
individual and community health” 
Although no figures are available, health literacy and numeracy are low in 
Libya. Since people with low health literacy have poorer health than those with 
adequate health literacy, improving health literacy is an important factor in 
reducing health inequalities (Anderson & Blenkinsopp, 2011). Health education 
is not only concerned with the communication of information, but also with 
fostering the motivation, skills and confidence (self-efficacy) necessary to take 
action to improve health (Anderson & Blenkinsopp, 2011). 
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1.4.2. Safe and effective use of medicine 
Reporting errors is a vital part of every health professional’s job and the UK’s 
National Patient Safety Agency (NPSA) reporting and learning service (now the 
responsibility of NHS Improvement) encouraged this (Knapp et al., 2011). 
Research undertaken in 2005 showed that both pharmacists and support staff 
were, however, very unlikely to report incidents to the NPSA or even within the 
pharmacy (Ashcroft et al., 2005). Managing risk often involves changing 
procedures. This may be very simple or require extensive collaborative work. 
Simple solutions to reduce errors resulting from products with similar names or 
packaging could be placing them in different locations within the dispensary, or 
putting up warning signs indicating products should be double checked before 
dispensing (Knapp, et al., 2011). When patients move from one health care 
setting to another, or between health care and other settings, information about 
their medicines needs to move with them. There are many situations when 
these dos not occur and a proportion of these can result in harm (Krska & 
Godman, 2011). 
1.4.3. Medicine adherence 
Adherence to therapies is a primary determinant of treatment success. Failure 
to adhere is a serious problem, which not only affects the patient but also the 
health care system.  Adherence to a medication regimen is generally defined as 
the extent to which patients take medications as prescribed by their health care 
providers (Osterberg & Blaschke, 2005). Another definition of medicine 
adherence existing in a WHO (2003) document adopted from Haynes and Rand 
is “the extent to which a person’s behaviour – taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed 
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recommendations from a health care provider”. It includes the initiation of the 
treatment, implementation of the prescribed regime, and discontinuation of the 
pharmacotherapy (Vrijens et al., 2012). Adherence in diabetes can defined as 
“the active, voluntary involvement of the patient in the management of his or her 
disease, by following a mutually agreed course of treatment and sharing 
responsibility between the patient and health care providers” (Barofsky, 1978). 
The word “adherence” is preferred by many health care providers, because 
“compliance” suggests that the patient is passively following the doctor’s orders 
and that the treatment plan is not based on a therapeutic alliance or contract 
established between the patient and the physician (Osterberg & Blaschke, 
2005). 
Meanwhile, some studies classify adherence as either primary or secondary. 
Primary nonadherence is the frequency with which patients fail to fill 
prescriptions when new medications are started so it is related to refilling and 
initiation of the medication therapy (Fischer et al., 2010). Secondary 
nonadherence is defined as the medication being not taken as prescribed when 
prescriptions are filled. It does not only affect the clinical outcome but also affect 
the financial outcome of the health system (Solomon and Majumdar, 2010). 
Various methods have been reported and are in use to measure adherence. 
The methods available for measuring adherence can be broken down into direct 
and indirect methods of measurement. Direct methods include direct observed 
therapy, measurement of the level of a drug or its metabolite in blood or urine 
and detection or measurement of a biological marker added to the drug 
formulation, in the blood. Direct approaches are one of the most accurate 
methods of measuring adherence but are expensive. Moreover, variations in 
35 
 
metabolism and "white coat adherence" can give a false impression of 
adherence (Osterberg and Blaschke, 2005). Indirect methods include patient 
questionnaires, patient self-reports, pill counts, rates of prescription refills, 
assessment of patient’s clinical response, electronic medication monitors, 
measurement of physiologic markers, as well as patient diaries. Each method 
has its own advantages and disadvantages and no method is considered as the 
gold standard (Wagner et al., 2001, Alcoba et al., 2003).  
Diabetes is further complicated by a multitude of other factors, such as, the 
‘chronic’ nature of the disease, lifelong requirement for medications, 
requirement for changes in lifestyle, and the need to cope with social, cultural 
and psychological distress that may occur with the disease. In the midst of such 
complexities, remaining adherent to treatment recommendations may be a 
challenge (Lerman, 2005). Treatment adherence, in the context of diabetes, 
covers adherence to an array of self-care behaviours, constituting home 
glucose monitoring, adjustment of food intake, and administration of medication, 
regular physical exercise, foot care and regular medical visits (Sabatae, 2003). 
Although adherence to each self-care measure contributes to the effective 
management of diabetes (Sapkota et al., 2015). Adherence rates are typically 
higher among patients with acute conditions, as compared with those with 
chronic conditions (Jackevicius & Mamdani, 2002; Haynes & McDonald 2002). 
Adherence to oral hypoglycaemic medications in patients with T2D is 36 to 93% 
and to insulin is 63% (Crsmer, 2004). The low level of medication adherence is 
likely to be one of the major factors contributing to sub-optimally controlled 
diabetes (Bailey and Kodack, 2011, Rhee et al., 2005). 
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1.4.4. Patient counselling 
‘Patient counselling’ is the term employed by the pharmacy profession to 
describe the verbal activities that constitute the extended role (Pilnick, 2003). In 
practice, it ranges from simply stating the dosage of a drug as it is handed over 
to the client, through counter prescribing for common ailments, to giving advice 
with regard to lifestyle and health promotion issues, like smoking cessation, 
cholesterol testing and contraception (Pilnick, 2003). Patient counselling has a 
central part to play in the ‘extended role’, which is seen as the way forward for 
the profession (RPSGB, 1996). Through counselling, it is hoped both that 
clients will be equipped with the resources to use any medications more safely 
and effectively, and that the perception of the pharmacist as the ‘first port of call’ 
for general advice on medicines and health will become commonplace (Pilnick, 
2003). 
Counselling involves helping some to explore a problem and to identify 
conflicting issues so that they can decide for themselves what to do. In other 
words this involves helping people to help themselves.  
1.5. Chapter summary 
Type II diabetes has become a global epidemic. Type II diabetes is associated 
with more than a twofold excess mortality from cardiovascular disease, 
devastating microvascular complications affecting the eyes, kidneys and 
nerves, as well as with significant comorbidities including cancer, infections and 
psychosocial stress. If left untreated, the microvascular complications will 
ultimately lead to blindness, overt kidney failure, foot ulcers and amputations. 
There is an enormous challenge for society and the health care system to 
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organise treatment and management for people with diabetes to reduce its 
serious impact on the health of the individual, as well as to reduce the otherwise 
extreme expenditure (for example, to compensate for lost working years as well 
as for managing blindness, dialysis, and amputations and so on). Many 
landmark achievements within diabetes care have been obtained during recent 
years, including definitive knowledge that multifactorial pharmacological as well 
as non-pharmacological intervention targeting physical inactivity, smoking, 
reduction of blood pressure and lipids, as well as lowering glucose, significantly 
improve the most important clinical outcome variable in people with diabetes 
(Thomas, et al., 2016).  
Pharmacists have an important role to play in the care of patients with diabetes. 
The goal of pharmaceutical care is to ensure that patients make the best use of 
their medications and achieve the desired therapeutic outcomes. Pharmacists 
in an ambulatory care setting have an excellent opportunity to educate patients 
about diabetes and its complications, proper self-management, and the correct 
use of medications and self-care devices. 
In Chapter Two the practice and concepts of pharmaceutical care will be 
reviewed in detail. 
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2. Literature Review 
This chapter describes the scope of knowledge and practice with respect to 
type II diabetes among patients and community pharmacists. The overall goals 
of this chapter were firstly to establish the significance of the general field of 
study, and secondly to identify a place where a new contribution could be 
made. The bulk of the chapter critically evaluates the different research 
methodologies used in this field in order to identify the appropriate approach for 
investigating the research question(s). 
The chapter is structured into five sections. Section 2.1 highlights methods of 
literature review applied in the current thesis. The management of type II 
diabetes including self-management and theories related to self-efficacy are 
highlighted in Section 2.2.  An overview of pharmacy practice is provided in 
Section 2.3 including pharmaceutical care or medicine management relating to 
type II diabetes management and the accessibility of community pharmacists.  
Diabetes health literacy along with the impact of type II diabetes knowledge, 
practice and attitudes in patients and pharmacists is outlined in Section 2.4. 
The chapter summary is in Section 2.5. Aims and objectives relating to the 
knowledge gap identified in the literature review are then stated in Chapter 3. 
Two kinds of literature review were carried out (scoping and systematic) to (a)  
provide a clear picture of the management of type II diabetes in practice and (b) 
identify specific evidence for the role of the community pharmacist in diabetes 
management. 
The specific objectives of this chapter are to: 
 Identify the standard of care for management of type II diabetes. 
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 Establish the effectiveness of community pharmacists’ type II diabetes 
care by assessing high quality randomised controlled clinical trials. 
 Recognise any social and behavioural issues related to type II diabetes 
self-management (for example: self-care behaviours, empowerment, and 
health beliefs). 
More broadly, the literature review explored ideas and themes around: 
 the effectiveness of diabetes self-management  
 the effectiveness of community pharmacists’ roles in relation to diabetes 
management 
 comparing and contrasting comprehensive diabetes management 
guidelines from a developed (SIGN) and less developed (LDCG) 
healthcare economy. 
 
2.1. Methods 
In the current study, both scoping and systematic review were conducted to 
identify gaps in knowledge and critically analyse studies meeting specific 
criteria (by systematic review). The systematic review focuses on community 
pharmacist interventions in type II diabetes management. However, the scoping 
review focuses on broader topics of importance to the thesis such as: 
medication adherence; pharmacist and patient diabetes knowledge; health 
literacy; self-efficacy etc. 
The scoping review was completed by searching in different databases 
Medline, PubMed, Science Direct and Wiley online library. The key words were: 
type II diabetes management, diabetes health literacy, patient counselling, 
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patient empowerment, and diabetes knowledge. The literature review adopted 
in this research is centred on generating information relevant to the current 
study themes. The most well-known method for conducting a systematic review 
is produced by the Cochrane collaboration (Aveyard, 2007). For this reason, the 
Cochrane library and policy document guidelines were used to guide the search 
for and evaluation of relevant high-quality literature. 
A systematic search was carried out in five electronic databases (Medline, 
Embase, Scopus, Cochrane Library and Web of Science) with the help from a 
subject specialist librarian. The publications were searched from 2011 to 2017. 
The search terms used included medical subjects headings and text terms 
combined with Boolean operators. The detailed search strategy used for each 
database is provided in Appendices 1 to 5. 
Studies were included in the review if they were randomised controlled trials or 
cluster- randomised controlled trials evaluating the effectiveness of 
interventions delivered only by community pharmacists and directed at patients 
with type II diabetes in comparison with usual care. Studies that took place in 
hospital or outpatient primary care were excluded (see Figure 2.1). Studies 
were included if they reported one or more of the following outcomes: HbA1c, 
and blood glucose (FPG). The risk of bias in included studies was assessed by 
using the Cochrane risk of bias tool. 
The researcher extracted and screened all the data received from the electronic 
databases using the pre-specified inclusion criteria. Then, the abstracts 
screened for the specific inclusion criteria after that the full text articles were 
screened carefully. The excluded and included studies were sent to a 
supervisor to review. Data was extracted from included studies using Microsoft 
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Word. The data extracted from each study included authors, publication year, 
study design, setting and country where the study took place, sample size, 
patient age and gender, follow-up duration, details of pharmacist intervention 
and control as well the pharmacist training and study primary and secondary 
outcomes (see Tables 2.1 and 2.2). This review summarised data for the 
outcome measures HbA1c and FPG. The results are reported as baseline, 
follow up and p-value for both control and intervention groups (see Table 2.3).  
Risk of bias was assessed by using the Cochrane of risk bias tool (Higgins et 
al., 2011). The risk of bias in each study was assessed according to the 
following criteria: suitability of random sequence generation, concealment of 
allocation, blinding of outcome assessment, completeness of outcome data, 
selective outcome reporting, and other sources of bias. Each risk of bias item 
was rated as “low risk” if it was unlikely that a bias would seriously alter the 
results; “unclear” if it was likely that a bias would raise some doubt about the 
results; or “high risk” if it was likely that a bias would seriously alter the results. 
2.1.1. Justifying the methodology of literature review 
The literature review is a fundamental source of information and without it the 
study should not be conducted because the gap in knowledge would not be 
clear. Therefore, comprehensive literature review is considered to be essential 
for understanding the accumulated knowledge about the topic being reviewed 
(Garrard, 2007). A literature review uses as its database primary or original 
scholarship, and does not report new primary scholarship itself. Systematic 
review strives to identify all the information available on a topic, whilst 
describing a clear, comprehensive (search and evaluation) methodology. 
Systematic reviews take a highly structured approach, aiming to minimise the 
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effect of biases and random errors in conclusions (Bowling, 2014). They include 
information on materials and methods in relation to the published and 
unpublished literature (Chalmers and Altman, 1995). In quantitative research, 
systematic reviews are mostly based on Randomised Controlled Trials RCTs, 
but do include information derived from other designs when appropriate 
(Bowling, 2014). One of the main features of systematic review is that reviewers 
follow a strict protocol to ensure that the review process undertaken is robust by 
using explicit and rigorous methods to identify, critically appraise, and synthesis 
relevant studies in order to answer a predefined question.  The reviewers then 
develop a comprehensive searching strategy, and leave no stone unturned in 
the search for relevant literature, and do not regard the process complete until 
the search is exhausted.  
The reasons for choosing two types of review were:  
 the systematic review enables the reader to appraise critically the most 
robust evidence available in an attempt to synthesize what is known, and 
not known, about the efficacy of particular interventions.  
 systematic review aims to answer a particular question or test a 
hypothesis (when this can be specified) usually in relation to a particular 
health care intervention on a particular population group. 
 systematic reviews place an emphasis on judging the quality of 
evidence. 
 a scoping study tends to address broader topics where many different 
study designs might be applicable (Arksey and O'Malley, 2005). 
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 a scoping study is less likely to seek to address very specific research 
questions nor, consequently, to assess the quality of included studies 
(Arksey and O'Malley, 2005). 
Scoping reviews can be used in a number of ways, for example identifying 
research gaps and summarizing findings of research (Arksey and O'Malley, 
2005). They can also be used to inform systematic reviews, in particular to:  
 explore the extent of the literature in a particular domain without 
describing findings in detail.  
 help identify appropriate parameters of a review (i.e. define the targeted 
population, intervention, comparison, and outcomes, otherwise known as 
PICO).  
 to identify the potential scope of a systematic review and associated 
costs (Brien et al., 2010, Arksey and O'Malley, 2005). 
Scoping review would likely reveal that there are numerous forms of 
interventions used in a range of settings. This would help to identify a more 
specific research question of interest, based on what was already known (or not 
known) for each of those interventions within each setting, as well as the 
commissioning body and/ or review author’s area of interest. It would also 
facilitate a more realistic budget estimate based on the breadth of the work 
required, since a scoping review should provide an indication of the number of 
studies likely to be retrieved for each of those interventions/settings. Scoping 
reviews to inform systematic reviews typically do not include a quality 
assessment of included studies, which limits data synthesis and interpretation. 
They are therefore intended to be conducted reasonably rapidly (Armstrong et 
al., 2011). 
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To make this method of literature review more rigorous, Arksey and O'Malley 
developed a framework for conducting a scoping review (Davis et al., 2009). 
Levac et al. (2010) developed scoping review and introduce six key phases; 
which are listed below. 
 Identifying the research question, 
 Identifying relevant studies, 
 Study selection, 
 Charting the data, 
 Collating, summarizing and reporting the results, 
 Optional consultation. 
The studies analysed in this literature review are both quantitative and 
qualitative. These research methods complement each other: qualitative studies 
allow an understanding of patient and professionals opinions toward diabetes 
management; quantitative research allows an understanding of epidemiology 
and clinical effectiveness. There is much debate in the research literature about 
the relative merits of both qualitative and quantitative research, with some 
researchers proclaiming the superiority of one approach over another. It is 
argued that these debates are not important. What is important is that the most 
appropriate research methodology is used to address the research topic in 
question (Aveyard, 2007). 
Qualitative research is concerned with exploring meaning and phenomena in 
their natural settings. There are a wide variety of approaches to qualitative 
research. Russell and Gregory (2003) reported that over 40 approaches have 
been identified in the literature. Aveyard, (2007, pp: 31) stated that qualitative 
data “are not numerical but are collected, often through interview, using the 
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words and descriptions given by participants. The data are used to generate 
understanding and insight of the situation being researched. There is no use of 
statistics in qualitative research, the results are descriptive and interpretative”. 
2.1.2. Results of search 
The search phase of systematic review yielded 127 citations (Figure 2.1). After 
screening titles and abstracts, 56 citations potentially met the inclusion criteria. 
Of these: 21 were clinic or hospital based studies, 10 were systematic reviews, 
6 were general reviews, 4 were non- randomised clinical trials, 2 were unrelated 
to the study focus, 1 was in the Chinese language, 1 wasn’t related to diabetes, 
1 was an observational study, 1 concerned the economic impact of diabetes, 
and 1 was a narrative review. In total, 8 studies met the inclusion criteria and 
were included in this systematic review. 
2.1.3. Demographic and contents of intervention, control and 
training methods of included studies  
The characteristics of the included studies included were: 
 1 cluster randomised controlled trial in which the participating 
pharmacies were randomly assigned to either the intervention or control 
group (Mehuys et al., 2011); 
 studies conducted in India (Venkatesan et al., 2012, Ganawar et al., 
2014); 
 studies in Europe (Ali et al., 2012, Mehuys et al., 2011, Kjeldsen et al., 
2015); 
 1 in USA (Kraemer et al., 2012) , one in Brazil (Paulo et al., 2016) and 
one in Iran (Jahangard-Rafsanjani et al., 2015). 
All the studies took place in community pharmacies. Pharmacist interventions 
varied across the included studies and encompassed one or more of the 
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following: counselling and education on diabetes, medication, lifestyle 
modification, and self-monitoring; reinforcement of medication adherence or 
complications screening; provision of materials such as educational leaflets; 
medication review; identification and resolution of drug- related problems; 
adjustment of pharmacotherapy; and referrals to other health care 
professionals. Two studies mentioned motivational interviews as a technique 
used to deliver advice to patients (Ganawar et al., 2014, Kjeldsen et al., 2015). 
In most studies the control group received usual care from physician or 
community pharmacist. Only one study the control group not reported type of 
care received (Kjeldsen et al., 2015). Overall, the included studies involved 
1558 participants. The duration of follow up ranged from five months to twenty 
four months. A detailed description of the characteristics of included studies is 
presented in Table 2.1 and 2.2. 
Most studies mentioned that community pharmacists were provided with 
training (see Table 2.2) in: pharmacotherapy; diabetes management; and 
referrals for eye and foot care management. As well as training on 
pathophysiology, pharmacology and non-pharmacological management of type 
II diabetes (Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, Mehuys et al., 
2011). One study did training on drug related problems and medication review 
(Gngawar et al., 2014). In another study the pharmacists attended training on 
patient education, empowerment, documentation and billing procedures for 
counselling services (Kraemer et al., 2012). There is a study that trained the 
pharmacists on motivational interviewing and self-efficacy in relation to 
behaviour (Kjeldsen et al., 2015). Two studies do not describe training of 
pharmacists (Venkastesan et al., 2012, Paulo et al., 2016).  
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Figure  2.1: Prisma flowchart of study selection process
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Records excluded  
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Full-text articles assessed 
for eligibility  
(n = 56) 
Full-text articles excluded, with 
reasons  
(n = 48) 
4 non randomised clinical trials 
21 clinic or hospital based studies  
1 Chinese language 
1 non related to diabetes 
1 observational study  
1 economic impact of diabetes 
10 systematic reviews  
1 narrative review 
6 reviews 
2 non related to study focus  
  
 
 
Studies included  
(8) 
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Table  2.1: Characteristic of included studies  
Author, Year  Setting/ 
country 
Method of 
study  
Population 
(IG/CG) 
Lost to follow 
up (IG/CG) 
Age Gender Duration of 
diabetes  
Duration of 
follow up 
Ali et al., 
2012 
Community 
pharmacies/
UK 
 
RCT N=46 
23/23 
0/2 66.4 
(±12.7)/66.8(
±10.2) 
10 
(43.5%)/13 
(56.5%) male 
7.5 (±4.8 
years)/6.8 
(±3.5 years) 
12 months  
Jahangard-
Rafsanjani et 
al., 2015 
Community 
pharmacy/Ira
n 
RCT N=101 
51/50 
6/10 57.3 
(±8.6)/55.9 
(±8.7) 
25(49%)/26(5
2%) female 
4.6(±4.3)/5.7(
±5.9) years 
5 months 
Venkatesan 
et al., 2012 
Community 
pharmacy/Ind
ia 
RCT N= 39 
19/20 
None of the 
participants 
lost to follow 
up 
51.47(±9.99)/
57.05(±12.05
) 
8 (21%)/10 
(26%)male 
5.21(±4.88)/5
.80(±5.34) 
8 months 
Mehuys et 
al., 2011 
Community 
pharmacy/ 
Belgium 
Cluster RCT N= 288 
153/135 
5/3 63.0/62.3 
years 
51.0/53.7 
male 
ND 24 months  
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Ganawar et 
al., 2014 
Community 
pharmacies/ 
India 
Prospective 
RCT  
N= 723 
 
ND ND Both groups 
389 (50.80%) 
Not more 
than 10 
years: 
247(34.16) 
11 to 20 
years: 224 
(30.98) 
21 to 30 
years: 108 
(14.94) 
Unknown 
duration: 070 
(09.68) 
One year  
Kraemer et 
al., 2012 
Community 
pharmacy/ 
Oregon USA 
RCT N= 67 
36/31 
1/1 55.6(±6.8)/52
.6(±9.2) 
14(38.89%)/1
9(61.29%) 
female 
9.9(±10.3)/8.
0(±7.4) 
One year  
Paulo et al., 
2016 
Community 
pharmacy/Br
azil 
Prospective 
RCT 
Single 
blinded study 
N= 89  
47/42 
Non 56.89(±10.0)/
59.62(±9.0) 
27(57.5%)/22
(52.4%) 
female 
6.63(±6.63)/7
.2(±6.6) 
6 months  
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Kjeldsen et 
al., 2015 
Community 
pharmacy/ 
Denmark 
RCT N= 205 
Comparing to 
interventions 
basic 
intervention 
BI= 39/ 
Extended 
intervention 
EI=41/ 
Control group 
CG= 125 
BI/EI/CG=6/4
/23 
BI/EI/CG= 
63.1(±8.8)/63
.4(±7.8)/62.1(
±10.2) 
BI/EI/CG=22(
57.9%)/25(59
.5%)/78(62.4
%) 
ND 6 months 
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Table  2.2: The intervention, control and training community pharmacist’s components of included studies along with primary and secondary 
outcomes   
Author/ Year  Pharmacist 
intervention  
Control  Pharmacist training   Primary outcomes  Secondary Outcomes  
Ali et al., 
2012 
Patients in the 
intervention group 
received a programme 
of education about 
diabetes, its treatment 
and associated 
cardiovascular risk 
factors. These patients 
were seen for 
monitoring ⁄ 
counselling by a 
community 
Pharmacist  
Patients in the 
control group did 
not receive 
specific 
counselling or 
education over 
and above usual 
care. 
The training about up to 
date diabetes 
management and referrals, 
an overview of the use of 
diagnostic equipment’s 
and the data collection 
forms. 
BMI,  
BP(mmHg) 
BG (mmol/l), 
HbA1c(mmol/l) 
HbA1c(%), LDL (%), 
 HDL (%),  
Total 
cholesterol(mmol/l), 
Triglycerides 
(mmole/l) 
Short Form-36 
Diabetes 
Knowledge Test (DKT) 
Beliefs about Medicines 
Questionnaire (BMQ) 
Satisfaction with 
Information received about 
Medicines(SIMS) 
Diabetes Quality of Life 
(DQOL) 
Jahangard-
Rafsanjani 
et al., 2015 
Qualified community 
pharmacist educated 
patients about diabetes 
medications, clinical 
goals, self-care 
activities and self-
monitoring of blood 
glucose. As well 
recommended 
physician visit when 
necessary   
Patients in this 
group received 
usual care from 
the physician 
during the study 
period. Baseline 
assessments 
were performed 
by the 
community 
pharmacist at the 
recruitment visit.  
The training about 
pharmacotherapy of 
diabetes and health care 
professionals on diabetes 
education  
HbA1c Medication adherence  
Self-care activity  
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Venkatesan 
et al., 2012 
Patients in the 
intervention group 
received diabetic 
medication 
counselling, printed 
educational material 
and instructions on 
dietary regulation, 
exercise and lifestyle 
modifications from the 
community pharmacist, 
The control 
group patients 
did not receive a 
counselling  
No pharmacist trained 
mentioned 
FPG 
BMI 
Diabetes care profile 
questionnaire to measures 
social and psychological 
factors  
Self-care practices. 
Diabetes knowledge test  
Mehuys et 
al., 2011 
Counselling on 
diabetes and 
complications, 
medication and healthy 
lifestyles, facilitation of 
medication adherence, 
and reminders about 
annual eye and foot 
examinations.  
Patients in the 
control group 
received usual 
pharmacist care 
the intervention 
pharmacists underwent a 
training session on the 
pathophysiology of type II 
diabetes and its 
nonpharmacological and 
pharmacological 
management according to 
t treatment guidelines, and 
the study protocol. The 
control pharmacists only 
received training on the 
study protocol 
FPG 
HbA1c 
Medicine adherence. 
Diabetes knowledge test  
Diabetes Self- 
management 
Ganawar et 
al., 2014 
Patients received 
medication review and 
provided with 
counselling of Drug 
Related Problems 
(DRPs) to identity 
The control 
group was given 
usual care (no 
medication 
review given) 
For the control 
Community pharmacist in 
intervention arm trained on 
DRPs in medication review 
while control pharmacists 
not attending medication 
review. However, both 
Calculation of the 
incidences of DRPs 
 FPG 
 Hypoglycaemic 
episodes, morbidity, 
adverse effects  
 total incidence of 
patient visit to 
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complexity of 
medication regimen 
and problems 
detected. As well, 
provided with 
psychological Aspect 
Treatment (PAT) to 
educate patients about 
medicine 
contraindication, 
indications, side effects 
administration and 
frequency of the 
medicines. 
group no PAT 
test was 
performed. 
groups of community 
pharmacists were 
explained on motivational 
interviewing and decision 
making as well as 
communication skills. 
diabetiologist for 
consultation of 
probable drug related 
problem 
 The incidence of clinic 
visit was obtained from 
the prescriptions. 
Kraemer et 
al., 2012 
Patients in the 
intervention group 
received counselling 
on managing diabetes 
from pharmacist 
Control-group 
participants were 
provided written 
educational 
information 
about managing 
diabetes (no 
counselling) 
The participating 
pharmacists attend training 
on patient education and 
empowerment, clinical 
intervention techniques, 
patient care 
documentation, and billing 
procedures for counselling 
services.  As well, the 
pharmacists trained on the 
protocol of study in terms 
of collecting patient 
information, educating and 
coaching patients with 
diabetes, and documenting 
outcomes, they were not 
HbA1c LDL, HDL, cholesterol, 
Triglycerides, total to HDL 
ratio, fasting blood 
glucose, other clinical 
parameters; systolic and 
diastolic blood pressure, 
weight circumferences, 
BMI.     
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required to use specific 
educational or clinical 
practice protocols. In 
addition, they required to 
fax, e-mail, or mail a 
progress note to the 
patient’s primary care 
physician after each visit 
Paulo et al., 
2016  
 The intervention group 
had monitoring 
program performed by 
community pharmacist 
to evaluate DRPs. 
Received usual 
care  
Not mentioned  HbA1c 
FPG 
Triglycerides 
Total Cholesterol  
HDL cholesterol  
LDL cholesterol 
Blood Pressure 
Kjeldsen et 
al., 2015 
The intervention model 
sought to identify drug-
related problems as 
well as issues 
experienced by the 
patient in relation to 
medicines use, and 
consequently find 
individually tailored 
solutions to address 
the identified problems. 
Despite the potential 
complexity of the 
problems, the targeted 
solutions could be 
simple, e.g. provision 
of medication 
Not mentioned  The pharmacist trained on 
delivering aspects of 
intervention model. Control 
and intervention 
pharmacists trained on 
motivational interviewing 
adapted from Levensky et 
al., 2007. Pharmacists in 
EI provided with additional 
training tools for coaching 
to support establishing and 
maintaining self-efficacy in 
relation to behaviour 
change 
Systolic blood 
pressure (mm Hg) 
Medication adherence  
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information or 
introducing a dose 
administration aid 
(DAA). 
 
 
56 
 
2.1.4. Studies risk of bias  
The risk of bias varied among the included 8 studies (see Chart 2.1).  In half 
(50.0%) of the studies, the allocation sequence was adequately generated, and 
random number tables or a computer-generated randomized list were the most 
commonly used methods. The allocation sequence was concealed in only one 
study (13%).. Only one study (13%) blinded participants and personnel to 
pharmacist intervention. None of the studies described clearly that the outcome 
assessment was executed by an assessor blinded to treatment assignment. 
Only three studies (38%) reported outcome data completely, and 6 studies 
(75%) were free from other sources of bias. The details of Cochrane bias 
judgement is provided in Appendix 6.  
 
Chart  2.1: Risk of bias in included studies presented as percentage across all 
studies 
 
2.1.5. HbA1c and FPG outcomes in included studies 
Five studies considered the primary outcome measures HbA1c and FPG (Ali et 
al., 2012, Jahangard-Rafsanjani et al., 2015, Venkatesan et al., 2012, Mehuys 
et al., 2011, Kraemer et al., 2012, Paulo et al., 2016). HbA1c mean value 
0% 20% 40% 60% 80% 100%
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decreased in the intervention group during the follow-up period in five of the 
studies (Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, Venkatesan et al., 
2012, Mehuys et al., 2011, Kraemer et al., 2012, Paulo et al., 2016). In three 
studies, the reduction in HbA1c in the intervention group was greater than that 
recorded in the control group by approximately 0.5% or more (Ali et al., 2012, 
Jahangard-Rafsanjani et al., 2015,  Mehuys et al., 2011). In another study, 
HbA1c mean value decreased in the intervention group by 0.12%, while there 
was a 0.41% increase in the control group (Paulo et al., 2016). Five studies 
presented balance between the baseline HbA1c mean values of both groups 
(Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, Venkatesan et al., 2012, 
Mehuys et al., 2011, Kraemer et al., 2012, Paulo et al., 2016). Only one study 
show the statistical significance of improvement (p-value <0.001) in HbA1c (Ali 
et al., 2012). The other studies showed no significant improvement between 
groups in HbA1c (Jahangard-Rafsanjani et al., 2015,  Mehuys et al., 2011, 
Kraemer et al., 2012, Paulo et al., 2016). The difference in HbA1c change from 
baseline to final follow up ranged from -0.34% to 1%. The detailed difference 
between baseline and final follow up is explained in Chart 2.2 
Regarding FPG, 4 studies reported this parameter as an outcome measure 
(Table 2.4). There was always a decrease in FPG in the intervention group 
from baseline to final follow-up, and all 4 studies reported a greater 
improvement in this outcome in the intervention group than the control group. 
The difference in change between groups ranged from -7.2 mg dL-1 to -25.74 
mg /dL. This was not statistically significant with one exception (Ali et al., 2012). 
The changes between baseline line and final follow up in FPG among the four 
studies are described in Chart 2.2 
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2.1.5.1. Blood pressure, lipid profile and body mass index 
outcomes 
Five studies out of eight evaluated the change in systolic and diastolic blood 
pressure during the course of study (Ali et al., 2012, Jahangard-Rafsanjani et 
al., 2015, Kraemer et al., 2012, Paulo et al., 2016, Kjeldsen et al., 2015) (see 
Table 2.4). One study reported the change in systolic blood pressure during the 
study (Kjeldsen et al., 2015). Only one study shows that the reduction in mean 
systolic blood pressure in intervention group from baseline to final follow-up 
better improvement than control group (Ali et al., 2012).  Only one study shows 
that the systolic blood pressure increased in the intervention group compared 
with control group (Jahangard-Rafsanjani et al., 2015).  For systolic blood 
pressure the difference in change between the groups ranged from -5.3mmHg 
to 0 3mmHg and was shown to be statistically significant only in two studies 
(Alie et al., 2012, Kjeldsen et al., 2015).  
Four studies reported diastolic blood pressure outcome (Ali et al., 2012, 
Jahangard-Rafsanjani et al., 2015, Kraemer et al., 2012, Paulo et al., 2016) 
(see Table 2.4).  Two studies show that diastolic blood pressure increased in 
the intervention group compared with control group (Jahangard-Rafsanjani et 
al., 2015, Kraemer et al., 2012). The mean diastolic blood pressure decreased 
in intervention group only in two studies (Ali et al., 2012, Paulo et al., 2016). 
The difference in change between both groups ranged from -1.8 mmHg to 1.8 
mmHg.  
Three studies out of eight reported lipid profile, one study reported lipid profile 
as a primary outcome (Ali et al.,2012) and the other two studies reported it as a 
secondary outcome (Kraemer et al., 2012, Paulo et al., 2016). The normal value 
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for Total Cholesterol was less than 200mg/dL and the normal range for LDL 
Cholesterol was 100-129mg/dL. For HDL Cholesterol the range was 40—59 
mg/dL and higher values are considered better protection against heart 
disease, for Triglycerides the normal value was less than 150 mg/dL.  
Total cholesterol reduced in the intervention group more than control group in 
two studies (Kraemer et al., 2012 and Paulo et al., 2016). The difference in 
change between both groups ranged from -6.7 mg/dl to 0.49mg/dl and one 
study shows this to be statistically significant (Ali et al., 2012) (see Table 2.5).  
Regarding LDL cholesterol, three studies reported data on this outcome. The 
mean reduction in intervention group was more than control group (see Table 
2.5). However, the difference in change in both groups ranged from -4.1 to 
1.43mg/dl, which means two studies show an increase in LDL level (Paulo et 
al., 2016 and Ali et al., 2012).  
Among the three studies reporting HDL cholesterol as an outcome measure 
(see Table 2.5), two studies described gradual increase in the intervention 
group from baseline to follow up. One study observed a decrease in 
intervention group (Kramer et al., 2012).  Nevertheless the difference in change 
between both groups ranged from -2.7 to +0.37mg/dl. 
Triglycerides (TG) was reported on in three studies (Table 2.5). Two studies 
show there is decrease in TG in intervention group compared with control group 
(Kraemer et al., 2012, Paulo et al., 2016). However, the difference in change 
between both groups was not statistically significant in three studies (see Table 
2.5) (Ali et al., 2012, Kraemer et al., 2012, Paulo et al., 2016).  
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For studies reporting Body Mass Index (BMI), two reported the baseline data for 
both groups but not the final follow up (see Table 2.6)  (Venkatesan et al., 
2012, Mehuys et al., 2011). The other two studies show reduction in 
intervention group compared with control group. The difference in change in two 
groups ranged between -0.5 kg/m2 and -1.02kg/m2. 
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Table  2.3: The results for HbA1c in included studies 
HbA1c (%) 
Author  IG 
Before 
IG 
After 
Mean 
Change  
CG 
Before 
CG 
After 
Mean 
Change  
Difference in change 
between groups  
p-value a 
Ali et al., 2012 8.2 6.6 -1.6 8.1 7.5 -0.6 -1 p<0.001a 
Jahangard-Rafsanjani et al., 
2015 
7.6 6.6 -1 7.5 7 -0.5 -0.5 p=0.09a 
Venkatesan et al., 2012 NDR NDR NDR NDR NDR NDR NDR NDR 
Mehuys et al., 2011 7.7 7.1 -0.6 7.3 7.2 -0.1 -0.5 p=0.009 a 
Ganawar et al., 2014 NDR NDR NDR NDR NDR NDR NDR NDR 
Kraemer et al., 2012 7.28 6.78 -0.5 7.38 7.22 -0.16 -0.34 p=0.0757 a 
Paulo et al., 2016 7.1 6.98 -0.12 7.2 7.61 0.41 -0.53 p= 0.143 a 
Kjeldsen et al., 2015 NDR NDR NDR NDR NDR NDR NDR NDR 
  
                                                          
a
 P-value Independent Sample t-test (to show intervention effect between intervention and control group) 
b Convert  mmol/l to mg/dl by multiple 18 
 NDR  No Data Reported  
IG  Intervention Group 
CG  Control Group  
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Table  2.4: The results for Fasting Plasma Glucose (FPG) in included studies 
FPG (mg/dl) 
Author  IG 
Before 
IG 
After 
Mean 
Change  
CG 
Before 
CG 
After 
Mean 
Change  
Difference in change 
between Groups  
P-valuea 
Ali et al., 2012 158.4b 123.84b -34.56 171.54b 162.72b -8.82 -25.74 p<0.001a 
Jahangard-Rafsanjani et 
al., 2015 
NDR NDR NDR NDR NDR NDR NDR NDR 
Venkatesan et al., 2012 155.58 NDR NDR 150.3 NDR NDR NDR NDR 
Mehuys et al., 2011 154.1 138.8 -15.3 153.9 145.8 -8.1 -7.2 p=0.193a 
Ganawar et al., 2014 NDR NDR NDR NDR NDR NDR NDR NDR 
Kraemer et al., 2012 148.8 128.1 -20.7 137.2 126.8 -10.4 -10.3 p=0.8552a 
Paulo et al., 2016 159.3 147.64 -11.66 157.7 159.8 2.1 -13.76 p=0.125a 
Kjeldsen et al., 2015 NDR NDR NDR NDR NDR NDR NDR NDR 
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Chart  2.2: The changes from baseline and final follow-up in both parameters HbA1c and FPG 
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Table  2.5: The results of Blood pressure among included studies  
Blood Pressure (mmHg) 
Author    IG B IG F Mean 
Change  
CG B CG F Mean 
Change  
Difference in 
change 
between 
Groups  
P-valuea 
Ali et al., 2012 systolic BP 146.26 126.17 -20.09 136.22 139.17 2.95 -23.04 P=0.012a 
Diastolic  87.13 81.04 -6.09 85.65 81.7 -3.95 -2.14 P=0.748a 
Jahangard-Rafsanjani et 
al., 2015 
systolic BP 132 132.8 0.8 136.4 134.2 -2.2 3 P=0.5a 
Diastolic  81.7 82.2 0.5 83.3 82 -1.3 1.8 P=0.5a 
Venkatesan et al., 2012 systolic BP NDR NDR NDR NDR NDR NDR NDR NDR 
Diastolic  NDR NDR NDR NDR NDR NDR NDR NDR 
Mehuys et al., 2011 systolic BP NDR NDR NDR NDR NDR NDR NDR NDR 
Diastolic  NDR NDR NDR NDR NDR NDR NDR NDR 
Ganawar et al., 2014 systolic BP NDR NDR NDR NDR NDR NDR NDR NDR 
Diastolic  NDR NDR NDR NDR NDR NDR NDR NDR 
Kraemer et al., 2012 systolic BP 136.3 132.7 -3.6 129.5 131.8 2.3 -5.9 P=0.9644a 
Diastolic  78.4 80.6 2.2 75.3 79.3 4 -1.8 P=0.6144a 
Paulo et al., 2016 systolic BP 137.7 137.28 -0.42 137 136.74 -0.26 -0.16 P=0.625a 
Diastolic  83 82.56 -0.44 82 81.51 -0.49 0.05 P=0.820a 
Kjeldsen et al., 2015 systolic BP 138 131.3 -6.7 139 137.6 -1.4 -5.3 P=0.033a 
Diastolic  NDR NDR NDR NDR NDR NDR NDR NDR 
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Table  2.6: The results of Lipid Profile among included studies  
Lipid profile 
Author  Lipid  IG B IG F Mean 
Change  
CG B CG F Mean 
Change  
Difference 
in change 
between 
Groups  
P-valueb 
Ali eta., 2012 TC 4.15mmol/la 
160.4 mg/dl 
 
4.12mmol/la 
 
159.3mg/dl 
-0.03 3.66 mmol/la 
141.5mg/dl 
3.14 mmol/la 
121.4mg/dl 
-0.52 0.49 P<0.001 
TG 1.35mmol/la 
119.5 mg/dl 
 
1.52mmol/la 
134.6 mg/dl 
0.17 1.44 mmol/la 
127.5 mg/dl 
 
1.78 mmol/la 
157.6mg/dl 
 
0.34 -0.17 P=0.404 
LDL 2.35 mmol/la 
90.8 mg/dl 
1.97mmol/la 
76.1mg/dl 
 
-0.38 1.81mmol/la 
69.9 mg/dl 
1.25mmol/la 
48.3mg/dl 
-0.56 0.18 P<0.001 
HDL 1.19mmol/la 
46.0 mg/dl 
 
1.46mmol/la 
56.4 mg/dl 
0.27 1.2mmol/la 
46.4 mg/dl 
1.25mmol/la 
48.3mg/dl 
0.05 0.22 P=0.041 
Jahangard-Rafsanjani 
et al., 2015 
TC NDR NDR NDR NDR NDR NDR NDR NDR 
TG NDR NDR NDR NDR NDR NDR NDR NDR 
                                                          
a
 Convert mmol/l to mg/dl in TC (Total Cholesterol, HDL, and LDL multiply mmol/L by 38.67, For triglycerides multiply mmol/L by 88.57.  
b P-value Independent Sample t-test 
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LDL NDR NDR NDR NDR NDR NDR NDR NDR 
HDL NDR NDR NDR NDR NDR NDR NDR NDR 
Venkatesan et al., 
2012 
TC NDR NDR NDR NDR NDR NDR NDR NDR 
TG NDR NDR NDR NDR NDR NDR NDR NDR 
LDL NDR NDR NDR NDR NDR NDR NDR NDR 
HDL NDR NDR NDR NDR NDR NDR NDR NDR 
Mehuys et al., 2011 TC NDR NDR NDR NDR NDR NDR NDR NDR 
TG NDR NDR NDR NDR NDR NDR NDR NDR 
LDL NDR NDR NDR NDR NDR NDR NDR NDR 
HDL NDR NDR NDR NDR NDR NDR NDR NDR 
Ganawar et al., 2014 TC NDR NDR NDR NDR NDR NDR NDR NDR 
TG NDR NDR NDR NDR NDR NDR NDR NDR 
LDL NDR NDR NDR NDR NDR NDR NDR NDR 
HDL NDR NDR NDR NDR NDR NDR NDR NDR 
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Kraemer et al., 2012 TC 177.1 165.4 -11.7 186.4 181.4 -5 -6.7 P=0.1362 
TG 164.6 155.8 -8.8 172.2 166.4 -5.8 -3 P=0.9231 
LDL 99.5 95.6 -3.9 100.7 100.9 0.2 -4.1 P=0.4411 
HDL 46.2 39.9 -6.3 50.7 47.1 -3.6 -2.7 P=0.1594 
Paulo et al., 2016 TC 191.1 181.53 -9.57 209.9 210.3 0.4 -9.97 P=0.187 
TG 186.7 177.87 -8.83 176.1 185.8 9.7 -18.53 P=0.314 
LDL 110.8 102.6 -8.2 131 130.2 -0.8 1.43 P=0.254 
HDL 43 43.63 0.63 43.6 43.86 0.26 0.37 p=0.479 
Kjeldsen et al., 2015 TC NDR NDR NDR NDR NDR NDR NDR NDR 
TG NDR NDR NDR NDR NDR NDR NDR NDR 
LDL NDR NDR NDR NDR NDR NDR NDR NDR 
HDL NDR NDR NDR NDR NDR NDR NDR NDR 
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Table  2.7: Body Mass index among included studies  
BMI (Kg/m2) 
Author IG B IG F Mean 
Change 
CG B CG F Mean Change Difference in change 
between Groups 
P-value 
Ali et al., 2012 30.84 26.98 -3.86 29.82 28.73 -1.09 -2.77 NDR 
Jahangard-Rafsanjani et al., 
2015 
29.3 29.1 -0.2 29.4 29.7 0.3 -0.5 P=0.02 
Venkatesan et al., 2012 25.09 NDR NDR 25.81 NDR NDR NDR NDR 
Mehuys et al., 2011 31 NDR NDR 30.5 NDR NDR NDR NDR 
Ganawar et al., 2014 NDR NDR NDR NDR NDR NDR NDR NDR 
Kraemer et al., 2012 NDR NDR NDR NDR NDR NDR NDR NDR 
Paulo et al., 2016 NDR NDR NDR NDR NDR NDR NDR NDR 
Kjeldsen et al., 2015 NDR NDR NDR NDR NDR NDR NDR NDR 
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2.2. How to improve type II diabetes management? 
Once diagnosed, type II diabetes patients are initially managed by a 
combination of restricted energy intake and an increase in physical activity 
(Keenan, 2010). From this perspective the study focused on two aspects of 
diabetes management: self-management (i.e. how people manage everyday life 
in terms of diet, exercise, feet care, eye care) and medicine management (i.e. 
oral hypoglycaemic adherence). In the long term, diabetes cannot be managed 
by medicine or diet alone, as it is on first diagnosis. Older people have to take 
oral hypoglycaemic tablets to control blood glucose levels, and may progress to 
management with insulin. 
The current study focuses on the improvement of type II diabetes management. 
So, the starting point for review was searching through clinical diabetes 
guidelines, specifically I started by creating a comparison between SIGN 
diabetes guidelines and LDCG. Generally speaking, the reason for comparison 
was to identify any differences or any missing information in the LDCG and fill 
any gaps in diabetes knowledge by using SIGN, which was a more 
comprehensive standard (see Table 2.3). Another reason for using SIGN rather 
than NICE guidelines was that SIGN provided recommendations based on 
current evidence of best practice in the management of diabetes. The grade of 
a recommendation relates to the strength of the evidence on which it is based. 
It does not reflect the clinical importance of the recommendation and also SIGN 
was broader than NICE. The information in both guidelines was similar but 
SIGN determined strength of recommendation according to clinically based 
evidence. The main aim of comparison was to emphasise those aspects of 
diabetes care that should be followed and implemented by health care 
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providers to improve diabetes care and glycaemic control. It was also an aim to 
make sure that there was no difference in the standard of care that was 
recommended to enable design of the intervention study for improvement in 
glycaemic control. 
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Table  2.8: The key difference between Scottish Intercollegiate Guideline Network and Libyan Diabetes Care Guideline  
Source: (SIGN, 2013, NDCGAB, 2010)  
Key differences Scottish Intercollegiate Guideline 
Network SIGN 
Libyan Diabetes Care Guideline 
LDCG 
Clinical recommendation Ranked by using four grades A,B,C,D No rank for recommendation to enable 
health professional to work on 
Based on evidence The rank of recommendation based on the 
strength of supporting evidence 
The evidence not mentioned 
Management of diabetes Divided according to types, classification, 
risk factors and complication of diabetes 
Divided according to diabetes control such 
as glycaemic control and treatment option. 
Lifestyle management Focused on four areas: 
 delivery of lifestyle interventions, 
 structured education, 
 self-monitoring of glycaemic control. 
 specific areas of smoking, obesity, 
physical activity, healthy eating and 
alcohol. 
(more comprehensive) 
 
The focus of lifestyle management on two 
aspects is diet and exercise. 
(less comprehensive) 
Delivery of lifestyle intervention  Intervention based on theoretical 
knowledge model. 
 Using computer assisted education 
package and telephone prompting. 
 Training healthcare professionals 
Not mentioned  
Structured education More precise description  which provides 
structured education to both type I and II 
diabetes for adults, children and adolescents 
Highlighted in a general way and focused 
more on the structure of programme and 
what it should include. 
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Structured education for type II Focused on on principles of adult learning 
(including patient empowerment and 
experiential learning) is associated with 
improved psychological well-being, reduced 
anxiety and overall improvement in quality of 
life in patients with type II diabetes 
Not mentioned 
Physical activity Highly recommended that people with type II 
diabetes should be encouraged to participate 
in physical activity or structured exercise to 
improve glycaemic control and 
cardiovascular risk factor 
Highlights the importance in general. 
 
Performance and duration of exercise  aged 18–64 years should build up to 
achieve a minimum of 2.5 hours each 
week of moderate- intensity 
 vigorous-intensity aerobic physical 
activity intensity75mis each week o 
 150min/week of moderate –intensity. 
 90min/week of vigorous aerobic 
exercise 
Days recommended of exercise 30 mins of activity on at least five days of the 
week. 
At least 3 days/week 
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Self- monitoring of blood glucose (SMBG) in 
people with type II diabetes 
May be considered in the following groups of 
people with type II diabetes who are not 
using insulin: 
 Those at increased risk of hypoglycemia 
 Those experiencing acute illness 
 Those undergoing significant changes in 
pharmacotherapy or fasting, for example, 
during Ramadan 
 Those with unstable or poor glycaemic 
control (HbA1c>8.0% (64 mmol/mol)) 
 Those who are pregnant or planning 
pregnancy. 
 Self-monitoring of urine glucose in people 
with type II diabetes is not recommended 
 People with type II diabetes on insulin 
should be taught how to self-monitor and 
record their blood glucose levels with 
home meters and to adjust their insulin 
doses accordingly 
 For people not on insulin, SMBG may be 
useful in achieving glycaemic goals, 
through support for self-management 
 People should receive initial instruction, 
but also routine follow-up evaluation of 
SMBG techniques and their ability to use 
data to adjust therapy 
 
Smoking cessation  Healthcare professionals should continue to 
monitor smoking status in all patient groups. 
(Similar recommendation) 
Smoking cessation counselling and 
treatment should be offered to smokers. 
Weight management Strongly recommend that obese adults with 
type II diabetes should be offered 
individualised interventions to encourage 
weight loss (including lifestyle, 
pharmacological or surgical interventions) in 
order to improve metabolic control. 
It is not mentioned 
Healthy eating 
 
 
People with type II diabetes can be given 
dietary choices include: 
1. simple caloric restriction 
2. reducing fat intake 
3. Consumption of carbohydrates with low 
rather than high glycaemic index. 
The total food energy and carbohydrate 
intake should be distributed as follows: 
 Carbohydrates>50% (encouraging 
complex unrefined high fibre 
carbohydrate and moderate sucrose 
intake) 
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4. restricting the total amount of dietary 
carbohydrate (a minimum of 50 g per day 
appears safe for up to six months) 
 
 Fats 30-35% (<10% saturated fat, <10% 
polyunsaturated fat & >10% 
monounsaturated fat, with low trans-fatty 
acids). 
 Proteins 10–15% (decreasing with age) 
 Five portion of fruit and vegetable per day 
 
Pharmacological management of glycaemic 
control in people with type II diabetes 
The pharmacological  management of 
glycaemic in SIGN more detailed and the 
strategy of taking Oral Hypoglycaemic 
medicines (OHMs) more comprehensive. 
The recommendations sets in Appendix (6) 
 
The pharmacological management of OHMs 
similar to SIGN guideline but lack of detailed 
strategy and the recommendations not 
included the strategy of therapy (see 
appendix 7) 
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2.2.1. Type II diabetes self-management 
Patients with chronic conditions make day-to-day decisions about self-
managing their illnesses. This reality introduces a new chronic disease 
paradigm: the patient-professional partnership, involving collaborative care and 
self-management education. Diabetes self-management education is defined as 
a collaborative process through which persons living with diabetes gain 
knowledge and skills to modify behaviour and eventually manage themselves 
successfully (American Diabetes Association, 2014). Self-management 
education complements traditional patient education in supporting patients to 
live the best possible quality of life with their chronic condition. Whereas 
traditional patient education offers information and technical skills, self-
management education teaches problem-solving skills. A central concept in 
self-management is self-efficacy, that is, confidence to carry out behaviour 
necessary to reach a desired goal. Self-efficacy is enhanced when patients 
succeed in solving patient identified problems (Bodenheimer et al., 2002). 
Self-care is defined as “a deliberate action that individuals, family members and 
the community should engage in to maintain good health. Ability to perform self-
care varies according to many social determinants and health conditions” 
(WHO, 2009: 1). Self-care regimens include diet modification, adherence to 
medication, regular exercises, foot care and self-monitoring of blood glucose 
(Funnell et al., 2007). The deterioration of glycaemic control after completing 
intensive management may ‘relapse’ because of return to old behaviours 
(Rothman & Elasy, 2005). Patients may know what should be done and be 
motivated to change by the management program, but they may relapse back 
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to their ‘unhealthy’ behaviours if they encounter problems or barriers to 
achieving self-care activities. 
For people with type II diabetes, the impact of trying to make multiple lifestyle 
changes to control their conditions can be substantial, and is one of the major 
barriers to people initiating change. Some people feel they have been told to 
make so many changes in their lives that they cannot manage all of them, so 
feel it is pointless or hopeless and do not do anything. It is important to 
remember that it is not how much the ‘objective’ impact that diabetes has on 
people, but what each person perceives the impact to be. Some people say that 
diabetes has changed their life, but they see the changes in lifestyle in a 
positive way, such as making them feel healthier. As a result they do not 
perceive the impact of lifestyle changes to be so great (Banks, 2005). 
There has been much research on how people’s belief about the long-term 
complications of diabetes relate to how they manage their condition. Many 
health care professionals have worked on the basis that the more severe 
people think the complications are, and the more likely they think they are to get 
these complications, the more proactive individuals will be in managing their 
diabetes. However, this does not always seem to be the case. Although some 
research shows that a greater perceived threat of complications (more serious, 
or more likely to get them) is associated with better self-management, there are 
as many studies that that show no relationship, and even some that show the 
greater perceived threat is associated with poorer self-management (Skinner et 
al., 2005). 
In self-management, a person’s trust in self-efficacy plays a key role in 
implementing the behaviours required to achieve the desired outcomes 
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(Bodenheimer et al., 2002). In guiding the relationship between health 
professionals and patients, empowerment has been recognized as an 
alternative to compliance since; through this approach, patients take 
responsibility for their own choices and for the respective consequences 
(Funnel & Anderson, 2003; Anderson et al., 2005). Several studies have linked 
self-management education to a better understanding of diabetes and improved 
self-care behaviours to reduced levels of HbA1c, weight loss and a better 
quality of life (Norris et al., 2001; Norris et al., 2002; Gary et al., 2003; Ellis et 
al., 2004; Warsi et al., 2004; Heinrich et al.,2010; Steed et al., 2003). Self-
management education guides and helps these patients to take decisions, 
resolve problems, learn self-care behaviours and set up an active collaboration 
with the team of health professionals. This leads to improved clinical outcomes, 
health status and quality of life, optimal cost–benefit ratios, with an approach 
focused on empowerment and patient- and family-centred care (Norris et al., 
2002; Funnell & Anderson, 2003; Lewin et al., 2005; Chen & Li, 2009; Funnell 
et al., 2007). 
One factor not always considered in research studies is how people feel about 
whether or not they can affect their chances of getting complications. If people 
feel they are highly likely to get complications, and they feel it is inevitable no 
matter what they do to manage their diabetes, then it might make sense to them 
not to follow the diet, activity, monitoring and medication recommendations. 
After all, what is the point of doing it all if it will not change things? Trying to 
scare people into following treatment recommendations is often counter-
productive. A more positive approach is to help people to understand their 
diabetes and the possible complications. By encouraging people to think about 
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the options available for preventing these problems, the health care team can 
help people reflect more accurately on their risks. In many cases this alone can 
have a substantial impact on people’s quality of life (Banks, 2005). 
Patients, through support and education about self-management, assume 
charge of the management of their own disease and are encouraged to resolve 
their own problems in partnership with health professionals (Holman and Lorig, 
2000). Patients and health professionals jointly decide about the care to be 
provided (collaborative care). Patients show a higher level of adherence to 
recommendations, thus achieving better outcomes (van Dam et al., 2005; 
Williams et al., 2007; Peyrot & Rubin, 2006; Tang et al., 2010; Duncan et al., 
2011). Internal motivations of the patient are more effective for lifestyle change 
than external motivation (Arnold et al., 1995; Glasgow & Anderson, 1999; 
Anderson & Funnell, 1999).  
Self-management and self-management support (SMS) are central concepts in 
diabetes care (Funnell et al., 2012, Haas et al., 2012). This can be credited to 
recognition of the burden of diabetes (Nicolucci et al., 2013), to the role of 
health behaviours in clinical outcomes (Ford et al., 2009, Li et al., 2008), and to 
the Expanded Chronic Care Model (Coleman et al., 2009, Stellefson et al., 
2013). Despite widespread acceptance, a useful question to ask is how well 
self-management support is being translated into clinical care. Barr et al., 
(2003) stated that self-management support interventions might result in too 
much focus being placed on individual responsibility, creating a judgmental 
environment in which patients are blamed for their circumstances. This 
judgmental context can stem from a fundamental misunderstanding of self-
management support. Unless the context in which self-management 
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interventions are implemented reflects self-management support, potentially 
valuable behavioural-change interventions might be found to be wanting and to 
be abandoned (Vallis, 2015). 
US studies of diabetes self-management in Hispanics have reported low 
income, low education, low acculturation, spoken language and literacy issues, 
different cultural beliefs and values, such as fatalism and machismo, limited 
social support and medical comorbidities as barriers to effective self-
management (Ghaddar et al., 2010, Weiler and Crist, 2009). It has been 
reported by Elkharam et al (2013) that diabetes knowledge in the Libyan 
population is very poor for both types of diabetes, especially among those 
classed as non- educated. Modernization of Arab countries and the rapid 
development in large cities and towns increased urbanization of the population; 
an important difference between urban and rural sectors. In the Arabic-speaking 
countries there is an increased exposure to a more Western lifestyle (Madanat 
et al., 2008). In Saudi Arabia, 25.5% of the urban population is diabetic in 
comparison with 19.5% in rural areas. There are also regional differences in the 
prevalence of type II diabetes, with the Northern (27.9%) and Eastern (26.4%) 
provinces experiencing greater rates than the Southern region (18.2%), where a 
rural lifestyle is more common and the population less prone to obesity than 
those on the Northern and Eastern provinces (Al-Nozha et al., 2004; Al 
Othaimeen et al., 2007).  The ratio of people with type II diabetes in urban and 
rural areas is 235 to 100 in Oman and 400 to 100 in Egypt (Al‐Lawati, et al., 
2002; Herman, 1997). In the US, more Hispanics live in poverty (23.2%) than 
non-Hispanic Whites (8.6%) (DeNavas-Walt et al., 2011) and many more 
Hispanic Americans with diabetes (60%) than non-Hispanic Whites with 
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diabetes (28%) have an annual income below $20,000 (Gary et al., 2003). 
Hispanics with diabetes also have poorer access to care and poorer health 
status (Nwasuruba et al., 2009). Lack of health insurance (Lopez-Class and 
Jurkowski, 2010) and the cost of medications have been identified as barriers to 
diabetes self-management for Mexican-Americans (Benavides-Vaello et al., 
2004, Bailey et al., 2012).  Major contributory factors for type II diabetes 
mellitus, which is most prevalent in Middle Eastern countries, include low 
activity levels, poor diet, and excess body weight (Yahia, 2014). Lack of health 
awareness, health beliefs, attitudes, and lifestyle are all contributing to the rising 
prevalence of obesity and diabetes in the Middle East (Musaiger, 2004). In 
particular, lack of awareness about nutritional information and the significance 
of healthy eating have led to adoption of a poor diet (Al-Kaabi et al., 2008, 
Abahussain and El-Zubier, 2005). Social and economic changes are also 
important. These include changing lifestyles in terms of urbanization and 
changing dietary habits. Increased wealth resulting from oil production leads to 
most people able to own cars as a consequence there is decreased physical 
activity along with rising levels of obesity and smoking (Azab, 2001, WHO, 
2008). 
Another potential barrier is resistance to change on the part of healthcare 
professionals, many of whom have been traditionally trained to deliver care to 
their patients; different skills are needed to effectively support people living with 
long-term conditions such as diabetes. Although healthcare professionals may 
see value in helping people to self-manage, it can cause conflict between 
people with diabetes who want to do things for themselves and healthcare 
professionals who feel they are responsible for these things, or in some cases 
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do not agree with them. Part of the process of supporting self-management 
involves healthcare professionals increasing their own skills and confidence in 
understanding what self-management means, so they can learn to support 
people with diabetes more effectively (Diabetes UK, 2009) 
Barrier identification is critical in minimizing adverse effects on adherence to 
self-management programmes (Sprague et al. 1999). Self-management 
programmes are complex, require time and involve all aspects of a person’s life. 
Patient adherence is not only affected by barriers, but also by people’s lifestyle 
and confidence in their ability to implement a self-management plan 
(Whittemore et al. 2005).  Each day patients make multiple decisions about 
managing their diabetes based on their knowledge, beliefs, attitudes, resources 
and support systems. Healthcare providers who are sensitive to the barriers 
experienced by patients and the effective strategies they use can work 
collaboratively to facilitate the development of realistic self-management 
programmes. Underestimating or not identifying barriers to self-management 
adversely affects adherence (Aljasem et al. 2001).  
Suboptimal adherence, once viewed as a patient problem, is now seen as an 
indication of patients’ self-management of chronic disease within the interactive 
framework of providers, healthcare systems, families and communities (Walker 
and Usher, 2003). Within this framework, the dynamic interaction of patient, 
healthcare providers and systemic factors can influence the overall 
management of diabetes (Brown et al., 2002). The care of patients with 
diabetes has largely encompassed new and more efficacious diabetic 
treatments and improved medication delivery systems (American Diabetes 
Association,  2003), but literature highlights the importance of integrating self-
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management education (Brown et al., 2002; Norris et al., 2002; Po, 2000). To 
adequately address barriers to diabetes self-management and identify 
strategies to overcome them, it is important to examine whether there are 
additional barriers that still exist (Onwudiwe et al., 2011).  
2.2.1.1. Diabetes Self-care behaviour 
Evidence from earlier studies supports the notion that having good knowledge 
and education influences good care and can reduce diabetes complications 
significantly (Al-Qazaz et al., 2011). Knowledge not only enhances the self-care 
behaviours (Aschner et al., 2012), but it enables DM patients to adhere to their 
treatment effectively. It has also been noted that age, lack of resources and 
perceived side effects have significant association with poor adherence to 
medication (Wabe et al., 2011). 
Knowledge, self-care behaviours and adherence to medications in diabetes 
could be helpful for early case detection, prevention, and minimization of 
complications, and improvements of the quality of life of affected individuals. 
Previous studies have reported poor health outcomes to be associated within 
insufficient knowledge, poor self-care behaviours and adherence to medications 
among diabetic patients (Islam et al., 2015, Feleke et al., 2013, Al-Maskari et 
al., 2011).  
Recent work on the social determinants of health found that diabetes outcomes 
are influenced by factors such as level of education, economic conditions, and 
social support with specific factors being found to have a direct relationship with 
diabetes self-care behaviours (Walker et al., 2014a, Walker et al., 2014b). As 
such, the need for tailored interventions and treatment plans that target 
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individual, social, and behavioural factors associated with diabetes care are 
being given greater attention (Schulz et al., 2005, Ludwig et al., 2011). 
However, better understanding of the underlying mechanisms that increase risk 
of poor diabetes outcomes, outside of traditional demographic factors, may lend 
to greater methods of prevention and development of treatment interventions 
(Campbell et al., 2017). 
Self-care behaviours are an integral aspect of comprehensive care for patients 
with type II diabetes, including exercise, diet, blood sugar testing, foot care, and 
adherence to oral medications (American Diabetes Association, 2014, Centers 
for Disease Control and Prevention, 2011). As diabetes self-management 
education (DSME) is a critical element for improving self-care, clinicians and 
researchers continue to investigate how to enhance current efforts. (American 
Diabetes Association, 2014, Funnel et al., 2012, Marrero et al., 2013). Current 
standards note that there is no one ‘best’ approach, and recommend 
consideration of behavioural and psychosocial strategies and development of 
personal strategies (Funnel et al., 2012, Delamater et al., 2001, Ismail-Beigi et 
al., 2011).  One overarching framework to use in considering how to develop 
individualized strategies is consideration of how social determinants of health 
may influence whether patients engage in self-care behaviours. Social 
determinants of health are the circumstances in which people are born, live, 
work, and age (Department of Health and Human Services, 2014).  This 
includes socioeconomic circumstances, neighbourhood environments, 
psychosocial factors, and upstream political, economic and sociocultural drivers 
(Marmot, 2010). Current evidence suggests that social determinants of health 
influence diabetes prevalence and outcomes (Marmot, 2010, Walker et al., 
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2014). Consideration of social determinants known to influence DSME may 
assist in understanding how to personalize DSME efforts and improve self-care 
(Walker et al., 2015). 
2.2.2. Lifestyle intervention toward type II diabetes  
Combined lifestyle interventions (CLIs) in primary care, including dietary advice 
and physical activity, have been advocated as an effective instrument in efforts 
to reduce the growing problem of overweight and obesity (Tuomilehto et al., 
2001; Brown et al., 2009). Enhanced levels of physical activity and a healthier 
diet maintained over a longer period of time have shown to be associated with 
better health outcomes for obese individuals (Brown et al., 2009; Ho et al., 
2012). However, low enrolment rates, high dropout rates and incomplete 
implementation have limited the effectiveness of CLIs in real life situations 
(Reinehr et al., 2009; Linmans et al., 2011). In contrast to reaching immediate, 
short-term changes (Wang et al., 2008, Unick et al., 2011), it has proved difficult 
to achieve sustained behaviour change, which is required to prevent weight 
regain and chronic diseases such as type II diabetes or cardiovascular diseases 
among obese individuals (Wing et al., 1998; Wu et al., 2009). 
Research has demonstrated that the probability of maintaining higher levels of 
physical activity and healthier dietary behaviour improve when people are more 
intrinsically motivated to change their behaviour (Silva et al., 2011; Teixeira et 
al., 2012).  In a recent review on motivation and self-regulation in relation to 
weight reduction (Teixeir et al., 2012), the authors indicated that interventions 
may so far have focused too much on influencing cognitions and skills, but 
ignored the importance of perceived autonomy in the process of adopting new 
behaviours (Teixeir et al., 2012). 
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Intrinsic motivation is the most pronounced type of autonomous motivation 
described in Self-Determination Theory (SDT) (Deci & Ryan, 1990; Ryan & 
Deci, 2000). This theory distinguishes 3 types of motivation: amotivation, 
extrinsic motivation and intrinsic motivation. Extrinsic motivation is sub-divided 
into four types of motivational regulation: two controlled types, external and 
introjected regulation; and two autonomous types, identified and integrated 
regulation. The theory indicates that the quality of the motivation to engage in 
certain behaviour can shift from motivation and/or more controlled types of 
motivational regulation towards the autonomous types of regulation and 
towards the ultimate form of autonomous motivation, intrinsic motivation. To 
reach this shift, SDT indicates that there are three basic needs (autonomy, 
competence and relatedness) that should be supported. If individuals 
experience an insufficient level of one of these needs it hampers the shift 
towards autonomous motivation.  
To promote the shift in motivation towards the more autonomous types, 
facilitator-led CLIs have been developed. An example is the Dutch BeweegKuur 
(exercise therapy) intervention, which, in addition to physical activity support 
and dietary advice, includes lifestyle coaching by means of motivational 
interviewing (Helmink et al., 2010; Berendsen et al., 2011). Through the 
combination of these three components the intervention touches on the need 
for autonomy by means of lifestyle coaching, on competence by means of 
lifestyle coaching and physical activity and dietary behaviour guidance and on 
relatedness by means of group sessions. By the inclusion of autonomy 
supportive lifestyle coaching (LSC), the intervention intends to produce 
sustainable changes in energy balance related behaviours. The objective of the 
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intervention is to enhance overweight or obese participants’ levels of physical 
activity and improve their dietary behaviour. The BeweegKuur intervention 
distinguishes 3 programmes that all include 7 lifestyle coaching sessions and 2 
individual and 5 group sessions with a dietician. The programmes differ in the 
extent and intensity of physical activity support. The independent exercise 
programme includes no physical activity support by a physical therapist (PT). 
While the Start-up programme includes six PT sessions in three to four months 
and the supervised exercise programme includes 3–4 months of intensive PT-
guided training at least twice a week. Individuals are assigned to the 
programmes on the basis of their weight-related health risk, which is based on 
their Body Mass Index BMI, their waist circumference and the presence of risk 
factors for type II diabetes or cardiovascular disease, or of comorbidities. A low 
or moderate level of physical activity is also an inclusion criterion for the 
BeweegKuur intervention. The LSC carries out the primary assessment and 
includes people in the intervention. LSCs involved in the BeweegKuur 
intervention, which in most cases are general practitioner assistants and 
sometimes physical therapists, are trained in motivational interviewing (MI), a 
method for autonomy-supportive coaching (Rutten et al., 2014).  
2.3. Pharmacy practice in developing countries 
As pharmacists from around the world communicate, in developed and 
developing countries, they find that there are many practice similarities, areas of 
focus include: 
 Assuring effective delivery of medications to patients 
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 Assisting health care providers and patients to become more 
knowledgeable about medications 
 Promoting medication adherence  
 Assuring the quality of medicines 
 Assuring access to medications under conditions of inadequate financial 
resources 
The culture and traditions in different countries can determine the place of 
pharmacists in society and the reliance that health care consumers place on 
pharmacists, who are the most accessible health care professional and have 
great opportunity to recommend and implement wellness and treatment 
strategies. What pharmacists can contribute to health care is determined by the 
nature of their training and the legal authority within their country. However, in 
many countries the number of pharmacists not sufficient to provide the type of 
care that is needed. Knowing how care by pharmacists is provided in different 
countries will assist all pharmacists in identifying the best practices and striving 
to use them in their own country. While pharmacy practice varies considerably 
among countries, there is a consistent and growing interest in progressive 
pharmacy practice that goes by different terms, such as clinical pharmacy or 
pharmaceutical care. It is patient-focused practice where the pharmacist has a 
responsibility to the patient (Fatherlrahman, et al., 2016). 
An important factor that will surely advance practice in all countries is the quality 
of pharmacy education, both for students entering the profession and for 
practitioners advancing their knowledge. Pharmacy education is becoming 
more standardized at a higher level than in the past. As education improves, so 
will practice progress in pharmacy education and practice is coming from many 
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different countries throughout the world. All countries have something to learn 
from what others are doing to improve practice (Fatherlrahman, et al., 2016). 
The pharmaceutical sector and its overall conditions in developing countries are 
under researched. There is a scarcity of studies and information on 
pharmaceutical health services systems (Fatherlrahman, et al., 2016). In many 
parts of the world, pharmacists have played a significant role in the provision of 
pharmaceutical care services. The dilemma of pharmacy education and 
practice in developing countries are that pharmacy colleges in developing 
countries strives to produce a qualified pharmacy graduate prepared with 
essential knowledge, skills, competencies, and the positive attitude required for 
practice. As a result students are overloaded with heavy subjects, such as 
analytical and organic chemistry, pharmacognosy, pharmaceutics, and other 
courses taught by didactic or practical methods (Fatherlrahman, et al., 2016). 
However, pharmacy graduates in many developing countries are the only 
graduates among other professions who do not actually apply what they have 
been taught in colleges. The International Pharmaceutical Federation (IPF), in 
its policy document on good pharmacy education practice, recommended that 
basic first degree education programmes should provide pharmacy students 
and graduates with a sound and balanced grounding in the natural 
pharmaceutical and health care services that provide the essential foundation 
for pharmacy practice in a multi-professional health care delivery environment. 
According to Waterfield (2010) it is important for the colleges to have a 
comprehensive curriculum on pharmaceutical sciences and practice-related 
courses and for educators to prepare the future knowledge-based pharmacists.  
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Waterfield (2010: 3) stated that “the use of tacit skill and knowledge by 
pharmacists is well documented through terms such as reflective practice” 
when coming to practice pharmacy graduates discover that very small 
proportions of that overwhelming knowledge and skills that they have been 
given are actually needed for practice as pharmacists. On the other hand, in 
many developing countries and in many situations pharmacists jobs are 
occupied by non-pharmacists such as traditional practitioners, drug sellers, 
pharmacy assistants in community pharmacy, veterinary doctors, and non-
health related individuals in the field of marketing and promotion of 
pharmaceutical products, and chemists and chemical engineers in the 
pharmaceutical industry (both as production managers and as quality control 
analysis) (Fatherlrahman, et al., 2016). The author stated that they are not 
holding a discrimination philosophy against those professions. However, there 
is a great concern for the possibility of a substantial mismatch between the 
practice of pharmacists and the pharmacy education provided to them. 
Basically, if pharmacy education and practice matched each other properly, for 
example the right knowledge and skills provided to practice, there would be no 
room for others to complete with pharmacists. Those competitors practice in a 
manner similar to how pharmacists are supposed to practice and with 
qualifications unrelated to those normally received by pharmacy graduates.  
2.3.1. Information regarding pharmacy and medicine schools in 
Libya  
The purpose of highlighting some higher education infrastructure in Libya is to 
provide the reader with the picture of the quality of education given to health 
care workers in Libya. There are two universities, Garyounis (now called 
Benghazi University) in Benghazi and El Fateh (now called Tripoli University) in 
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Tripoli. The first medical students graduated from Garyounis in January, 1977, 
and from El Fateh in January, 1980. Most of the medical students are Libyan; 
the number of women admitted to the medical school has risen steadily to 
almost one-third of the total students. The training the medical students 
received was at first almost entirely from foreign academics. The language of 
medical instruction is English. It was natural therefore, that many of the 
lecturers themselves should have received their training under a British-based 
system (Lancet, 1982). 
All medical care and services are free. Almost all private practice has been 
abolished (Lancet, 1982). The health service is administered jointly by 
committees of the Ministry of Health and the faculties of medicine of the 
universities. Policy decisions are determined by committees on which all groups 
of workers within the health service are represented. The hospitals and health 
centres were initially staffed by doctors from abroad. They are drawn mainly 
from India, Pakistan, Egypt, and Eastern Europe. Gradually, however, Libyan 
graduates are taking over from these foreign doctors. 
At that time the universities extended to postgraduate teaching and persist till 
now. They have in some departments made formal arrangements with 
institutions abroad, such as the Liverpool School of Tropical Medicine, in 
specified areas of training for doctors, senior technicians, and nurses. At 
present Libya sends many Libyan doctors abroad on scholarships to train as 
specialists. In 1982 the Libyan population was only 3 million (Lancet, 1982). 
The first college of pharmacy was established in Tripoli University (previously El 
Fateh) in 1975, offering a bachelor’s degree in pharmacy as well as a master’s 
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degree in pharmaceutical sciences (Lancet, 1982). Admission to pharmacy 
faculty is based upon secondary school performance; there is a pre-requisite of 
a one year course followed by four years in pharmacy school. However, there 
are no Pharm D programmes. Opportunities for graduates to work are similar to 
other countries where the vast majority of pharmacists work in the private 
sector, typically as community pharmacists, whereas institutional and 
pharmaceutical industry positions are very limited. While community 
pharmacies are readily accessible to the public, the poor image of pharmacists 
in this country prevents them from being fully utilized in health care facilities. 
Until very recently, graduates did not have to pass any qualification exam to get 
the practice license or to complete their registration within the Libyan Society of 
Pharmaceutical Sciences. However, this is no longer true as pharmacy leaders 
and stakeholders have already started to establish their new reforms agenda 
(Abduelkarem, 2014). 
2.3.2. Pharmaceutical services  
With a strategic location in the heart of the community, extended opening hours 
and no appointment required for seeking healthcare advice, community 
pharmacy has great potential as a setting in public health. Moreover, pharmacy 
in the region has often become patients’ first point of healthcare contact 
(Chalker et al. 2005, Ngorsuraches et al. 2008, Chua et al. 2013). These 
benefits provide a platform for more proactive involvement of community  
Pharmaceutical services are expanding in some parts of developing countries. 
As elsewhere, community pharmacy practice in South-East Asia has evolved in 
response to the changing healthcare environment. Significantly, provision of a 
range of healthcare services beyond traditional dispensing has been trialled in 
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community pharmacies across the region. Although relatively new, such 
services include blood pressure monitoring, chronic disease screening, smoking 
cessation and weight management programmes (Nimpitakpong et al. 2010, 
Dhippayom et al. 2013, Chua et al. 2013, Phimarn et al. 2013). However, there 
is a dearth of evidence on the extent of implementation of these services in 
everyday practice and their impact on public health 
The impact of pharmaceutical services on patient outcomes has been reviewed 
by Singhal et al. (1999). They searched MEDLINE (1966–December 1998) and 
International Pharmaceutical Abstracts (1970–December 1998). They found 21 
out of 95 selected studies met their criteria to: be in community pharmacy and 
ambulatory care settings; have randomized, controlled designs; with major 
tasks performed by pharmacists; and measuring economic, clinical, and 
humanistic outcomes (ECHO). Few studies employed adequate research 
designs to control threats to internal and external validity. No study measured 
all three types of economic, clinical and humanistic outcomes (ECHO). They 
recommended that in order to obtain a comprehensive and accurate picture of 
the impact of pharmaceutical services on patient outcomes, an attempt must be 
made to measure all three (ECHO) variables while employing adequate 
research design.  
The Ashville project was designed to assess short-term clinical, economic, and 
humanistic outcomes of pharmaceutical care services (PCS) for patients with 
diabetes in community pharmacies. A clear temporal relationship was found 
between PCS and improved HbA1C, improved patient satisfaction with 
pharmacy services, and decreased all-diagnosis costs. Findings from Ashville 
project demonstrates that pharmacists provided effective cognitive services and 
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disprove the idea that pharmacists must be certified diabetes educators to help 
patients with diabetes to improve clinical outcomes (Cranor and Christensen, 
2003).  
2.3.3. The accessibility of community pharmacist 
Community pharmacists are the most accessible health care professional 
(Centres for Disease Control and Prevention, 2012, Food and Drug 
Administration, 2011). According to Gamble (2011) pharmacists are among one 
of the most trusted groups of professionals in the United States. According to 
Simone (2013) “Nearly all Americans live within five miles of a community 
pharmacy. As the face of neighbourhood healthcare, pharmacists are better 
serving patients through accessible, convenient and personalized health care in 
partnership with other healthcare providers.” 
In the UK, there are 438 million visits to community pharmacy a year for health 
related reasons. There are over 11,500 community pharmacies in England 
providing NHS services. Community pharmacies are highly accessible, located 
in the heart of communities where people live; work and shop in the areas of 
highest deprivation almost 100% of households live within walking distance of a 
pharmacy. 96% of the population can get to a pharmacy within 20 minutes by 
walking or using public transport. Adults in England visit a pharmacy on 
average 16 times a year. Many pharmacies are open for extended hours in the 
evenings and weekends and nearly 900 of them are open for 100 hours a week. 
Pharmacists train for five years, are experts in medicines and can be consulted 
without an appointment (NHS, 2015).  In New Zealand there are 0.22 
pharmacies per 1000 people, while in European countries numbers per 1000 
people vary from around 0.05 in Denmark to 0.78 in Greece (Kanavos et al., 
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2011). In countries with areas of low population density (e.g., New Zealand, 
Australia, Norway, Finland and Canada) access to pharmacies in rural and 
remote areas can be problematic (Law et al., 2011; Norris, 1997; Sunderland et 
al., 2006). 
2.3.4. Pharmaceutical Care  
Pharmaceutical care (PC) in developing countries is still a work in progress 
because the healthcare and educations systems work differently, for instance in 
Jordan the undergraduate pharmacy education (BSc) has little focus on 
pharmaceutical care skills and therapeutics. This contributes to the situation 
where the principal responsibilities of the pharmacist in Jordan are dispensing 
and marketing (Al-Wazaify and Albsoul-Younes, 2005). 
In Qatar, around 800 pharmacists are working in different pharmacy practice 
settings including hospitals, community pharmacies and clinics. Around 55% 
are male pharmacists, and more than 70% obtained their highest pharmacy 
degree from one of four countries: Egypt, Jordan, India, and Sudan (El Hajj et 
al., 2011, Supreme Council of Health, 2013). El Hajj et al. (2014) stated that 
pharmaceutical care in Qatar does still not exist. However, Qatar pharmacy 
students had positive attitudes toward PC. But they mentioned there are 
barriers to practicing it such as lack of access to patient information, inadequate 
drug information sources, and time constraints. If there is no pharmaceutical 
care how can pharmacists have a positive attitude towards it? It may be that 
students know about the components of pharmaceutical care from their 
educational modules but not practice in the real world. 
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Several studies have discussed the practice of community pharmacy in the 
UAE and have shown that most community pharmacists only counsel patients. 
However, UAE has taken initiatives to allow and prepare community 
pharmacists to practice ‘extended’ roles (Sadek et al., 2015). 
While in Libya students study four-years plus one year foundation and the 
programme consists of mixed education: theoretical and laboratory work, three 
sessions of 8-10 week summer training in the fields of community pharmacy, 
hospital pharmacy, clinical pharmacy, and pharmaceutical technology 
conducted at the end of the first, second, and third years of the four-year 
program (Abrika et al., 2012). No study reveals that the concepts of 
pharmaceutical care are taught at undergraduate level unless there are some 
initiatives to introduce social pharmacy in the programme of undergraduate 
studies in Libya (Abrika et al., 2012). I remember when I was studying an 
undergraduate pharmacy practice module we got some educational materials 
that focused on what patient centred care means. Patient-centred care, defined 
as respecting and responding to the needs and preferences of patients, 
empowering them to make decisions that best fit their individual needs, has 
been identified by the Institute of Medicine as an essential element of high-
quality care (Institute of Medicine Committee on Quality of Health Care, 2001). 
Patient-centred care is a quality of personal, professional, and organizational 
relationships. Thus, efforts to promote patient-centred care should consider 
patient-centeredness of patients (and their families), clinicians, and health 
systems (Epstein and Street, 2007, Epstein et al., 2010). Helping patients to be 
more active in consultations changes centuries of physician-dominated 
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dialogues to those that engage patients as active participants (Epstein and 
Street, 2011).  
2.3.5. The Impact of pharmacist on diabetes care  
Most studies confirmed that pharmacists can improve glycaemic control for type 
II diabetes patients compared with usual care (Aguiar et al., 2016, Collins et al., 
2011, Hassali et al., 2015, Omran et al., 2012, Pousinho et al., 2016, Sapkota 
et al., 2015). Pharmacists have expanded their services further than drug 
dispensing, and they often participate directly in the management of patients 
with the delivery of clinical services (Campbell, 2002). Pharmacists are 
especially alert to certain aspects of care, such as the occurrence of adverse 
drug reactions and interactions, and specific features associated with aging and 
comorbidities (Pousinho et al., 2016). Because of the complex nature of 
diabetes, and as recommended by the American Diabetes Association, a 
collaborative and integrated team approach should be sought for its 
management, in which the patient must play an active role along with a 
multidisciplinary health care team (American Diabetes Association, 2015). In 
this context, pharmacists can also contribute positively to diabetes management 
by providing pharmaceutical care programs, which involve working closely with 
the patient and other health care professionals in designing, implementing, and 
monitoring therapeutic plans to achieve specific outcomes that will improve 
patient quality of life (Hepler and Strand, 1990). 
The studies were principally conducted in outpatient clinics where pharmacists 
commonly worked collaboratively with the medical staff and discussed face-to-
face on drug therapy problems (Aguiar et al., 2016). According to Van et al. 
(2012), the level of trust and cooperation of the physicians seems to be higher 
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in this setting compared with a community pharmacy, where contacts are 
usually not personal and occur at a distance. Despite the trend towards greater 
reduction in HbA1c levels in a non-community pharmacy setting, trials vary 
widely in relation to pharmacist health interventions and population 
characteristics, generating results based on substantial statistical heterogeneity 
(Aguiar et al., 2016). Among the key components of pharmacist interventions, 
the level of pharmacist-patient interaction presented great variability across 
studies. This finding may reflect the need to develop clinical pharmacy services 
adapted to the context reality, but also the uncertainty about which of the 
options could be more effective. Although increasing evidence indicates that 
telephone interventions are effective for glycaemic control in patients with 
diabetes (Liang et al., 2011). However, meta-analysis found no difference in 
effect compared with studies that performed face-to face contact only (Aguiar et 
al., 2016). Furthermore, the duration of pharmacist intervention was not 
associated with change in HbA1c levels, contrary to a recent systematic review 
on patient activation interventions that showed the greatest improvements in 
HbA1c levels with longer study duration (Bolen et al., 2014). 
There has been a growing body of literature assessing the effectiveness of 
pharmacist involvement in the management of type II diabetes in various 
settings. The number of systematic reviews has been published on this topic, 
and some of them evaluated pharmacist interventions in patients with type II 
diabetes relatively small (Aguiar et al., 2016, Antoine et al., 2014, Collins et al., 
2011, Omran et al., 2012, Pimouguet et al., 2011, Pousinho et al., 2016). One 
narrative review assessed seven evidence based factors from diabetes 
guideline: glycaemic, cholesterol and blood pressure control; medication, 
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lifestyle, education, and cardiovascular risk factors. The findings concluded that 
even though pharmacists’ contribution towards improving clinical outcomes of 
diabetes patients was well documented; the methods used to deliver structured, 
consistent evidence-based care were not clearly stipulated. Therefore, 
approaches to achieving long term continuity of care are uncertain.   
2.4. Patient diabetes health literacy 
This thesis focuses on type II diabetes knowledge, attitudes and self-care 
behaviour. Therefore, this section is essential to review the diabetes heath 
literacy among type II patients with diabetes. Literacy has been defined as “an 
individual’s ability to read, write, speak, and compute and solve problems at 
levels of proficiency necessary to function on the job and in society, to achieve 
one’s goals, and develop one’s knowledge and potential”  (Ad Hoc Committee 
on Health Literacy for the Council on Scientific and American Medical 
Association, 1999: 552). Health literacy is defined as “a constellation of skills, 
including ability to perform basic reading and numerical tasks required to 
function in the health care environment (Ad Hoc Committee on Health Literacy 
for the Council on Scientific, Affairs American Medical, Association, 1999: 553) 
Patients with low literacy may have trouble in reading prescriptions, following 
medical instructions, and interacting with the health care system. They also 
have lower disease specific knowledge, report lower quality of life, and have 
poorer health related outcomes – even after adjusting for potential confounders 
such as educational level, insurance, and other factors (Ad Hoc Committee on 
Health Literacy for the Council on Scientific Affairs and American Medical 
Association, 1999, Rothman et al., 2003). Numeracy, as an important 
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component of literacy, can be defined as the ability to understand and use 
numbers in daily life (Rothman et al., 2006). Numeracy is particularly important 
to patients with diabetes because diabetes requires self-management skills that 
rely on mathematics such as counting carbohydrates, interpreting glucose 
monitoring, applying a sliding scale for insulin, and calculating insulin doses 
based on carbohydrate intake. These skills require not only basic maths skills, 
but also the ability to apply those maths skills in the context of diabetes care 
(Xu et al., 2014). 
Low literacy is common among patients with diabetes, and appears closely 
associated with less knowledge of diabetes self-management and worse clinical 
outcomes (Rothman et al., 2004, Rothman et al., 2003, Schillinger et al., 2002, 
Williams et al., 1998). Williams et al. (1998) found that 55% of diabetes patients 
in the United States had inadequate literacy. It was reported that, of patients 
with inadequate literacy, 50% did not know the symptoms of hypoglycaemia, 
62% did not know how to treat hypoglycaemia, and 42% did not know the 
normal blood glucose range despite the fact that 73% of the patients had 
attended previous diabetes education. Among over 400 patients with diabetes, 
Schillinger et al. (2002) observed an independent association of poor literacy 
with worse glycaemic control and higher rates of retinopathy. Most of the 
studies, to date; on the role of literacy in health care have focused specifically 
on verbal literacy with little examination of quantitative skills (Xu et al., 2014). 
While there is a strong correlation between verbal literacy and quantitative 
skills, there are many patients who have adequate verbal literacy but are still 
unable to use math skills appropriately or are anxious/ intimidated about math 
(Cavanaugh et al., 2008). Recent studies have demonstrated that providing low 
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literacy materials or low literacy forms of communication can improve patient 
comprehension for patients with both low and high literacy (Dewalt et al., 2004, 
Pignone et al., 2005). A randomized controlled trial (RCT) of a comprehensive 
disease management intervention demonstrated that literacy was a significant 
factor in predicting patients’ improvement in HbA1c from the intervention, and 
suggested that addressing literacy could improve patient outcomes (Rothman et 
al., 2004). Two coordinated RCTs performed at two academic medical centres 
of the United States from 2006 to 2008 rigorously examined the role of 
addressing both literacy and numeracy, and found that the literacy and 
numeracy-sensitive diabetes care can lead to significant improvements in 
glycaemic control, self-efficacy, and other outcomes (Cavanaugh et al., 2009). 
A survey conducted in older diabetes patients in Beijing showed that diabetes 
knowledge was very limited in this population (Hu et al., 2013). In a study 
conducted in Hong Kong, a negative correlation was observed between literacy 
and glycaemic control among patients with diabetes (Tang et al., 2008) 
Addressing literacy and numeracy through improved healthcare provider 
communication skills and improved educational materials is a potentially 
successful strategy. It is an innovative approach to optimize patient 
understanding, promote shared decision-making, and enhance patient self-
efficacy and self-management behaviours (Xu et al., 2014). 
Proper diabetes self-care requires patients to have considerable knowledge, a 
range of skills, and to sustain multiple health behaviours (Funnell et al., 2009, 
Bodenheimer et al., 2002). Not surprisingly, limited literacy has been linked to 
inadequate treatment knowledge, poorer self-care and glycaemic control (Wolf 
et al., 2005, Sarkar et al., 2010). Interventions that have been designed for use 
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among individuals with lower literacy skills are needed; some approaches have 
been developed and evaluated, with promising results (Rothman et al., 2004, 
Kandula et al., 2009). Yet, questions remain on how best to implement these 
interventions in the most effective, efficient, and sustainable manner. This is 
critical for patients receiving primary care in community health centres that have 
limited resources and disproportionately care for patients with limited literacy 
(Paasche‐Orlow et al., 2005). 
A national team, led by the American College of Physicians Foundation, 
developed a patient-centred, low literacy intervention promoting diabetes self-
care (Seligman et al., 2007, DeWalt et al., 2009). It includes: 
 Diabetes Guide that uses plain language and descriptive photographs to 
teach core diabetes concepts and empower patients to initiate behaviour 
change; 
 Brief counselling strategy to assist patients in developing short term, 
explicit and attainable goals for behaviour change (‘action plans’);  
 Training module for healthcare providers (physicians, nurses, medical 
assistants) that using the Diabetes Guide as a teaching tool; and  
  Electronic tracking and monitoring tools for primary care practices.  
A prior efficacy trial found that the Diabetes Guide improved patient knowledge, 
self-efficacy, intent to adopt recommended behaviours, and reduced diabetes 
related distress (Wallace et al., 2009, DeWalt et al., 2009). 
A study conducted by Wolf et al. (2014) in Missouri in US to compare two 
implementation approaches for a health literacy diabetes intervention designed 
for community health centres. One of approaches called a ‘carve-in’ strategy 
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composed of medical directors, physicians, nurses, and medical assistants at 
clinics assigned to receive an extensive orientation to the Diabetes Guide. 
Other approach titled ‘carve-out’ strategy consists of clinic staff briefly oriented 
to the purpose of the trial. They were asked to distribute the Diabetes Guide to 
eligible patients, briefly review it and then refer them to a diabetes educator who 
would contact them by telephone. Both approaches had tracking systems to 
follow up patients via telephone at 2 weeks and 2 months, and via telephone or 
in-person at 3, 6, and 9 months. The difference was that ‘carve in’ counselling 
of patients was provided by clinic staff and ‘carve out’ counselling was provided 
by a diabetes educator. The study found that the carve-out model was a more 
reliable approach for contacting patients over time to initiate action plans 
compared to the carve-in arm. This was backed by patients’ own recall of 
activities, and their greater satisfaction with and desire to continue to receive 
services in the carve-out arm. The study seems to show that a diabetes 
educator engaged with patients in delivering counselling more than clinic staff. 
Although health literacy is a complex and multifaceted construct, researchers 
have developed instruments that assess literacy skills using health-context 
materials. Two such literacy assessments are widely used. One is the Test of 
Functional Health Literacy in Adults (TOFHLA), (Lopez-Class and Jurkowski, 
2010, Baker et al., 1999) which is the instrument most often used for literacy 
assessment in health care research. The TOFHLA is available in English and 
Spanish and has good psychometric characteristics, but the length of time 
required for administration of the TOFHLA (18 to 22 minutes for the full version 
and 7 to10 minutes for a short version) precludes its use in busy primary care 
settings. The second test, the Rapid Estimate of Adult Literacy in Medicine 
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(REALM), can be administered quickly (less than 3 minutes) but it, too, has 
limitations. In particular, the REALM is only available in English (Gottfredson, 
1997, Baker et al., 1999). The Newest Vital Sign (NVS) is the most recent 
instrument developed to measure health literacy (Weiss et al., 2005). The 
Newest Vital Sign (NVS) is a 6-item literacy assessment structured around the 
activity of reading and demonstrating an understanding of information included 
on a nutrition label. The NVS is brief and available in both English and Spanish. 
Information on the validity of the NVS is limited to a single study that compared 
the NVS against the full-length TOFHLA (Osborn et al., 2007). The NVS uses 
the nutrition label from an ice cream container to answer six questions which 
focus on participants’ mathematical abilities (Weiss et al., 2005). The NVS is a 
functional health literacy test that is used to measure participants’ 
comprehension of health information and whether or not they can perform the 
tasks they have been given (Moore, 2012). It also assesses participants’ 
document and quantitative literacy (Morrison et al., 2014).  
 
Physical activity, improved diet and weight loss all lead to improvements in 
these risk factors. Engaging people with type II diabetes in active self-
management of their condition is challenging (Norris et al., 2002). Previous 
failure to control weight is an important factor for some in the development of 
the condition. Taking regular medication is also a challenge that presents 
difficulties. Many people with diabetes need to take nine or ten tablets a day, 
often on two or three occasions. Concerns about harms arising from 
educational materials may cause problems for some; others encounter difficulty 
in remembering to take their medication (Horne et al., 1999). Further developing 
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interventions to support patients in dealing with these challenges and engage 
better with self-management and self-care may lead to more effective care. 
Leventhal's Common Sense Model (CSM) (Leventhal et al., 1997) has been 
used extensively to study these self-management behaviours in people with 
diabetes (Hampson, 1997). It has also informed the design of numerous self-
management interventions for people with diabetes (Mc Sharry et al., 2011). 
The CSM proposes that how people cope with their illness crucially depends 
upon their beliefs about the illness, specifically their beliefs about its cause, 
identity (symptoms and the label attached to those symptoms), timeline, 
consequences, and how the illness can be controlled and cured. The CSM has 
now been used in hundreds of published studies, usually to examine the impact 
of illness beliefs on coping procedures (Cameron and Moss-Morris, 2004). A 
major category of coping procedures consists of lifestyle behaviours such as 
smoking, physical activity and diet (Hagger and Orbell, 2003). 
However, despite its extensive use, the extent of prediction of lifestyle 
behaviour by beliefs about illness is typically small. The most systematic 
evidence comes from a meta-analysis which examined the capacity of the CSM 
to predict a variety of coping outcomes, including a behavioural category: 
“problem focussed coping specific” (Hagger and Orbell, 2003). One possible 
way to improve prediction and change of these lifestyle behaviours is not only to 
consider beliefs about illness, as proposed by Common Sense Model 
(Leventhal et al., 1997), but also to consider beliefs about the behaviours being 
examined. The logic of targeting beliefs about behaviour rather than beliefs 
about illness in behaviour change interventions has already been proposed and 
widely accepted for the behaviour of medication adherence (Hornel, 2003). 
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French et al. (2013) assessed the generality of the finding that perceptions of 
treatment may be more predictive than illness perceptions. They demonstrated 
that beliefs about behaviour are at least as important as beliefs about illness in 
predicting several health-related behaviours. This suggests the possibility that 
behaviour change interventions with patient groups would be more effective by 
targeting beliefs about behaviour, rather than beliefs about illness. 
Many factors including knowledge, psychosocial support, health beliefs or 
attitudes, self-efficacy, socioeconomic status and behavioural or lifestyle factors 
affect glycaemic control (Brown et al., 2000; Heisler et al., 2003). Diabetes 
knowledge is a predisposing factor that contributes to outcome expectancies 
related to glycaemic control (Brown 1990, Padgett et al. 1988).  
However, self-efficacy seems to be a powerful predictor of glycaemic control. 
According to Bandura (1997), self-efficacy is a specific and dynamic behaviour, 
in that it focuses on beliefs about personal abilities in a specific setting or with 
regard to a particular behaviour, such as dieting or exercise. Enhancing self-
efficacy in people with diabetes has been shown to have a positive effect on 
behavioural change and positively influence long-term glycaemic control 
(Aijasem et al., 2001; Grembowski et al., 1993; Lorig et al., 2005; Montague, 
2002; Uitewaal et al., 2005). Hurley and Shea (1992) also stated that self-
efficacy was the predictor of self-care, and patients with the highest self-efficacy 
scores reported greater adherence to diabetes treatment recommendations.  
Enhancing self-efficacy may enhance diabetes self-management and improve 
glycaemic control. Several meta-analyses have shown the efficacy of 
behavioural strategies derived from social learning theory to impact self –
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reported behaviours and glycaemic control (Brown 1988, 1990; Lorig et al. 
2001a, b; Padgett et al. 1988). Educational strategies focused on improving an 
individual’s attitudes and motivations, rather than just increasing knowledge, 
have been effective in improving diabetic control (Lockington et al. 1989). 
Success of a medical regimen depends on an individual’s attitude towards the 
illness, including willingness to work with the physician to manage the diabetes 
and self-efficacy or confidence in his/her ability to contribute to the management 
of illness (Wigal et al. 1993).  
2.4.1. Knowledge, awareness and practice of Type II patients with 
diabetes  
Knowledge, attitudes and practice (KAP) can be defined as key elements to 
improve glycaemic control among patients with diabetes. Therefore, various 
studies have been conducted to assess patients’ and health care provider 
knowledge and practice toward diabetes. In order to improve patients’ 
outcomes and to provide health carers with required training. The knowledge, 
attitudes and practice (KAP) can be assessed for different topics concerning 
diabetes for instance some studies have assessed KAP around nutritional and 
eating habits. Wang et al. (2014) assessed the KAP around nutrition and eating 
habits for type II diabetes considering that diet is the key element in controlling 
blood glucose. The study was based on educational intervention for 54 patients 
selected randomly from 162 participants recruited from three hospitals located 
in Yakeshi city in China. The findings stated that the participants had positive 
attitudes, but relatively poor nutrition knowledge and practices. Nutritional and 
eating education was effective in improving diabetics’ nutrition knowledge and 
practices, and this optimal practice helped them control blood glucose 
effectively. The education intervention was based on four steps: 
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 Nutrition lectures were given, during which food exchange lists and 
nutrition knowledge materials were distributed to every participant and 
food and nutrition hygiene knowledge was explained using real food and 
food models. Lectures were controlled to within 1 hour and 10–15 
minutes were left for answering questions and for discussion.  
 According to the knowledge misunderstandings that occurred in the 
questionnaire, wrong answers were explained and the relevant nutrition 
knowledge was given to the patients face-to-face.  
 Patients and their families were taught to develop individualized nutrition 
therapies based on their height, weight, labour intensity, blood glucose, 
blood lipids, renal function, liver function and personal eating habits 
according to the concept of food exchange portion.  
 Follow-up telephone calls were made once per month to understand 
patients’ exercise, drugs and treatment situation and to solve their actual 
nutrition issues.  
In the study by Breen et al (2015), the level of nutrition knowledge was lower 
than awareness relating to other aspects of type II diabetes, such as 
development and management of diabetes complications. This is not surprising, 
given that previous studies have suggested that dietary adherence is among 
the most difficult cornerstones of diabetes management (Rahati et al., 2014).  
Information on nutritional components has grown extensively in the past 
decades, and it is challenging to translate the complex messages resulting from 
nutritional investigations into practical guidance to patients. This may lead to the 
general confusion about specific components, such as the lack of information 
on diverse types of fats found by the authors (Breen et al., 2015). Moreover, 
reduction of the chronic over nutrition is extremely challenging because it is 
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linked to central reward mechanisms (Nolan et al., 2011), which favours 
patients’ denial or undervaluation of dietary information (Dominguez, 2015).  
 
Some studies attribute poor knowledge of diabetes to the level of education. Al-
Adsani et al. (2009) investigated the level of diabetes knowledge among 5114 
patients with type II diabetes by using the Arabic Translated Michigan Diabetes 
Knowledge Test. The authors found that the level of knowledge was poor 
among participants. The KAP toward type II diabetes studied in Qatar found 
poor practice of: regularly inspecting feet to detect signs of neuropathy, taking 
medication in relation to meals, modifying doses when necessary and setting 
goals for therapy (Kheir et al., 2011). In Pakistan, a study was conducted to 
assess the general characteristics, knowledge, attitude and practices of patients 
with type II diabetes attending the Out-Patient Department (OPD) of Baqai 
Institute of Diabetology and Endocrinology (Karachi, Pakistan). Fifty-seven 
percent of the patients were overweight or obese. Only 10.7% had good 
glycaemic control. Sixty seven percent did not do exercise of any kind. The 
overall awareness about the risk of complications was satisfactory but the 
misconceptions regarding diet, insulin and diabetes were quite common. The 
study highlighted the need for better health information to the patient through 
large scale awareness programmes (Badruddin et al., 2002). 
2.4.2. Knowledge, attitudes and practice toward type II diabetes 
among community pharmacists  
Knowledge regarding diabetes pathophysiology has quickly accumulated and 
has led to the development of new medications. In addition to knowledge 
updates, the attitudes of health care professionals toward current concepts 
about diabetes care are even more critical. The core philosophy of modern 
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diabetes care puts emphasis on patient autonomy and optimal utilisation of 
health care professionals’ different specialties (Chen et al., 2004). 
The proper control of the illness is dependent on the patient’s adherence to 
medications, life style modifications, frequent monitoring of blood glucose, etc. 
and can be influenced by appropriate education and counselling of the patient. 
Pharmacists, being one of the indispensable members of the health care team, 
have an immense responsibility for counselling patients. Pharmacist 
consultations provided to patients with diabetes can minimize total healthcare 
costs in a health maintenance organization (Gerber et al., 1998). Community 
pharmacists’ interventions on improving knowledge and glycaemic control have 
shown better progress in recovery of diabetics. Continuous counselling and 
monitoring play an important role in the improvement of glycaemic control 
(Venkatesan et al., 2012). Intervention by community pharmacists has a 
beneficial effect on the clinical management of type II diabetes (Mehuys et al., 
2011). Assessing the knowledge and practice of community pharmacy 
personnel can help to design appropriate targeted educational training for the 
benefit of patients with diabetes (Shrestha et al., 2015). 
The community pharmacist KAP previously studied in Tripoli/ Libya showed 
their knowledge was good. Most pharmacists did not have special training 
about diabetes but the helpful sources of information used in diabetic education 
were books and journals, learning from colleagues, published literature and 
attending lectures (Bisheya et al., 2011). However, community pharmacists in 
Nepal show that there is poor knowledge and practice toward diabetes. In this 
study the sample size of 315 community pharmacies, selected by systematic 
random sampling were surveyed by using pre-validated self-administered 
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questionnaires. The first set of questions evaluated the community pharmacy 
personnel’s diabetes knowledge based on a pre-validated 20-item 
questionnaire. The second set of 22 questions documented the practice of 
community pharmacy personnel with respect to diabetes mellitus management. 
The findings highlighted that 76.5% of respondents had poor knowledge and 
86.4 % had negative practice of diabetes mellitus management. Only 26.2% of 
respondents had good knowledge as well as good practice. 31.4% of 
respondents had poor knowledge as well as poor practice of diabetic 
management. The author attributes poor knowledge in the study to a lack of 
continuing education programmes. Conducting continuing education 
programmes for pharmacists to enhance their ability to perform pharmaceutical 
care for diabetes has been shown to increase the participants’ knowledge 
(Chen et al., 2004).  
The author suggested that the reason for low level of knowledge and practice 
among the respondents in this study may be due to the fact that in Nepal, 
community pharmacy personnel come from diverse educational backgrounds, 
and thus may not have the intensive knowledge and practice skill required for 
their profession (Shrestha et al., 2015).  
The Diabetes Attitude Scale (DAS) is a well-validated instrument and has been 
successfully and widely used to measure attitudes in physicians, nurses, 
dieticians, medical students, and physician assistant students (Donnelly and 
Anderson, 1990, Fisk et al., 2001). But prior research has provided little 
information on pharmacists’ attitudes toward diabetes and the relationship 
between educational intervention and attitude change. Pharmacists’ knowledge 
and attitudes toward diabetes could significantly influence patient outcomes. 
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Given the prevailing concept of a team approach toward diabetes care, only 
when all health care providers share the same high level of knowledge and 
positive attitudes could the quality of patient care be ensured (Chen et al., 
2004a). 
Studies on the attitudes of health care professionals (HCPs) toward diabetes 
have demonstrated different attitude patterns across different parts of the world. 
For example, Odili and Oparah (2012) used the DAS-3) and found that although 
HCPs (nurses, physicians, pharmacists) in Nigeria were in agreement regarding 
the benefits of diabetes special training programs for HCPs, significant 
differences with regards to other attitude subscales were noted among 
participants with nurses demonstrating low attitudes toward seriousness of 
diabetes, value of tight glycemic control, and patient autonomy (Odili and 
Oparah, 2012). 
However, doctors and pharmacists had more positive attitudes toward the value 
of tight glycaemic control than nurses. Physicians had stronger attitudes about 
the seriousness of type II diabetes than nurses and pharmacists. In a cross-
sectional study in Yemen, Babelgaith et al. (2013) found that nurses and 
pharmacists demonstrated weaker attitudes than physicians with regards to the 
seriousness of diabetes whereas physicians had stronger attitudes toward the 
value of tight glycaemic control followed by nurses and pharmacists (Babelgaith 
et al., 2013). In that study, nurses had weaker attitudes on all subscales than 
physicians and pharmacists and all HCPs surveyed were in agreement 
regarding the importance of empowering patients toward self-management of 
diabetes (Babelgaith et al., 2013). 
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In a multinational survey to assess attitudes of HCPs toward diabetes in eight 
countries (France, Germany, United Kingdom (UK), Italy, Netherlands, Spain, 
Sweden, and United States), it was found that physicians tended to have 
stronger attitudes regarding the seriousness of diabetes and psychosocial 
impact of the disease (Hajos et al., 2011). Study indicated that diabetes related 
attitudes of nurses and dieticians in the US were consistently more positive than 
the attitudes of physicians, especially regarding the seriousness aspects of the 
disease (Anderson et al., 1991). Anderson and Donnelly (1990) found that 
physicians tended to view themselves as in control of diabetes with less 
appreciation of patients’ autonomy, unlike nurses and dietitians who valued 
patients’ involvement in decisions related to diabetes (Anderson and Donnelly, 
1990). Both studies underscored the importance of interdisciplinary team work 
in diabetes management and the values of understanding patients’ perceptions 
and emotional status by HCPs to establish therapeutic relationship and 
enhance patients’ coping and emotional well-being (Anderson et al., 1991, 
Anderson and Donnelly, 1990). Stansfield et al (2007) reported that HCPs 
underestimated patient autonomy and emotions related to diabetes but 
overestimated the challenge patients associate with the cost of diabetes 
(Stansfield et al., 2007). Similar results were noted in a later study in the US 
which found that HCPs had negative attitudes toward patient ability to handle 
low blood sugar and the psychosocial aspects of diabetes (Fitzgerald et al., 
2008). 
The study conducted in Auckland/ New Zealand aimed to quantify and compare 
knowledge of diabetes including risk factors for diabetes- related complications 
among the three main groups of primary health care nurses in Auckland: 
113 
 
Practice Nurses (PN), District Nurses (DN) and two specialist nurse groups 
(Diabetes Specialist Nurses (DSN) and Chronic Care Management (CCM) 
nurses). The findings showed that most nurses had good knowledge of obesity 
as a risk factor for type II diabetes mellitus and elevated plasma glucose levels 
as a risk factor for diabetes-related complications compared with knowledge of 
cardiovascular risk factors, particularly smoking (Daly et al., 2014). The nurses 
in Auckland had good knowledge about diabetes that allows patients with type II 
diabetes to be manged appropriately in primary care. Another reason that 
nurses have good diabetes knowledge is because they study and follow 
diabetes guidelines (Ministry of Health, 2008a). National surveys show that 
patients in New Zealand are increasingly consulting nurses (Ministry of Health, 
2008b). 
Another study carried out in the North East of England (UK) aimed to describe 
the views and practices of community pharmacists regarding services for 
people with type II diabetes. The study found that community pharmacists do 
not engage in discussions about medication with their patients with diabetes, 
nor is their potential to provide health promotion advice being met 
(Abduelkarem et al., 2003). An interesting study conducted in Egypt, Alexandria 
aimed to examine Egyptian pharmacists’ knowledge regarding management of 
diabetes during Ramadan. It also explored pharmacists’ willingness to attend a 
one day workshop on medication regimen adjustment during Ramada. The 
study identified considerable gaps among community pharmacists’ knowledge 
of diabetes management during Ramadan in Egypt, a country with a Muslim 
majority. It also shows willingness among the majority of pharmacists, 
especially Muslims, to attend a workshop dealing with medication regimen 
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adjustment during Ramadan. Different learning strategies may be of interest for 
pharmacists who regularly assist Muslim patients, but cannot attend such 
workshops (Amin and Chewning, 2014). 
2.4.3. Antidiabetic medication adherence 
Patients with chronic illnesses often experience difficulty in adhering to 
treatments recommended to them and consequently do not always receive 
optimal benefit from their prescribed drug therapy (Arifulla et al., 2014). There is 
a significant relationship between glycaemia (HbA1c levels) and clinical 
complications with the higher the levels, the greater the complications (Stratton 
et al., 2000, Selvin et al., 2012). There are many factors that influence 
glycaemic control, including older age, higher education level, higher patient 
activity, lower diabetes-related emotional distress, better diet and exercise 
behaviours, low body mass index (BMI), shorter duration of disease, and 
knowledge of HbA1c targets, which have all been shown by multiple linear 
regression to be associated with good glycaemic control (Rogvi et al., 2012). In 
addition, adherence to medicines may be associated with glycaemic control. 
Oral medication for patients with type II diabetes mellitus plays an important 
role in diabetes care and is associated with a high level self-care behaviour and 
self-management (WHO, 2003). However, poor adherence to diabetes 
treatment is common which causes severe health complications and increased 
mortality (Cramer et al., 2004, Ho et al., 2006).  This is reflected for instance by 
an increase in the risk of cardiovascular diseases, neuropathy, retinopathy, 
nephropathy and hospitalization rates (Vermeire et al., 2005, Currie et al., 2012, 
WHO, 1999).  Barriers to adherence may consist of complex treatment 
regimens often along with long-term multi-therapies, side effects due to the 
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medication as well as insufficient, incomprehensible or confusing information or 
instructions provided by the health care provider. Further barriers challenging 
adherence could also be related to socioeconomic issues, memory impairment, 
psychological wellbeing and personal beliefs (Currie et al., 2012, Nam et al., 
2011, Odegard& Gray, 2008). Multidisciplinary approaches can support 
adherence success and can enable a more effective management of diabetes 
care. Several models for diabetes care have been developed and evaluated 
(Mehuys et al., 2011). The responsibilities of pharmacists involve for example 
the long-term supervision, patient education activities, the consideration of 
medication-related issues (e.g. drug interactions) and of patient needs as well 
as the optimization of the medicinal treatment and adherence. Studies have 
shown that pharmacist interventions positively influence health outcomes and 
patient satisfaction, which are crucial indicators for quality of health care and a 
key factor for medication adherence (Spinewine et al., 2012). 
Low patient adherence is a major barrier to realizing the benefits of medications 
that have been shown to do more good than harm in clinical trials. Such trials 
are typically done among patients who are volunteers, and who are followed 
closely to assure high adherence. Benefits are greatly reduced or nullified in 
usual clinical practice where adherence rates are low. Interventions to improve 
adherence have the potential to multiply benefits for patients, but at the time of 
previous review, no method of helping patients to follow self-administered long-
term treatments had been proven effective, actionable, and affordable in usual 
care settings (Haynes, 2008). Many patients stop taking their medication in the 
first months following initiation, often without informing their provider, with 
further attrition over time. In addition, many patients who continue their 
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medication do not consistently take it as prescribed. As a result, adherence 
rates average around 50% and range from 0% to over 100%, and there is no 
evidence for substantial change in the past 50 years (Sackett, 1979; Gialamas, 
2009; Naderi, 2012). 
Medication non-adherence is often defined as taking less than 80% of 
prescribed doses, although it has to be noted that non-adherence can also 
include taking too many doses, and it is associated with an increased risk for 
poor health, adverse clinical events, and mortality. Thus many people who 
could benefit from medications do not, and much of the public and private 
investment in health research and health care is undermined. Obviously, low 
adherence is associated with an increased risk of mortality, and high levels of 
adherence to drug therapy are associated with positive health outcomes; even 
high levels of adherence to placebo are associated with lower mortality 
(Simpson, 2006). Therefore, enhancing medication adherence is a priority and 
could improve patient outcomes, primarily through the effect of medications, but 
also possibly through the overall ‘healthy adherer’ effect. African Americans 
have lower levels of adherence to diabetes medication than Whites (Trinacty et 
al., 2009), and, as a result, have worse glycaemic control (Heisler et al., 2007). 
However, the factors that explain racial disparities in diabetes medication 
adherence are unknown. One potential explanatory factor is health literacy, or 
one’s ability to understand, engage, and actively apply health information 
toward the goal of improving one’s health (Institute of Medicine, 2004). Racial 
and ethnic minority groups are disproportionately affected by low health literacy, 
with an estimated 41% of Hispanics, 24% of African Americans, and 9% of 
Whites having below basic health literacy skills (National Centre for Education 
Statistics, 2006). 
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Adisa et al (2009) studied the factors associated with non-adherence behaviour. 
The study showed that several factors ranging from dose omission, 
forgetfulness, high cost and fear of side effects of some oral hypoglycaemic 
medications, to a collection of difficulties encountered during filling and 
ingestion of prescribed medications, constitute barriers to medication 
adherence among patients with type II diabetes. Even in a country such as 
France with a high level of access to healthcare low levels of medication 
adherence have been found in type II patients with diabetes. The study 
conducted in 3,637 persons with type II diabetes found that 39% of patients 
reported good medication adherence, 49% medium adherence and 12% poor 
adherence (Tiv et al, 2012). 
Many systematic reviews have been published focused on specific 
(demographic, disease, or medication) populations, interventions, or on an even 
more specific combination of both.  Generally, these reviews reported similar 
conclusions: some intervention components are potentially effective, but small 
sample sizes and suboptimal methodology often prevented strong conclusions; 
the variety of adherence measures limited study comparability; and most 
studies lacked a theoretical underpinning (van Dulmen 2007).  
A study conducted by Osborn et al. (2011) to explore the relationship between 
low health literacy and suboptimal medication adherence found both more 
prevalent in minority ethnic groups than majority white populations, Little is 
known about the relationship between these factors in adults with diabetes, and 
whether health literacy or numeracy might explain racial and ethnic disparities 
in diabetes medication adherence. The finding shows that the African American 
race was associated with poor medication adherence (r= -0.10, p<0.05). Health 
literacy was associated with adherence (r= 0.12, p<0.02), but diabetes-related 
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numeracy and general numeracy were not related to adherence. Furthermore, 
health literacy reduced the effect of race on adherence to non-significance, 
such that African American race was no longer directly associated with lower 
medication adherence (r=0.09, p=0.14). The author concluded that diabetes 
medication adherence promotion interventions should address patient health 
literacy limitations. The author surmises that health literacy is the key factor to 
solve the problem of medication adherence (Osborn et al., 2011).  
2.5. Chapter summary 
To summarize this chapter shows that the effectiveness of clinical pharmacists 
to control blood glucose is supported by different studies (Aguiar et al., 2016, 
Collins et al., 2011, Hassali et al., 2015, Omran et al., 2012, Pousinho et al., 
2016, Sapkota et al., 2015). However, the impact of community pharmacists on 
type II diabetes is still in progress or developing. A few studies suggested that 
community pharmacists might be able to control blood glucose  (Ali et al., 2012, 
Jahangard-Rafsanjani et al., 2015, Mehuys et al., 2011, Venkatesan et al., 
2012, Ganawar et al., 2014, Kraemer et al., 2012 ,Paulo et al., 2016, Kjeldsen 
et al., 2015).  
The systematic review found some studies that assessed the effectiveness of 
community pharmacists in relation to type II diabetes by implementing 
pharmaceutical care models in different shapes (i.e. counselling, diabetes 
education, medicine review, quality of life, satisfaction). Some studies strongly 
agree that community pharmacists can manage glycaemic control for patients 
with type II diabetes (Mehuys et al., 2011, Kjeldsen et al., 2015,Venkatesan et 
al., 2012). Another pilot study found that the community pharmacists’ 
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involvement can yield improved type II diabetes management, as evident by 
improvement in primary and secondary outcomes (Ali et al., 2012). However, 
few studies support, but do not provide clear evidence for, the premise that 
pharmacist counselling for health care plan beneficiaries with diabetes results in 
better disease control and improved empowerment to better self-manage this 
disease (Kraemer et al., 2012) (Paulo et al., 2016) (Gangwar et al., 2014). The 
duration of studies ranged from five months to twenty four months. However, it 
seems that the studies exceeding 6 months duration provide significant 
improvement in HbA1c (Mehuys et al., 2011; Ali et al., 2012), and also a trend 
toward improvement in HbA1c (Kramer et al., 2012). It has been highlighted by 
Mehuys et al (2011) that there is still question in sustainability of improvement 
of glycaemic control in patients with type II diabetes. 
Management of type II diabetes can be enhanced by applying clinical 
guidelines. Self-management is important and can be enhanced in order to 
improve health for patients with diabetes (if the patients are willing and able). 
The barriers to self-management comprise: physical barriers (including the 
nature of their medical condition(s) where people have different needs); and 
system barriers (including conflicting advice, or a lack of collaborative working, 
between healthcare and social care professionals in providing services and on-
going support for self-management). The research stated that it is essential to 
address barriers to diabetes self-management and identify strategies to 
overcome them, and it is important to examine whether there are additional 
barriers that still exist. 
The educational infrastructure implemented in medical and pharmacy schools in 
Libya is based on the British educational system. This means the English is the 
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first language used in education in both these schools. Therefore, most 
healthcare professionals, physicians, pharmacists, veterinarian and dentists 
understand medical terms in academic English. Studies suggest that both 
developed and developing countries share components of pharmacy practice, 
but the difference is that developing countries do not apply their learning (with 
respect to clinical and cognitive services) in practice. The education system is 
loaded with heavy basic subjects such as analytical chemistry, organic 
chemistry and so on, with little focus on practice as a pharmacist. There are 
many studies to improve practice in developing countries and implement 
pharmaceutical care, they can be successful by simplifying the stages of 
pharmaceutical care to match the nature of pharmacies in those countries. To 
enhance clinical outcomes for patients with type II diabetes improving 
glycaemic control is important. Many studies take an opportunity to implement 
medicines management or pharmaceutical care from a perspective that the 
community pharmacist is the most accessible health care professional for 
patients without appointment.  Recently, different strategies to enhance the role 
of the pharmacist have shown a degree of success. 
To understand barriers to self-efficacy among patients with type II diabetes their 
knowledge, attitude and practice has been studied. Most studies found that 
patients have relatively poor knowledge, attitude and practice (KAP). In order to 
improve KAP for patients with diabetes it seems important to understand 
community pharmacists KAP around type II diabetes. Studies show that 
pharmacists have good knowledge about type II diabetes and positive attitudes, 
but they require attention to improve practice. Starting from this view, I shaped 
my proposal for investigation to ensure pharmacists have proper KAP toward 
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type II diabetes, and then use this to improve patient-related outcomes. My 
intention is to improve glycaemic control for patients with type II diabetes by 
applying pharmaceutical care as an intervention in a clinical trial conducted in 
Tripoli/Libya. Medication adherence studies show that strategies and models to 
help patients adhere to diabetic medicine still require improvement. Diabetes 
counselling can be effective, especially in areas of nutrition and improving 
physical activity. The next chapter outlines the aims and objectives of this 
investigation in detail. 
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3. Research aims and objectives 
3.1. Research aims and objectives 
This chapter describes the fundamental aims and objectives of the study along 
with the research questions. The study was organised or structured into four 
connected stages, in an attempt to achieve the intended clinical outcome (an 
improvement in glycaemic control). 
This short chapter is structured into six sub-headings. The general aims and 
objectives of the whole thesis are highlighted in Section 3.1. Aims and 
objectives of a community pharmacy premises survey are highlighted in 
Section 3.2.  Aims and objectives of a community pharmacist diabetes 
knowledge and practice survey are provided in Section 3.3. Aims and 
objectives of a training stage to enhance community pharmacist knowledge and 
practice toward type II diabetes are outlined in Section 3.4. The aims and 
objectives of a randomised controlled trial to improve type II diabetes 
management are provided in Section 3.5. The chapter summary is provided in 
Section 3.6. 
Type II diabetes is a chronic health condition associated with significant 
morbidity and mortality. Many countries are still unaware of the full social and 
economic impact of diabetes. This lack of understanding is the biggest barrier to 
effective prevention strategies that could help halt the unstoppable rise of type II 
diabetes (IDF, 2015). To enable effective management of this increasing 
problem and to reduce costs, multidisciplinary team approaches to diabetes 
care seem necessary (ADA, 2009), and over the years, several innovative 
models of diabetes care have been evaluated (Renders et al., 2001). One of 
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these approaches has included pharmacist cooperation in diabetes 
management, in-line with greater involvement of the pharmacy profession in 
patient-oriented activities (Hepler and Strand, 1990, Hepler, 2004). The current 
study aims to improve type II diabetes management via community pharmacist 
intervention. 
3.1.1. General aims of the whole study 
 Improve type II diabetes glycaemic control.  
 Development of the role of community pharmacists by engaging them in 
type II diabetes medicine management or pharmaceutical care.  
3.1.2. General objectives of whole study 
In order to achieve the above aims, the following objectives were set: 
 Assessment of pharmacists’ knowledge, attitudes and practices towards 
diabetes care in community pharmacies within Libya. 
 Assessment of type II patients with diabetes’ awareness, attitudes and 
self- management  
 Introduction of diabetes non pharmacological management intervention 
via community pharmacist (randomised controlled trial) to measure level 
of glycaemic control improvement (FPG and HbA1c) 
3.1.3. General research questions of whole thesis 
 What is the level of pharmacists’ diabetes knowledge, attitudes and 
practices in community pharmacists in Tripoli, Libya? 
 What improvements can be implemented in order to help people with 
type II diabetes in Tripoli, Libya?  
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 How can pharmacists’ performance with respect to diabetes care be 
optimised in the context of Tripoli, Libya? 
The first stage (pharmacy premises exploration) was centred on collecting data 
about the structure of community pharmacy premises and pharmaceutical 
services in Tripoli, Libya. The plan was to distribute 426 copies of a community 
pharmacy premises questionnaire in Tripoli, Libya (see Appendix 11), in order 
to provide a picture of community pharmacy premises and pharmaceutical 
services. This then informed plans to improve pharmaceutical services. 
3.2. Aims of stage one: structure of community pharmacy 
premises and pharmaceutical services 
 Explore structure of community pharmacies premises in Tripoli, Libya.  
 Define existing pharmaceutical services in community pharmacies.  
3.2.1. Objectives of stage one 
 To describe pharmaceutical services that exist 
 To determine the number of community pharmacists and pharmacist 
technicians that works in each community pharmacy 
 To identify diabetes care services that exist in community pharmacy in 
Tripoli, Libya 
3.2.2. Research question 
 What is the premises structure of community pharmacies and the 
pharmaceutical services that exist in Tripoli, Libya? 
The second stage (pharmacist knowledge, practice and recruitment) was 
centred on reaching pharmacists by distributing self-competition questionnaires 
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to community pharmacies located in Tripoli, Libya. This stage was divided into 
two steps, the first being a pilot stage. The pilot involved distribution of 53 
copies of a self-completion questionnaire (Appendix 8). Then, the main 
questionnaire titled community pharmacist diabetes knowledge and practice 
toward type II diabetes (Appendix 9) was distributed to 125 community 
pharmacies.  
3.3. Aims of stage two: diabetes knowledge and practice toward 
type II diabetes among community pharmacist in Tripoli, Libya 
(piloting and main study) 
There were two aims for the piloting stage: 
 To recruit as many as community pharmacies as possible for the 
intervention study  
 To test questionnaires in terms of response rate and understandability. 
The aims of the main study were: 
 To recruit pharmacists who were happy to volunteer and;  
 To explore pharmacists knowledge and practices towards diabetes II 
care.  
3.3.1. Objectives of stage two 
The objectives can be categorised as following: 
 To evaluate the level of pharmacists’ diabetes knowledge and practice.  
 To randomly sample from the list of geographical areas in which 
community pharmacies were surveyed. 
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3.4. Aims of stage three: enhancing community pharmacists type II 
diabetes knowledge and practice (training stage) 
The third stage was centred on training community pharmacists to improve 
diabetes knowledge. The community pharmacies were randomised into control 
and intervention groups. The diabetes educational materials (Appendix 12) 
along with diabetes knowledge test (Appendix 13) provided to intervention 
group.  
 Development of role of community pharmacists towards type II diabetes 
management. 
 Enhancement of community pharmacists’ diabetes knowledge and 
practice in order to increase counselling skills for people with type II 
diabetes.  
3.4.1. Objectives of stage three 
In order to achieve to the above aims the following objectives were sets out: 
 Assess diabetes knowledge and practice before educational intervention 
(Appendix 12). 
 Determine the level of diabetes knowledge and practice after educational 
intervention for the intervention pharmacies. 
The fourth stage (an intervention study) was centred on implemented a 
randomised controlled trial. The trial focused on type II diabetes education and 
counselling provided to people with type II diabetes. The patients were recruited 
via community pharmacies randomised into eighteen control community 
pharmacies and 22 intervention community pharmacies.   
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3.5. Aims of stage four: Type II diabetes management intervention 
study   
 To improve glycaemic control via the community pharmacist intervention. 
 Enhance effectiveness of community pharmacist diabetes medicine 
management by engaging pharmacists to assist patients with diabetes to 
improve their diabetes knowledge, self-management and attitudes.  
3.5.1. Objectives of stage four 
In order to achieve the above aims the following objective set: 
 Evaluate diabetes knowledge in both control and intervention groups 
before starting the intervention to set a baseline (Appendix 15). 
 Assess diabetes self-care behaviour in both groups before starting the 
intervention (Appendix 16). 
 Determine diabetes attitudes in both groups and to set a baseline 
(Appendix 17) 
 Determine FPG and HbA1c in both groups and to set a baseline. 
3.5.2. Research questions  
 How to improve blood glucose control among patients with type II 
diabetes? 
 What is the role of community pharmacists to enhance diabetes 
knowledge, self- management and attitudes (via the intervention)? 
 What is the clinical impact of the intervention on the patients with type II 
diabetes?  
 Can the proposed intervention be successful in this challenging context? 
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3.6. Chapter summary 
To sum up, the chapter provides the key aims and objectives for each stage of 
the study. The overall aim of study was to improve type II diabetes 
management by co-operation between community pharmacists and patients 
with diabetes. To achieve the intended outcomes it was important to understand 
the level of diabetes knowledge and practice among community pharmacists. It 
was fundamental to explore community pharmacists’ premises to shape the 
intervention in the context of available pharmaceutical services; then to ensure 
that the intervention study was implemented correctly it was vital to train 
pharmacies in the intervention group. After that the intervention was 
implemented. In Chapters Four, Five, Six and Seven the four stages will be 
described in detail, including (in each case) methods, results, discussion and 
conclusion. 
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4. Structure and pharmaceutical services exist in community 
pharmacies in Tripoli/Libya 
This chapter is divided into six sections. The introduction, Section 4.1, outlines 
the structure of community pharmacy in developed and developing countries. 
The methods and design of the study are described in Section 4.2. The 
statistical results are provided in Section 4.3, the discussion in Section 4.4 and 
the conclusion in Section 4.5. The chapter summary provided in Section 4.6 
This chapter was created to provide the reader with information about the 
structure and organisation of community pharmacies in Tripoli/Libya, because 
there is a lack of existing documentation or data. The nature of pharmacy 
services in Tripoli must be understood before the thesis moves on to describe 
how community pharmacy might improve the care of patients with Type II 
diabetes, by improving pharmaceutical care or medicines management. 
4.1. Community pharmacy premises structure 
The aim of this chapter is to explore the structure of community pharmacies 
premises in Tripoli/Libya and to define the existing pharmaceutical services. In 
a number of countries, community pharmacy is moving through a period of 
fundamental change. In the UK, community pharmacists were known in the past 
as chemists (PSNC, 2016). Community pharmacies can be found on the high 
street, at the heart of the most rural villages and in the centre of the most 
deprived communities. Many are open long hours when other health care 
professionals are unavailable. There are several different types and sizes of 
community pharmacies, ranging from the larger multiples to the small 
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individually owned pharmacies. The traditional role of the community 
pharmacist as the white coat wearing healthcare professional who dispenses 
prescriptions written by doctors has changed. In recent years community 
pharmacists have been developing clinical services in addition to the traditional 
dispensing role to allow better integration and collaborative working with other 
health and social care providers; and more importantly to deliver better patient 
care (PSNC, 2016). 
Community pharmacists are the health professionals most accessible to the 
public in many countries. They supply medicines in accordance with a 
prescription or, when legally permitted, sell them without a prescription. In 
addition to ensuring an accurate supply of appropriate products, their 
professional activities also cover counselling of patients at the time of dispensing 
of prescription and non-prescription drugs, drug information to health 
professionals, patients and the general public, and participation in health-
promotion programmes. They maintain links with other health professionals in 
primary health care. Today, an increasingly wide range of new and analogous 
products are used in medicine, including high-technology biological products 
and radio-pharmaceuticals. There is also the heterogeneous group of medical 
devices, which includes some products analogous to medicines, some of which 
demand special knowledge with regard to their uses and risks (e.g., dressings, 
wound management products, etc.). Pharmacists have progressively undertaken 
the additional task of ensuring the quality of the products they supply (WHO, 
2016).  
The pharmaceutical sector and its overall conditions in developing countries are 
under- researched. There is a scarcity of studies and information on 
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pharmaceutical health services systems researched (Fathelrahman et al., 
2016). The definition of pharmacy and pharmacists have been subjected to 
numerous changes throughout the history of the pharmacy profession and 
historically many names have been used to describe those who practice 
pharmacy or who are involved in certain aspects related to pharmacy. 
Community pharmacists provide an established and visible network, extending 
to remote areas, of easily accessible health care professionals (Fathelrahman 
et al., 2016). It is recognised that in most developing countries, pharmaceutical 
services are virtually exclusively carried out from the institutions or premises at 
which the worker is based. Little attempt has, therefore, been made to explore 
domiciliary services (IPF, 1998) i.e. those provided in the patients’ home.  There 
is an extensive network of over 600 community pharmacists in Tripoli/ Libya. 
We thought it a golden opportunity to explore the role of these pharmacies in 
diabetes education since diabetes care was currently concentrated in only a 
couple of specialist centres (Bisheya et al., 2011). 
 
Research suggests that the primary health care consultation rate in Australian 
pharmacies may be as high as 43 million per year. The consumer can consult a 
pharmacist without an appointment and with minimal waiting times. This is 
where community pharmacists can assist. Pharmacists are nationally 
recognised as providers of long-term care for people with diabetes and it is 
logical that they should help the Australian health care system cope with the 
burgeoning issue of type II diabetes and its intensive, evidence-based 
management. Moreover pharmacists should be identified as part of the diabetes 
care team (Krass et al., 2004). Every day about 1.6 million people visit a 
pharmacy in England NHS (PSNC, 2016). 
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Community pharmacies are an under-used resource: many are now open 100 
hours a week in the UK with a qualified pharmacist on hand to advise on minor 
illnesses, medication queries and other problems. We can capitalise on the 
untapped potential, and convenience, that greater utilisation of the skills and 
expertise of the pharmacy workforce can offer (Loader, 2014). 
Recently, the role of the pharmacist developed in UK and cited by Twigg ( 2013, 
p2) that “One of the most important functions of a pharmacist at this time, and 
until the founding of the National Health Service (NHS), was to advise and treat 
patients who could not afford to see a general practitioner (GP). If someone 
wanted to see a GP, they had to pay for the consultation and then pay for the 
medicine that either the GP or the pharmacist would dispense. Patients who 
saw a pharmacist only had to pay for any medicines which the any medicines 
which they recommended. In a time when universal healthcare had not yet 
been established and wages were low, this was the only option available to 
many people”. 
4.2. Methodology  
Sampling was started based on WHO data (WHO, 2007) as shown in the Table 
4.1 that the number of private pharmacies in Tripoli/Libya was 426. However, 
there was no list of pharmacy locations, structure or the kind of services that 
exist.  It was decided to collect data from all of the pharmacies in Tripoli to see 
how many now exist, what kind of services they provide and their structure. 
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Table  4.1: Total number of private pharmacies and other clinics in Libya 
Source: (WHO, 2007) 
Private Sectors 
No 
Name of 
Shabiat 
In 
patient 
clinics 
No of 
beds 
Outpatient 
clinics 
Dental 
clinics 
Pharmacies 
1 Albetnan 1 20 7 2 38 
2 Derna 2 12 7 4 38 
3 
Al-Gebal-
Alakhdar 
0 0 11 4 42 
4 Almarege 0 0 9 3 33 
5 Benghazi 16 272 78 41 250 
6 Al-Wahat 0 0 10 4 27 
7 Al-Kufra 0 0 3 1 5 
8 Sirte 2 26 6 5 45 
9 Al-Jufra 0 0 3 1 12 
10 Misurata 9 112 27 25 81 
11 Al-Merghip 11 120 33 5 39 
12 Tripoli 27 502 126 124 426 
13 Joufara 1 120 26 7 135 
14 Alzawea 3 82 32 6 79 
15 
Al-Gebal-
Lgharbi 
0 0 16 7 55 
16 Naloot 0 0 2 2 20 
17 Sebha 4 25 7 12 57 
18 Ghat 0 0 0 0 2 
19 Morzig 0 0 2 1 9 
20 Wadi-Alhiat 0 0 2 2 16 
21 
Wadi- 
Alshati 
0 0 6 2 29 
22 
Al-Nequt-
Alghmis 
8 70 18 1 64 
 Total 84 1361 431 259 1502 
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4.2.1. Methods 
The study was designed to explore the structure of community pharmacies 
premises and pharmaceutical services that exist in Tripoli/Libya. There is no 
sampling method used because a census of current pharmacists was intended. 
A total of 426 copies of the self-completion questionnaire (see Appendix 11) 
were distributed by hand in July 2015. The questionnaire was distributed by 
hand. 
4.2.2. Justification of Methodology  
This survey aims to provide description of community pharmacies premises and 
pharmaceutical services that exist in Tripoli/ Libya. The data relating to this aim 
were collected using the methods discussed below.  
4.2.2.1. Self- administered questionnaire 
The questionnaire was presented to the respondents by the representatives of 
another pharmacist and the purpose of the inquiry was explained. The 
respondents were then left alone to complete the questionnaire, which was 
picked up later. This method of data collection can ensure a high response rate, 
accurate sampling and minimum of investigator bias, while permitting 
investigator assessments, providing necessary explanations (but not 
interpretation of questions) and giving the benefit of a degree of personal 
contact (Opeenheim, 1992). The questionnaire was adapted from 
pharmaceutical needs assessments (PNA) with amendments that fit community 
pharmacies in Libya as a developing country (see Appendix 11). Permission to 
adapt the PNA questionnaire was sought from the PSNC. 
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4.2.2.2. Structure of questionnaire 
The survey was adapted from the pharmaceutical needs assessments (PNA) 
survey in England where there is “a statutory responsibility to publish and keep 
up to date a statement of the needs for pharmaceutical services for the 
population” (Sangha and Rowson, 2015: 7). The structure of community 
pharmacy in Tripoli/Libya was explored in order to describe the infrastructure of 
pharmacies in Libya. In addition, it could help other researchers to shape new 
pharmaceutical services. The information was collected to explore the premises 
and pharmaceutical services available in community pharmacies in Libya, but 
there was no intention (at that stage) to make any change or improvement. The 
aim of this chapter is to provide the reader with structure of community 
pharmacies. Another reason for this kind of survey was to establish the 
representativeness of participants the trial stage. The only information known 
was that were 426 pharmacies in Tripoli (WHO, 2007), but there is no published 
list of pharmacies (or services). Therefore, the exploratory study provided 
essential background information. 
The questionnaire was structured into four sections (Appendix 11). Section one 
provided data about pharmacy premises consisting of: 
 Name of pharmacy 
 Geographic area (i.e. the name of area that the pharmacy was 
located in) 
 Name of street (if applicable, some places do not have street 
names) 
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 Type of pharmacy (i.e. whether the pharmacy was private or public: 
public pharmacies supply free medicines, but private ones sell 
them) 
 Type of location (whether located in commercial or residential 
places) 
This gives an idea about how accessible community pharmacies are to people. 
Then to understand availability of staff in the pharmacy to help patients these 
questions were asked: 
 Number of staff working in the pharmacy  
 Number of community pharmacists working in each pharmacy 
 Number of community pharmacy technicians 
Section two asked about opening and closing hours of the community 
pharmacy on each day of the week to understand availability of pharmacy 
services. The next section provided data about availability of consultation 
services: 
 Asking about availability of a consultation area in the pharmacy 
 If the respondent answered yes to this, then further questions: 
o Where is the consultation area? Whether on or off the premises? 
o Have you got washing facilities in the consultation area? 
o Whether people attending consultations have access to a toilet? 
It has been supported by different studies that the consultation area is essential 
for medicines use reviews (MURs), which are part of medicines management. 
Areas should be designed to allow confidential consultations and a place where 
both the person receiving MUR services and the registered pharmacist 
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providing those services are able to sit down together and talk at normal 
speaking volumes without being overheard by any other person (Local 
Government Association, 2013) (Everden, 2015).  This survey was adapted 
from the PNA in England, which reported that over 90 per cent of pharmacies 
have a private consultation room and many have already taken on a wider 
public health role, for example running weekly clinics to help people lose 
weight, stop smoking or to monitor blood pressure or cholesterol (Local 
Government Association, 2013). From this perspective the questions were 
adapted to investigate whether in Libya as a developing country these 
strategies had been initiated. 
Section four asked questions about pharmaceutical services provided. The 
section divided into three topics: 
 Essential services: can be defined as services that should be available 
in each community pharmacy, services include dispensing, promoting 
healthy lifestyles and signposting which all community pharmacies must 
provide (Everden, 2005) (Prescribing and Primary Care team, Health 
and Social Care Information Centre, 2013). This topic asked questions 
about: 
o Whether the pharmacy dispensed appliances or not? 
o What type of appliances (if any) dispensed? 
o Whether the pharmacy provided repeat dispensing 
services? 
o The average number of monthly repeat items (if any)? 
o Whether the pharmacy disposed of unwanted medicine? 
o If the pharmacy disposed of unwanted glucose strips? 
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 Advanced services - questions about: 
o whether or not providing diabetes medicine management 
and glucometer  
o If applicable, which kind of diabetes medicines 
management was provided: 
 Patient education 
 Initial assessment and monitoring 
 Check height, weight and calculate BMI 
 Check smoking status 
 Glucose control 
 Dietary advice 
 Referral for management of glucose control 
These questions about diabetes medicines management were introduced by 
the investigator and not part of the original PNA questionnaire (PSNC, 2013) 
(Everden, 2015). The original PNA did ask questions about components of 
medicine management including: 
 Medicine use review 
 New medicines services 
 Appliance use review 
 Stoma appliance review 
 Disease specific medicines management 
Disease specific medicines management has been defined by The National 
Health Service Act (2006, p:17) as “a service underlying purpose of which is for 
a registered pharmacist to advise on, support and monitor the treatment of 
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patients with specified conditions, and where appropriate to refer the patient to 
another health care professionals”. In developing countries this is possible but 
not as advanced as in developed nations (Smith, 2016) . There might be 
discussions with a patient and advice from the pharmacist but no active 
interventions. Simply, the pharmacist might provide advice but state that a 
doctor should be consulted or recommend self-monitoring using simple 
equipment, for example, a blood pressure monitor or glucometer. 
Questions were asked about disease specific medicine management that the 
community pharmacy might provide or be willing to provide:  
 Allergies 
 Alzheimer’s 
 Depression 
 Diabetes type I  
 Diabetes type II 
 Epilepsy 
 Heart failure 
 Hypertension 
 Parkinson’s disease 
4.2.3. Data Analysis  
The data has been analysed with the use of Statistical Package for Social 
Sciences (SPSS) and Excel. Descriptive statistics were used for demographic 
characteristics, opening hours among community pharmacies, availability of 
consultation area and providing essential services. Tables and bars were used 
illustrate the descriptive statistics. Tables were used to describe premises 
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structure by using frequency and percentages. Similar methods of presentation 
were applied to other parts of analysis. 
Bar charts used to highlight pharmacies that providing or were willing to provide 
enhanced services. Pie charts used to indicate frequency of premises details, 
consultation service and pharmaceutical services. 
 
4.3.  Results of the community pharmacy survey in Tripoli/ Libya 
A total of 426 questionnaires were distributed by hand; of these, three hundred 
and eighty nine were returned a total of 37 refused participation for different 
reasons; 10 participants stated a lack of time, whilst 17 neglected to fill in the 
questionnaire and were not interested in the study and 10 missing to collect. 
The statistical results of this survey can be categorised into four parts: 
 demographic information about community pharmacy premises 
 information about opening and closing hours of community 
pharmacies 
 consultation area availability and facilities 
 information about pharmaceutical services 
4.3.1. Demographic profile of community pharmacist premises 
Table 4.2 shows the responses of 389 self-completion questionnaires. Three 
quarters were private (341, 88%) rather than public pharmacies (48, 12%). Most 
pharmacies were located in commercial (212, 54.5%) rather than residential 
areas (177, 45.5%).  
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Table 4.3 shows the number of staff working in each pharmacy ranged from 2-9 
and 93 pharmacies reported that 5 people worked in each pharmacy. Only 2 
pharmacies reported that 9 people worked in each pharmacy. Table 4.2 shows 
that the number of community pharmacists working in 386 pharmacies ranged 
from two to five. The highest number of pharmacies (166) reported that each 
pharmacy had two community pharmacists working. For community pharmacist 
technicians, 156 pharmacies reported that two technicians worked in each 
pharmacy. The total number of community pharmacists working in 386 
pharmacies was 858 and the total number of community pharmacist technicians 
working was 760 in 378 pharmacies.  
Table  4.2: Community pharmacy premises structure  
Description Frequency (Percent) 
Total number of respondents 389 
Type of pharmacy: 
Private 
Public 
 
341(88%) 
48(12%) 
Location of pharmacy: 
Commercial 
Residential 
 
212(54.5%) 
177(45.5%) 
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Table  4.3: Total number of staff working in each pharmacy 
No of pharmacies  Number of staff working 
in each pharmacy  
 
59  2 118 
76  3 228 
91  4 364 
93  5 465 
51  6 306 
17  7 119 
2  9 18 
389 36 1618 
 
Table  4.4: The distribution of community pharmacists and technicians among 
pharmacies  
No of 
pharmacies  
No of community 
pharmacist  
No of pharmacies  No of community 
pharmacist 
technician   
89 1 123 1 
166  2 156 2 
97 3 75 3 
29  4 20 4 
5  6 4 5 
386  378  
 
4.3.2. Opening and closing hours of community pharmacies in 
Tripoli/ Libya 
This result shows the accessibility for community pharmacies in Tripoli Libya. 
Most pharmacies were open between 85 and 90 hours weekly (155, 44%). A 
quarter was open between 75 and 80 hours (92, 24%) and between 70 and 75 
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hours (86, 22%). A lower number were open between 90 and 100 hours (56, 
14%) see (Table 4.5). 
Chart 4.1 shows opening hours of pharmacies on weekdays (Saturday till 
Thursday) by city district. Most community pharmacies were open between 9:00 
am and 11:00 pm (174, 45%). The lowest numbers were open early in the 
morning (7:30 am until 7:30 pm: 37, 10%) or for the hours 9:00 am-10 pm (37, 
10%). Table 4.6 describes the working hours on Friday, which is public holiday 
in Libya. The lowest number of community pharmacies is open in the morning 
at 10:00am (37, 9%). The largest number of pharmacies opens at 4:00 pm 
(175, 45%). 
Table  4.5: Number of hours of pharmaceutical services available each week in 
Tripoli, Libya  
 
Number of hours Number of 
pharmacies 
Percentage 
More than 70hrs and up to 75hrs 86 22 
More than 75hrs and up to 80 hrs 92 24 
More than 85 hrs and up to 90 hrs 155 40 
More than 90 hrs and up to 100 hrs 56 14 
Total 389 100 
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Table  4.6 Number of community pharmacies open in the morning and evening 
on Friday  
Private and public pharmacies opening hours in the morning  and evening on 
Friday 
The pharmacies 
beginning hours to open 
whether in morning or 
afternoon  
Number of pharmacies Percentage 
10:00 am 37 9 
4:00 pm 175 45 
5:00 pm 123 32 
5:30 pm 54 14 
Total 389 100.0 
 
 
Chart  4.1: Opening hours of pharmacies on weekdays (by district) 
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4.3.3. Availability of consultation area  
Table 4.7 and Chart 4.2 show that most community pharmacies do not have a 
consultation area (353, 92%) and only 8% (32) have a consultation area. When 
present, consultation areas are usually on (30, 94%) rather than off (2, 6%) the 
premises. Hand wash facilities are available in one-third of consultation areas 
(11, 34%) or close by in some cases (2, 6%). Two-thirds of consultation areas 
do not have hand wash facilities (19, 59%). 
Table  4.7: Availability of consultation area in community pharmacy  
Consultation area Frequency Percent 
Do you have consultation 
area? 
Yes 
No 
 
 
32 
353 
 
 
8% 
92% 
Is the consultation area 
located? 
On premises 
Off premises 
 
 
30 
2 
 
 
94% 
6% 
During consultation are 
there any hand wash 
facilities? 
No hand washing 
Hand washing facility in 
consultation room 
Hand washing facilities 
close to consultation room 
 
 
 
 
19 
11 
 
2 
 
 
59% 
34% 
 
6% 
Total 389 100 
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Chart  4.2: Availability of consultation area in community pharmacy in Tripoli 
4.3.4.  Essential services 
Table 4.8 shows that a minority of pharmacies dispense appliances (168, 46%). 
The most appliance that found dressing at (124, 32%) and just (25, 7%) have all 
appliances in pharmacies. For repeat prescription (219, 57%) provide repeat 
dispensing. Half of pharmacies dispense repeat prescription with monthly 
average from zero till 10 prescriptions at (193, 50%). Most community 
pharmacies do not dispose medicine (367, 95%) and also do not dispose 
unwanted glucometer strips (361, 95%). 
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Table  4.8: availability of essential services among community pharmacies in 
Tripoli/ Libya  
Items  Frequency  Percentage  
Dispensing appliances 
Yes  
No   
 
168  
200  
 
46% 
54% 
Type of appliances dose the pharmacy 
dispense: 
 All types 
 All excluding stoma appliances 
 All excluding stoma and 
incontinence appliances  
 Just dressing  
 
 
25 
6 
4 
 
124 
 
 
 
7% 
2% 
1% 
 
32% 
Dose the pharmacy provide repeat 
dispensing? 
Yes  
No  
 
219 
168 
 
57% 
43% 
Average of monthly repeat dispensing  
0-10 
11-20  
21-30 
 
192 
23 
6 
 
87% 
11% 
2% 
Do you dispose unwanted medicine? 
Yes 
No  
 
20 
367 
 
5% 
95% 
Do you dispose unwanted glucometer 
strips? 
Yes 
No  
 
19 
361 
 
5% 
95% 
Total  389 100 
 
4.4. Discussion  
The United Nations (UN) classifies countries into developed (or industrial) and 
developing based on their level of economic and industrial development. A sub-
group of developing countries are designed as least developed countries 
(LDCs) (Smith, 2001). These are countries with very low per capita income 
(Smith, 2001). The World Health Organisation has identified particular problems 
in developing countries in relation to the supply and use of drugs. In response 
to these difficulties, the WHO believes that pharmacists can make an important 
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contribution in health care, by promoting the safe and appropriate use of 
Medicines (WHO, 1988).  
Pharmaceutical services in developing countries face some specific challenges 
unlike those faced by pharmacists in the developed world. In most developing 
countries, lack of appropriate and good-quality medicines are the most common 
problem encountered (Farris et al., 2005). Irrational use of medicines and weak 
regulatory enforcement of drug sales are also serious issues in developing 
countries. For example, findings from a survey conducted in a rural region of 
Ghana revealed that drug retailers in five pharmacy shops were found to have 
little or no training in pharmacy; the population bought drugs without 
prescriptions; the staff of these shops contributed to drug misuse by providing 
misinformation about drugs and selling drugs according to popular demand 
(Wolf-Gould et al., 1991). 
The pharmaceutical service in Libya has been poorly documented. The current 
study reveals that the consultation areas are scarce in community pharmacies 
in Tripoli. Out of 389 pharmacies, 32 (8%) pharmacies have had consultation 
areas compared with a Northumberland survey where (out of 75 pharmacies) 
71 (99%) had a consultation room, and 56 (79%) could access hand washing 
facilities, either in the consultation area or close to it (Everden, 2015). According 
to Everden (2015) a consultation room is essential to provide advanced 
services, e.g. Medicine Use Reviews (MURs) and many locally commissioned 
services. However, simple interventions such as checking patient blood glucose 
levels, or hypertension, or giving advice could be done even without dedicated 
consultation areas. There is no fundamental barrier to providing pharmaceutical 
care, due to a lack of consultation areas. However, the availability of 
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consultation areas can offer some advantages. These consultation areas allow 
the patient and the pharmacist to interact in a setting that respects the privacy 
of the patients. The patient’s consultation areas, when used to discuss 
medication and other health issues, enhance the professional interaction and 
relationship between the patient and the pharmacist. It also facilitates and 
encourages patients to request and benefit from the professional input and 
counselling they require from the pharmacist Everden (2015). 
The requirement to have a consultation area, within a pharmacy, already exists 
in many countries including Scotland, The Netherlands and Australia. It is 
widely recognised that patient consultation areas are a beneficial resource for 
patients Everden (2015). The availability and use of such areas aims to improve 
patient confidentiality and ultimately patient outcomes. A patient consultation 
area that is correctly designed and used allows the patient and the pharmacist 
to interact in a setting that respects the privacy of the patient. The patient 
consultation area, when used to discuss medication and other health issues, 
enhances the professional interaction and relationship between the patient and 
the pharmacist. It also facilitates and encourages patients to request and avail 
of the professional input and counselling they require from the pharmacist. In 
addition, a designated area within a pharmacy, specifically for patient 
consultation, will enable the pharmacist to become a more integral part of the 
multidisciplinary team involved in a patient’s care. The confidential and personal 
nature of a consultation, within a consultation area, has huge potential to 
improve patients’ health by increasing patient education, encouraging the 
appropriate and rational use of medication, and thus reducing medication-
related problems (The Pharmaceutical Society of Ireland, 2010). 
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Repeat prescribing in Libya is carried out by patients going to hospital to see a 
doctor to prescribe the medicine then going to a pharmacy to have the medicine 
dispensed. For long term disease such as diabetes the patients have a special 
green card.  The patients go to a special diabetic hospital where both the doctor 
and dispensing pharmacist work. If the patient wants to collect their medicine 
from a community pharmacy (called a private pharmacy in Libya) they must first 
see a doctor to obtain a prescription. Some patients, especially elderly people, 
obtain their medicine by showing the packaging to the pharmacist and ask to 
buy their medicine without going to see a doctor. There is repeat dispensing but 
not organised systematically as in the UK. 
In the UK, repeat prescribing accounts for approximately 75% of all general 
practice prescribing and many patients are on poly-pharmacy regimes. Current 
practices for generating repeat prescriptions are generally acknowledged to 
provide inadequate control. This results in over-prescribing, stockpiling of drugs 
and infrequent review of therapy, which may lead to failure to identify issues 
such as drug interactions, adverse drug reactions, poor compliance and 
inappropriate treatment (Bond, 2016). An early randomised study demonstrated 
that pharmacists can appropriately manage repeat prescribing with a resultant 
increase in the detection of problems such as adherence problems and 
identification of adverse (Bond, 2016). There is also a reduction in drug 
wastage and cost avoidance by patients, as well as improved clinical benefits 
(Bond et al., 2000). Repeat dispensing involves authorising a community 
pharmacist to dispense repeat prescriptions for a patient, over an agreed time 
period, without the need for the patient to go back to the doctor (Morecroft et al., 
2006).  
151 
 
The data shows that pharmacy opening hours reached at maximum of 91 hours 
per week, and long hours were routine. In comparison, the UK has core 
pharmacy opening hours of 40 hours a week, unless a reduction is agreed by 
NHS England. These core hours are provided as an essential pharmacy 
service. The UK also has a number of 100 hour pharmacies, but these are in 
the minority Everden (2015). 
4.5. Conclusion  
Three hundred and eighty nine community pharmacies participated in the study. 
The majority of community pharmacies were private therefore the patients have 
to pay for their medicine. Most pharmacies were open from 9:00am until 
11:00pm. The majority of pharmacies do not have a consultation area. Many 
pharmacies do not dispose of waste medicines or glucometer strips. The 
majority of pharmacies did not have a consultation area. Many pharmacies did 
not dispose of waste medicines or glucometer strips. This information helped to 
shape the clinical trial in terms of accessibility of community pharmacies, 
however, the fact that there were few consultation areas was not a barrier to 
further research. 
4.6. Chapter summary 
This chapter provides the reader with a basic structure of community 
pharmacies in Tripoli, Libya; this includes premises characteristics and 
pharmaceutical services offered. One of the most significant changes in health 
care delivery in recent years has been recognising the importance of patients’ 
individual biographies. Pharmaceutical services reflect this, as their focus shifts 
from being largely centred on drug-product to a concern for the patient as an 
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individual, as exemplified by international recognition of the pharmaceutical 
care concept (Harding & Taylor, 2016). As Libya is a developing country the 
data shows that there are deficiencies in some pharmaceutical services 
considered essential elsewhere, for example, disposing of waste medicines and 
availability of consultation areas. However, long opening hours provide good 
patient access compared to a 40 hour norm in the United Kingdom (NCC, 
2015).  
In Chapter Five community pharmacies knowledge and practice with respect to 
type II diabetes is explored. This builds on the structural information provided in 
Chapter 4, by providing more detail about care processes. 
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5. Exploration of community pharmacist diabetes knowledge and 
practice toward type II diabetes in Tripoli, Libya 
Introduction 
This chapter is divided into six sections: a brief introduction about pharmacists’ 
knowledge and practice toward type II diabetes care is provided in Section 5.1. 
In the next Section 5.2 the methods are described. Then, statistical data 
analysis is in Section 5.3. The discussion is provided in Section 5.4 and the 
conclusion in Section 5.5.  The summary of key points is found in Section 5.6. 
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Abstract 
Aims/objectives: To explore community pharmacists’ knowledge and practice 
with respect to type II diabetes care in a developing country. This assessment is 
the first stage of an intervention to improve the delivery of care and will inform 
the design of training materials prior to a clinical trial. 
Research design and methodology: The study was carried out as an 
exploratory study in 125 community pharmacies located in diverse areas of 
Tripoli in Libya, which is Arabic-speaking. These pharmacies were chosen 
through purposive sampling and a self-completion questionnaire was distributed 
by hand. The project was approved by a Research Ethics Panel at the 
University of Bradford. 
Results: One hundred and eight questionnaires were returned, a response rate 
of 86%. There were roughly equal numbers of males (55) and females (53). The 
mean (± sd) number of years’ experience as a community pharmacist was 5.9 
(±5.13). The community pharmacists had good knowledge of diabetes with 
average scores of 21/29 (±3.18). The results show that the most common 
things pharmacists (always) give information about are: how to use the 
medicine (n=80/103, 79%); what the medicine is for (n=61/101, 61%); when to 
use medicines (n=54/98, 56%); and special storage instructions (n=47/99, 
48%). On the other hand, when comparing with other Standard Operating 
Procedures (SOPs), the lowest percentages of provision (always) include: 
discussing information about medicines with the patient (not just giving) 
(n=12/101, 12%); checking that patients have any information they need about 
medicines (n=15/99, 15%); and offering patients information about medicines 
before they are prescribed (n= 17/100, 17%). 
Conclusion/discussion: The community pharmacists had good knowledge about 
diabetes, which could be a foundation for more clinical practice. Basic provision 
of information for patients appeared to be good; however, there were 
opportunities to enhance the level of care provided. 
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5.1. A brief introduction about pharmacists’ knowledge and 
practice toward type II diabetes care  
Pharmacists’ particular body of knowledge and skills relates to the use of 
medicines and falls into board areas. Firstly, all pharmacists share scientific 
knowledge about medicines and their clinical applications and uses. Secondly, 
there is a body of knowledge about how to make best use of medicines, both 
applied to the needs and circumstances of individual patients (for example: 
selection of delivery system, advice and usage) and in terms of overall efficacy 
and effectiveness (such as development of formularies, organisation of supply). 
This knowledge is based primarily in the biological and physical sciences but 
draws crucially on various social science disciplines, including psychology, 
sociology and economics (Mays, 1997). 
The traditional medication dispensing function undertaken by community 
pharmacists in the UK over the last 30 years has become more efficient as a 
result of advances in information technology, automation and the provision of 
medicines in original packs (Department of Health, 2005). Consequently, as 
professional qualification now entails a four year undergraduate education 
course and one year’s workplace training, the government and wider 
community have repeatedly identified that the clinical knowledge and skills of 
the community pharmacist need to be utilised to better effect to benefit 
individual patients and reduce the burden on other healthcare professionals 
(Department of Health, 2005). 
Assessing the knowledge and practice of community pharmacy personnel can 
help to design appropriate targeted educational training for the benefit of 
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patients with diabetes. This stage of the current research was built on a 
previous study carried out in Tripoli, Libya between 2001 and 2002, which was 
centred on evaluating the knowledge and attitudes of community pharmacists 
toward diabetes care (Bisheya et al., 2011). The results showed that community 
pharmacists have good knowledge. The study had some limitations. 
Convenience sampling has its inherent limitations; however, the included 
pharmacists were likely to be fairly representative of the target population based 
on the sample size (146 out of 700) and the fact that they were based in all 
parts of the city and the response rate was very high.  
In addition, there seemed to be fairly uniform size, distribution, staffing levels 
and professional activities among pharmacies in the city. The survey employed 
mostly closed ended questions, multiple choice questions and 3 to 4 point 
scales to simplify the answers. The knowledge questionnaire was basic (Amoah 
et al., 2000, Al-Fadhel and Naylor, 2002) as the aim of the study was to assess 
pharmacists’ ability to educate rather than their academic performance. Hence 
it was administered in an Arabic version (Al-Fadhel and Naylor, 2002) as this 
would be the language that pharmacists would use to communicate with the 
patients even though they may have been educated in English. The study is in 
grey literature and the standard of English is poor. However, it is a good source 
of information and it can be used as a starting point to shape the current 
intervention study. From this foundation, a questionnaire was designed to 
explore knowledge and practice among community pharmacists in Tripoli, Libya 
in order to update the information and also to recruit community pharmacies 
and pharmacists for a subsequent clinical trial. 
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Where patients were not involved in a particular service, the pharmacist has 
been found to be used primarily by patients to gain information specifically 
about drug interactions and side effects, with fewer patients wanting to discuss 
their condition, adherence and impact on their lifestyle (McAuley et al., 2009). 
The study carried out by Twigg et al., (2013) indicated that many patients saw 
the pharmacist as having the knowledge and time to discuss their medicines 
and condition but as being impeded from doing so by the community pharmacy 
environment. The barriers to patients asking pharmacists questions appear to 
fall into two categories: patient and pharmacist-related (Krueger and 
Hermansen-Kobulnicky, 2011). The patient-related barriers include: fear or 
embarrassment, lacking initiative, having no need for any information and time 
constraints. The pharmacist-related barriers include being seen as less 
approachable and not being seen as such a credible or trustworthy information 
source. In UK study the participants highlighted their trust in the physician to 
provide most of their information and also raised the fear that by speaking to the 
pharmacist they might be in some way going against their doctor (Twigg et al., 
2013). Specific patient groups have highlighted where they view the role of the 
pharmacist and this largely depends on their personal experience. Patients also 
have an idea about how far this role extends to the greater management of their 
condition with most indicating that they still need the physician to be involved in 
their care if they are to trust what the pharmacist is doing for them (Twigg et al., 
2013). The author stated that the information is important to the the 
government’s vision for pharmacy is to be realised in patients with chronic 
conditions (Twigg et al., 2013). 
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5.2. Methodology 
The aims of this stage are to explore community pharmacists’ knowledge and 
practices towards type II diabetes care. The reason for completing a review of 
pharmacists’ diabetes knowledge and practices is to gain understanding of their 
weaknesses and strengths. This is recognised as a descriptive stage; therefore, 
the study can be seen as self-completion questionnaire (Appendix 1 and 2) in 
order to generate the relevant data that can both inform and provide a clear 
picture regarding the current situation of the study problem.  
The current study explores community pharmacist knowledge and practice 
toward type II diabetic management. The questionnaire has been piloted 
because it is highly recommended to pilot questionnaires in successful research 
(Oppenheim, 1992). Pilot work may be costly, but it will save time and money in 
the end. With this noted, it is true to state that ‘pilot work can produce some 
nasty surprises, but it is never dull’ (Oppenheim, 1992). Therefore, pilot work is 
considered an intellectual challenge in the conceptualisation and re-
conceptualisation of the key aims of the study, as well as in making 
preparations for field work and analysis so that not too much will go wrong and 
nothing will have been left out. The questionnaire was first distributed to 53 
participants and then to 125. 
5.2.1. Methods of Study  
This stage was built on a study carried out in Tripoli, Libya, between 2001 and 
2002, which was centred on evaluating the knowledge, attitudes and practice of 
community pharmacists toward diabetes care (Bisheya et al., 2011). 
The stage was completed in two steps: 
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First step: piloting phase. The pilot was carried out for the following reasons: 
 To recruit as many as community pharmacies as possible for the 
intervention study  
 To test the questionnaires in terms of response rate and understandability  
Second step: main study of community pharmacists’ type II diabetes knowledge 
and practice. For the same above reasons to recruit more community 
pharmacists except for making sure that questionnaire is easy to understand.   
5.2.2. Study Design  
The study involved purposeful or targeted sampling sometimes called 
judgement sampling, where respondents are selected because they have 
knowledge that is valuable to the research process (Bowling, 2005). The 
purpose of this sampling was to explore community pharmacists’ diabetes 
knowledge and practice. The questionnaire (Appendix 9) was distributed and 
returned by hand to 125 community pharmacies located in diverse areas in 
Tripoli, which is Arabic speaking. Participants in purposeful samples are 
grouped into predefined criteria; i.e. they have particular characteristics that will 
allow the researcher to investigate the research topic as fully as possible. In this 
study the criteria used were that the targets should be community pharmacies 
located in Tripoli and employ a community pharmacist. This stage was also a 
recruiting stage for pharmacies to participate in the next stage (a randomised 
clinical trial). The study was approved by the Ethics Panel at the University of 
Bradford. 
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5.2.3. Justification of Methodology  
The data relating to the aim of this chapter were collected using the methods 
discussed below. 
5.2.4. Self-administered structured questionnaire 
A questionnaire, as defined by Oppenheim (1992, p. 100), is ‘a set of questions 
including perhaps some open-ended ones, from more rigidly constructed scales 
or tests’. Siniscalco & Auriat (2005) define a questionnaire in more detail by 
stating that a questionnaire is a survey instrument used to collect data from 
individuals about themselves, with the questionnaire said to be standardised 
when each respondent is exposed to the same questions and the same system 
of coding responses.  
The questionnaire adopted in the current study is a self-completion or 
administered structured questionnaire (SASQ). The self-administered structured 
questionnaire can be disseminated by hand (i.e. delivered at a person’s home 
or office), by post (i.e. via snail-mail), or otherwise via e-mail (Eliselen et al., 
2005).  
There are several advantages associated with the SASQ: it is a common 
method of covering a large geographically spread population relatively quickly 
and economically; the method is considered less of a social encounter than an 
interview method; there are fewer bias problems, which is useful for sensitive 
topics as there is more anonymity (Bowling, 2009); they are convenient since 
respondents can complete them at a time and place suitable for them; and they 
are relatively easy to administer and analyse. However, In contrast the method 
is unsuitable for respondents of poor literacy as well as for those with language 
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difficulties, which do not exist in this case. There is generally a low response 
rate, although this can be improved. Furthermore, there is no opportunity to 
correct misunderstandings or to probe or to offer explanations or help, nor is 
there any control over the order in which questions are answered, and no check 
on incomplete responses (Oppenham, 1992).  
Bowling (2009: 285) cites that “there is some evidence that postal 
questionnaires leads to an underestimate of patients’ health problems in 
comparison with personal interview techniques” (Doll et al., 1991). Bowling 
agrees with the statement made by Doll by suggesting that “it may be that 
personal interviews can carry more social desirability bias and thus 
overestimate health problems” (Bowling et al., 1999; Bowling, 2005). 
Accordingly, Bowling highlights the belief that, if postal questionnaires 
underestimate health problems, interviews also overestimated them; I strongly 
agree with this statement the consequences of questionnaires that collecting 
data about general health problems but interview could provide ideas about the 
internal aspect of problem. 
Centres for Disease Control and Prevention (CDCP, 2008) highlight that, when 
gathering data about knowledge, beliefs, attitudes and behaviours, 
questionnaires are helpful in providing information that is unique to individuals. 
As such, owing to the research being concerned with type II diabetes 
knowledge, attitudes and practices amongst community pharmacists, this 
methodology has been selected. 
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5.2.5.  Structure of Questionnaire  
Oppenheim (1992: 120–121) states that “in reality, questioning people is more 
like trying to catch a particularly elusive fish, by casting different kinds of bait at 
different depths, without knowing what is going on beneath the surface! The 
function of a question in an interview schedule or questionnaire is to elicit a 
particular communication.” This quotation means that the questionnaire is rather 
difficult to design. Owing to the frequency of their use in all contexts in the 
modern world, the structure of the questionnaire should have some robustness 
in order to collect valuable data. One of the factors centred on increasing the 
response rate is a covering letter; it is polite to attach this to the questionnaire. 
The covering letter contains basic information about the study and associated 
contact information.  
A pilot questionnaire see (Appendix 8) was structured into four sections: 
section one designed to collect information about pharmacists and premises; 
section two concerned with the availability of oral hypoglycaemic and glucose 
and urine meters; section three sought to establish the workload and 
awareness of standard operating procedures; finally, section four aimed to 
achieve insight into family history and knowledge of diabetes. The diabetes 
knowledge test questions used in this section were taken from the Michigan 
Diabetes Research Training Centre (MDRTC). However, the main study 
questionnaire see (Appendix 9) was structured into three sections: section one 
contained information about people and geographical location of premises; 
section two concerned with the frequency of implementing standard operating 
procedures and the awareness of pharmacological management of glycaemic 
control in people with type II diabetes and also sought to understand reasons 
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for not providing patient counselling; finally, section three aimed to achieve 
insight into family history and knowledge of diabetes 
The components of the questionnaire (see Appendix 9) are described below. 
Section one comprised questions about: 
1. Pharmacy staff 
a. Level of education  
b. Programme studied (i.e. pharmacy, medicine or veterinarian etc.) 
c. Type of institution (i.e. whether graduate from university or 
college) 
d. Year of graduation  
e. Work experience  
f. Gender  
g. Diabetes specialized training 
2. Pharmacy premises details 
a. Name of pharmacy  
b. Address  
c. Type of area (whether commercial or residential)   
Section Two comprised questions about counselling practice. This section was 
divided into three parts: Standard Operating Procedures (SOPs); oral 
hypoglycaemic medicines (OHMs) recommendations adopted from SIGN; and 
reasons for not providing patient counselling. 
1. Questions to understand the frequency of practice among participants. 
Items had been identified in two documents (Nursing and Midwifery 
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Council, 2007) and (WHO) but the questions were new not a direct 
adoption. The questions were: 
a. How to use the medicine? 
b. What the medicine is for? 
c. Special storage instructions 
d. When to use the medicine? 
e. Side effects to expect 
f. How the medicine is likely to affect their condition? 
g. Offer patients information about medicines before the medicines 
are prescribed 
h. Check that patients have any information they need about 
medicines when the medicines are dispensed 
i. Discuss information about medicines with the patient rather than 
just presenting it 
The standard operating procedures questions used to assess the practice of 
community pharmacist toward type II diabetes is general questions regarding 
the pharmacist practice but not specific to the diabetes management. The 
justification of using this kind of questions it simple and easy to understand. It is 
possibly avoiding ambiguity and bias.  
Pharmacists were asked about SOPs which mainly concern safe dispensing 
practice. The pharmacist should engage both dispensing skills and clinical 
knowledge. The delivery of effective pharmaceutical care to patients requires 
pharmacists to practice in a way that uses their time effectively and reflects their 
responsibility and accountability.  
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1. The pharmacological management of diabetes means that the disease is 
treated with antidiabetic medicines, which could be oral hypoglycemic 
(OHMs) and/or insulin. The reason of asking questions about antidiabetic 
medicines was to understand the level of knowledge among community 
pharmacists. The questions ask pharmacists to rank recommendations 
about OHMs according to Scottish Intercollegiate Guidelines Network 
(SIGN) in order to assess community pharmacist’s knowledge. The grade 
of recommendation relates to the strength of the evidence on which the 
recommendation is based. It does not reflect the clinical importance of the 
recommendation. Grade A means at least one meta-analysis, systematic 
review, or RCT rated as 1++, and directly applicable to the target 
population; or a body of evidence consisting principally of studies rated as 
1+, directly applicable to the target population, and demonstrating overall 
consistency of results. Grade B means a body of evidence including studies 
rated as 2++, directly applicable to the target population, and demonstrating 
overall consistency of results; or extrapolated evidence from studies rated 
as 1++ or 1+. A tick means recommended as a best practice based on the 
clinical experience of the guideline development group. The statements in 
the questionnaire were adopted from SIGN and also recommended in the 
Libyan Diabetes Care Guideline (LDCG). The sets of recommendations 
adapted from SIGN were considered pharmacological questions.  
2.  
a. Metformin should be considered as the first line oral treatment 
option for overweight patients with type II diabetes 
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b. Sulfonylureas should be considered as first line oral agents in 
patients who are not overweight, who are intolerant of, or have 
contraindications to metformin. 
c. Pioglitazone can be added to metformin and sulfonylurea therapy, 
or substituted for either in cases of intolerance. 
d. Pioglitazone should not be used in patients with heart failure 
e. The risk of fracture should be considered in the long term care of 
female patients treated with pioglitazone 
f. Patients prescribed pioglitazone should be made aware of the 
increased risk of peripheral oedema. 
3. Questions about patient counselling: the reasons for not providing patient 
counselling adopted from Krska et al. (1995). 
a. Lack of pharmacist’s time 
b. Lack of patient’s interest 
c. Lack of patient’s time 
d. Lack of support staff 
e. Lack of knowledge/training 
f. Lack of self-confidence 
g. Lack of pharmacist’ interest 
h. Counselling not part of role 
Section Three was an assessment of community pharmacists’ diabetes 
knowledge. This section was divided into three parts: history of diabetes; 
background diabetes knowledge adopted from Michigan Diabetes Knowledge 
Test (MDKT) (Fitzgerald et al., 1998); practical diabetes knowledge adopted 
from Australian Diabetes Knowledge test (ADKT) (Eigenmann et al., 2011). 
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Therefore, the non- pharmacological diabetes questions were in this section. 
The non-pharmacological therapy consists of lifestyle modifications such as 
nutrition therapy, physical activity, avoidance of smoking and diabetic education 
(Meltzer et al., 1998). The set of questions adapting from MDKT and ADKT 
were about diet and exercising management of diabetes (non-pharmacological 
management awareness): 
1. The good diabetic diet is: 
a) The way most Libyan people eat  b) A healthy diet for most 
people 
c) Too high in carbohydrate for most people d) Too high in protein for 
most people 
2. Which of the following is highest in carbohydrate? 
a) Baked chicken     b) Edam chess  
c) Couscous     d) Almond  
3. Which of the following is highest in fat? 
a) Low fat milk     b) Orange juice 
c) Sweet Corn     d) Honey 
4. Which of the following is a sugar free food? 
a) Any unsweetened food 
b) Any dietetic food (specially made for people with diabetes) 
c) Any food that says “sugar free” on the label 
d) Any food that has less than 20 calories per serving 
5. What effect does unsweetened fruit juice have on blood glucose? 
a) Lowers it 
b) Raises it 
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c) Has no effect 
6. Which should not be used to treat low blood glucose? 
a) 3 hard candies 
b) 1/2 cup orange juice 
c) 1 cup diet coca cola 
d)  1 cup skim milk 
7. For a person in good glycaemic control, what effect does exercise have on 
blood glucose? 
a) Lowers it 
b) Raises it 
c) Has no effect 
8. Eating foods lower in fat decreases your risk for: 
a) Nerve disease 
b) Kidney disease 
c) Heart disease  
d) ye disease 
9. Which of the following statements about diabetes and diet is true?  
Please circle ONE answer only 
a) People with diabetes should eat a sugar free diet 
b)  It is OK to eat fried take away food three times a  week  
c)  Red meat is a carbohydrate food 
d)  A diet which is low in fat, high in fibre, low in added sugar is 
recommended for everyone with diabetes 
e) Unsure 
10. How often should people with diabetes exercise or be physically active?  
Please circle ONE answer only 
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a) Most days of the week for at least 30 minutes 
b) Once a week for at least 30 minutes 
c) Once a month for one hour 
d) At least every fortnight for two hours 
e)  Unsure 
11. Why is doing regular exercise or being physically active good for your 
health?  
Please circle AS MANY as apply, or circle ‘Unsure’ 
a) It can help to control blood glucose levels 
b) It can lower blood pressure 
c) It can help to regulate a person’s mood 
d)  It can reduce the risk of skin cancer 
e)  It can lower cholesterol levels 
f)  Unsure 
12. If a person with diabetes has a hypo (low blood glucose level) reaction, s/he 
should: Please circle ONE answer only 
a)  Immediately take some insulin or diabetes tablets 
b)  Rest and wait until s/he feels better 
c)  Immediately have some sugary food or drink (e.g. jelly beans, soft 
drink) 
d)  Drink some diet soft drink 
e)  Unsure 
1. Family history compromised the following items: 
a. Which kind of diabetes is suffered? 
b. Do you have a family history of diabetes? 
c. Who in your family has diabetes? 
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2. Background diabetes knowledge consisted of: fourteen items adopted 
from MDKT with slight changes in the types of food to fit availability in 
Libya or Libyan cuisine; and four questions generated from glucometer 
guidelines: 
a. MDKT questions 
b. Correct method of measuring blood glucose 
c. Normal range of blood glucose pre prandial  
d. Normal range of blood glucose after 2 hours from eating 
e. How to note your blood glucose measurements? 
3. Eleven items adopted from the ADKT 
The pilot (Appendix 8) and main questionnaire (Appendix 9) were similar in 
Section One and the MDKT questions. There was a difference in: 
 Availability of OHMs (biguanides, sulfonylureas, benzoic acid & phenylanine 
derived, thiazolidiones, alphaglucosidase inhibitors, DDP-4 inhibitors 1 and 
GLP-1 
 Availability of glucose meter and urine dipsticks. Caseload and workload. 
 Reasons for pharmacy visits. 
The reasons for this difference were: 
 The availability of hypoglycaemic medicine and glucometers is not one of 
the study objectives the study concerned with clinical outcomes of glycaemic 
control (in terms of counselling and education). 
 The current study does not concern the reasons why the clients visit the 
pharmacy. 
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5.2.6. Brief description of Michigan Diabetes Knowledge Test 
(MDKT) and Australian Diabetes Knowledge test (ADKT) 
The knowledge question used were taken from both the Michigan Diabetes 
Research Training Centre (MDRTC) and the Australian National Consensus 
Position (ANCP) on Outcomes and Indicators for Diabetes Education (O&IDE), 
which identified knowledge and understanding as the outcomes most directly 
affected by diabetes education (Eigenmann& Colagiuri, 2011).  
The Michigan Diabetes Knowledge Test (MDKT) comprises 23 knowledge test 
items; the first 14 items are used in the current study to assess pharmacists’ 
knowledge (University of Michigan Health System, 2013). Fitzgerald et al (1998) 
stated that the knowledge diabetes test is reliable and valid, and is supported 
because the coefficient Alfa for the general diabetes test is ≥0.7. This suggests 
that the test is appropriate for a variety of settings. The test is also appropriate 
as a measure of general diabetes knowledge levels for researchers. It can be a 
useful method for group comparisons and for assessing knowledge over time. 
The usefulness of this test, as an outcome measure for educational 
interventions, remains to be fully determined. Al-Qazaz (2010) conducted a 
study to measure the reliability and validity of a Malaysian translated version of 
the MDKT. The findings of the validation study indicate that the Malaysian 
version was a reliable and valid measure of diabetes knowledge, and could be 
used in clinical and research practice. Importantly, MDKT data confirms its 
reliability and validity—even when translated into another language (Al-Qazaz, 
2010). 
The Australian National Consensus Position (ANCP) on Outcomes and 
Indicators for Diabetes Patient Education (O&IDPE) (Eigenmann & Colagiuri., 
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2007 , Colagiuri and Eigenmann, 2009) identified four patient-centred key 
outcome areas of knowledge and understanding, self-management, self-
determination and psychological adjustment expressed in the order in which 
each area is most influenced by diabetes education. The ANCP developed their 
questionnaire by evaluating the available tools on their ability and suitability for 
measuring changes in the four key outcomes (Eigenmann et al., 2009).While 
three knowledge assessment tools were identified, none met all of the 
systematically derived quality appraisal criteria. 
The first of the three tools, the diabetes knowledge test (DKT), was developed 
and validated in the mid-1980s by the Michigan Diabetes Research and 
Training Centre to address the need for a valid and reliable diabetes specific 
knowledge instrument that could be used by diabetes educators and 
researchers (Hess and Davis, 1983, Fitzgerald et al., 1998).  In 1984, a series 
of three diabetes knowledge assessment scales (DKNA, DKNB and DKNC, 
each of 15 items) were developed and validated for the Australian environment 
(Dunn et al., 1984).  None of the DKN scales had since been updated and they 
no longer reflected current Australian guidelines and standards of care (e.g. 
they referred to urine sugar testing which was no longer recommended) and, 
like the DKT, they contained many questions regarding insulin therapy, which 
did not fit the criteria for a generic tool that is applicable to all people with type I 
or II diabetes. The third identified validated knowledge questionnaire, the 
ADKnowl, was developed and tested in the UK (Speight and Bradley, 2001). It 
consists of 23-item sets with a total of 104 questions/ items which makes it a 
more comprehensive, thus a more onerous and resource intensive tool for 
application in a clinical setting, and hence did not meet the Australian criteria for 
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a brief tool. Given the lack of an up-to-date, validated instrument, The ANCP 
aimed to develop, pilot and validate a generic, brief ADKQ capable of 
measuring knowledge change following a diabetes education intervention and 
which would be suitable for people with both type I and II diabetes. 
The ADKQ includes separate questions for people not taking diabetes 
medication (12 items), people taking diabetes medication and/or insulin (two 
items) and additional items for people with type I diabetes only (total 15 items). 
The ADKQ is a brief, 15-item knowledge questionnaire with seven additional 
demographic questions added if required, taking between 5–15 minutes to 
complete – hence making it feasible to apply in a busy clinical setting. The 
readability, using the ‘Flesch Reading Ease’ test, was considered highly 
acceptable, hence making the tool applicable to people with a low literacy level. 
The importance of consumer input has been increasingly advocated by 
consumer and health care provider organisations.  
The knowledge questions used were taken from both the Michigan Diabetes 
Research Training Centre (MDRTC) and the Australian National Consensus 
Position (ANCP) on Outcomes and Indicators for Diabetes Education (O&IDE), 
which identified knowledge and understanding as the outcomes most directly 
affected by diabetes education (Eigenmann & Colagiuri, 2011).  
The Michigan Diabetes Knowledge Test (MDKT) comprises 23 knowledge test 
items; the first 14 items are used in the current study to assess pharmacists’ 
knowledge (University of Michigan Health System, 2013). Fitzgerald et al (1998) 
stated that the knowledge diabetes test is reliable and valid, and is supported 
because the coefficient Alfa for the general diabetes test is ≥0.7. This suggests 
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that the test is appropriate for a variety of settings. The test is also appropriate 
as a measure of general diabetes knowledge levels for researchers. It can be a 
useful method for group comparisons and for assessing knowledge over time. 
The usefulness of this test, as an outcome measure for educational 
interventions, remains to be fully determined. Al-Qazaz (2010) conducted a 
study to measure the reliability and validity of a Malaysian translated version of 
the MDKT. The findings of the validation study indicate that the Malaysian 
version was a reliable and valid measure of diabetes knowledge, and could be 
used in clinical and research practice. Importantly, MDKT data confirms its 
reliability and validity—even when translated into another language (Al-Qazaz, 
2010). 
The Australian National Consensus Position (ANCP) on Outcomes and 
Indicators for Diabetes Patient Education (O&IDPE) (Eigenmann and Colagiuri, 
2007;Colagiuri and Eigenmann, 2009) identified four patient-centred key 
outcome areas of knowledge and understanding, self-management, self-
determination and psychological adjustment expressed in the order in which 
each area is most influenced by diabetes education. The ANCP developed their 
questionnaire by evaluating the available tools on their ability and suitability for 
measuring changes in the four key outcomes (Eigenmann et al., 2009).While 
three knowledge assessment tools were identified, none met all of the 
systematically derived quality appraisal criteria. 
In the professional questionnaire both knowledge tests were used in order to 
assess diabetes background information and diabetes practice information. The 
first 14 items from the MDKT (Fitzgerald et al., 1998) were chosen and 11 items 
from the ADKT (Eigenmann et al., 2011). The selection of items was based on 
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knowledge of five basic aspects of diabetes management (diet, blood glucose, 
feet, exercise, complications, and check-up managements) that were suitable to 
assess pharmacists’ knowledge. A comparison was made between both tests 
(see Table 5.1).The table shows the differences around specific key 
managements of type II diabetes. The findings show that the MDKT asks about 
background information rather than practical concerns. Conversely, the ADKT 
address diabetes practice information. A view was taken that practical 
information provided a better understanding of professional or patient 
knowledge, and also it is easy to remember. However, background information 
may be it easier to forget and the context of background questions can be 
difficult to understand. Most studies using the MDKT for patients have found 
that patients with diabetes have poor knowledge (Al-Maskari et al., 2013, Al-
Adsani et al., 2009, Odili et al., 2011). The validity of the MDKT cannot be 
questioned but it may present difficulties for both patients and professionals as 
a baseline assessment (rather than following specific training). 
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Table  5.1: Outline comparison between Michigan Diabetes Knowledge Test 
and Australian Diabetes Knowledge Test 
MDKT ADKT 
Concerns background diabetes 
information 
Concerns practical diabetes 
information 
Somewhat complicated questions Simple questions 
Somewhat difficult to understand Easy to understand 
Valid and reliable when translated 
into other languages 
Not translated into other 
languages 
Questions do not provide reader with 
knowledge  
Questions provide reader with 
diabetes knowledge 
Different studies used Is not used by other researchers  
Old test Recent test  
There are no questions about 
diabetes health check-ups, diabetes 
medicine management and the 
definition of diabetes 
There is questions about 
diabetes health check-ups, 
diabetes medicine management 
and the definition of diabetes 
 
The detailed comparison between the MDKT & ADKT is provided in (Appendix 
10). Both tests may be reliable and valid, but there are some differences in the 
way of asking questions. Concerning diet management, both define healthy diet 
but the ADKT adds that a healthy diet contain high fibre. Concerning blood 
glucose measurement management, the ADKT provides the respondent with 
the knowledge that HbA1c measures the average blood glucose over the past 2 
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to 3 months and tests the understanding of optimal blood glucose level. 
Concerning impact of infection on blood glucose the MDKT covers the 
consequences of infection. However, the ADKT covers self-management when 
you get cold or practical methods to manage the infection. 
Concerning foot care management, the MDKT tests knowledge of foot care 
management and symptoms and the ADKT tests knowledge about symptoms of 
neuropathic complications. Concerning exercise management, the ADKT 
describes the importance of exercise precisely by testing the frequency of 
exercising and reason for exercising, while the MDKT asks about the impact of 
exercising when you have good blood glucose control. Concerning blood 
glucose management, the ADKT highlights the reason for monitoring blood 
glucose, but the MDKT highlights the best method of blood glucose 
measurement. MDKT tests the respondents understanding about diabetes 
complications. However, the ADKT highlights the benefit of good diabetes 
management on patients’ health and address the complications of diabetes at 
the same time. Concerning hypoglycaemic management, the MDKT defines 
which sweet drink should be avoided whilst the ADKT asks how to manage 
hypoglycaemia effectively and clarifies which sugary drink is recommended. 
Concerning check-up management, in the MDKT there are no questions about 
the importance of check-ups but the ADKT shows concern for the importance of 
health check-up for eyes, feet and kidney. Concerning diabetes medication 
management, there are no questions in the MDKT, nor any questions about the 
definition of diabetes. 
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5.2.7. Study Hypotheses  
The hypothesis below were tested in the pilot questionnaire (with a small 
sample size) and re-tested in the analysis of the main questionnaire. 
 More years of experience would be associated with higher MDKT scores. 
 More years of experience would be associated with greater adherence to 
SOPs. 
5.2.8. Statistical Analysis  
The data was analysed using Statistical Package for Social Sciences (SPSS) 
and Excel. Descriptive statistics were used for demographic characteristics. Bar 
charts used to highlight frequency of SOPs, reasons for not providing patient 
counselling and categories of type II diabetes knowledge test. Regression 
analysis was used to test the association between acquiring high scores of 
MDKT and more years’ experience. 
Questions about SOPs had the options “always”, “frequently”, “sometimes”, 
“rarely” “never”. The “always” and “frequently” option was considered as good 
practice and other options were considered as negative practice. One score 
was given to each “always” and “frequently” option and the practice score was 
calculated by adding the points for each “always” and “frequently” answer. The 
total score for practice was classified into “positive practice” for score ranging 
(5.5–11) and “negative practice” for (0–5). This kind of analysis was adopted 
from Al-Maskari et al. (2013) and Shrestha et al. (2015). 
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5.3. Results of Community Pharmacists Their Knowledge and 
Practice toward Type II Diabetes 
The study was carried out in Tripoli, Libya, in which there are 426 community 
pharmacies (WHO, 2007).  One hundred and twenty five copies of the 
questionnaire were delivered by hand; of these, one hundred and eight were 
returned (86% response rate); seventeen (13%) were not returned. This is the 
first stage of a wider study and was considered an exploration to enable 
shaping of the training for community pharmacists for the remainder of the 
project. 
5.3.1. Response rate 
The piloted sample and main sample participants are completely different to 
avoid study bias. For the piloting stage, a total of 53 copies of the self-
completion questionnaire (Appendix 8) (see flow chart Figure 5.1) were 
distributed by hand. There were 30 Arabic translated versions (distributed on 
October 1, 2012) from which 8 refused participation for different reasons: 5 
participants stated a lack of time, whilst 3 neglected to fill in the questionnaire 
and were deemed not interested in the study. Furthermore, 23 copies of the 
English version of the questionnaire were distributed by hand on December 18, 
2012 with all collected (Elhatab, 2013). 
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Figure  5.1 : Flow chart showing distribution of pilot self-completion 
questionnaire 
For the main type II diabetes knowledge and practice questionnaire a total of 
125 copies of the final self-completion questionnaire (Appendix 9) were 
distributed by hand in August 2014; of these, one hundred and eight were 
returned a total of 17 refused participation for different reasons; 10 participants 
stated a lack of time, whilst 7 neglected to fill in the questionnaire and were not 
interested in the study (see flow chart Figure 5.2). 
  
8 refused to 
respond 
53 copies of self-completion 
questionnaire distributed to community 
pharmacists 
23 copies of 
questionnaire 
distributed in 
English  
30 copies of 
questionnaire 
translated into 
Arabic  
22 of 
community 
pharmacists 
responded 
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Figure  5.2: flow chart of main study 
5.3.2. Respondents’ Demographic and Characteristics  
Data was gathered from 108 copies of the main self-completion questionnaires 
(see Appendix 9) distributed to 30 areas located in Tripoli. Table 5.2 shows the 
demographic characteristics of community pharmacists in Tripoli, Libya. Nearly 
three quarters were qualified with a bachelor degree (n=74/100, 74%), in almost 
all cases this was pharmacy (n=93/98, 95%) and studied at university 
(n=90/100, 83%); there were equal numbers of males (n=55/108, 50%) and 
females (n =53/108, 49%). The mean (±sd) years of experience as a community 
pharmacist were 6 (±5.13). Over three quarters of respondents did not have 
diabetes special training (84/107, 79%). Just over half of the community 
pharmacies were located in commercial areas (n=63/108, 58%). 
Table 5.3 indicates the personal history of diabetes among participants. Most of 
the pharmacists did not have diabetes (103/108, 95%).  However, more than 
three quarter of respondents had a family history of diabetes (81/108, 75%) and 
for half of participants this was close relatives with their parents having diabetes 
(54/108, 51%). 
125 copies of self-completion 
questionnaire distributed  
108 community 
pharmacists responded 
and returned 
questionnaire  
17 refused to 
participate  
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Table  5.2: Demographic characteristics of respondents  
Parameter Number  Percent 
Total number  108  100% 
Academic Qualification  
Higher diploma 
Bachelor 
MSc 
 
13/100 
74/100 
13/100 
 
13% 
74% 
13% 
Which faculty graduated 
from: 
Facility of Pharmacy 
Facility of Medicine  
 
93/98 
5/98 
 
95% 
5% 
Institution 
University 
College 
 
90/100 
10/100 
 
83% 
9% 
Years of graduation  
1981-1990 
1991-2000 
2001-2010 
2011-2013 
 
3/101 
4/101 
76/101 
18/101 
 
3% 
4% 
75% 
18% 
Years of profession as 
community pharmacy 
1-10 
11-20 
21-30 
31-40 
 
 
94/101 
4/101 
2/101 
1/101 
 
 
93% 
4% 
2% 
1% 
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Continue…… Table 5.2   
Parameter Number  Percent 
 
Gender 
Male  
Female  
 
55/108 
53/108 
 
51% 
49% 
Special diabetes training  
Yes 
No 
 
23/107 
84/107 
 
22% 
79% 
Area location  
Residential 
Commercial 
 
45/108 
63/108 
 
42% 
58% 
Number of participants 
provided contact details  
Yes  
No 
 
 
55/108 
53/108 
 
 
50% 
49% 
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Table  5.3: Personal history of diabetes 
Parameter Number  Percent 
Personal diabetes  
Type I 
Type II 
No 
 
4/108 
1/108 
103/108 
 
4% 
1% 
95% 
Family history of diabetes  
Yes 
No 
 
81/108 
27/108 
 
75% 
25% 
Who have diabetes in 
your family? 
Father or mother 
Aunt or uncle 
Brother or sister 
Grandparents  
 
 
 
54/108 
14/108 
4/108 
11/108 
 
 
50% 
13% 
4% 
10% 
 
5.3.3. Frequency of implementing standard operating procedures 
(SOPs) 
Table 5.4 shows that the community pharmacist generally had negative 
practice (60/103, 58%). Table 5.5 and Chart 5.1 show that the most common 
practices that pharmacists always performed were to give information about: 
how to use the medicine (n=80/103, 79%); what is the medicine for (n=61/101, 
61%); when to use medicines (n=54/98, 56%); and special storage instructions 
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(n=47/99, 48%). On the other hand, when comparing with other SOPs, it can be 
seen that the highest percentages of SOPs that are never performed include: 
discuss information on medicines with the patient rather than just presenting 
(n=22/101, 22%); offer patients information about medicines before the 
medicines are prescribed (16/100 16%); and check that patients have any 
information they wish about medicines when the medicines are dispensed 
(n=15/99, 15%). 
Kruskal Wallis Test results (see Table 5.6) shows there is no difference 
between years of experience and greater adherence to SOPs, the prior 
hypothesis was rejected. With respect to offering patients information there is a 
trend (p=0.06) towards an associated with years of experience. 
Table  5.4: Positive and negative practice toward type II diabetes 
Practice scores Frequency Percent 
5.5-11(positive Practice) 43/103 42% 
0-5 (Negative Practice) 60/103 58% 
Total 108 100 
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Table  5.5: Frequency of implementing standard operating procedures (SOPs) 
Items of SOPs Always 
N 
(%) 
Frequently 
N 
(%) 
Sometimes 
N 
(%) 
Rarely 
N 
(%) 
Never 
N 
(%) 
How to use the 
medicine 
80/103 
79% 
19/103 
18% 
2/103 
2% 
2/103 
2% 
0/103 
0% 
What is the 
medicine for? 
61/101 
61% 
 
30/101 
29% 
7/101 
7% 
3/101 
3% 
0/101 
0% 
Special storage 
instructions 
47/99 
48% 
22/99 
22% 
18/99 
17% 
7/99 
7% 
5/99 
5% 
When to use 
medicines 
54/98 
56% 
19/98 
20% 
17/98 
17% 
5/98 
5% 
3/98 
3% 
Food/drinks to 
avoid 
40/100 
39% 
20/100 
20% 
25/100 
25% 
10/100 
10% 
5/100 
5% 
Special 
instructions 
35/100 
35% 
23/100 
23% 
21/100 
21% 
15/100 
15% 
6/100 
6% 
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Side effects to 
expect 
26/97 
27% 
24/97 
25% 
28/97 
29% 
14/97 
15% 
5/97 
5% 
How the medicine 
is likely to affect 
their condition 
(that is, benefits) 
27/100 
27% 
25/100 
25% 
31/100 
31% 
9/100 
9% 
8/100 
8% 
Offer patients 
information about 
medicines before 
the medicines are 
prescribed  
17/100 
17% 
9/100 
9% 
35/100 
35% 
23/100 
23% 
16/100 
16% 
Check that 
patients have any 
information they 
wish about 
medicines when 
the medicines are 
dispensed 
15/99 
15% 
14/99 
14% 
28/99 
28% 
27/99 
28% 
15/99 
15% 
Discuss 
information on 
medicines with 
the patient rather 
than just 
presenting it  
12/101 
12% 
12/101 
12% 
29/101 
29% 
26/101 
26% 
22/101 
22% 
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Chart  5.1: Frequency of implementing standard operating procedures (SOP) 
  
79% 
61% 
47% 
56% 
39% 36% 
27% 28% 
17% 15% 12% 
0%
10%
20%
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40%
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60%
70%
80%
90% Always
Frequently
Sometimes
Rarely
Never
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Table  5.6: Kruskal Wallis Test to test hypothesis that more years of experience 
is associated with greater adherence to SOPs 
Items of SOPs Chi-Square Df Asymp. Sig. 
How to use the medicine 2.862 3 0.413 
What is medicine for? 2.457 3 0.483 
Special Storage 4.332 3 0.228 
When to use the 
medicine 
1.703 2 0.427 
Food/drinks to avoid 4.764 3 0.190 
Special instruction 3.700 3 0.296 
Side effects to expect 3.327 3 0.344 
How the medicine is 
likely to affect your 
condition 
3.977 3 0.264 
Offer patients 
information 
7.286 3 0.063 
Check that patient have 
information they need 
about the medicine 
3.891 3 0.274 
Discuss information on 
medicine 
5.055 3 0.168 
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5.3.4. Reasons for not providing patient counselling 
Patient counselling is a key competency element of the pharmaceutical care 
process (NBPS, 2015). In practice, it ranges from simply stating the dosage of a 
drug as it is handed over to the client, through counter prescribing for common 
ailments, to giving advice with regard to lifestyle and health promotion issues, 
like smoking cessation, cholesterol testing and contraception (Pilnick, 2003). In 
Libya, there is a lack of patient counselling strategy and understanding what 
hiders patient counselling is important. 
As shown in Table 5.7 the lack of support staff (4.03 ±1.17) was rated as a very 
important reason for counselling not being given. Less important reasons were 
counselling not being part of role (1.80 ±0.97), lack of knowledge/training (1.81 
±1.17), lack of pharmacists interest (1.84 ±1.02), lack of self-confidence (1.92 
±1.01), lack of patients interest (2.13 ±1.23), lack of pharmacists time (2.32 
±1.40) and lack of patients time (2.50 ±1.13). 
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Table  5.7: Reasons for counselling not being provided 
Reasons  
Number of 
pharmacists 
Rating (Mean ±SD, scale 1 
very low to 5 very high) 
Lack of pharmacists time 101 2.32 ±1.40 
Lack of patients interest 101 2.13 ±1.23 
Lack of patients time 101 2.50 ±1.13 
Lack of support staff 100 4.03 ±1.17 
Lack of 
knowledge/training 
101 1.81 ±1.17 
Lack of self confidence 100 1.92 ±1.01 
Lack of pharmacists 
interest 
101 1.84 ±1.02 
Counselling not part of 
role 
101 1.80 ±0.97 
Total 108  
5.3.5. Awareness of oral hypoglycaemic medicine 
recommendations  
Table 5.8 assesses pharmacist awareness regarding type II diabetes oral 
hypoglycaemic agent recommendations, which were adopted from SIGN. The 
items used from SIGN 116 are also recommended in Libyan Diabetes Care 
Guidelines (LDCG) but with slight differences. Nearly three quarters of 
participants correctly answered with grade A that metformin is first line therapy 
(74/100, 74%) and 45% (43/96) answered correctly that pioglitazone should not 
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be used in patients with heart failure. While just one quarter (23/98, 24%) 
answered correctly that the risk of fracture should be considered in the long 
term care of female patients treated with pioglitazone. A low number of 
pharmacists were aware that patients prescribed pioglitazone should be made 
aware of the increased risk of peripheral oedema (15/98, 15%). 
5.3.6. Pharmacists’ Diabetes Knowledge Test 
The DKT used comprised 29 items; the statistics show that the community 
pharmacist average scores was 21/29 (±3.16) with a range of 12–26, meaning 
they generally had good diabetes knowledge. Table 5.9 & Chart 5.2 show the 
items of the diabetes knowledge test characterised into four categories (with 
average scores and correct percentage): measuring blood glucose (5.03±1.19, 
72%), lifestyle management (8.08±1.61, 67%), foot care and infection 
management (4.99±1.10, 83%) and diabetes general management (2.86±0.93, 
72%). Table 5.10 shows that the average scores in each tool of diabetes 
knowledge test. The ADKT average scores were 8.9/11±1.56 and average 
scores for MDKT were 9.3/14±2.17 and the items of testing pharmacist’s 
knowledge toward measuring blood glucose 2.7/4±1.00.  
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Table  5.8: Responses of Scottish Intercollegiate Guidelines Network 
Recommendation 
Items Grade A Grade B 
 Recomm
ended 
best 
practice 
Metformin should be considered as 
first line oral treatment option for 
overweight patients with type II 
diabetes  
74/100 
74% 
14/100 
14% 
12/100 
12% 
Sulfonylureas should be considered  
as first line oral agents in patients 
who are not overweight, who are 
intolerant of, or have 
contraindications to, metformin  
24/97 
25% 
43/97 
44% 
30/97 
31% 
Pioglitazone can be added to 
metformin and sulfonylurea therapy, 
or substituted for either in cases of 
intolerance. 
33/96 
34% 
33/96 
34% 
30/96 
31% 
Pioglitazone should not use in 
patients with heart failure 
43//96 
45% 
21/96 
22% 
32/96 
33% 
The risk of fracture should be 
considered in the long term care of 
female patients treated with 
pioglitazone.  
46/98 
47% 
23/98 
24% 
29/98 
30% 
Patients prescribed pioglitazone 
should be made aware of the 
increased risk of peripheral oedema.  
66/98 
67% 
17/98 
17% 
15/98 
15% 
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Table  5.9: The responses to the diabetes knowledge test 
Categories of DKT No of items Mean (SD) Correct 
answers (%) 
Measuring blood 
glucose  
7 5.07(±1.22) 72% 
Lifestyle management 
(diet and exercise) 
12 8.08(±1.61) 67% 
Foot care and infection 
management 
6 4.99(±1.10) 83% 
Diabetes general 
management 
4 2.86(±0.93) 72% 
Total knowledge score 29 21.0(3.16) 72% 
 
Chart  5.2: The results of four categories of pharmacist’s diabetes knowledge 
test 
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Table  5.10: The average scores in the ADKT, MDKT and blood glucose 
measurement test 
Parameters  ADKT MDKT Blood glucose 
measurement test 
Mean (± sd) 8.9±1.56 9.3±2.17 2.7±1.00 
Number of questions  11 14 4 
Total of respondents:  108 
A prior hypothesis was that more years’ experience would be associated with 
higher DKT scores. In the pilot sample an association was seen. However, the 
results of regression analysis in this larger sample showed no relationship 
between years of experience and acquiring high DKT scores (b= 0.03; p=0.56). 
Therefore, the null hypothesis was accepted that there is no difference between 
pharmacist’s diabetes knowledge and years of experience practicing as 
community pharmacist (in the current sample). 
5.4. Discussion 
Pharmacists are part of a multidisciplinary team. This team normally consists of 
pharmacist, physician, nurse, technician, nutritionist, and other health care 
professions. Intensive diabetes education and care supervision can progress 
patient outcomes, glycaemic control and improve standard of life in patients 
(McMurray et al., 2002). Our study shows that the community pharmacists have 
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good knowledge about type II diabetes care. The response rate was very good 
at 86.4%. As reported by Elerby et al., (1993) and Rosenbloom (2000), attitude 
surveys suggest 32% of pharmacists participate in pharmacy practice research, 
but actual involvement rates were as low as 6%. For the diabetes knowledge 
test, a previous study found that the participants’ mean knowledge score was 
10.67/20 (Shrestha et al., 2015); while the mean score in the current study was 
21/29 (±3.16). 75% of participants in the current study had a family history of 
diabetes, which could be a factor in pharmacist’s good knowledge about type II 
diabetes management. 83% of participants scored higher in the awareness of 
foot care and infection management it seems that most pharmacists were 
aware that damage to the nerves of the foot can mean small nicks and cuts 
aren't noticed and this, in combination with poor circulation, can lead to foot 
ulcers. However, the knowledge about lifestyle management (diet and exercise) 
was the lowest at 67%, which is the main focus in the current study regarding 
non-pharmacological management of type II diabetes. This is the reason to do 
training in next stage of the study to make sure that the community pharmacists 
are able to provide patient participants with the recommended information. 
The study shows that the diabetes knowledge is better than in the study 
conducted by Bisheya et al (2011). The questions used to measure awareness 
among community pharmacists were the Michigan Diabetes Knowledge Test 
(MDKT) and the Australian Diabetes Knowledge Test (ADKT). Average scores 
in the ADKT were better than the MDKT that is because the MDKT asks 
background questions (which are easy to forget) rather than practical ones. I 
used the concept of standard operating procedures (SOPs), which includes all 
the written protocols and procedures in place within a pharmacy. They state the 
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way that the pharmacy expects tasks to be carried out to ensure provision of a 
quality service. They include, for example, the questions that must be asked of 
a patient so that his or her needs can be correctly identified and appropriate 
action taken (Langley & Belcher, 2012). A commonly encountered strategy for 
improving patient safety is the standardisation of healthcare practice, often by 
developing and implementing standardised procedures (in the form of 
guidelines, protocols and standard operating procedures (SOPs) (Harrison & 
Smith, 2004). In principle, procedures provide assurance by holding healthcare 
staff to a minimum standard of practice and controlling aspects of their work 
that may create patient safety hazards (Berwick, 1991; Smith, 2009). Some 
studies found that the implementation of SOPs has had a more limited effect on 
working practices than anticipated (Pittet et al., 2000; Smith et al., 2006; Walker 
et al., 2001; Watson et al., 2006). Our results are consistent with previous 
studies around SOPs, which indicated that community pharmacist had limited 
adherence to some (recommended) tasks (categorised in the current study as a 
negative practice). Thomas et al (2017) suggested that such findings have led 
researchers to examine the relationship between procedures and practice in 
healthcare. Reason et al (1998) and Dekker (2003) noted that strict adherence 
to inflexible procedures can make a task inefficient, or even unachievable, in 
practice.  
The relationship between procedures and practice can be understood in terms 
of organisational ‘resilience’ that is, the ability of an organisation or its members 
to maintain effective and efficient work in the face of a dynamic environment 
that is characterised by discontinuities in care, hazards, trade-offs and multiple 
goals (Cook et al., 2000; Jeffcott et al., 2009). According to the notion of 
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resilience, staff may adapt their work activity in order to achieve task goals 
under the prevailing circumstances, thus creating a divergence between ‘work 
as imagined’ (as represented by the formal procedures) and ‘work as done’ (as 
represented by actual practice at a given time or in a given location) (Dekker, 
2003; Hollnage et al., 2007; Hollnagel, 2015). Hence, the effect of implementing 
procedures is determined by the relationship between these two aspects of 
work. 
There are some limitations and difficulties faced in the study. Despite the fact 
that self-administered questionnaires are often the only financially viable option 
when collecting information from large, geographically dispersed populations, it 
has been shown that this method of data collection has various disadvantages 
(Smeeth et al., 2001, Edwards et al., 2002). The questionnaire was distributed 
by hand due to the unstable situation in Libya.  The method of collecting data is 
stressful and time was limited. Moreover, other difficulties were faced in that the 
collection of data took a prolonged time because the data was returned via air 
to the UK. Is not easy delivering questionnaires by hand; it is an old method; 
however, the situation in Libya is difficult and so there was no choice. 
5.5. Conclusion  
This study identified the current diabetes knowledge and practice of community 
pharmacists in Tripoli, Libya. In general, our results suggest that community 
pharmacists had good knowledge about diabetes, which could be a foundation 
for more clinical practice. Basic provision of information for patients appeared to 
be good; however, there were opportunities to enhance the level of care 
provided.  
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5.6. Chapter summary  
The survey highlights the knowledge and practice toward type II diabetes 
among community pharmacists in Tripoli, Libya. Reliable tools were used to 
measure diabetes knowledge: Michigan Diabetes Knowledge Test (MDKT) 
(Fitzgerald et al., 1998) and Australian Diabetes Knowledge Test (ADKT) 
(Eigenmann et al., 2011). A comparison between MDKT and ADKT showed that 
the tested background knowledge while the measured practical diabetes 
knowledge. For this reason, both tests were used to provide a full picture of 
community pharmacists’ diabetes knowledge. This knowledge will be employed 
for the next stage of study, a randomised controlled trail. The counselling 
practice (Nursing and Midwifery Council, 2007) identified in our study suggests 
that the community pharmacist require training to enhance their counselling 
practices. This data agrees with a study completed in Saudi Arabia, which also 
observed pharmacist counselling practice and found that there were 
deficiencies in appropriate dispensing practices and medication counselling in 
community pharmacies (Alaqeel and Abanmy, 2015). The authors 
recommended that policy makers, stakeholders, and researchers should 
collaborate to design interventions to improve the current dispensing practices 
in community pharmacies (Alaqeel and Abanmy, 2015).  
In Chapter Six the training stage will be described and evaluated. 
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6. Enhancing community pharmacists knowledge (training stage) 
This chapter explains the importance of pharmacist education to enhance the 
role of pharmacists in type II diabetes disease management. This chapter is 
divided into six sections. The introduction Section 6.1 highlights the main 
aspects of pharmacist training. The methods and study design are outlined in 
Section 6.2. Statistical results are provided in Section 6.3. The discussion is in 
Section 6.4 and the conclusion in Section 6.5. A chapter summary is provided 
in Section 6.6.  
6.1. Background of the main aspects of pharmacist training  
The aim of the current study is to develop the role of community pharmacists in 
type II diabetes management. Enhancement of community pharmacists’ 
diabetes knowledge and practice is needed to improve counselling skills for 
patients with type II diabetes. Pharmacists are highly accessible to chronically ill 
patients such as those with diabetes, especially when the disease becomes 
controlled and the patient only needs to visit a pharmacy to have their 
prescription refilled. Pharmacists’ knowledge and attitudes toward diabetes 
could significantly influence patient outcomes. Given the prevailing concept of a 
team approach toward diabetes care, only when all health care providers share 
the same high level of knowledge and positive attitudes could the quality of 
patient care be ensured (Chen et al., 2004). 
Pharmaceutical care has significantly reduced the occurrence of drug-related 
problems and fulfilled the desired outcomes of drug therapy in other diseases 
and conditions such as anticoagulation, hyperlipidaemia, and asthma 
(Garabedian-Ruffalo et al., 1985, Pauley et al., 1995). Studies have also shown 
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that pharmacists’ participation in the care of poorly controlled patients with type 
II diabetes resulted in better outcomes (Davidson et al., 2000, Mehuys et al., 
2011, Poolsup et al., 2013). However, even in developed countries like the 
USA, pharmacists participating in diabetic care are still not required to be 
Certified Diabetes Educators (CDEs); and applying the practice of 
pharmaceutical care to CDE certification could strengthen the team approach 
toward diabetes care and therefore warrants careful consideration (Chen et al., 
2004). 
The practice of diabetes care has dramatically changed during the past two 
decades. Knowledge regarding diabetes pathophysiology has quickly 
accumulated and has led to the development of new medications. In addition to 
knowledge updates, the attitudes of health care professionals toward current 
concepts in diabetes care are even more critical. The core philosophy of 
modern diabetes care puts emphasis on patient autonomy and optimal 
utilization of health care professionals’ from different specialties. Research 
evidence derived from clinical, economic, and humanistic outcomes also 
strongly supports the importance of patient autonomy and a team approach to 
diabetes care. To address the needs in clinical practice in the USA, a continuing 
education (CE) programme and a Certificated Diabetic Educator (CDE) 
designation were created to help pharmacists catch up with the developments 
in diabetes care (Chen et al., 2004). 
The efficacy of a diabetes CE programme should be systematically evaluated to 
ensure the fulfilment of its goal of bridging the gap between current practice and 
the most up-to-date evidence-based guidelines. Using short-term indicators to 
evaluate the impact of a CE programme could be an essential part of 
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establishing integrated diabetes care. Assessing changes in knowledge 
provides direct, initial understanding of the impact of a CE programme. 
However, improvements in knowledge often cannot predict the improvements in 
practice (Chen et al., 2004). The theory of reasoned action states that people 
intend to perform behaviour, such as encouraging patients to monitor blood 
glucose levels, only when they evaluate it positively (Ajzen and Fishbein, 1977). 
Knowledge as well as health care providers’ attitudes will influence their clinical 
practice and patient outcomes. Measuring changes in attitudes toward diabetes 
provides better insight into the true influences of a CE programme (Sharp and 
Lipsky, 1999). Continuing professional development (CPD) is a framework for, 
or approach to, lifelong learning and is being discussed as a potential model for 
pharmacists in the United States. CPD is not a replacement for continuing 
education (CE), as quality-assured CE is an essential component of CPD 
(Rouse, 2004).  
6.2. Methods 
The training of community pharmacists was carried out after randomisation at 
the areas level or geographical classification of areas (see Appendix 24). 
There were 40 pharmacies in the clinical trial, which were split into 18 control 
and 22 intervention locations. The education materials (see Appendix 12) were 
provided to intervention community pharmacists only. The education material 
was adapted from a website called diabetescare.net and permission requested 
from David Day the web content manger. The material is provided on the 
website as education for type II diabetes patients. The study protocol was 
provided to both control and intervention pharmacists. The education materials 
were sent by email to some places and hand delivered to others, because of 
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difficulty with internet connections. If intervention pharmacists had weak 
knowledge in any area, then they were sent a specific communication to correct 
and enhance that knowledge. 
Method of training: 
The twenty two intervention community pharmacists had been assessed with a 
diabetes knowledge test combining the Australian diabetes test and the 
Michigan diabetes test (Eigenmann et al., 2011, Fitzgerald et al., 1998). The 
reliability and validity of both tests is known. The investigator assessed 
pharmacists’ knowledge then sent education materials to the participants (see 
Appendix 11). The sheets highlighted areas of weakness for each respondent 
to improve their knowledge in specific areas. The documents were sent by 
email to 10 participants and to 11 by hand. Then, the participants were 
contacted by telephone to understand how they were doing and to explain the 
study protocol. After three months the community pharmacists were contacted 
by email and telephone and requested to take the test again to re-assess their 
knowledge (see Appendix 12). The study protocol was provided to both control 
and intervention pharmacists. Eighteen community pharmacists in the control 
arm were trained just for the study protocol. The study protocol was explained 
via telephone and Skype contact by asking the community pharmacist to: 
 Greet the patient; 
 Provide the patient with a glucometer; 
 Ask the patient to record the FPG on three consecutive days by 
recording the measurements on the FPG recording sheet (Appendix 
28); 
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 Provide patients with three printed sheets of questionnaires 
(Appendices, 18, 19 and 20). Ask the patient to fill the entire 
questionnaire and after three days return both the FPG record sheet and 
questionnaire sheets.  
 After six months of study. The patients were contacted by the phone to 
attend the pharmacy. To provide the patients with FPG record sheet and 
three sheets of questionnaire. 
Rationale for educational materials 
The training educational materials (Appendix 12) cover the components of the 
intervention: 
 Education about type II diabetes and it complications 
 Education about the correct use of oral hypoglycaemic agents (timing in 
relation to food);  
 Healthy lifestyle education (diet, physical exercise and smoking 
cessation); and 
 Reminders about annual eye and foot examinations 
Defining type II diabetes along with complications was described in section one 
& two. The information regarding oral hypoglycaemic medicines was highlighted 
in section two and section five, the healthy lifestyle information is in section two 
and section four. Reminders regarding annual health checks were described in 
section two. Other information about hypoglycaemic management was 
highlighted in section two (Rule of 15) and the diabetes emergency plan was 
described in section three.  
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In the educational materials health literacy is not described in context. However, 
the investigator used plain language in the printed educational materials 
(Appendix 25, 26) that were handed to patients in the intervention study (see 
Chapter 7). 
6.2.1. Study design 
The study was designed as a randomised clinical trial, the community 
pharmacies were randomised before the start of the training stage. Random 
sampling justify that each individual have same opportunity to include in the 
study. The flow chart (Figure 6.1) shows the distribution of community 
pharmacies in the training step. 
6.2.2. Statistical analysis  
Knowledge before and after training was analysed using SPSS 22. The 
descriptive statistics generated were: frequency, standard division, and range of 
scores. The detailed analysis plan split the twenty nine questions into four sub-
scales: Measuring Blood Glucose (MBG), Lifestyle Management (LSM), Foot 
Care and Infection Management (FCIM) and General Diabetes Management. 
The sub-scales contained: seven items for MBG, twelve items for LSM, five 
items for FCIM and five items for (GDM). Then each sub-scale was compared 
visually before and after training by using multiple bar charts paired samples t-
test compared before and after performance on each sub-scale and the 
average score for the whole questionnaire 
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Figure  6.1: Flow Chart of training community pharmacies 
6.3. Statistical results 
6.3.1. Demographic characteristics of respondents 
Table 6.1 describes the participants’ demographic profile in the training stage. 
There were 11 (61%) female pharmacists in the control group and 9 (41%) in 
the intervention group. In the control group 6 (33%) pharmacists had received 
special training about diabetes against 2 (9%) in the intervention group. Most 
18 community pharmacy 
control 
108 community pharmacies 
 
22 community 
pharmacy intervention 
18 pharmacists 22 pharmacists  
Both did training to avoid 
bias 
Random selection of 40 
community pharmacies  
Trained just for 
study protocol Trained for both study 
protocol and type II 
diabetes 
pharmacological effect  
Contains 
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participants did not have personal experience of diabetes, except for one in the 
intervention group. In both control and intervention groups the prevalence of 
diabetes family history was high (18, 100% vs 21, 95%). 
Table  6.1: Demographic characteristics in the training stage 
Items Control Intervention 
Total 18 22 
Gender 
Male  
Female 
 
7 (39%) 
11 (61%) 
 
13 (59%) 
9 (41%) 
Special Diabetes Training 
Yes 
No 
 
6 (33%) 
12 (67%) 
 
2 (9%) 
20 (91%) 
Location 
Commercial 
Residential  
 
13 (72%) 
5 (28%) 
 
8 (37%) 
14 (64%) 
History of diabetes 
Yes 
No 
 
0 (0%) 
18 (100%) 
 
1 (5%) 
21 (95%) 
Family history of diabetes 
Yes 
No 
 
14 (78%) 
4 (22%) 
 
13 (59%) 
9 (41%) 
6.3.2. Diabetes knowledge test  
The diabetes knowledge test was used to assess the intervention group before 
and after training to measure any improvement in diabetes knowledge among 
participants. There were 29 questions about type II diabetes. The average 
knowledge score before training in the control group was 19.4/29±3.14 vs 
21.6/29±3.09 intervention to facilitate comparison, before and after results for 
the four sub-scales are shown in Charts 6.1 to 6.4 
Chart 6.1 shows that before training the number of correct responses were 
lowest for understanding the HbA1c test (12, 55%). Chart 6.2 shows an 
improvement after training in knowledge about HbA1c (16, 73%) and 
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improvement in knowledge about: correct glucometer use; the normal range of 
blood glucose (BG); and the normal range of BG after 2 hours of meal. 
Reasons for testing blood glucose were well understood both before and after 
training (22, 100%). 
Chart 6.2 shows the level of awareness about lifestyle management before 
training. The worst knowledge revealed is the awareness of sugar free food 
answered correctly by 6 out of 22 (27%) but after training the number of 
respondents answering correctly increased to 20 (91%) .Lower levels of 
knowledge were also apparent before training for the question asks: Which 
should not be used to treat low blood glucose (8, 36%), the effect of 
unsweetened juice on hypoglycaemia (10, 45%), and the kinds of food high in 
fat (10, 45%). 
The third sub-scale (diabetes foot care and infection management) is presented 
in Chart 6.3. This shows the worst knowledge around the impact of infection or 
influenza on blood glucose (15/22, 68%) but this is improved after training 
(20/22, 91%). 
General diabetes knowledge management is presented in Charts 6.4. . Before 
training the worst knowledge is seen for a question about the recommended 
frequency of medical check-ups for eyes, nerve and kidney function. The 
correct answer (once a year) was given by only 9 out of 22 (41%) but this 
improved after training to 18 (82%). 
Table 6.2 shows the improved scores before and after training for the 
intervention pharmacists. The data shows that there was a significant 
enhancement in the diabetes knowledge test around measuring diabetes 
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knowledge and lifestyle management (P>0.001).
 
Chart  6.1: Responses before and after training for diabetes knowledge of 
measuring blood glucose among community pharmacists  
 
Chart  6.2: Responses before and after training for diabetes knowledge about 
lifestyle management  
0
5
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0
5
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210 
 
 
Chart  6.3: Responses before and after diabetes knowledge about foot care and 
infection  management  
 
Chart  6.4: Responses before and after general diabetes knowledge test  
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Table  6.2: Average scores and paired samples t-test before and after intervention for the four sub-scales. 
Sub-scales names No of 
items 
Scores Before Training Scores after training 
  Mean±Sd Range  P-valuea Mean±Sd Range  P-valuea 
Measuring Blood 
Glucose 
7 5.45±1.01 4-7 >0.001 6.59±0.73 5-7 >0.001 
Lifestyle management  12 8.22±0.81 5-10 >0.001 11.0±0.87 9-12 >0.001 
Foot care and 
infection management  
5 4.09±0.81 2-5 0.004 4.72±0.55 3-5 0.004 
General diabetes 
knowledge  
5 4.0±1.02 2-5 0.034 4.63±0.90 2-5 0.034 
Total diabetes 
knowledge score 
29 21.63±3.0 15-26 >0.001 26.95±1.58 24-29 >0.001 
                                                          
a
 Paired sample t-test to show the training effect   
212 
 
 
 
Chart  6.5: Sub-scales of diabetes knowledge test before training  
 
Chart  6.6: Sub-scales of diabetes knowledge test after training 
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6.4. Discussion  
The training was successful and led to a significant improvement in overall 
knowledge among participants in intervention group (p-value < 0.001). Before 
training the pharmacists was assessed to understand their diabetes knowledge, 
this allowed educational material to be targeted at weaker areas of knowledge. 
The educational materials used in the current thesis for training purposes were 
easy to understand for pharmacists. There was an impact on community 
pharmacists’ type II diabetes knowledge and their confidence. 
In diabetes, health literacy is related to diabetes knowledge, self-efficacy and 
self-care behaviours and glycaemic control. Health literacy may also provide a 
better understanding of racial disparities observed in patients with diabetes. 
Strategies to address health literacy, based upon this understanding of its role, 
provide a means to improve diabetes care (Cavanaugh, 2011). The educational 
material provided to community pharmacists was able to (help them) improve 
type II diabetic patients’ knowledge and attitudes. The materials cover various 
information regarding type II diabetes: defining diabetes, understanding 
complications, symptoms and how to manage hypoglycaemia, how to take 
medication, kinds of food to eat and to avoid. 
Recognizing that low health literacy is common and associated with many 
facets of diabetes care including important outcomes, strategies to address 
health literacy have been developed, tested and promoted (Cavanaugh, 2011). 
The foundation of these strategies rests with the principles of clear health 
communication, including assessment of understanding, use of plain language, 
emphasizing a few key points and using effective printed materials (Kripalani 
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and Weiss, 2006). In the current study, health literacy was taken into account 
by enhancing community pharmacist’s knowledge and practice toward type II 
diabetes to increase the confidence. This then can have an impact on patients.  
Although there are many resources available in brochures, fact sheet and web-
based formats to deliver information to patients with diabetes, the complexity of 
the content, including the reading level of the text, often surpasses the skill of 
patients and presents a barrier for information delivery to those with low health 
literacy (Hill-Briggs and Smith, 2008; Kerr, 2007). The educational material that 
was adapted from diabetescare.net was designed for patients but it seems 
rather difficult for patients at different educational levels, and it was used here 
for community pharmacists. Recently, several diabetes materials have been 
developed specifically to address low health literacy and to be used interactively 
between patients and providers to promote patient understanding, 
empowerment and improved self-efficacy with self-care behaviours. 
In the present study, few participants had special training about diabetes. 
Because pharmacists’ functioning as Certified Diabetes Educators CDEs in 
their natural work environment is relatively new (Alzahrani et al., 2015). Even in 
developed countries such as Canada there are presently 3760 certified 
diabetes educators (CDEs) in Canada and out of these 1379 are pharmacists 
(Alzahrani et al., 2015). As a profession, pharmacists make up one third of all 
CDEs in Canada and are the quickest growing sub-division of CDEs in Canada 
(Alzahrani et al., 2015). Taking into account their accessibility and recent 
willingness to gain CDE designation, there are a vast amount of opportunities 
for pharmacists to get more involved in diabetes education (Alzahrani et al., 
2015). In Japan, Certified Diabetes Educator of Japan (CDEJ) is a qualification 
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obtained by nurses, dieticians, pharmacists, clinical laboratory technicians, and 
physiotherapists. Presently, there are approximately 11,778 certified diabetes 
educators in Japan (Kawaguchi, 2007).   
The average score for intervention pharmacists before training was good 
(21.63/29) but training seems fundamental to ensure the pharmacists are able 
to provide pharmaceutical care for the patients. It could be argued that the 
items used normally assess patient knowledge, but the questions appear 
difficult for most patients (in this context). The Michigan diabetes knowledge 
test has been previously used by researchers as a measure of general diabetes 
knowledge. It can be a useful method for group comparisons and for assessing 
knowledge change over time. This test's usefulness as an outcome measure for 
educational interventions remains to be determined (Fitzgerald et al., 1998). 
The detailed data analysis showed exactly which knowledge needed to be 
improved in the intervention group.  
6.5. Conclusion 
The study shows the effectiveness of educational materials used to enhance 
diabetes knowledge among participants, even though the community 
pharmacists began with relatively good knowledge. But it was essential to do 
training to ensure the pharmacists in the randomised controlled trail had 
outstanding knowledge. 
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6.6. Chapter summary 
The key point of current chapter is that the community pharmacist enhanced 
their diabetes knowledge during participation in the study. In Chapter 7 the 
randomised clinical trial is described 
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7. The Effectiveness of Community Pharmacists in Tripoli /Libya in 
Managing Patients with Type II diabetes by Improving Their 
Glycemic Control, Knowledge, Attitudes and Self-Care Behaviour 
via Randomised Controlled Clinical Trial 
This chapter provides the reader with the specific analysis and results of clinical 
trial intervention. In order to understand poor glycaemic control among people 
having type II diabetes it is essential to evaluate diabetes knowledge, attitudes 
and self-management. This enables the researcher to identify reasons of poor 
glycaemic control, and therefore, modify the required intervention to improve 
glycaemic control among participants.  
This chapter is structured into: an introduction (Section 7.1) that briefly 
describes the effectiveness of community pharmacists in relation to type II 
diabetes care and approaches to clinical trial intervention; the methods and 
study design provided in (Section 7.2); the results from participants (Section 
7.3); discussion (Section 7.4); conclusion (Section 7.5); and chapter summary 
(Section 7.6). 
The randomised controlled clinical trial is an ideal experimental method for the 
evaluation of the effectiveness of health services and interventions in relation to 
specific conditions. 
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Abstract 
Objective:  An association between improved glycaemic control and a sustained 
decrease in the rate of diabetic complications has been shown in randomized 
clinical trials. The main aims of study are to improve glycaemic control via the 
community pharmacist intervention. Enhance effectiveness of community 
pharmacist diabetes medicine management by engaging pharmacist assist 
diabetic patient to improve patient’s diabetes knowledge, self-management and 
attitudes. 
Methods: 40 community pharmacies were randomly assigned to be control (18) 
or intervention (22) premises. Then each pharmacy recruited 4 or 5 type II 
patients with diabetes. Overall, 225 patients were recruited and assigned to 
receive usual pharmacist care (n=100) or a predefined pharmacist intervention 
(n=125). Each patient completed a questionnaire in which demographic 
information, disease history, medication history, diabetes knowledge and self-
care activity levels were collected. At inclusion patients measured their fasting 
plasma glucose (FPG) on three consecutive days. The data was analysed by 
IBM SPSS Statistics 22. 
Results: the time effect of intervention shows that the FPG decreased 
significantly in the intervention group (P≤0.001) as well in the control group 
(p=0.004). However, the intervention effect on FPG was not significantly 
improved with P- value (0.268). HbA1c of patients in the intervention group 
decreased significantly during the 6-month study period (P≤0.001), and HbA1c 
of the control group patients was also reduced, but not significantly (P = 
0.0622). However, the differences between control and intervention group in 
HbA1c were not significant (P= 0.1424). In patients diabetes knowledge there is 
a balance between intervention effect and time effect (i.e. there was significant 
improvement in the intervention group with p value 0.031). Diabetes self- 
management improved significantly in blood glucose measurements (P≤0.001) 
and physical exercising (P = 0.001). The diabetes attitude toward value of tight 
control improved (P≤0.001).  
Conclusion: The differences between control and intervention group in HbA1c 
and FPG changes were not significant. However, time effect before and after 
study showed improvement in glycaemic control for intervention group.  
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7.1. The effectiveness of community pharmacists in relation to 
type II diabetes care and approaches to clinical trial 
intervention 
Diabetes is further complicated by a multitude of other factors, such as, the 
‘chronic’ nature of the disease, lifelong requirement for medications, 
requirement for changes in lifestyle, and the need to cope with social, cultural 
and psychological distress that may occur with the disease (Sapkota et al., 
2014). Ongoing patient self-management education and support are critical to 
preventing acute complications and reducing the risk of long-term 
complications. Significant evidence exists that supports a range of interventions 
to improve diabetes outcomes (ADA, 2015). It has been evident in some 
systematic reviews that pharmacist interventions improve glycaemic control in 
patients with type II diabetes compared with usual care and suggest that 
younger patients or those with higher baseline HbA1c levels may be the main 
beneficiaries of pharmacist care. Most studies assess that pharmacists working 
in different settings (outpatient clinic, hospital pharmacy and community 
pharmacy) are able to improve glycaemic control in patients with type II 
diabetes (Aguiar et al., 2016; Ayadurai et al., 2016; Collins et al., 2011; 
Pousinho et al., 2016).  
However, in the current study a review focused on the impact of community 
pharmacists toward type II diabetes care (see Chapter 2). The findings 
suggested that a limited number of studies took place in the community 
pharmacy setting (Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, Mehuys et 
al., 2011, Venkatesan et al., 2012, Ganawar et al., 2014, Kraemer et al., 2012 
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,Paulo et al., 2016, Kjeldsen et al., 2015). The impact of community 
pharmacists on type II diabetes is still in development.  
Pharmacists can help patients with type II diabetes improve adherence to 
antidiabetic medications. Interventions to help improve medication adherence 
generally included an educational strategy combined with one or more other 
strategies to address behavioural, affective and provider-related issues of 
adherence (Omran et al., 2012; Collins et al., 2011). Medicaition adherence is 
measured as a self-management/self-care behavioural outcome at the same 
time as other measures, for instance adherence to diet, exercise, foot care, and 
blood glucose testing. In the current thesis the assessment of adherence 
focused on lifestyle changes by using Summary of Diabetes Self Care Activities 
(SDSCA). Patient self-report, pharmacy refills and claims data and electronic 
measures were also used to assess adherence. A range of tools are available 
to measure medication adherence, each having their own pros and cons 
(Osterberg, and Blaschke, 2005). The choice generally depends on the ease of 
use, validity and reliability (Horne et al., 2005). Overall, self-report tools were 
the more common tools used in the studies reviewed, as seen in most 
adherence studies (Lehmann et al., 2014). Self-report tools are popular 
because of their flexibility, ease of use, cost effectiveness and ability to gather 
social, situational and behavioural data (Lehmann et al., 2014). SDSCA was the 
most commonly used self-report tool to estimate adherence in type II diabetes 
patients. In addition to the inherent advantages that SDSCA has as a self-report 
tool, include being brief, reliable and valid for use in both research and clinical 
practice (Toobert et al., 2000). 
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One of the main components to provide pharmaceutical care services is training 
for community pharmacists. Most studies reviewed provided the pharmacist 
with specific training to comply with components of the study intervention (Ali et 
al., 2012; Jahangard-Rafsanjani et al., 2015; Mehuys et al., 2011; Ganawar et 
al., 2014; Kraemer et al., 2012; Kjeldsen et al., 2015). The training was focusing 
on pharmacotherapy; diabetes management; and referrals for eye and foot care 
management. As well as training on pathophysiology, pharmacology and non-
pharmacological management of type II diabetes. In the current study, training 
(see Chapter 4) was provided for pharmacists to ensure that pharmacists were 
able to provide pharmaceutical care service in the correct way. However, the 
uniqueness in this study is that pharmacists’ knowledge and practice were 
assessed (see Chapter 5) before training to understand their requirements 
while in most reviewed studies this stage does not exist.  
The impact of pharmacist interventions in diabetes care has been studied and 
their intervention significantly reduced patients’ glycosylated haemoglobin 
(HbA1c) levels compared to usual care (Machado, 2007). The medicines 
management of type II diabetes was studied in a United Arab Emirate’s military 
hospital for a follow up period of 12 months. The results showed better 
glycaemic control and a reduction of cardiovascular risk scores (Almazroui et 
al., 2009). Mehuys et al (2011) showed that community pharmacist intervention 
in the clinical management of people with type II diabetes leads to better care. 
The study showed that a diabetes education programme resulted in improved 
self-management and better knowledge of diabetes and significant reductions in 
Fasting Plasma Glucose (FPG). 
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Farmer and colleagues advocated that knowledge remains an important 
prerequisite to good compliance with medical therapy (Farmer et al., 2006). 
Attitudes and beliefs towards medications have also been found to be highly 
correlated to medication compliance (Wilson et al., 2006). A Saudi study 
reported low levels of knowledge, attitude and compliance with medications 
among Saudi female patients with type II diabetes, suggesting a need for 
sustained active patient education, support and evaluation to increase patient 
involvement and self-reliance in the management of diabetes (Binhemd, 1992). 
The authors recommended the involvement of appropriately trained and 
culturally aware members of the primary healthcare team in patient education 
and in partnership with other secondary care services (Kheir et al., 2011).  
The proposition that increased knowledge about a specific health problem leads 
to improved adherence to treatment plans and subsequently to desirable health 
outcomes is not limited to Type II diabetes: educational programmes in 
osteoporosis were found to increase knowledge about the disease and increase 
self-reported adherence to pharmacological treatment over a period of time 
(Nielsen et al., 2010). On the basis of what has been published in the literature 
and what could be considered intuitively sensible, it would appear that patient’s 
health-related knowledge, attitudes and practices constitute important 
constructs affecting medication adherence and medication-improving the 
general well-being of patients with diabetes by addressing these areas in their 
day-to-day interactions with the patients. In addition, pharmacists in particular 
because of their unique skills in therapy management, should be able to 
improve health outcomes by addressing the medication-taking behaviour of 
patients (Wu et al., 2009).  Indeed, an involvement of pharmacists and other 
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stakeholders in relevant clinical cognitive activities (including encouraging 
patients to self-manage their disease) had been advocated (Serrano-Gil and 
Jacob, 2010, Scott et al., 2007).  
A clinical trial is defined by Bowling (2009) as “…an experiment with patients as 
participants. Strictly, however, for clinical trials to qualify for the description of a 
true experiment, random allocation between experimental and control groups is 
required.” 
The National Institute of Health (NIH) defines five different types of clinical trials 
(Kaura, 2013):  
a. Treatment trials: involve testing interventions for example (drugs, a new 
surgery procedure, and a new radiological approach) or a combination of 
interventions. 
b. Prevention trials: involve investigating methods for the primary 
prevention (methods for preventing healthy people from developing a 
disease), secondary prevention (methods for slowing down the 
progression of a disease or for treating it in its early stage whilst the 
patient is still asymptomatic) and tertiary prevention (methods for 
preventing further physical deterioration in chronic symptomatic disease 
states) of a disease. These methods may include drugs, vaccines, 
lifestyle change and so on. 
c. Diagnostic trials: involve investigating better procedures or tests for 
diagnosis a particular disease or condition. 
d. Screening trials: involve investigating ways for detecting a particular 
disease or health condition. 
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e. Quality of life trials: involve exploring ways for improving the quality of life 
for individuals with a chronic disease.  
The current clinical trial was not a treatment clinical trial but it can be 
categorised as a quality of life trial. The trial focuses on improving poor 
glycaemic control among type II patients with diabetes via enhancing diabetes 
knowledge, self-management and attitudes among diabetic participants. The 
study approaches are: 
• Enhance diabetes knowledge 
• Enhance diabetes self-care behaviour among participants 
• Enhance diabetic people attitudes 
• Control blood glucose  
• Enhance community pharmacist professionalism through employing 
their knowledge to help type II patients with diabetes to reach their 
goals  
  Outcomes of current study divided into two outcomes: 
 Primary outcomes: 
 Fasting plasma glucose (FPG ) 
 Glycated haemoglobin HbA1C 
 Secondary outcomes: 
 Diabetes knowledge 
 Diabetes self-management 
 Diabetes attitudes. 
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7.2. Methods  
The study took place in Tripoli/ Libya with a population size nearly 6 million. The 
study conducted in 40 community pharmacies located in Tripoli, the Arabic- 
speaking country and located in the western part of Libya. The pharmacists 
recruited according to the first stage (see Chapter 4 & 5) and participated 
voluntary for the second stage (Intervention study). Each pharmacy was asked 
to recruit between 4 and 5 patients. Ethics approval has been granted by the 
Chair of the Biomedical, Natural and Physical Sciences Research Ethics Panel 
at the University of Bradford (Appendix 27). All patients were given written 
study information sheet and informed consent form (see Appendix 21& 22).  
The diabetes knowledge assessed by using Australian Diabetes Knowledge 
Test (Eigenmann et al., 2011); diabetes self-care activities by using Summary 
of Diabetes Knowledge test (Toobert et al., 2000); and diabetes attitudes by 
using 25 statements adopted from Michigan diabetes attitudes scale (UMDRTC, 
1998) were collected from both groups at baseline.  The four measurements of 
FPG (before breakfast, before lunch, before dinner, before sleep) were 
collected for three consecutive days at T0 for both groups and after three 
months of study at (T12 weeks) collected from the intervention group.  After 6 
months (T24 weeks) FPG, diabetes knowledge, self-care activities and attitudes 
were gathered from both groups.  
7.2.1. Study design  
The design of study is a randomised controlled trial. This is ideal, true 
experimental method for the evaluation of the effectiveness of health services 
and interventions in relation to specific conditions (Bowling, 2014). The reason 
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of randomisation to assess the intervention is a simple and commonly used 
clinical design which compares two treatments. Usually a test therapy is 
compared with a standard therapy. The allocation of subjects to groups is 
usually achieved by randomisation.  
The cluster randomisation was done to avoid sample contamination (see 
Appendix 23). According to Bowling (2014) it may be preferable, for reasons of 
cost or feasibility, to randomise the clusters containing individuals for instance 
clinics or hospitals rather than individuals themselves. 
Randomisation was performed at the pharmacy level. I surveyed one hundred 
and eight community pharmacies in Tripoli/ Libya (see Chapter 5). 108 
community pharmacies were recruited for the next stage of study (intervention 
study).  Then the randomisation took place on the geographical locations of 
community pharmacies (see Appendix 24) by using Excel 2010.  
There were 108 community pharmacies that agreed to take part, located in 40 
different geographical areas in Tripoli/Libya. Then the Excel sheet was used to 
generate clusters, and the name of areas recorded in the Excel sheet. The 
number of areas was aggregated from 40 to 16, which were randomised into 11 
control clusters and 5 intervention clusters. In the 11 control clusters there were 
18 community pharmacies and in the 5 intervention clusters there were 22 
community pharmacies. Thus in total, the number of pharmacies randomised 
was forty: eighteen control and twenty two in the intervention arm. However, 
because small numbers of clusters were randomized, there is a possibility of 
chance baseline imbalance between the randomized groups, in terms of either 
the clusters or the individuals (Higgins et al., 2008).  
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7.2.2. Patient criteria  
Type II diabetes patients were recruited consecutively in the participating 
pharmacies. To be eligible, patients were required to have a prescription for oral 
hypoglycaemic medication. In consecutive order, patients visiting the pharmacy 
were invited to participate in the study when fulfilling the following inclusion 
criteria: age between 35 years and 75 years, treatment with oral hypoglycaemic 
medication for at least 12 months, and a regular visitor of the pharmacy. Since 
metformin can also be used for other indications (such as prediabetes), patients 
were asked for which indication they used metformin.  
7.2.3. Intervention 
Patients in the control group received usual pharmacist care (i.e. the pharmacist 
provide control group with glucometer along with FPG record sheet (Appendix 
28). The pharmacist asked the patients with type II diabetes to record their FPG 
on three consecutive days at the start of study at T0 and at the end of study 
after six months T24weeks). Patients in the intervention group received a 
protocol-defined intervention at the start of study and at each prescription-refill 
visit (for hypoglycaemic medication) during the course of the study. The 
pharmacist provided patients in the intervention group with glucometer and FPG 
record sheet (Appendix 28). The pharmacist educated patients about how to 
use glucometer and take readings properly. The pharmacist asked patients to 
record their FPG in three consecutive days at T0, T12 weeks and T24 weeks. 
The pharmacist provided patients with Arabic educational leaflets (Appendix 25 
& 26).  
The intervention was adapted from a previous trial Mehuys et al., (2011).The 
components of intervention implemented were: 
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i. Education about type II diabetes and its complications:  
ii. Education about the correct use of oral hypoglycaemic agents (timing in 
relation to food);  
iii. Healthy lifestyle education (diet, physical exercise and smoking 
cessation); and 
iv. Reminders about annual eye and foot examinations.  
The adherence to lifestyle activities has been assessed by using Summary of 
Self-Care Activities (SSCA). Education about non- pharmacological aspects 
was provided using printed materials about diabetes (Appendix 25 & 26) and 
assessed by using Australian Diabetes Knowledge Test ADKT (Appendix 18 
(Translated Arabic version) & Appendix 15 (English version)).  
These elements were implemented by the pharmacist on each visit of the 
patient during the 6-month intervention period. Before the start of the study, the 
intervention pharmacists underwent a training session on the pathophysiology 
of type II diabetes and its nonpharmacological and pharmacological 
management according to current treatment guidelines, and the study protocol. 
The control pharmacists only received training on the study protocol. 
7.2.4. Primary outcomes 
Fasting plasma glucose: Each study participant was provided with a 
complimentary glucose meter (Accu-Chek), taught on its correct use, and asked 
to record a glucose day curve (see Appendix 28) (i.e., four FPG measurements 
⁄ day (to ensure reliable FPG data): before breakfast, before lunch, before 
dinner, and before sleep), on three consecutive days. The FPG data are 
expressed as the mean of these 12 measurements. Patients in the control 
group were asked to perform these 12 FPG measurements at the start (T0) and 
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at the end of the study (T24 weeks). Patients in the intervention arm performed 
the measurements every 12 weeks (at T0, T12weeks, T24 weeks), to obtain 
data for assessing the impact of the intervention over time. Glycosylated 
haemoglobin (HbA1c): At the end of the study, the community pharmacist 
asked each patient to provide with the current HbA1c and HbA1c for the 
previous 6–9 months prior. 
7.2.5. Secondary outcomes 
Knowledge about diabetes: Patients’ knowledge about type II diabetes was 
evaluated at the start of the intervention period and after 6 months’ follow up 
using an Arabic translation (Appendix 18) of the Australian diabetes knowledge 
test (Eigenmann et al., 2011). 
Self-management: The diabetes self-care activities of the patients were 
assessed with a validated Arabic translation of the Summary of Diabetes Self- 
Care Activities (SDSCA) questionnaire (see Appendix 19), a brief self-report 
instrument for measuring levels of self-management across different 
components of the diabetes treatment (‘general diet’, ‘specific diet’, ‘physical 
exercise’, ‘foot care’, space carbohydrate evenly and ‘smoking’) (Toobert et al., 
2000). The SDSCA questionnaire was completed at the start of the study and 
after 6 months follow-up.  
Diabetes attitudes: Patient’s attitudes toward type II diabetes was evaluated at 
the start of intervention and after six months of study follow up using an Arabic 
translation (Appendix 20) of the Michigan Diabetes Attitudes Survey 
(MDAS)(UMDRTC, 1998). 
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7.2.6. Rational for patient questionnaire 
 Type II diabetes awareness questionnaire (see Appendix 15) 
• Section one: personal information 
The general aim was to audit knowledge of diabetic people in Tripoli/Libya and 
also to study the burden of diabetes. 
• The aim of this section was to enable me to organise data and split 
the data into groups 
• To understand the amount of knowledge that patients with diabetes 
know about the disease and management.  The questionnaire asked 
about: 
1. Age 
2. Gender 
3. Duration of diabetes 
4. Type of diabetes 
5. Amount of knowledge information if the patient 
receives when first diagnosed; two types of information: 
 a. written      b. Verbal. This question adopted from (Jenny 
Harris et al., 2007).  
• Section two: diabetes knowledge test  
The aim of this section was to assess diabetic patient’s knowledge in different 
areas of diabetic management. The items were adopted from (Eigenmann et 
al., 2011). The questionnaire was a validated version. The items asked about 
different areas of management: 
1. Diet management 
2. Blood glucose measurement 
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3. Foot care management 
4. Exercise management 
5. Complication of diabetes understanding 
6. Hypoglycaemic management 
7. Check-up management 
8. Diabetic medication knowledge 
9. Fact of diabetes 
 Diabetes self-management (see Appendix 16) 
To assess patients with type II diabetes self-management through the adoption 
of the summary of diabetes self-care activities SDSCA (Toobert et al., 2000). 
The SDSCA measure is a brief self-report questionnaire of diabetes self-
management that includes items assessing the following aspects of the 
diabetes regimen: general diet, specific diet, exercise, blood-glucose testing, 
foot care, and smoking. The reliability and validity of SDSCA assessed by 
Toobert et al. (2000) in his study.  
The questionnaire consists of six items related to everyday activities. The 
rational of using these questions are: 
1. From Q1 till Q5: At first time the pharmacist met the patient after the 
consent form the patient and willingness to participate in the study. The 
pharmacists gave the patient the questionnaire then after that the 
questionnaire gave again to the patients. Then the data analysed for 
both groups.   
2. While Q6: this question about Self Care Recommendations will be used 
to measure consistency between self-care activities and 
recommendations. Then series of hypothesis going to be tested as: 
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a. Does the patient follow the self-care activities recommendation? 
b. Do patent know more about recommendation but not follow 
them? 
 Diabetes attitudes (see Appendix 17) 
The questionnaire used to test the attitudes toward diabetes is the third version 
of diabetes attitude scale has been developed by the University of Michigan 
Diabetes Research and Training Centre (UMDRTC, 1998). The number of 
items is 28 and the items divided into five discrete subscales. The subscales 
were attitudes toward the following:  
1. Need for special training to provide diabetes care,  
2. Seriousness of type 2 diabetes, 
3. Value of tight glucose control, 
4. Psychosocial impact of diabetes, and 
5. Attitude toward patient autonomy.  
7.2.7. Statistical analysis 
Sample size was calculated according to the ability to detect an absolute 
HbA1c-reduction of 0.5% (SD=1.3) at 6 months in the intervention group 
compared with the control group, with 80% power at the 0.05 significance level. 
Based on an attrition rate of 20%, at least 121 patients were required in each 
study group. (Hulley et al., 2013). The online sample size calculator used to 
provide two-group studies assume that the groups are of equal size. (See Table 
7.1.). Software utilities were provided by Michael Kohn.  
Parameters defined as following: 
 Q1: proportion of subjects in group 1 
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 E=effect size 
 S=standard deviation in the population 
 
Table  7.1: Sample size calculation to detect population size required to provide 
reliable results from clinical trial study 
Alpha (Two-tailed) Beta Q1 Q2 E S E/S 
0.05 0.2 0.44 0.56 0.5 1.3 0.384615384615 
 
Z-
Alpha 
Z-Beta 
1.96 0.84 
A = 4.06 
B = 7.85 
C = 0.15 
AB/C = 215.33 
N1 95 
N2 121 
Total 216 
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The success of randomization was assessed by comparing baseline 
characteristics of the study groups using independent sample t-tests for 
continuous variables and chi-square tests for categorical variables. Outcomes 
for continuous variables were analysed using: paired t-tests to study the effect 
within each study group at T24 vs T0; and independent sample t-tests to 
evaluate the study group effect (i.e., mean change from baseline in the 
intervention group vs mean change from baseline in the control group). For 
categorical variables only the study group effect was investigated, using chi-
square tests. The answers on domains 1–6 of the SDSCA questionnaire 
(ordinal data) were evaluated with the Wilcoxon signed ranks test (time effect) 
and a Mann– Whitney U-test (study group effect). It seemed likely that patients 
with poor glycaemic control at baseline would benefit the most from the 
intervention. Therefore, it was decided a priori to perform a subgroup analysis 
of the FPG change as a function of the patients’ FPG at baseline. All statistical 
analyses were conducted with SPSS version 22. A two-tailed significance level 
of 0.05 was used.  
7.3. Results  
The results collected from 225 patients with type II diabetes are provided in this 
section. The results include: 
 demographic profile of participants in terms of age, duration of having 
diabetes, level of education,  number of smokers, number of 
hypoglycaemic tables taken to control blood glucose or insulin users and 
measurements of fasting plasma glucose and glycated haemoglobin.   
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 Diabetes awareness data compromise of fifteen questions subscales into 
thirteen as following; Diabetes definition, Infection management, Reasons 
of exercise, Understanding of neuropathy complication, Reasons of test 
Blood Glucose, Understanding diabetes complication, Understanding eye 
check-ups, Understanding of diet plan, Recording Blood Glucose (BG) 
measurements, Medication checks, Normal range of BG postprandial, 
Frequency of exercise, Hypoglycaemic management, Normal range of BG 
pre-prandial, Practical Method of test BG. 
  Diabetes self-care activities data the activities divided into seven scales 
are; General diet, Foot care, Physical exercise, Specific diet, Blood 
glucose measurements, space carbohydrate evenly, Smoking status.  
 Diabetes attitudes subdivided into six scales of attitudes are; Seriousness, 
Impact of patient lives, Value of tight control, Patient Autonomy, Need for 
special training and Psychosocial Impact.  
7.3.1. Recruitment and follow up diagram 
 The control pharmacies recruited 100 participants whereas the intervention 
pharmacies recruited 125 participants. Nearly all patients completed the study 
(control group: 97⁄100; intervention group: 121⁄125). Reasons for non-
completion were: lost to follow up (5) and hospitalization (2). The flow chart of 
participants through the study highlighted in (Figure 7.1) 
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Figure  7.1: Flow chart of randomised controlled clinical trial 
7.3.2. Participant’s demographic data 
Table 7.2 shows the demographic characteristics of participants. Overall 
number of participants 225 patients with type II diabetes splits into two groups 
control and intervention groups. Each group compromises of (100 patients) 
control and intervention (125 patients). Control consist of (42% men and 58% 
women) vs intervention (45% Men and 55% Women). There were no baseline 
differences in mean (± s.d.) age (56±13 vs. 55±12.3) or duration of having 
40 community pharmacy 
18 community 
pharmacy control  
 
22 community 
pharmacy 
intervention  
100 patients  
Control 
125 patients 
Intervention  
97 patients of 
control complete 
the study  
121 patients of 
intervention 
complete the 
study  
Randomisation 
Start of 
Study 
End of 
Study  
3 lost to follow  4 lost to follow 
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diabetes (7.7±6.1 vs. 7.52±4.88). There was low number of participants with no 
education with nearly same baseline in both groups (6 % (6) vs 6% (8)). While, 
the highest number of respondents acquire primary education at (41% (41) vs 
40 % (50). Low smoking status among participants in both groups (12% (12) vs 
18% (23)). The highest number manage their blood glucose with one tablet in 
both groups are (46% (46) vs 45% (55) and low number using insulin in both 
participants (3% (3) vs (5% (6)).  There were no baseline differences in mean 
FPG (176.88±41.30mg/dl vs 177.93±39.69mg/dl). The baseline FPG is much 
higher than the normal range of 90-130 mg/dl, which indicates capacity to 
benefit from better care. 
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Table  7.2: Demographic Characteristics for patients with type II diabetes in both 
control and intervention groups  
  Parameter Control group  
(n=100) 
Intervention group 
(n=125) 
Male 
Female 
42% (42) 
58% (58) 
45% (56) 
55% (69) 
Age (years) 56±13  (35-80)a 55.22±12 (37-85)a 
Duration of having diabetes 7.7±6.1 (1-21)a 7.52±4.88 (1-25)a 
Education 
No education 
 Primary school 
Secondary school 
High education (i.e. BSc, 
MSc) 
 
6%(6) 
41% (41) 
33% (33) 
20% (20) 
 
6% (8) 
40% (50) 
32% (40) 
22% (27) 
Smokers 12% (12) 18% (23) 
People manage their blood 
glucose control with: 
One tablet 
Two tablets 
Three tablets 
 
 
46% (46) 
38% (38) 
9% (9) 
 
 
45% (55) 
36% (45) 
11% (13) 
Insulin users 3%(3) 5% (6) 
FPG  (mg/dl) 176.88 ± 41.30  
(107.5-372.9) 
177.93±39.69 
(107.5-372.9) 
 
HbA1c (%) 7.8 ±1.38b 7.9 ± 1.6b 
                                                          
a
 Range of age and duration of having diabetes   
b
 HbA1c at baseline was available for 44% of the control group patients and for 50% of the intervention 
group patients. 
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7.3.3. Fasting plasma glucose and glycated haemoglobin results  
There were not signification changes between control and intervention 
(p=0.268) with a mean decrease of 11.4 mg/dl (7.1 to 15.7 mg/dl, P<0.001) in 
the intervention group compared to a decrease of 7.7mg/dl (2.6 to 12.8 mg/dl, 
p=0.04) in the control group (Table 7.3). The time effect was significant (before 
and after) whereas the intervention effect was not significant (control and 
intervention). The proportion of patients having an FPG between 90 and 130 
mg⁄dl (ADA glycaemic target) was increased in both study groups (control 
group: +5.1%; intervention group: + 15.7%).) (Table 7.3). 
7.3.4. HbA1c 
The baseline and final HbA1c values for 43 patients of the control and 60 
patients of the intervention. Patients’ demographic and clinical parameters at 
baseline did not significantly differ as a function of the availability of HbA1c 
values. There was also no difference in FPG at the end of the study between 
both groups. For the primary outcome, HbA1c there was no significant 
difference between the two study groups (p=0.1424) with a mean absolute 
decrease of 0.53% (CI: 0.28%, 0.79%, p<0.001) in the intervention group 
compared to a decrease of 0.26% (CI: 0.14%, 0.53, p=0.0622) in the control 
group (Table 7.3). In other words, the data suggested that the intervention 
effect was not significant but time effect was significant. The duration of study 
was only six months, and the intervention effect might have improved if the 
duration was more than six months.  
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 Control group (n = 97) Intervention group (n =121)  
Parameter 0 months 24 weeks Mean change
a
 0 months 12 weeks  24 weeks Mean change
a
 
Difference 
b
(95% 
CI) , p-value 
FPG (mg/Dl) 176.93 ±53.1 169.2 ± 44.4 -7.7 (-2.6  to –12.8) 177.93±59.6 172.76±50.9 166.51±45.2 
-11.4 (-7.1 –
15.7 ) 
-3.7 (-10.3 to -  
2.9   ) 
 
 
  p = 0.004
a
    p <0.001
a
 p = 0.268
b 
FPG within 90-130 mg/dL 
range 
(% patients) 
19.6% 24.7 % ------- 21.5% 26.4% 37.2 % -------- 
-2.08 (-10.4  to  
6.2) 
P =0.618 
Chi-Square
 
p=0.001
c
 
HbA1c (%) 7.8 ±1.38 7.5 ±1.24 
- 0.26 (-.014 to  
0.53) 
7.9 ± 1.6 ………… 7.4 ± 1.3 
-0.53(-0.79 to-
0.28) 
-0.28 (-0.65 to  
0.095) 
   p = 0.0622
a
    p <0.001
a
 p =  0.1424
b
 
HbA1c <7 % 
(% patients ) 
11.6% 14% ------- 11.7% ………….. 30% -------- 
0.58 (-0.09 to  
1.24) 
p= 0.0767
b
 
HbA1c <8 % 
(% patients ) 
51% 63% ------- 42% ………… 63% ------- 
-0.24(-0.68 to   
0.20) 
p =  0.2795
b
 
Table  7.3: Fasting plasma glucose and HbA1c measurements to show glycaemic control among participants 
 
                                                          
a
  Mean change from baseline ‘time effect’ (95% CI), P value. (paired sample t test) 
b
 Difference in mean change from baseline between intervention and control group ‘intervention effect’ (independent-sample t test) 
c
 Chi-Square test to show the significance of FPG intervention effect in both groups 
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Figure  7.2: Box plot for the Fasting Plasma glucose change between baseline 
and at the end of study for intervention group  
 
 
Figure  7.3: Box plot for the Fasting Plasma glucose change between baseline 
and at the end of study for control group 
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7.3.5. Diabetes knowledge Test responses 
Patients' knowledge differed significantly between intervention and control 
groups (p=0.031).For the time effect the data shows there were significant 
improvement in the intervention group (knowledge score: +0.33, p=0.003) see 
(Table 7.4). In the control group, knowledge scores showed a small, but non-
significant improvement (knowledge score: +0.13, p >0.1). The detailed 
diabetes knowledge test (see Table 7.5) shows that the diabetes knowledge 
among participants seems to be poor at T0 or at baseline. The lowest 
knowledge in defining diabetes at (4% vs 5%), infection management (11% vs 
22%), reasons of doing exercise (16%vs 20%) and understanding of  
neuropathy complication ( 17% vs 21%). The highest knowledge exists in 
practical methods of testing blood glucose (88% vs 87%) and normal range of 
blood glucose pre-prandial (73% vs 74%). The awareness of   Medication 
checks (50% vs 52%), Normal range of BG postprandial (51% vs 52%), 
Frequency of exercise (60% vs 61%), and hypoglycaemic management (65% 
vs 66%).  After six months of intervention it shows there is some improvements 
in defining diabetes in both groups control and intervention (11% vs 23%), 
awareness of flu infection (17% vs 40%), reasons of exercising (21% vs 25%), 
foot care management (26% vs 27%), Reasons of testing Blood Glucose (47% 
vs 30%), Understanding diabetes complication (39% vs 41%), Understanding 
eye check-ups (37% vs 43%). The knowledge of understanding diet plan 
increased in control group at 64% vs 46% in intervention group. While, 
awareness of normal range of BG postprandial improved in intervention gr 
(64%) vs control group (41%) 
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 Control group (n = 97) Intervention group (n =121)  
Parameter 0 months 24 weeks Mean changea 0 months 24 weeks Mean changed Difference (95% CI)b , 
p-value 
Knowledge test 
score (15) 
6.21 ± 2.5 6.34±2.7 
0.13(-0.38–0.11) 
p = 0.292 
6.70 ± 2.2 7.02±1.7 
0.33 (-0.55-0.11)  
p =0.003 
0.24 (0.47-0.02)  
p= 0.031 
Knowledge test 
score (%, 0-
100) 
41.37% ± 
16.9 
 
42.27% ± 
15.2 
 
0.89 (-2.6 -0.78) 
 p = 0.292 
44.6%±14.4 46.8%±11.5 
2.20 (-3.6 -0.73 )  
p = 0.003 
1.7(3.1-0.15)  
p= 0.031 
Table  7.4: T-test of type II diabetes knowledge among participants  
 
                                                          
a
 Mean change from baseline ‘time effect’ (95% CI), P-value measured by paired sample T- test  
b
 Difference in mean change from baseline between intervention and control group ‘intervention effect’ measured by Independent t -test  (intervention 
effect) 
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Table  7.5: The Detailed Diabetes Knowledge Test 
Questions 
about: 
Control 
T0 
Correct 
answers 
Control 
T24 
Correct 
answers 
Mean 
change 
Control 
group 
Intervention 
T0 
Correct 
answers 
Intervention 
T24 
Correct 
answers 
Mean 
change 
intervention 
group 
Mean±SD 6.2±2.5 6.31±2.25 0.13 6.69±2.16 7.02±1.72 0.33 
Diabetes 
definition 
4(4%) 11(11%) 7 6(5%) 28(23%) 22 
Infection 
management 
11(11%) 17(17%) 6 27(22 %) 48(40%) 21 
Reasons of 
exercise 
16(16%) 20(21%) 4 25(20%) 30(25%) 5 
Understanding 
of neuropathy 
complication 
17(17%) 25(26%) 8 26(21%) 33(27%) 7 
Reasons of test 
Blood Glucose 
24(24%) 46(47%) 22 34(27%) 36(30%) 2 
Understanding 
diabetes 
complication 
31(31%) 38(39%) 7 45(36%) 50(41%) 5 
Understanding 
eye check-ups 
33(33%) 36(37%) 3 43(34%) 52(43%) 9 
Understanding 
of diet plan 
46(46%) 62(64%) 16 60(48%) 56(46%) -4 
Recording BG 
measurements 
47(47%) 41(42%) -6 79(63%) 68(56%) -11 
Medication 
checks 
50(50%) 43(44%) -7 65(52%) 57(47%) -8 
Normal range of 
BG postprandial 
51(51%) 40(41%) -11 65(52%) 78(64%) 13 
Frequency of 
exercise 
60(60%) 52(54%) -8 76(61%) 62(51%) -14 
Hypoglycaemic 
management 
65(65%) 50(51%) -15 83(66%) 71(59%) -12 
Normal range of 
BG pre-prandial 
73(73%) 53(55%) -20 93(74%) 85(70%) -8 
Practical Method 
of test BG 
88(88%) 79(81%) -9 109(87%) 96(79%) -13 
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7.3.6. Diabetes self-management activities results 
At the end of the study, intervention-group patients showed significant 
improvements in the domains of foot care (+0.19, p>0.001), blood glucose 
measurement (+0.52 day ⁄ week, p=0.01), physical exercise (+0.23day ⁄ week, 
p=0.021), general diet (+0.28 day ⁄ week, p=0.032), space carbohydrate evenly 
(+0.26, p= 0.035), and specific diet (+  0.24, p=0.047) (Table 7.5). For patients 
in the usual care group, no improvement was seen in any of the six domains. 
There was a significance between-study group difference regarding the 
domains of blood glucose measurement (p<0.001), physical exercise (p=0.001) 
and foot care (p=0.025). There is no significant difference on specific diet, 
general diet and space carbohydrate evenly. 
7.3.7. Patients attitudes toward type II diabetes 
At the end of the study, intervention group patients showed slightly better 
attitudes at impact of patients’ lives (p=0.01), patient autonomy (p=0.031) and 
seriousness (p=0.033). While, patients in the usual care no attitude 
improvements seen (Table 7.7). However, there is significant improvement in 
value of tight control between study groups (p≤0.001). The impact of patient 
lives is significantly enhanced between groups (p=0.016), patient autonomy 
(p=0.021) and seriousness (p=0.003).  
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Table  7.6: Diabetes Self-care activities  
Self-
management 
Control 
group 
at T0 
Control 
group 
at 
T24 
Mean 
change 
a
, p-
value
 b
 
Intervention 
group at T0 
Intervention 
group at 
T24 
Mean 
change 
f
, 
P-
Value 
g
 
Difference 
95% CI, P- 
value
c
 
General diet , 
scale 0-7 
2.49 
±1.73 
2.53 
±1.68 
0.04 
P =  
0.839 
2.59 ±1.58 2.87 ±1.42 
0.28 
P =  
0.032 
P =  0.036 
Foot care , 
scale 0-7 
3.23 
±1.97 
3.36 
±1.53 
0.13 
P =  
0.05 
2.71 ±1.65 2.90 ±1.10 
0.19 
P =  
0.009 
P =  0.025 
Physical 
exercise, 
scale  0-7 
2.15 
±2.02 
2.21 
±1.73 
0.06 
P =  
0.566 
2.49 ±1.82 2.72 ±1.28 
0.23 
P =  
0.021 
P =  0.001 
Specific diet , 
scale 0-7 
3.95 
±1.14 
3.92 
±1.16 
-0.3 
P =  
0.682 
4.05 ±1.05 4.29 ±0.91 
0.24 
P =  
0.047 
P =  0.006 
Blood glucose 
measurments 
, scale 0,7 
2.79 
±1.81 
2.82 
±1.64 
0.03 
P =  
0.968 
3.28 ±1.99 3.80 ±1.52 
0.52 
P =  
0.01 
P <0.001 
Space 
carbohdrate 
evenly, scale 
0,7 
2.77 
±2.19 
2.71 
±1.79 
-.0.06 
P =  
0.623 
2.61 ±1.99 2.87 ±1.64 
0.26 
P =  
0.035 
P =  0.426 
Smoking 
status 
11% 11% _ 18% 18% _ _ 
 
 
 
 
 
                                                          
a
 Mean change between control and intervention  
b
 Wilcoxon signed ranks test measuring time effect  
c
 Mann–Whitney U-test measuring intervention effect  
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Table  7.7 : Type II diabetes attitudes  
Parameter Control group (n = 97) Intervention group (n =121)  
Attitudes 
scales 
0 
months 
24 
weeks 
Mean 
change
a
, p 
value
b
  
0 
months 
24 
weeks 
Mean 
change, p 
value
 
 
Difference 
(95% CI)
c
 , 
p-value 
Seriousness 
3.5 
±0.6 
3.6 
±0.6 
0.1 
p = 0.117 
3.7 
±0.6 
3.8 
±0.6 
0.1 
p = 0.033 
p = 0.003 
Impact of 
patient lives 
3.3 
±0.6 
3.2 
±0.7 
-0.1 
p = 0.129 
3.3 
±0.6 
3.4 
±0.6 
0.1 
p = 0.01 
p = 0.016 
Value of tight 
control 
3.2 
±0.6 
3.1 
±0.6 
-0.1 
p= 0.194 
3.9 
±0.5 
4.0 
±0.5 
0.1 
p= 0.036 
p<0.001 
Patient 
Autonomy 
4.1 
±0.5 
4.0 
±0.5 
-0.1 
p = 0.506 
3.8 
±0.5 
3.9 
±0.5 
0.1 
p = 0.031 
p = 0.021 
Need for 
special 
training 
4.3 
±0.6 
4.3 
±0.6 
0 
p = 0.491 
4.4 
±0.6 
4.4 
±0.6 
0 
p = 0.936 
p = 0.095 
Psychosocial 
Impact 
3.9 
±0.7 
3.9 
±0.6 
0 
p = 0.625 
4.0 
±0.7 
4.0 
±0.7 
0 
p = 0.229 
p = 0.288 
 
                                                          
a
   Mean change between control and intervention 
b
 Wilcoxon signed ranks test measuring time effect 
c
 Mann–Whitney U-test measuring intervention effect 
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7.4. Discussion  
Our study shows that the time effect was significant in the intervention group 
(p<0.001) for HbA1c and FPG. While, for the control group change in FPG 
(p=0.004) was significant and change in HbA1c was not (p=0.0622). However, 
the intervention effect was not significant for both FPG (p=0.268) and HbA1c 
(p=0.124). These findings were agreed with Paulo et al (2016) who found that 
glycated haemoglobin (p=0.143) and FPG (p=0.125) did not change 
significantly, and Kraemer et al (2012) (HbA1c, p= 0.0757; FPG, p= 0.08552). 
The effectiveness of community pharmacists in relation to glycaemic control has 
been studied in various contexts (Ali et al., 2012, Jahangard-Rafsanjani et al., 
2015, Venkatesan et al., 2012, Mehuys et al., 2011, Kraemer et al., 2012, Paulo 
et al., 2016).  
It could be argued that the duration of studies has an impact on intervention 
effect. The studies with a duration longer than six months have better 
intervention effects (p<0.001, Ali et al., 2012) (p=0.009, Mehuys et al., 2011). 
However, the sustainability of primary outcomes studied by Mehuys et al (2011) 
suggested that HbA1c after eighteen months was not significantly changed 
even though more patients in the intervention arm reached a target HbA1c <7% 
than in the control group (53.3% vs. 39.1%).   
For the secondary outcomes the diabetes self-care activities improved in 
exercising (p=.0.001) and blood glucose measuring (p<0.001). The attitude that 
improved was value of tight control (p<0.001). This finding could mean a better 
attitude towards tight control improves adherence to blood glucose 
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measurement. Diabetes knowledge improved significantly in both groups 
(P=0.03). 
The efforts to improve the care of patients have focused on a team approach in 
which professionals from multiple disciplines use their specialized training to 
make significant contributions to patient care (Clemmer et al., 1998, Papa et al., 
1998).  With the advent of pharmaceutical care, pharmacists have focused their 
services on the care of the patient and have become integral members of care 
teams.  
Many studies suggest that coordinated care between physicians and 
pharmacists can improve patient care outcomes (Boudreau et al., 2002, 
Borenstein et al., 2003). That is, pharmacists often can impact patient outcomes 
through a cooperative relationship with a patient’s physician (Zillich et al., 
2004). However, the current study argues for an implementation of structured 
physician-pharmacist collaboration in primary care.  
Treatment of hyperglycaemia is one of the main priorities in type II diabetes 
patients; an HbA1c target of 7.0% (53 mmol/mol) among people with type II 
diabetes is reasonable to reduce risk of microvascular disease and 
macrovascular disease. A target of 6.5% (48 mmol/mol) may be appropriate at 
diagnosis. Targets should be set for individuals in order to balance benefits with 
harms, in particular hypoglycaemia and weight gain (SIGN, 2013).  According to 
UKPDS, each 1% reduction in HbA1c over 10 years is associated with risk 
reductions of 21% for any diabetes-related end point, 21% for diabetes- related 
mortality, 14% for myocardial infarctions and 37% for microvascular 
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complications (Stratton et al., 2000). No HbA1c threshold value, for risk of any 
complication, was reported (Stratton et al., 2000).  
This implies that pharmacists should focus on these high-risk patients, who may 
have little contact with other health care professionals and ⁄ or require more 
attention in their diabetes management. The programme was welcomed by the 
participating patients and the low drop-out rate may indicate the patients’ need 
for a more intensive follow-up and education on their condition. The intervention 
consisted of several components; it is difficult to identify the elements that 
contributed most to the observed improvement in glycaemic control. However, 
this study showed that the program enhanced the patients’ practical knowledge 
about diabetes, as well as their self-care activities and diabetic patient’s 
attitudes. So, it seems likely that small improvements in lifestyle contributed, at 
least partly, to the results. Other possible explanatory factors are the more 
intensive patient-pharmacist contact and the regular glucose self-
measurements. 
7.5. Conclusion 
To sum up, the study showed that the differences in primary outcomes of 
HbA1c and FPG were not significant (i.e. there were no improvements in 
glycaemic control between intervention and control). However, the time effect 
shows there were differences in the intervention group before and after study 
for both HbA1c and FPG. HbA1c showed more improvement after six months of 
study in the intervention group than control. Whereas, FPG improved in both 
groups before and after the study.  For self-activities there were significant 
improvements in blood glucose measurement and physical exercising. The 
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diabetes attitudes improved towards values of tight control in type II diabetes. 
The findings could suggest that a longer duration of study should be 
considered. In addition, the community pharmacist intervention is beneficial and 
it seems that a little help sometimes could improve patients with type II 
diabetes’ ability to reach to glycaemic control target This study has been 
completed in a developing country that lacks a systematic health care network. 
7.6. Chapter summary 
The effectiveness of community pharmacists support for patients with type II 
diabetes had been previously and recently studied (Mehuys et al., 2011, Clifford 
et al., 2002, Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, Venkatesan et 
al., 2012, Kraemer et al., 2012, Paulo et al., 2016). Most studies showed that 
the community pharmacist could play a valuable role in type II diabetes 
management. This chapter describes a randomised controlled clinical trial to 
improve care for patients with type II diabetes. The results show that the 
intervention effect was not significant for either FPG and HbA1c. The study 
provides new insight that providing pharmaceutical care in a developing country 
in Libya, Tripoli shows a slight improvement in outcomes over time.  
The next Chapter 8 will discuss the whole thesis. 
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8. General Discussion and Future Studies 
This chapter provides readers with the thesis discussion and conclusion; it is 
divided into eleven sections. The community pharmacy premises and 
pharmaceutical services structure is discussed in Section 8.1 and the 
community pharmacist knowledge and practice towards type II diabetes survey 
is discussed in Section 8.2. The enhancement of type II diabetes care 
management among community pharmacists in the training stage is discussed 
in Section 8.3. The effectiveness of community pharmacists in improving type II 
diabetes knowledge, attitudes and self-management for patients with type II 
diabetes (measured by glycaemic control) is discussed in Section 8.4. The 
implications of the study for health care practice are explored in Section 8.5. 
The conclusion of stage one of the study (exploring community pharmacy 
premises and structure) is provided in Section 8.6. Section 8.7 sums up the 
results of stage two, exploring community pharmacist type II diabetic knowledge 
and practice. Section 8.8 concludes the findings of stage three, enhancing 
community pharmacists’ knowledge of type II diabetes. Section 8.9 concludes 
the findings of stage four, improvement of type II diabetes glycaemic control via 
a randomised controlled trial. A chapter summary is provided in Section 8.10. 
The implications of the findings for future research are highlighted in Section 
8.11.   
The overall discussion can be categorised into four themes: 
 Engagement and participation of patients and pharmacists.  
 Co-production of care (i.e. assisted self-management). 
 Improvement of self-care activities by patients with type II diabetes. 
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Integration of the findings from the research undertaken with the published 
literature will be presented. This study aimed to improve type II diabetes 
patients' knowledge, attitudes and practice in Tripoli, Libya. The findings show 
that the primary outcomes (i.e. fasting plasma glucose FPG and glycated 
haemoglobin HbA1c) were improved among patients with type II diabetes. The 
hypothesis stated that improving patient knowledge and monitoring primary 
outcomes (FPG and HBA1c) in patients with patients would lead to 
improvements in blood glucose control. 
8.1. The community pharmacy premises and pharmaceutical 
services structure  
The World Health Organisation (WHO) has always maintained that pharmacists 
can make a better contribution to providing healthcare (WHO 1998; WHO 
1996). This is especially true in developing countries as the health needs of 
people there are greater and the provision of health care is limited (Smith, 
2016). Pharmacists aim to provide and promote the safe use of medications. 
They are considered to be professionals who can give advice about managing 
symptoms and long-term illnesses (Smith, 2016). They have the potential to 
contribute more to healthcare in the future (Smith, 2016). 
With the specific needs of developing countries in mind, the International 
Pharmaceutical Federation (FIP) set up a working party, this delivered 
proposals for STEPwise usage of Good Pharmacy Practice (GPP) in these 
nations (FIP 1998). These suggestions concentrated on four aspects of 
services: access to pharmaceutical employees, with  a definitive point that all 
individuals ought to have admittance to a qualified drug specialist; the training 
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requires of pharmacy employees, ranging from the providing of essential 
training for community health employees to ongoing professional development 
for qualified pharmacists; the promotion of high standards regarding dispensing, 
premises, labelling, advice-giving, pharmaceutical care and the establishment 
of legislation for national drugs policies (Smith, 2004).   
Despite the fact that in most high income countries the role played by the 
pharmacist within the realm of public health is commonly accepted, this is not 
the case in developing countries (Krass & Bell, 2011). In many countries in the 
world there are no health promotions strategies and community pharmacists are 
viewed as shopkeepers, rather than health professionals. In most cases, there 
is no distinction made between prescribing and dispensing-doctors. On the 
other hand, community pharmacists sell a wide variety of medications and 
usually people will go to them first before seeking alternative health advice 
(Krass & Bell, 2011). Most people in developing countries pay for medication 
themselves, rather than being funded by the government. There is not much 
collaboration between pharmacies, governments and other healthcare 
professionals. In addition to this, the structure and organisation of pharmacies is 
not effective and the resources pharmacies have are limited (Krass & Bell, 
2011). 
In developing countries, pharmacists want to improve their status and make 
their role wider. Pharmacists have good qualifications and there is increasing 
interest from people to study pharmacy at university. Furthermore, governments 
are increasingly realising the importance of public-private partnerships for 
improving patient outcomes and achieving better cost benefits (Krass & Bell, 
2011). 
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Pharmaceutical services in developing countries are confronted with different 
issues to those in developed countries (Krass & Bell, 2011). In the present 
study, the data showed that the community pharmacies in Libya can be found in 
both commercial and residential areas, as described in Chapter Four (Section 
4.3.1 in Table 4.2). Compared with community pharmacies in the UK, the 
Pharmaceutical Services Negotiating Committee (PSNC, 2016) indicates that 
community pharmacies can be found on the high street at the heart of most 
rural villages and in the centre of the most deprived communities. The 
community pharmacies in Libya are widely available, but are not the same as in 
the UK in terms of their structure or services. When the availability of 
community pharmacies is wide this leads to good implications for the health of 
communities (PSNC, 2016).   
The pharmaceutical service in Libya has been poorly documented. The current 
study reveals that consultation areas are scarce in community pharmacies in 
Tripoli. Out of 389 pharmacies, 32 (8%) pharmacies had consultation areas 
compared with a Northumberland survey where (out of 75 pharmacies) 71 
(99%) had a consultation room, and 56 (79%) could access hand washing 
facilities, either in the consultation area or close to it (Everden, 2015). According 
to Everden (2015) a consultation room is essential to provide advanced 
services, e.g. Medicine Use Reviews (MURs) and many locally commissioned 
services. However, simple interventions such as checking patient blood glucose 
levels, or hypertension, or giving advice could be done even without dedicated 
consultation areas. There is no fundamental barrier to providing pharmaceutical 
care, due to a lack of consultation areas. However, the availability of 
consultation areas can offer some advantages. These consultation areas allow 
256 
 
 
the patient and the pharmacist to interact in a setting that respects the privacy 
of the patients. The patient consultation areas, when used to discuss 
medication and other health issues, enhance the professional interaction and 
relationship between the patient and the pharmacist. It also facilitates and 
encourages patients to request and benefit from the professional input and 
counselling they require from the pharmacist Everden (2015). 
Furthermore, having a designated area inside a pharmacy that is specifically for 
carrying out patient consultations will allow pharmacists to play a more integral 
role in the multidisciplinary team and take better care of patients. Consultations 
should be confidential and personal and should take place with a dedicated 
consultation area, which has a positive effect on patients’ health through the 
promotion of patient education, encouraging the appropriate and rational use of 
medication, and therefore lowering the incidence of medication-related 
problems (The Pharmaceutical Society of Ireland TPSI, 2010).  
Community pharmacists are the health care professionals who are the most 
accessible by people in communities. Patients appreciate the fact they do not 
have to make an appointment to see a pharmacist (NHS, 2013). Pharmacists’ 
accessibility in regards of location, as well as long opening hours is considered 
to be a great benefit for the public (NHS, 2013). Furthermore, to ensure there is 
a correct supply of suitable products, pharmacists also provide counselling of 
patients when they dispense medication to them and take part in health-
promotion programmes (WHO, 2016). They keep strong links with other health 
professionals in primary health care. In current times, an increasingly broader 
range of new products are used in medicine, such as high-technology biological 
products and radio-pharmaceuticals. In addition to this, there is also a 
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heterogeneous group of medical devices, including some products that are 
analogous to medicines. Some of these require specialised knowledge for use, 
as they carry risks (for example, dressings, wound management products, etc.). 
Pharmacists have increasingly undertaken the supplementary task of making 
sure the quality of the products they supply is high (WHO, 2016). 
8.2. Exploration of community pharmacist diabetes knowledge and 
practice.  
The conventional role of the pharmacist is to produce and supply medication 
(Wiedenmayer et al., 2006). In more recent times, however, the role of 
pharmacist has changed into taking a more patient-centred approach. This had 
led to some doctors becoming increasingly concerned that their role is 
threatened. A study carried out in the state of Wyoming, in the mountain region 
of the western United States, found that physicians felt most comfortable with 
pharmacists’ duties highlighting errors in prescription, giving patient advice, 
suggesting other non-prescription medications and recommending prescription 
medications to doctors (Ranelli and Biss, 2000). An additional study conducted 
in the UK revealed that doctors were happy to delegate jobs to pharmacists that 
they found challenging or dull, for example checking drug adherence and 
producing repeat prescriptions (Edmunds and Calnan, 2001). Doctors were 
more sceptical about pharmacists carrying out clinically orientated activities. 
Pharmacists’ particular body of knowledge and skills relate to the use of 
medicines and this falls into broad areas (Mays, 1997). All pharmacists share 
scientific knowledge about medicines and their clinical applications and uses 
(Mays, 1997). There is a body of knowledge about how to make the best use of 
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medicines, both applied to the needs and circumstances of individual patients, 
for example, the selection of delivery system, advice and usage and in terms of 
overall efficacy and effectiveness such as development of formularies, 
organisation of supply. This knowledge is based primarily in the biological and 
physical sciences but draws crucially on various social science disciplines, 
including psychology, sociology and economics (Mays, 1997). Furthermore, 
clinical pharmacists now regularly work as part of a multidisciplinary team with 
physicians, nurses, technicians, nutritionists, and other health care 
professionals. Intensive diabetes education and care supervision has been 
shown to progress patient outcomes, glycaemic control and improve the 
standard of life of patients (McMurray et al., 2002). Pharmacists have an 
important role to play with regard to educating consumers on the proper use of 
medications. In particular, advice-giving by pharmacists on safe self-medication 
should be readily available (Chui and Li, 2005). In the present study, data from 
the diabetes knowledge test found that the median score was 21/29, with a 
range from 12–26 among community pharmacists, which is better than 16/23 
with a range from 8 to 22 found in a previous study done by Bisheya et al. 
(2011).Interestingly, the present study shows that community pharmacists have 
better diabetes knowledge compared with a previous study conducted in 2001 
in Tripoli, Libya (Bisheya et al., 2011). Following this confirmation that Libyan 
community pharmacists have good diabetes knowledge, the study to improve 
glycaemic control for patients with type II diabetes (i.e. the randomised 
controlled trial) was then carried out. This was despite the barrier presented by 
poor facilities in community pharmacy premises (lack of consultation areas). 
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Regardless of a lack of consultation areas, both pharmacists and patients show 
their willingness and readiness to participate in the next stage of study.  
Recently, a study by Shrestha et al. (2015) stated that diabetes knowledge 
among participants was poor with mean scores of knowledge being 10.67/20 in 
the Michigan Diabetes Knowledge Test (MDKT). The majority of the 
respondents (76.5 %) scored between 0 and 12, which corresponds to poor 
knowledge on Diabetes Management (DM) and only 1.9 % of the respondents 
had good knowledge compared with the current data, which shows that the 
community pharmacists scored between 20-29 and 73% (79) had good 
knowledge. Sixty-eight respondents (21.6%) in the previous study had a 
moderate level of knowledge i.e. they obtained scores ranging from 13 to 16 
(Shrestha et al., 2015), compared with moderate knowledge scores (14.5-19) in 
the current study for 27% (29).  
In summary, the current data shows that community pharmacists in Tripoli, 
Libya have good knowledge about type II diabetes management, but the 
number of studies assessing community pharmacist diabetes knowledge is 
small. Recent studies focused on the opinion of community pharmacists about 
continuing educations for diabetes management in Brazil (Kauffman et al., 
2015) or assessing diabetes management activities provided by community 
pharmacists in Alberta, Canada (Lo et al., 2016).  It is fundamental to assess 
community pharmacists’ knowledge and practice towards type II diabetes 
management within any (proposed) study population in order to ensure that 
diabetes services provided for patients with diabetes is appropriate. 
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8.3. The enhancement of diabetes knowledge among community 
pharmacists in the training stage. 
This step was to ensure that community pharmacists have the knowledge to 
provide patients with the required advice to reduce hyperglycaemia. The 
training was successful and significant improvements were shown among 
participants in the intervention group (p<0.001). The diabetes knowledge test 
used in this study was a combination of the previously validated Australian 
Diabetes Knowledge Test and Michigan Diabetes Knowledge Test MDKT 
(Eigenmann et al., 2011, Fitzgerald et al., 1998). Before training, the 
pharmacists were assessed to determine their diabetes knowledge to enable 
shaping of the educational materials to enhance their weaknesses in 
knowledge. Even though the average score for intervention pharmacists 
revealed they had good knowledge (score 21.63/29) but training seemed 
fundamental. This was to improve the consistency of pharmacist knowledge in 
order to reduce variation in outcomes for patients.  
It has been evident that in this type of intervention (controlled trial studies by 
community pharmacists) it is essential to provide training (Ali eta al., 2012; 
Jahangard-Rafasanjani et al., 2015; Mehuys et al., 2011; Ganawar et al., 2014; 
Kraemer et al., 2012; Kjeldsen et al., 2015). Most studies focused on training 
about pharmacological and non-pharmacological management of diabetes (Ali 
eta al., 2012; Jahangard-Rafasanjani et al., 2015; Mehuys et al., 2011; Kraemer 
et al., 2012).  
In an ideal world, those who suffer with diabetes should be educated about the 
importance of self-management of diabetes (Alzahrani et al., 2015). Diabetes 
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education is now recognised as a keystone of diabetes care and education 
enhances self-care and glycaemic control in those with diabetes (Mulcahy et al., 
2003, Funnell et al., 2009). Health care professionals are increasingly looking 
for or acquiring certification to be diabetes educators to recognise them as 
specialised in diabetes management (Alzahrani et al., 2015). The present study 
data reveals that out of forty community pharmacists who took part in a survey, 
only 8 (20%) had received special training in diabetes. No previous study had 
been done in Libya to show how many health care professionals had training or 
whether they were certified as diabetes educators (CDE). In comparison, in 
Canada CDE is provided by the Canadian Diabetes Educator Certification 
Board (CDECB) to health care professionals (Alzahrani et al., 2015). There are 
presently 3760 certified diabetes educators (CDEs) in Canada and out of these 
1379 are pharmacists (Alzahrani et al., 2015). As a profession, pharmacists 
make up one third of all CDEs in Canada and are the quickest growing sub-
division of CDEs in Canada (Alzahrani et al., 2015). Taking into account their 
accessibility and recent willingness to gain CDE designation, there are a vast 
amount of opportunities for pharmacists to get more involved in diabetes 
education (Alzahrani et al., 2015). In Japan, Certified Diabetes Educator of 
Japan (CDEJ) is a qualification obtained by nurses, dieticians, pharmacists, 
clinical laboratory technicians, and physiotherapists. Certified Diabetes 
Educator of Japan  CDEJ is a qualification awarded by the Japanese 
Certification Board for Diabetes Educator to registered nurses, registered 
dieticians, pharmacists, clinical laboratory technicians, physiotherapists, 
certified practical nurses, or dietitian. There are approximately 11,778 certified 
diabetes educators in Japan (Kawaguchi, 2007).   
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Despite the fact pharmacists have become progressively engaged with diabetes 
management in the recent past, pharmacists’ operating as CDEs in their natural 
work environment is a fairly new concept (Alzahrani et al., 2015). Naturally, 
these pharmacists consider their main duty is to advise patients about suitable 
medication use. Many of these pharmacists feel very comfortable with insulin 
management, interpretation of self-monitoring of blood glucose (SMBG) results 
and insulin dose titration. This is in line with previous literature, which 
discovered that non-CDE pharmacists do not feel comfortable advising on 
insulin use (Younis et al., 2001).   
The concept of pharmaceutical care is combined with treatment monitoring and 
the provision of medication education, and pharmacists play a more key role in 
delivering elements of the public health agenda, for example smoking cessation 
and vaccinations (Bryant et al., 2009; Paudyal et al., 2010). Community 
pharmacists also play a significant role in enhancing the use of medications and 
the management of chronic conditions. This will help to improve the quality of 
healthcare and to diminish the general costs of healthcare with regard to 
workload and time working for other healthcare professionals (Dunlop and 
Shaw 2002; Smith et al., 2011; Giberson et al., 2015). Furthermore, these 
progressive roles and duties could improve the professional status of 
pharmacists in terms of how other healthcare professionals perceive them and 
can improve the job satisfaction of pharmacists (Inch et al., 2005; Bryant et al., 
2009; Paudyal et al., 2011).  
Health education comprises enhancing knowledge and gaining life skills that 
are helpful for individual and community health. Health education is not only 
associated with communicating information, but also with promoting motivation, 
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skills and confidence (self-efficacy) needed to take action to enhance health. It 
comprises the communication of information regarding the underlying social, 
economic and environmental factors that affect health, in addition to individual 
risk factors, risk behaviours and the utilisation of the healthcare system 
(Anderson & Blenkinsopp, 2016).  
8.4. The effectiveness of community pharmacist in improving type 
II diabetes knowledge, attitudes and self-management for II 
patients with type II diabetes measured by glycaemic control. 
Our data suggests that this study supports, but does not provide clear evidence 
for, the premise that pharmacist counselling for health care plan beneficiaries 
with diabetes results in better disease control and improved empowerment to 
better self-manage this disease. The time effect showed significant 
improvement in HbA1c and FPG compared with the intervention effect. Care 
was improved for patients with diabetes over the duration of the study. Our data 
agreed with two previous studies (Kraemer et al., 2012; Paulo et al., 2016).  
Patients with type II diabetes make multiple daily choices about the 
management of their condition, such as appropriate dietary intake, physical 
activity, and adherence to drugs, often with minimal input from a healthcare 
professional (Jarvis et al., 2010). Programmes that are aimed at educating 
people about self-management are increasingly focused on by healthcare 
professionals and are recommended for patients with type II diabetes as a way 
to obtain the skills needed for active responsibility in their daily management of 
diabetes (Rutten, 2005). Furthermore, it has been proposed that education for 
self-management may play a vital role in confronting opinions about health and 
therefore enhance metabolic control, concordance with decisions about 
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medications, risk factors, and quality of life (Norris et al., 2002, Lorig, 2002). 
Pharmacists have the educational background and specific patient-related 
information to be actively involved in providing pharmacotherapeutic support to 
patients and prescribers. This support should help make pharmacotherapy as 
efficient and safe as possible. In many cases, the possibilities of the pharmacist 
are not used optimally.  For example, observing patient adherence to the 
recommended healthcare plan is, in most pharmacies, merely a part of the 
routine checks that are combined with dispensing (Van Wijk et al., 2005). 
Rather, observing and enhancing patient adherence should be part of the 
primary role of community pharmacies, because out of all healthcare providers, 
pharmacists hold the greatest position to notice issues concerning the 
prolonged use of medication (FIP, 2002). Thus, most pharmacy practice 
research has been carried out to reveal strategies for pharmacist intervention in 
patients’ medication-taking. Some of the strategies seem to have been 
successful, but others were not (Van Wijk et al., 2005).  
Treatment of hyperglycaemia is one of the main priorities in type II diabetes 
patients; an HbA1c target of 7.0% (53 mmol/mol) among people with type II 
diabetes is reasonable to reduce risk of microvascular and macrovascular 
complication. A target of 6.5% (48 mmol/mol) may be appropriate at diagnosis. 
Targets should be set for individuals in order to balance benefits with harms, in 
particular hypoglycaemia and weight gain (SIGN, 2013).  According to UKPDS, 
each 1% reduction in HbA1c over 10 years is associated with risk reductions of 
21% for any diabetes-related end point, 21% for diabetes- related mortality, 
14% for myocardial infarctions and 37%for microvascular complications 
(Stratton et al., 2000). 
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In the present study, the mean change reduction of FPG in the intervention 
group was significant at -11.4 (range -7.1 to -15.7) with p-value <0.001; 
compared with -7.7 (range -2.6 to -12.8) in the control group with p-value 
=0.004 (also significant). This shows that FPG improved in both groups over 
time. An FPG improvement in the control group was unexpected, but beneficial 
for patient participants. This improvement might be because the participants in 
the control group self-managed their glycaemic control well. Comparing our 
data with the Belgium study’s time effect shows that FPG in both groups had 
significant improvement with absolute mean decrease 14.1 mg/dl (-7.0 to -21.1 
mg/dl, p<0.001) in intervention compared with reduction of 8.1 mg/dl (-2.7 to -
13.6 mg/dl, p=0.004) (Mehuya et al., 2011). Our study suggested that the 
improvement in both groups in FPG was because of increased adherence in 
measuring blood glucose by using a glucometer and that is evident because the 
mean difference was significant in self-care activities assessment (p<0.001).    
This reveals that encouraging people to use a self-monitoring glucometer helps 
them to set their glycaemic goals and encourages them to improve their self-
care activities or self-manage their diabetes. In comparison, a similar study 
Belgium revealed that the FPG reduced significantly in the intervention group 
with a mean change of -14.1 (range -7.0 to -21.10) (p-value<0.001) and a mean 
change of -8.1 (range -2.7 to -13.6) in the control group (p-value=0.004) 
(Mehuys et al., 2011). Our finding regarding improvements in FPG is consistent 
with Mehuys et al’s (2011) study. It has been evident in a number of studies that 
pharmacist intervention for type II diabetes management is effective (Aguiar et 
al., 2016, Collins et al., 2011, Hassali et al., 2015, Omran et al., 2012, Pousinho 
et al., 2016, Sapkota et al., 2015).  
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However, the baseline FPG in the previous Belgium study (154.1mg/dl ± 44. 6 
intervention; 153.9 mg/dl ± 44.7 control) group was lower than the current 
Libyan study (177.93 mg/dl±59.6 intervention; 176.93 mg/dl ± 53.1 control) 
(Mehuys et al., 2011). The variation is possibly due to cultural and genetic 
differences. A study conducted by Ballotari et al. (2015) aimed to compare 
immigrants and Italians in regards to the differences in diabetes prevalence and 
to assess the inequalities in disease management and glycaemic control 
through the use of information taken from the Reggio Emilia (a province in 
northern Italy) diabetes register. The findings revealed that there was a 
considerably higher prevalence of diabetes for High Migration Pressure 
Countries (HMPC) citizens than in Italians and a lower prevalence for people 
from High Developed Countries (HDC) countries (Ballotari et al., 2015). 
Diabetes prevalence was especially high for North Africans and Southern 
Asians. These results are in line with similar studies carried out in Europe 
(Carlsson et al., 2013, Hawthorne et al., 1993, Uitewaal et al., 2004, Legro et 
al., 1999), in Canada (Creatore et al., 2010, Khan et al., 2011), in the USA 
(Venkataraman et al., 2004), and in Australia (Shamshirgaran et al., 2013). The 
high prevalence of diabetes amongst certain ethnic groups is likely to be due to 
a complicated interaction of genetic and environmental factors, such as 
acculturation, stress, social isolation, and employment and economic problems 
(Creatore et al., 2010, Misra and Ganda, 2007). Furthermore, people from 
Southern Asia appear to be genetically susceptible to type II diabetes (Abate 
and Chandalia, 2001, Mohan, 2004). In addition, some researchers have 
proposed that vitamin D deficiency, especially pertinent to migrant groups with 
267 
 
 
darker skin pigmentation, intensifies the risk of developing diabetes amongst 
African people (Alvarez et al., 2010, Renzaho et al., 2011).  
Global studies have generated strong evidence to show that ethnicity is a 
significant determinant of diversity in the incidence of diabetes (Carlsson et al., 
2013, Weijers et al., 1998). Furthermore, studies have revealed that many 
immigrants with diabetes are not being treated (Buja et al., 2013, Thabit et al., 
2009), and some ethnic groups are not likely to be testing their glycaemic index 
and are not achieving recommended levels of glycated haemoglobin (HbA1c) 
(de Rekeneire et al., 2003, Sundquist et al., 2011). Similar to other diseases, 
the link between diabetes and migration is complex as the former is affected by 
ethnic, socioeconomic, lifestyle, individual factors, and the latter is affected by 
country of origin, reasons for migration, age at arrival, and how long they stay in 
the host country (Ballotari et al., 2015). 
The present study showed HbA1c decreases (from T0 to T24) in the 
intervention group (mean -0.53%; range -0.79 to -0.28) and less decrease in the 
control group (mean - 0.26%; range -0.014 to -0.53). This HbA1c decrease was 
statistically significant in the intervention group, but not in the control group. In a 
Belgium study, when comparing baseline and 6 month data, HbA1c levels 
decreased by -0.6% (-0.3to -0.9) (p-value< 0.001) in the intervention group, and 
by -0.2% (-0.1 to -0.4) (p-value =0.162) in the control group (Mehuys et al., 
2011).  
Our data shows that poor glycaemic control and good glycaemic control could 
benefit from the intervention. The findings are in line with the findings of other 
studies (Machado et al., 2007; Mehuys et al., 2011). Our study followed the 
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design of a Belgium study in terms of analysing data for FPG and HbA1c but 
there is difference in the population. For example, in Belgium the mean baseline 
of FPG was 153.9mg/dl in control and 154.1 mg/dl in intervention (Mehuys et 
al., 2012). Whereas, our FPG baseline was higher than the Belgium study for 
control (176.93 mg/dl) and in the intervention arm (177.93 mg/dl). As well as the 
percentage of people with good glycaemic control being higher in the Belgium 
study than the current study; it was reported by Mehuys et al (2011) that the 
percentage of participants having FPG within 90-130 mg/dl was 34.1% in 
control group and 28.1% in intervention. Whereas our data shows that the 
percentage of participants within normal range of FPG was 19.6%in control and 
21.5% in intervention. Our programme was welcomed by the participating 
patients and the low drop-out rate may indicate the patients need for a more 
intensive follow up and education on their condition. As our intervention 
consisted of several components, it is difficult to identify the elements that 
contributed most to the observed improvement in glycaemic control. However, 
this study showed that our programme enhanced the patients’ self-care 
activities, especially improvement in measuring blood glucose by using 
glucometer. 
Studies that have involved patients with higher baseline HbA1c levels revealed 
better improvements throughout the course of a pharmacist intervention (Choe 
et al., 2005, Cioffi et al., 2004, Coast-Senior et al., 1998, Jaber et al., 1996, 
Nowak et al., 2002, Odegard et al., 2005, Rothman et al., 2003). The 
effectiveness of community pharmacists in managing type II diabetes has been 
studied previously (Al Mazroui et al., 2009, Clifford et al., 2002, Mehuys et al., 
2011, Rothman et al., 2005, Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, 
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Venkatesan et al., 2012, Mehuys et al., 2011, Kraemer et al., 2012, Paulo et al., 
2016).  
Sound knowledge about medication, diet, and exercise, self-monitoring of blood 
glucose and treatment modifications is required for the efficient self-
management of diabetes (Speight and Bradley, 2001). Nevertheless, 
knowledge alone does not ensure the necessary patient behaviour changes or 
successful self-management. It is important to evaluate diabetes-related 
knowledge as a significant outcome measure in diabetes education 
programmes (Nicolucci et al., 2000; Funnell et al., 2009). The current 
intervention comprised various elements; it was challenging to classify the 
factors that contributed most to the observed enhancement in glycaemic 
control. Nevertheless, this study revealed that the programme improved 
patients’ practical knowledge regarding diabetes, and in addition it also 
improved their self-management activities and attitudes. Therefore, it seems 
probable that minor improvements in lifestyle contributed to the positive results. 
Other potential factors are more patient-pharmacist contact and frequent 
glucose self-measurements.   
Previously, action taken to improve the healthcare of patients with diabetes 
emphasised a team approach, whereby professionals from various disciplines 
would utilise their professional training and knowledge to make substantial 
contributions to patient care (Clemmer et al., 1998, Papa et al., 1998). There is 
thus great potential for multidisciplinary care to enhance health outcomes and 
reduce healthcare costs (Wagner, 2000). Pharmacists now focus on caring for 
patients and have become very significant members of healthcare teams. 
Various studies have proposed that coordinated care between doctors and 
270 
 
 
pharmacists can enhance patient care outcomes (Boudreau et al., 2002, 
Borenstein et al., 2003). Pharmacists can influence patient care outcomes via 
building a supportive partnership with a patient’s doctor (Zillich et al., 2004).   
Many of the successful interventions for chronic disease management comprise 
the doctor delegating tasks to the healthcare team members to make sure that 
patients receive proven clinical and self-management support services (Calkins 
et al., 2004, Wagner, 1997, Wagner, 1998, Altschuler et al., 2012). It has been 
found a healthcare team can work more effectively when another healthcare 
discipline joins the team, for example, a pharmacist (Bero et al., 2000) or 
nursing case management (Wagner, 1998). Successful chronic illness 
programmes usually take advantage of the diverse skills of the team (Wagner, 
2000). Nevertheless, the current study generates evidence to show that type II 
diabetes can be managed by community pharmacists without the need for 
intervention from primary care professionals and this is supported by Mehuys et 
al. (2011).   
To take advantage of the benefits of modern medical treatments, there is a 
need for more efficient effective interventions to help people to follow medical 
regimens (Hayes et al., 2002). Some interest has been shown in expanding the 
role of the community pharmacist so they have additional responsibilities 
compared to traditional roles, such as the dispensing and distributing 
medication, to make the role more diverse within the realm of public health 
(O'Loughlin et al., 1999). The pharmacy profession is progressively being 
documented as playing a strategic role in health promotion, based on 
pharmacists’ in-depth knowledge of the practical use of medicines (Olsson et 
al., 2002). The role of the pharmacist in a multidisciplinary team should not 
271 
 
 
however be overstated (Narhi et al., 2000). There are various limitations to the 
potential role pharmacists play in the wider health care team; for example, in 
some countries, pharmacists do not have the power to prescribe medications 
and some do not have clinical experience (O'Donovan et al., 2011). These 
limitations can be made worse by economic challenges, especially in 
developing countries (O'Donovan et al., 2011).  
The complications of type II diabetes can have a negative impact on a patient’s 
quality of life (Koopmanschap, 2002); therefore any improvements in the quality 
of life of a patient may suggest a lower level of complications. The reported 
decrease in non-adherence to medication should eventually result in a lower 
number of complications, which is associated with better glycaemic control 
(Armour et al., 2004). Long term follow up was not possible in the context of the 
current study, but could have provided interesting further data. 
The consequences of pharmacist interventions in the existing study were 
positive when compared to other kinds of interventions aimed at controlling type 
II diabetes (O'Donovan et al., 2011). A systematic review of patient self-
monitoring of blood glucose in type II diabetes reported that it was “of limited 
clinical effectiveness in improving glycaemic control in people with T2DM on 
oral  agents, or diet alone, and is therefore unlikely to be cost-effective.” (Clar et 
al., 2010, p: xi). Another study assessed the effect of educating patients with 
type II diabetes, provided by diabetes educators and dieticians, and it was 
reported that “overall there did not appear to be a significant difference between 
individual education and usual care” (Duke et al., 2009, p:3 ). 
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8.5. Implication of the study for healthcare practice  
This study suggested that community pharmacists have ability to interact and 
counsel patients with type II diabetes. Even though, the current study reveals 
there were no significant improvement in HbA1c and FPG among participants 
caused by the intervention. The time effect suggested that gradual improvement 
in both primary outcomes was possible. The community pharmacists’ actions 
show a trend towards improvement of glycaemic control by improving simple 
things such as self-management and providing diabetes education. 
Interventions on pharmacotherapy seek to overcome drug-related problems; if 
needed pharmacists can give feedback to doctors and provide patient 
education and counselling on medication. Non-pharmacotherapy interventions 
comprise education and counselling for diet, exercise, disease, medication 
adherence, and life-style changes. Even in the present study the non-
pharmacological intervention carried out and the findings of study showed a 
trend towards being successful. 
This study has two main strengths. First, it is one of the (relatively few) 
randomised controlled trials (RCTs) on diabetes care in the community 
pharmacy setting (Krass et al., 2007a, Sriram et al., 2011, Mehuys et al., 2011, 
Rothman et al., 2005, Ali et al., 2012, Jahangard-Rafsanjani et al., 2015, 
Venkatesan et al., 2012, Kraemer et al., 2012, Paulo et al., 2016 ). Such studies 
are essential to objectively assess the effectiveness of pharmacist diabetes 
programmes. Moreover, this is the first such trial conducted in Libya. The mixed 
results suggest that further research is required to identify how clinical 
improvements could be sustained.  
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There are however limitations of this study. Firstly, the researcher may have 
underestimated how much of an impact the intervention had. Furthermore, only 
patients who had been on hypoglycaemic medication for at least a year were 
included; those who were newly diagnosed were excluded. Nevertheless, 
despite the fact all the patients had already been on pharmacotherapy for one 
year or more, the programme still had a positive effect on patients, as they have 
a higher requirement for information and education. Secondly, in an RCT it is 
possible the effect can be underestimated as the control group may improve 
their performance merely by partaking in the study. Furthermore, in the current 
study, the patients in the control group undertook self-measurements, which 
may have also had a positive impact on patient outcomes (Welschen et al., 
2005). Thirdly, it may have been that the patients might not have 
comprehensively represented the overall population of patients with type II 
diabetes, as their participation was voluntary. Furthermore, the researcher only 
recruited pharmacy customers so as to ensure follow up was possible. This 
convenience sampling may have meant the patients who took part were more 
willing to undertake self-management of diabetes, thus leading to potential bias 
in the results. Lastly, it was not possible to obtain HbA1c data for all 
participants. It has been suggested that blinding personal and participants were 
not convenient due to the nature of the interventions (Antonie et al., 2014; 
Pousinho et al., 2016; Aguiar et al., 2016). There is substantial evidence to 
suggest that non blinded outcome assessment can lead to biased estimates of 
treatment effect. It is therefore recommended that blinded outcome assessment 
is used to avoid this source of bias (Kahan et al., 2015). The blinding of 
outcomes assessment was not provided in the current study. Kahan et al (2015) 
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found that lack of blinded assessment was not associated with the outcome 
type (apart from action-based outcomes), but did differ according to the 
assessor. It has been highlighted that blinding of outcome assessors is 
infrequently used and poorly reported in open clinical trials. 
8.6. Conclusion for stage one 
Pharmacy is evolving from a drug-centred, supply-based activity to one which is 
increasingly focused on the health and medication needs of patients, effective 
pharmacy practitioners. The main finding in this stage was that the majority of 
community pharmacies were private therefore the patients have to pay for their 
medicine. Most pharmacies were open from 9:00 am until 11:00 pm. The 
majority of pharmacies did not have a consultation area. Many pharmacies did 
not dispose of waste medicines or glucometer strips. This information helped to 
shape the clinical trial in terms of accessibility of community pharmacies, 
however, the fact that there were few consultation areas was not a barrier to 
further research. 
8.7. Conclusion for stage two 
The results suggested that community pharmacists had good knowledge about 
diabetes, which could be a foundation for more clinical practice. Basic provision 
of information for patients appeared to be good; however, there were 
opportunities to enhance the level of care provided. 
8.8.  Conclusion for stage three 
To sum up, this stage showed the effectiveness of educational materials that 
are used to enhance diabetes knowledge among participants, even though the 
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community pharmacist has good knowledge. However, it was essential for the 
pharmacists to take part in training to improve the consistency of 
pharmaceutical care for people with type II diabetes provided by those who 
entered the clinical trial. 
8.9.  Conclusion for stage four 
This stage showed that the community pharmacist intervention was beneficial 
but the findings were not significant in reducing glycated haemoglobin and FPG. 
It seems that a little help could sometimes improve the ability of patients with 
type II diabetes to reach their glycaemic control target. This trial was completed 
in a developing country, which lacks a systematic health care network (i.e. is 
not an advanced developed country) and was in a state of political unrest. The 
main study findings are consistent with recent studies (Jahangard-Rfasnjani et 
al., 2015; kraemer et al., 2012; Paulo et al., 2016).   
8.10. Summary 
The key findings of the current study suggested that community pharmacist 
provision of type II diabetes care can lead to improved glycaemic control. The 
programme was greeted by the participating patients and the low drop-out rate 
may indicate the patients’ need for more intensive follow-up and education on 
their condition. The positive outcomes are attributable to three factors: (i) the 
provision of clear information by the pharmacist; (ii) the patients’ and 
pharmacists willingness to share and discuss decisions; and (iii) pharmacists’ 
interventions included diabetes education and counselling on drug, disease, 
diet, exercise, life style modification, providing materials that motivate patients 
to achieve a target goal.  
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8.11. Future studies 
Based on the findings and discussion in this study, there is a considerable 
burden of uncontrolled and poor glycaemic control in Libyans with type II 
diabetes in one of the main diabetes care settings.. Future research should 
focus on strategies to improve sustainability of effect, collaborative care of 
patients between physicians and pharmacists, and cost-effectiveness of 
pharmacist interventions. Furthermore, medication adherence and exercise 
promotion programmes would help in reducing the magnitude of poor glycaemic 
control. Further investigation is proposed to consider the viability of 
interventions addressing self-care issues in Libya, which has its unique culture 
and values. 
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Appendix 6: Details of risk bias judgement 
Random Sequence Generation 
Author Risk rank Description or (support for judgment) 
Ali et al., 
2012 
Low 
 
(computer generated randomised list) 
Jahangard-
Rafsanjani 
et al., 2015 
Low Randomisation sequence was generated based 
on block randomisation algorithm  (1:1 allocation 
ratio; block size :4) 
Venkatesan 
et al., 2012 
Unclear Just written that 39 patients allocated randomly 
to 19 in control and 20 to intervention group 
without any description kind of randomisation 
Mehuys et 
al., 2011 
Low Randomisation table generated using SPSS 
14.0 software 
Ganawar et 
al., 2014 
Unclear The method of randomisation unclear. I addition,  
the number of people in control or intervention 
group after randomised not mentioned 
Kraemer et 
al., 2012 
Unclear Just state that patient randomly assigned to 
control or intervention (no description method of 
randomisation) 
Paulo et al., 
2016 
Low The randomisation process was performed 
using a random number table 
Kjeldsen et 
al., 2015 
Unclear No clear description of method randomisation 
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Allocation concealment 
Authors Risk rank Support for judgement 
Ali et al., 
2012 
High 
 
 
The randomisation held by the researcher at the 
school of pharmacy). 
The question here was it independent or what? 
The risk might be high or unclear! 
Jahangard-
Rafsanjani 
et al., 2015 
Low 2 authors who were not involved in the recruitment 
process  had access to the randomisation list 
Venkatesan 
et al., 2012 
Unclear No description 
Mehuys et 
al., 2011 
High The sequence of allocation to control or 
intervention group was predetermined by the 
investigators 
Ganawar et 
al., 2014 
Unclear Not mentioned or no description 
Kraemer et 
al., 2012 
Unclear No description 
Paulo et al., 
2016 
High The principal investigator who was a pharmacist 
received the reporting of laboratory test results 
containing that number and then a constant 
number on the random table was assigned. The 
even numbers assigned to intervention group and 
odd numbers assigned to control group. 
Kjeldsen et 
al., 2015 
Unclear No description 
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Selective reporting 
Authors Risk rank Support for judgement 
Ali et al., 
2012 
Low All the primary outcomes: BMI, BP, BG, HBA1C, LDL, 
HDL, Total cholesterol and triglycerides reported. The 
secondary outcomes: DQOL, SIMs, PMQ, Heath status 
and DKT being reported 
Jahangard-
Rafsanjani 
et al., 2015 
Low All primary: HbA1c and secondary outcomes: BP, BMI, 
Medicine adherence, Diabetes self-care activities 
reported 
Venkatesan 
et al., 2012 
Low The study outcomes reported in terms of Fasting blood 
glucose, weight, BMI, diabetes care profile divided into 
four subscales (Health status, understanding, control 
problems and social and personal factors) and diabetes 
knowledge test reported 
Mehuys et 
al., 2011 
Low All the outcomes reported: FPG, HbA1c, medication 
adherence, DKT and self- care activities in addition to 
sustainability results of study. 
Ganawar et 
al., 2014 
High Not all of the outcomes reported. 
Kraemer et 
al., 2012 
High Not all of the outcomes reported 
Paulo et al., 
2016 
Low The primary and secondary outcomes all reported 
Kjeldsen et 
al., 2015 
High Not all of the outcomes reported 
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Blinding Participants and personnel 
Authors Risk rank Support for Judgement 
Ali et al., 
2012 
Unclear Quote: Patients’ general practitioners were informed of 
their participation, but not to which group the patient 
had been randomized. 
Jahangard-
Rafsanjani 
et al., 2015 
Unclear Not mentioned 
Venkatesan 
et al., 2012 
Unclear Not mentioned 
Mehuys et 
al., 2011 
Unclear No description 
Ganawar et 
al., 2014 
Unclear No description 
Kraemer et 
al., 2012 
Unclear Quote: The blinding of study participants was clearly 
not complete in this study. The research team is aware 
that employees of one employer talked among 
themselves and with their human resource manager 
about the study and thus blinding was doubtful among 
this subgroup. 
Paulo et al., 
2016 
High Single blinded study but not describe who is blinded 
Kjeldsen et 
al., 2015 
Unclear Not described 
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Blinding outcome assessment 
 Risk rank Support for judgement 
Ali et al., 2012 Unclear No description 
Jahangard-
Rafsanjani et 
al., 2015 
Unclear No description 
Venkatesan et 
al., 2012 
Unclear No description 
Mehuys et al., 
2011 
Unclear No description 
Ganawar et 
al., 2014 
Unclear No description 
Kraemer et al., 
2012 
Unclear No description 
Paulo et al., 
2016 
Unclear No description 
Kjeldsen et al., 
2015 
Unclear No description 
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Incomplete outcome data 
Authours Risk rank Support for Judgement 
Ali et al., 2012 High Quote: Patients’ views on their satisfaction 
with the service were also collected (data not 
included in this paper). 
Jahangard-
Rafsanjani et al., 
2015 
Low All outcomes reported 
Venkatesan et al., 
2012 
High In the demographic information marital 
status, education and income level not 
reported 
Mehuys et al., 
2011 
Low All outcomes reported 
Ganawar et al., 
2014 
 Not all of the outcomes reported. In the 
study mentioned that medication adherence 
measured by 8 items of self-report Morisky 
Medication Adherence but is not reported in 
the study 
Kraemer et al., 
2012 
High Quote: Four other parameters (total 
cholesterol-to-HDL ratio, weight, waist 
circumference, and body mass index) are 
not shown due to lack of changes from 
baseline and differences between groups. 
Paulo et al., 2016 Low All outcomes reported 
Kjeldsen et al., 
2015 
High Quote: Also HbA1c, LDL, HDL, and 
triglycerides as reported measured by the 
GP at the most recent visit were collected, 
but the response rate for these values was 
below 50% and consequently considered too 
low for inclusion in the analyses. 
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Other sources of bias 
 Risk rank Support for judgement 
Ali et al., 2012 Low  
Jahangard-
Rafsanjani et al., 
2015 
Low  
Venkatesan et al., 
2012 
High The title of study: Role of 
community pharmacists in 
improving knowledge and glycemic 
control of type 2 diabetes. In the 
methods of study diabetes care 
profile assessed based on 
Fitzgerald of the Michigan Diabetes 
Research and Training Center 
(MDRTC) it seems assessing the 
patients attitudes toward type II 
diabetes but not mentioned in title 
(attitudes of psychological and 
social behaviour) 
Mehuys et al., 2011 Low   
Ganawar et al., 
2014 
Unclear The descriptive statistics was 
unclear in  terms of demographic 
data (numbers of male and female 
in each group control or intervention 
and all other parameters of study) 
Kraemer et al., 2012 Low   
Paulo et al., 2016 Low   
Kjeldsen et al., 2015 Low   
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Appendix 7: The pharmacological management of type II diabetes  
Key differences SIGN  LDCG 
Pharmacological 
management of 
glycaemic control 
in people with 
type II diabetes 
 Metformin as first line for 
overweight patients with 
type II diabetes. 
 Pioglitazone can be 
added to metformin and 
sulphonylurea therapy, or 
substituted for either in 
cases of intolerance. 
 Pioglitazone should not be 
used in patients with heart 
failure. 
 The risk of fracture should 
be considered in the long 
term care of female 
patients treated with 
pioglitazone. 
 Patients prescribed 
pioglitazone should be 
made aware of the 
increased risk of 
peripheral oedema. 
 DPP-4 inhibitors may be 
used to improve blood 
glucose control in people 
with type II diabetes. 
 Alpha-glucosidase 
inhibitors can be used as 
monotherapy for the 
treatment of patients with 
type II diabetes tolerated. 
Step1 – lifestyle 
intervention and Metformin 
therapy should be started 
concurrently with lifestyle 
intervention at diagnosis. 
Metformin is 
recommended as the initial 
pharmacological therapy, 
in the absence of specific 
contraindications (in 
particular renal 
impairment), for its effect 
on glycaemia, absence of 
weight gain or 
hypoglycaemia, and 
relatively low cost. 
Metformin should be 
titrated to its maximally 
effective dose (2000 
mg/day or more over 1–3 
months, as tolerated). 
Step2: sulfonylureas and 
alternatives A sulfonylurea 
is usually added to 
metformin, when 
metformin and lifestyle no 
longer maintain glucose 
control to target levels. 
Hypoglycaemia is 
sometimes a problem with 
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 Oral metformin and 
sulphonylurea therapy 
should be continued when 
insulin therapy is initiated 
to maintain or improve 
glycaemic control. 
 Once daily bedtime NPH 
insulin should be used 
when adding insulin to 
metformin and/or 
sulphonylurea  herapy. 
Basal insulin analogues 
should be considered if 
there are concerns 
regarding hypoglycaemia 
risk. 
When commencing insulin 
therapy, bedtime basal insulin 
should be initiated and the 
dose titrated against morning 
(fasting) glucose. If the 
HbA1c level does not reach 
target then addition of 
prandial insulin should be 
considered. 
sulfonylureas, and in 
particular with 
glibenclamide. Where 
hypoglycaemia with other 
sulfonylureas is a problem, 
a thiazolidinedione or 
DPP-4 
inhibitor are alternatives, 
as is basal insulin therapy. 
Sulfonylureas are 
sometimes 
used first line where 
metformin in 
contraindicated, or for their 
rapid glucose lowering 
effect. 
Step3: basal insulin 
therapy and alternatives: 
Basal insulin therapy is 
highly effective provided 
proper dose titration and 
training 
are provided. It should be 
added to metformin + 
sulfonylurea. Risk of 
hypoglycaemia is a 
significant issue in many 
people using insulin 
education and Self-
monitoring should be 
provided. Alternatives at 
this stage are a 
thiazolidinedione or DPP-4 
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inhibitor (gliptin), or in the 
obese a GLP-1 mimetic or 
acarbose. 
Step4: multiple insulin 
therapy 
In people already on basal 
insulin therapy, multiple 
insulin injections including 
meal-time insulin or by use 
of pre-mixes may become 
necessary as islet L-cell 
failure progresses. Further 
educational and self-
monitoring support should 
be provided. 
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Appendix 8: Type II diabetes knowledge and practice awareness among 
community pharmacist in Tripoli/Libya in pilot stage. Pilot stage 
 
Medicines Management for Patients with Type II Diabetes 
Dear Colleague 
My name is Nesrin Mohamed Elhatab, I am a PhD student at the University of 
Bradford in the United Kingdom, supervised by Prof Kay Marshall, Dr Jon 
Silcock and Dr Steve Britland. I am conducting a research project about 
Improving Medicines Management for Primary Care Patients with Type II 
Diabetes in Tripoli, Libya. Your kind response to this questionnaire will be used 
to guide my research and help to improve medicines management in 
community pharmacies in Tripoli. 
The main aim of my research is to improve medicine management for Libyans 
with Type II diabetes by enhancing their knowledge, attitudes and self care. 
This questionnaire (the first part of my project) has the objective of assessing 
pharmacists’ knowledge, attitudes and practice with respect to Type II diabetes. 
Your response will be treated in complete confidence. If you wish it can also be 
anonymous, or you can volunteer to help with the next part of my project. You 
will not be identified in any reports based on the data collected. All responses 
will be aggregated as part of the analysis. This questionnaire has been 
assessed and approved by the research ethics committee at the University of 
Bradford. 
It should take about 15 minutes to complete this questionnaire. Your 
participation will help me to understand your practice for patients with Type II 
diabetes. Participation is voluntary, but I would be most grateful for your 
response. 
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Please return your questionnaire (whether completed or not) by hand to the 
person who gave it to you. Please do not hesitate to contact me if you have any 
questions or you would like a summary of the results. 
With kind regards 
Nesrin Mohammed Elhatab 
Email:  nmaelha@student.bradford.ac.uk  
Telephone: 0044-7414896689  
To be completed by the senior pharmacist 
Thank you for your time and cooperation completing questionnaire 
Section One: about pharmacy staff and premises 
This section includes questions about: level of education; experience of work 
and training; and the location of your pharmacy. 
1. What are your personal qualifications 
Level of 
education  
Topic  Institution Year of 
graduation  
    
    
    
    
 
2. How many years have you worked as a community pharmacist? 
 
3. Your gender (please circle) 
a) Male    b) Female 
4. Have you received any specialised training about diabetes (please circle) 
a) Yes    b) No 
If yes, please give details (where, when, what)? 
 
 
5. Could you provide: 
Name of pharmacy  
Area location  
Is that area commercial or 
residential? 
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Optional participation in next stage of project 
6. If you would like to volunteer to help with further research, then please give 
your contact details: 
Name  
E-mail address  
Telephone number  
Section Two: availability of type II diabetic medicines and glucose devices 
measuring 
This section includes questions about availability of oral hypoglycaemic 
medicines and self-monitoring devices in community pharmacies 
1. How often are these oral hypoglycemic medicines available in your 
pharmacy? Please cross (X) to indicate the normal level of availability. 
Class of 
medicine 
Generic 
name 
Alway
s 
Usuall
y 
Sometime
s 
Rarel
y 
Neve
r 
Biguanides Metformin       
Sulfonylureas 
Glibenclamid
e 
     
Glipizide      
Gliclazide      
Benzoic acid & 
phenylalanine 
derived 
Repaglindine      
Nateglindine      
Thiazolidinedione
s 
Rosiglitazone      
Pioglitazone      
Alphaglucosidase 
inhibitors 
Acarbose 
     
DDP-4 inhibitors I Sitagliptin      
GLP-1 
Exenatide      
Liraglutide       
 
2. How often these glucose measurement devices availability in your 
pharmacy? Please cross (X) to indicate the normal level of availability. 
Devices  Always  Usually Sometimes  Rarely Never 
Glucose meter       
Glucose meter 
strips  
     
Urine dipsticks       
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3. How frequently do type II diabetic patients request these glucose 
measurement devices? Please cross (X) to indicate the normal level of 
demand. 
Devices Often Sometimes Rarely Never 
Glucose meters     
Glucose meter strips     
Urine dipsticks      
 
Please circle the correct answer in the following questions 
4. The correct method for granting a glucometer is to:  
a. use small drop of blood to tell how much glucose is in your blood at that 
moment 
b. use lots of drops of blood to tell how much glucose is in your blood at that 
moment 
c. use large drop of blood to tell how much glucose is in your blood at that 
moment 
d. use three drops of blood to tell how much glucose is in your blood at that 
moment 
5. The  normal range of blood glucose pre-prandial in a Type II diabetic patient 
should be: 
a. 70- 130mg/dl 
b. 100-150 mg/dl 
c. 40-80 mg/dl 
d. 185-200 mg/dl 
6. The normal level of blood glucose 2 hours after eating in a Type II diabetic 
patient should be: 
a) >200mg/dl 
b) <180mg/dl 
c) <70mg/dl 
d) <400mg/dl 
7. What should patients do with their blood glucose measurements? 
a) Note them all in a daily diabetes record, and report exceptional values 
b) Note and report the day and time of exceptional values only 
Section Three: your workload and professional activities 
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This section is divided into two parts. Part One relates to caseload (number of 
patients) and workload (number of visits) in your pharmacy. Part Two concerns 
the dispensing procedures in your pharmacy. 
Part One: caseload and workload 
1. Please estimate how many of your regular customers have type II diabetes. 
(caseload) 
 
2. Please estimate how many customers with diabetes visit your pharmacy. 
(workload) 
Daily Weekly Monthly Yearly 
    
3. Please cross (X) in the following table how frequently patients with Type II 
diabetes visit your pharmacy for the following reasons. 
Reason for visits Often Sometimes Rarely Never 
Collect prescriptions     
General consultation about 
diabetes e.g. diet or general health  
    
Specific consultation e.g. seeking 
advice about using OTC medicines 
    
Interpretation of medical reports     
 
Part Two: dispensing procedures 
4. When dispensing a medicine for a Type II diabetic patients, how frequently 
do you complete the following actions? Please cross (X) to answer. 
Actions Always Frequently Sometimes Rarely Never 
Review the 
prescription 
by finding the 
generic name. 
     
Check the 
prescription is 
appropriate 
for the 
patients’ age, 
weight & sex. 
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Check the 
medicine 
form, 
strength, 
dosage is 
appropriate. 
     
Label the 
package with 
clear written 
instructions 
     
Tell the 
patient 
verbally how 
to use the 
medicine 
     
Check the 
patients’ 
understanding 
about how 
take the 
medicine 
     
Tell the 
patient how to 
store and 
keep the 
medicine 
away from 
children 
     
Tell the 
patient to 
adhere to the 
medicine and 
explain 
importance  
     
Give advice 
about 
possible side 
effects 
     
Advise about 
possible drug 
interaction 
     
Advise about 
what to do 
after a missed 
dose 
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Section Four: assessment of your knowledge about diabetes 
This section assesses your knowledge and experience of diabetes (please 
circle responses). 
1. Do you have diabetes yourself  
a) Type I  b) Type II  c) No 
2. Do you have family history of diabetes? 
a) Yes   b) No  
3. Who in your family has diabetes (circle all that apply) 
a) Father or Mother    b) Aunt or Uncle 
         c)  Brother or Sister    d) Grandparents 
4. The good diabetic diet is: 
b) The way most Libyan people eat  b) A healthy diet for most 
people 
d) Too high in carbohydrate for most people d) Too high in protein for 
most people 
5. Which of the following has the highest fat? 
b) Baked chicken     b) Edam chess  
d) Couscous     d) Almond  
6. Which of the following is highest in fat? 
a) Low fat milk     b) Orange juice 
c) Sweet Corn     d) Honey 
7. Which of the following is a sugar free food? 
e) Any unsweetened food 
f) Any dietetic food (specially made for people with diabetes) 
g) Any food that says “sugar free” on the label 
h) Any food that has less than 20 calories per serving 
8.   Glycosylated hemoglobin (hemoglobin Al) is a test that is a measure of 
your average blood glucose level for the past: 
a) Day  
b) Week 
c) 6-10 weeks 
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d) 6 months 
9. Which is the reliable and accurate method for testing blood glucose? 
a) Urine testing 
b) Blood testing 
c) Both are equally good 
10.  What effect does unsweetened fruit juice have on blood glucose? 
d) Lowers it 
e) Raises it 
f) Has no effect 
11. Which should not be used to treat low blood glucose? 
e) 3 hard candies 
f) 1/2 cup orange juice 
g) 1 cup diet coca cola 
h)  1 cup skim milk 
12. For a person in good glycaemic control, what effect does exercise have on 
blood glucose? 
d) Lowers it 
e) Raises it 
f) Has no effect 
13. Infection is likely to cause: 
a) An increase in blood glucose 
b) A decrease in blood glucose  
c) No change in blood glucose 
14.  The best way to take care of your feet is to: 
a) Look at and wash them each day 
b) Massage them with alcohol each day 
c) Soak them for one hour each day 
d) Buy shoes a size larger than usual 
15. Eating foods lower in fat decreases your risk for: 
e) Nerve disease 
f) Kidney disease 
g) Heart disease  
h) Eye disease 
16. Numbness and tingling may be symptoms of: 
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a) Kidney disease 
b) Nerve disease 
c) Eye disease 
d) Liver disease 
17. Which of the following is usually not associated with diabetes? 
a) Vision problems 
b) Kidney problems 
c) Nerve problems 
d) Lung problems 
 
Thank you for your help. 
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Appendix 9: Community pharmacist diabetes knowledge and practice 
toward type II diabetes  
 
Medicines Management for Patients with Type II Diabetes 
Dear Colleague 
My name is Nesrin Mohamed Elhatab, I am a PhD student at the University of 
Bradford in the United Kingdom, and supervised by Dr Jon Silcock and Dr Anne 
Graham I am conducting a research project about Improving Medicines 
Management for Primary Care Patients with Type II Diabetes in Tripoli, Libya. 
Your kind response to this questionnaire will be used to guide my research and 
help to improve medicines management in community pharmacies in Tripoli. 
The main aim of my research is to improve medicine management for Libyans 
with Type II diabetes by enhancing their knowledge, attitudes and self-care. 
This questionnaire (the first part of my project) has the objective of assessing 
pharmacists’ knowledge, attitudes and practice with respect to Type II diabetes. 
Your response will be treated in complete confidence. If you wish it can also be 
anonymous, or you can volunteer to help with the next part of my project. You 
will not be identified in any reports based on the data collected. All responses 
will be aggregated as part of the analysis. This questionnaire has been 
assessed and approved by the research ethics committee at the University of 
Bradford. 
It should take about 15 minutes to complete this questionnaire. Your 
participation will help me to understand your practice for patients with Type II 
diabetes. Participation is voluntary, but I would be most grateful for your 
response. 
Please return your questionnaire (whether completed or not) by hand to the 
person who gave it to you. Please do not hesitate to contact me if you have any 
questions or you would like a summary of the results. 
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With kind regards 
         Nesrin Mohammed Elhatab 
         Email: nmaelhat@student.bradford.ac.uk           
Mohamed.nesrin@yhaoo.com 
 
To be completed by the senior pharmacist 
Thank you for your time and cooperation completing questionnaire 
Section One: about pharmacy staff and premises 
This section includes questions about: level of education; experience of work 
and training; and the location of your pharmacy. 
13. What are your personal qualifications 
Level of 
education  
Topic  Institution Year of 
graduation  
    
14. How many years have you worked as a community pharmacist? 
 
15. Your gender (please circle) 
b) Male    b) Female 
16. Have you received any specialised training about diabetes (please circle) 
b) Yes    b) No 
If yes, please give details (where, when, what)? 
 
 
17. Could you provide: 
Name of pharmacy  
Area location  
Is that area commercial or 
residential? 
 
 
Optional participation in next stage of project 
18. If you would like to volunteer to help with further research, then please give 
your contact details: 
Name  
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E-mail address  
Telephone number  
 
Section Two: Counselling practice 
19. How often do you  offer these types of advice for patients with type II 
diabetes: 
Actions Always Frequently Sometimes Rarely Never 
How to use medicines       
 
 
 
Continue……………… 
What medicine is for?      
Special storage 
instructions  
     
When to use medicines       
Foods/drinks to avoid      
Special instructions       
Side effects to expect       
How the medicine is 
likely to affect their 
condition (that is, its 
benefits) 
     
Offer patients 
information about 
medicines before the 
medicines are prescribed 
     
Check that patients have 
any information they 
wish about medicines 
when the medicines are 
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dispensed 
Discuss information on 
medicines with the 
patient rather than just 
presenting it 
     
 
20. Highlight the strongest (5) and weakness (1) recommendation provided by 
Scottish Intercollegiate Guidelines Network (SIGN) about Oral 
Hypoglycaemic Medicine (OHGM) 
Recommendation  Recommendation rank 
 1 2 3 4 5 
Metformin should be 
considered as the first line 
oral treatment option for 
overweight patients with 
type II diabetes. 
     
Sulphonylureas should be 
considered as first line oral 
agents in patients who are 
not overweight, who are 
intolerant of, or have 
contraindications to, 
metformin. 
     
Pioglitazone can be added 
to metformin and 
sulphonylurea therapy, or 
substituted for either in 
cases of intolerance. 
     
Pioglitazone should not be 
used in patients with heart 
failure. 
     
The risk of fracture should 
be considered in the long 
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term care of female 
patients treated with 
pioglitazone. 
Patients prescribed 
pioglitazone should be 
made aware of the 
increased risk of peripheral 
oedema. 
     
 
21. Rates theses reasons (1 low, 5 high) for not providing patient counselling: 
Reason  1 2 3 4 5 
Lack of 
pharmacist’s time  
     
Lack of patient’s 
interest  
     
Lack of patient’s 
time  
     
Lack of support 
staff  
     
Lack of 
knowledge/training  
     
Lack of self-
confidence  
     
Lack of 
pharmacist’ 
interest  
     
 
Section Three: assessment of your knowledge about diabetes 
This section assesses your knowledge and experience of diabetes (please 
circle responses). This section divided into three parts: part one about history of 
diabetes, part two background knowledge of diabetes and part three practical 
knowledge of diabetes  
383 
 
 
Part One: History of diabetes  
22. Do you have diabetes yourself  
b) Type I  b) Type II  c) No 
23. Do you have family history of diabetes? 
b) Yes   b) No  
24. Who in your family has diabetes (circle all that apply) 
a) Father or Mother                    b) Aunt or Uncle 
c) Brother or Sister                     d) Grandparents 
Part Two: Background knowledge of diabetes (circle the correct answer)  
25. The correct method for granting a glucometer is to:  
a) use small drop of blood to tell how much glucose is in your blood at 
that moment 
b) use lots of drops of blood to tell how much glucose is in your blood at 
that moment 
c) use large drop of blood to tell how much glucose is in your blood at 
that moment 
d) use three drops of blood to tell how much glucose is in your blood at 
that moment 
26. The  normal range of blood glucose pre-prandial in a Type II diabetic patient 
should be: 
a) 70- 130mg/dl 
b) 100-150 mg/dl 
c) 40-80 mg/dl 
d) 185-200 mg/dl 
27. The normal level of blood glucose 2 hours after eating in a Type II diabetic 
patient should be: 
e) >200mg/dl 
f) <180mg/dl 
g) <70mg/dl 
h) <400mg/dl 
28. What should patients do with their blood glucose measurements? 
c) Note them all in a daily diabetes record, and report exceptional values 
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d) Note and report the day and time of exceptional values only 
29. The good diabetic diet is: 
c) The way most Libyan people eat  b) A healthy diet for most 
people 
e) Too high in carbohydrate for most people d) Too high in protein for 
most people 
30. Which of the following is highest in carbohydrate? 
c) Baked chicken     b) Edam chess  
e) Couscous     d) Almond  
31. Which of the following is highest in fat? 
a) Low fat milk     b) Orange juice 
c) Sweet Corn     d) Honey 
32. Which of the following is a sugar free food? 
i) Any unsweetened food 
j) Any dietetic food (specially made for people with diabetes) 
k) Any food that says “sugar free” on the label 
l) Any food that has less than 20 calories per serving 
33.   Glycosylated hemoglobin (hemoglobin Al) is a test that is a measure of 
your average blood glucose level for the past: 
e) Day  
f) Week 
g) 6-10 weeks 
h) 6 months 
34. Which is the reliable and accurate method for testing blood glucose? 
d) Urine testing 
e) Blood testing 
f) Both are equally good 
35.  What effect does unsweetened fruit juice have on blood glucose? 
g) Lowers it 
h) Raises it 
i) Has no effect 
36. Which should not be used to treat low blood glucose? 
i) 3 hard candies 
j) 1/2 cup orange juice 
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k) 1 cup diet coca cola 
l)  1 cup skim milk 
37. For a person in good glycaemic control, what effect does exercise have on 
blood glucose? 
g) Lowers it 
h) Raises it 
i) Has no effect 
38. Infection is likely to cause: 
d) An increase in blood glucose 
e) A decrease in blood glucose  
f) No change in blood glucose 
39.  The best way to take care of your feet is to: 
e) Look at and wash them each day 
f) Massage them with alcohol each day 
g) Soak them for one hour each day 
h) Buy shoes a size larger than usual 
40. Eating foods lower in fat decreases your risk for: 
i) Nerve disease 
j) Kidney disease 
k) Heart disease  
l) Eye disease 
41. Numbness and tingling may be symptoms of: 
e) Kidney disease 
f) Nerve disease 
g) Eye disease 
h) Liver disease 
42. Which of the following is usually not associated with diabetes? 
e) Vision problems 
f) Kidney problems 
g) Nerve problems 
h) Lung problems 
Part Three: Practical knowledge of diabetes  
43. Diabetes is a condition that: 
Please circle ONE answer only 
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a) Can be cured by adopting a healthy lifestyle 
b) Can be cured with tablets and/or insulin 
c) Is currently not curable 
d) Is always life threatening when first diagnosed 
e) Unsure 
44. Which of the following statements about diabetes and diet is true?  
Please circle ONE answer only 
f) People with diabetes should eat a sugar free diet 
g)  It is OK to eat fried take away food three times a  week  
h)  Red meat is a carbohydrate food 
i)  A diet which is low in fat, high in fibre, low in added sugar is 
recommended for everyone with diabetes 
j) Unsure 
45. Why are people with diabetes advised to test their own blood glucose (BG)? 
Please circle ONE option only 
a) To alert them to changes in BG level patterns 
b) To help make decisions in relation to exercise, treating ‘hypos’ (low 
BG) or sick-day management. 
c) It can make people more confident in looking after their diabetes 
d) All of the above 
46. What should a person with diabetes do if s/he becomes ill (e.g. flu, gastric 
upset, infection)? 
Please circle AS MANY as apply, or circle ‘Unsure’. 
a) Check blood glucose level more frequently (every 2 to 4 hours) 
b) Stop taking all diabetes tablets and/or insulin. 
c) Drink lots of non-sweet fluid if blood glucose levels are over 
15mmol/L 
d)  Seek medical attention if very unwell and unable to check blood 
glucose 
e) Try to do as much exercise as possible to lower blood glucose levels 
f)  Unsure 
47. What foot problems are people with diabetes most at risk of? 
 Please circle AS MANY as apply, or circle ‘Unsure’ 
a) Poor circulation 
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b)  Loss of feeling in the feet 
c) Foot ulcers 
d)  Hammer to Infections 
e) Unsure 
48. How often should people with diabetes exercise or be physically active?  
Please circle ONE answer only 
f) Most days of the week for at least 30 minutes 
g) Once a week for at least 30 minutes 
h) Once a month for one hour 
i) At least every fortnight for two hours 
j)  Unsure 
49. Why is doing regular exercise or being physically active good for your 
health?  
Please circle AS MANY as apply, or circle ‘Unsure’ 
g) It can help to control blood glucose levels 
h) It can lower blood pressure 
i) It can help to regulate a person’s mood 
j)  It can reduce the risk of skin cancer 
k)  It can lower cholesterol levels 
l)  Unsure 
50. If a person with diabetes has a hypo (low blood glucose level) reaction, s/he 
should: Please circle ONE answer only 
f)  Immediately take some insulin or diabetes tablets 
g)  Rest and wait until s/he feels better 
h)  Immediately have some sugary food or drink (e.g. jelly beans, soft 
drink) 
i)  Drink some diet soft drink 
j)  Unsure 
51. Well-managed diabetes decreases the risk of:  
Please circle AS MANY as apply, or circle ‘Unsure’ 
a) Kidney damage 
b) Blindness 
c)  Melanoma 
d)  Heart disease 
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e)  Foot ulcers 
f) Unsure 
52. People with diabetes need a medical check-up of their eyes, nerve and 
kidney function at least: Please circle ONE answer only 
a) Every month 
b) Six monthly 
c)  Once a year 
d) Every two to three years 
e)  Unsure 
53. Which of the following statements about diabetes medication is true?  
Please circle ONE answer only 
a) If blood glucose levels are normal for two months, diabetes 
medication can be stopped.  
b) Tablets for diabetes work by increasing blood glucose levels 
c)  Regular medical check-ups are necessary to assess the need for 
adjustments to diabetes medication. 
d) People taking diabetes medication do not need to worry about 
healthy eating 
e) Unsure 
Comments: could you please provide us with any comments it could help us 
and many thanks for your response.  
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Appendix 10: Detailed comparison between MDKT and ADKQ 
Items MDKT ADKT Comment 
1) Diet 
management  
 The 
diabetes 
diet is: 
a. the way 
most American 
people eat 
b. a healthy 
diet for most 
people* 
c. too high in 
carbohydrate 
for most 
people 
d. too high in 
protein for most 
people 
 
 Which of 
the 
following is 
highest in 
carbohydrat
e? 
a. Baked 
chicken 
b. Swiss 
cheese 
c. Baked 
potato* 
d. Peanut 
butter 
 Which of 
the 
following is 
Which of the 
following 
statements about 
diabetes and diet 
is true? 
Please circle ONE 
answer only 
a. People with 
diabetes should 
eat a sugar free 
diet 
b. It is OK to eat 
fried take away 
food three times a 
week 
c. Red meat is a 
carbohydrate food 
d. A diet which is 
low in fat, high in 
fibre, low in added 
sugar is 
recommended for 
everyone with 
diabetes 
e. Unsure 
MKDT highlights 
the importance of 
diet management 
and uses five items 
to cover a healthy 
diet: low in 
carbohydrate, low 
in fat, low in sugar, 
and why fatty food 
should be avoided. 
But in ADKT one 
item used to define 
healthy diet in a 
simple way. 
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highest in 
fat? 
a. Low fat milk* 
b. Orange juice 
c. Corn 
d. Honey 
 Which of 
the 
following is 
a "free 
food"? 
a. Any 
unsweetened 
food 
b. Any dietetic 
food 
c. Any food that 
says "sugar 
free" on 
the label 
d. Any food 
that has less 
than 20 
calories 
per serving* 
 
 Eating 
foods lower 
in fat 
decreases 
your risk for: 
a. nerve 
disease 
b. kidney 
disease 
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c. heart 
disease* 
d. eye disease 
2) Blood glucose 
measurement 
management 
Glycosylated 
haemoglobin 
(hemoglobin 
Al) is a test that 
is a measure of 
your 
average blood 
glucose level 
for the 
past: 
a. day 
b. week 
c. 6-10 weeks* 
d. 6 months 
A blood test called 
HbA1c (or A1c) 
measures the 
average blood 
glucose levels 
over the past 2 to 
3months. What is 
the HbA1c result 
that indicates a 
lowest risk of 
developing long-
term diabetes 
complications? 
Please circle ONE 
answer only 
a. Less than or 
equal to 7% 
b. Less than 8% 
c. 9% 
d. Less than or 
equal to 10% 
e. Unsure 
MDKT focus on the 
measurement of 
GbA1c. ADKT 
focus on the 
importance of test 
why it is done. 
Both questions are 
very important for 
knowledge 
assessment  
3) Impact of 
infection on 
blood glucose 
Infection is 
likely to cause: 
a. an increase 
in blood 
glucose* 
b. a decrease 
in blood 
glucose 
c. no change in 
blood glucose 
What should a 
person with 
diabetes do if s/he 
becomes ill (e.g. 
flu, gastric upset, 
infection)? 
Please circle AS 
MANY as apply, 
or circle ‘Unsure’ 
a. Check blood 
glucose level 
more frequently 
(every 
In MDKT the focus 
was on the cause of 
infection (when 
people are infected 
what happens to 
blood glucose). 
However, in ADKT 
the focus of the 
question is what the 
patient does when 
ill. 
MDKT tests the 
knowledge about 
consequences of 
infection. Whilst 
392 
 
 
2 to 4 hours) 
b. Stop taking all 
diabetes tablets 
and/or insulin 
c. Drink lots of 
non-sweet fluid if 
blood glucose 
levels 
are over 
15mmol/L 
d. Seek medical 
attention if very 
unwell and unable 
to 
check blood 
glucose 
e. Try to do as 
much exercise as 
possible to lower 
blood glucose 
levels 
f. Unsure 
ADKTQ tests the 
knowledge of 
management of 
diabetes after 
infection. 
Both aspects of 
knowledge are 
fundamental and 
important. 
4) Foot care 
management  
 The best 
way to take 
care of your 
feet is 
to: 
a. look at and 
wash them 
each day* 
b. massage 
them with 
alcohol each 
day 
c. soak them 
for one hour 
each day 
What foot 
problems are 
people with 
diabetes most at 
risk of? 
Please circle AS 
MANY as apply, 
or circle ‘Unsure’ 
a. Poor circulation 
b. Loss of feeling 
in the feet 
c. Foot ulcers 
d. Hammer toe 
e. Infections 
MDKT focus on the 
knowledge of foot 
care and also test 
the knowledge of 
nerve disease 
symptoms. 
However, ADKT 
focus on the 
consequences or 
causes or 
complications of 
foot disease 
(neuropathy).  
It is very important 
to understand how 
to avoid foot 
disease and also 
the mechanism of 
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d. buy shoes a 
size larger than 
usual 
 
 Numbness 
and tingling 
may be 
symptoms 
of: 
a. kidney 
disease 
b. nerve 
disease* 
c. eye disease 
d. liver disease 
f. Unsure disease. 
 
5) Exercise 
management  
For a person in 
good control, 
what effect 
does exercise 
have on blood 
glucose? 
a. Lowers it* 
b. Raises it 
c. Has no effect 
How often should 
people with 
diabetes exercise 
or be physically 
active? 
Please circle ONE 
answer only 
a. Most days of 
the week for at 
least 30 minutes 
b. Once a week 
for at least 30 
minutes 
c. Once a month 
for one hour 
d. At least every 
fortnight for two 
hours 
e. Unsure 
 
MDKT tests 
knowledge about 
exercise impact on 
blood glucose. 
ADKT highlights 
frequency of 
exercise 
recommended and 
also the benefits 
and impact of 
exercise on your 
health more 
precisely. 
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 Why is doing 
regular 
exercise or 
being 
physically 
active good for 
your health? 
Please circle AS 
MANY as apply, 
or circle ‘Unsure’ 
a. It can help to 
control blood 
glucose levels 
b. It can lower 
blood pressure 
c. It can help to 
regulate a 
person’s mood 
d. It can reduce 
the risk of skin 
cancer 
e. It can lower 
cholesterol levels 
f. Unsure 
 
6) Blood glucose 
management  
Which is the 
best method for 
testing blood 
glucose? 
a. Urine testing 
b. Blood 
testing* 
c. Both are 
equally good 
Why are people 
with diabetes 
advised to test 
their own blood 
glucose (BG)? 
Please circle ONE 
option only 
a. To alert them to 
changes in BG 
level patterns 
b. To help make 
decisions in 
relation to 
exercise, treating 
MDKT focus on the 
knowledge of blood 
glucose analysis.  
ADKT gives the 
reader more 
knowledge about 
the importance of 
blood glucose 
monitoring.  
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‘hypos’ (low BG) 
or sick-day 
management 
c. It can make 
people more 
confident in 
looking after their 
diabetes 
d. All of the above 
7) Complication of 
diabetes 
understanding 
Which of the 
following is 
usually not 
associated with 
diabetes: 
a. vision 
problems 
b. kidney 
problems 
c. nerve 
problems 
d. lung 
problems* 
Well-managed 
diabetes 
decreases the risk 
of: Please circle 
AS MANY as 
apply, or circle 
‘Unsure’ 
a. Kidney damage 
b. Blindness 
c. Melanoma 
d. Heart disease 
e. Foot ulcers 
f. Unsure 
MDKT tests the 
respondents 
understanding 
about diabetes 
complications. 
However, ADKT 
highlights the 
benefit of good 
diabetes 
management in 
diabetic patients’ 
health and address 
the complication of 
diabetes. 
8) Hypoglycaemic 
management  
Which should 
not be used to 
treat low blood 
glucose? 
a. 3 hard 
candies 
b. 1/2 cup 
orange juice 
c. 1 cup diet 
soft drink* 
d. 1 cup skim 
milk 
If a person with 
diabetes has a 
hypo (low blood 
glucose level) 
reaction, s/he 
should: 
Please circle ONE 
answer only 
a. Immediately 
take some insulin 
or diabetes tablets 
b. Rest and wait 
until s/he feels 
better 
Both MDKT and 
ADKT mention the 
importance of 
sugary drinks, but 
MDKT highlights 
the sweet drink that 
should be avoided 
when treating 
hypoglycaemia. 
ADKT tests 
knowledge in a 
more general way. 
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c. Immediately 
have some sugary 
food or drink 
(e.g. jelly beans, 
soft drink) 
d. Drink some diet 
soft drink 
e. Unsure 
9) Check-up 
management   
 People with 
diabetes need a 
medical check-up 
of their eyes, 
nerve and kidney 
function at least: 
Please circle ONE 
answer only 
a. Every month 
b. Six monthly 
c. Once a year 
d. Every two to 
three years 
e. Unsure 
 
10) Diabetes 
medication 
knowledge  
 Which of the 
following 
statements about 
diabetes 
medication is 
true? 
Please circle ONE 
answer only 
a. If blood glucose 
levels are normal 
for two months, 
diabetes 
medication can be 
stopped 
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b. Tablets for 
diabetes work by 
increasing blood 
glucose levels 
c. Regular medical 
check-ups are 
necessary to 
assess 
the need for 
adjustments to 
diabetes 
medication 
d. People taking 
diabetes 
medication do not 
need to 
worry about 
healthy eating 
e. Unsure 
11) Facts about 
diabetes  
 Diabetes is a 
condition that: 
Please circle ONE 
answer only 
a. Can be cured 
by adopting a 
healthy lifestyle 
b. Can be cured 
with tablets and/or 
insulin 
c. Is currently not 
curable 
d. Is always life 
threatening when 
first diagnosed 
e. Unsure 
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Appendix 11: Community pharmacy premises survey in Tripoli/Libya. 
  
Community pharmacy premises questionnaire in Tripoli/ Libya  
The study aims to find out the structure of community pharmacies in Tripoli. 
Your participation is voluntary and the data will be analyses anonymous and 
confidential.  
 
Q1      Please enter the premises details below:  
Name of pharmacy    
Area location    
Name of street     
Type of pharmacy: private or public     
The pharmacy located in commercial or 
residential?  
  
Number of staff work in the pharmacy    
Number of community pharmacist in the 
pharmacy  
  
Number of pharmacist technician work in 
the pharmacy   
  
  
 
Q2       Could you please write the opening hours and closed  
Day   Open from   To   
Saturday       
Sunday      
Monday      
Tuesday      
Wednesday      
  
Premises details     
  Opening hours    
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Consultation facilities    
Thursday       
Friday       
 
Presence of Consultation area:  
Q3       Do you have consolation area in your pharmacy?  
                    Yes                                                             
                     No    
Q4        If yes, could you tell about it?  
                     Is the consultation area located?  
                       On premises  
                      Off premises   
Q5       During consultations are there hand washing facilities?  
                          No hand washing facilities  
                          Hand washing facilities in consulting room  
                          Hand washing facilities close to consulting room  
Q6       Do patients attending for consultations have access to toilet facilities?  
 
Q7        Does the pharmacy dispense appliances?  
                 Yes  
                 No  
Q8        If yes, what type of appliances does the pharmacy dispense?  
                  All types  
                           Yes   
                           No   
  
  
Essential services :   
Pharmaceutical Services    
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                  All excluding stoma appliances  
                 All excluding incontinence appliances  
                 All excluding stoma and incontinence appliances  
                 Just dressings  
                 Other please specify  
 
 
   
Q9        Does the pharmacy provide repeat dispensing services for diabetic 
medicine?  
                     
       
 
Q10       If yes, what is the average monthly number of repeat dispensing 
clients?  
           0-10  
          11-20  
          21-30  
          31-40  
          Over 40  
Q11       Do you dispose unwanted medicines?  
           Yes                                                  
           No   
Q12        Do you dispose unwanted glucometer strips?  
 
Q12         Does the pharmacy provide the following services?  
            Yes    
            No    
  
  
Advanced Services    
Yes  
No  
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Diabetes medicine management  Yes   No   
Glucometer use review service  Yes   No   
   
Q13          Could you please select the diabetes medicine management that you 
provide?  
                     Patient education  
                     Initial assessment and monitoring:  
                    Check height, weight and calculate BMI;  
 
Q14      Which of the following services does the pharmacy provide, or would be 
willing to provide?  
Disease 
 specific 
medicines 
management 
service   
Not providing   Willing to provide 
in the future   
Providing   
Allergies         
Alzheimer’s/ 
dementia   
      
Depression         
Diabetes type I        
Diabetes type II         
Epilepsy         
Heart failure         
Hypertension         
Parkinson’s disease         
  
Thank you for your cooperation  
               Check smoking status   
               Glucose  Control   
               Dietary advice   
               Referral   
               Management of glucose control   
  Enhanced services     
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Appendix 12: Educational material about type II diabetes sent to 
community pharmacists 
 
Type II diabetes education 
Section one: Introduction 
When the body does not produce enough insulin or does not use it 
properly, type II diabetes (or insulin resistance diabetes) develops. Type II 
diabetes is most often diagnosed in overweight adults over the age of 40 with a 
family history of diabetes. However, type II diabetes is becoming increasingly 
common in younger people, especially adolescents. Certain racial and ethnic 
groups, are more prone to developing diabetes in their lifetime. Often, type II 
symptoms develop gradually, so people may have the disease for months or 
even years before it is diagnosed. Most people who develop type II diabetes 
first exhibit signs of pre-diabetes, with blood glucose levels elevated but below 
the diabetes range. 
Insulin is the gatekeeper of the body that assures that blood glucose, or blood 
sugar, is handled properly. When the response to insulin in the body is 
ineffective, glucose builds up in the blood and accumulates. 
As diabetes develops, other health problems, such as high blood pressure and 
high cholesterol are also likely to occur. Recent research on obesity in children 
also indicates there is an increased risk of hybrid or double diabetes. People 
with type I diabetes who become overweight and have high blood pressure are 
at risk of developing type II as well. 
What Happens When You Have Diabetes? 
With type II diabetes, a number of systems may be functioning poorly. It takes 
5-10 years for type II diabetes to develop. It is a slow progression of the 
following issues: 
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Your pancreas, particularly the beta cells, is not able to make enough insulin to 
control blood glucose levels. Your fasting blood glucose slowly creeps up over 
the years (pre-diabetes) until the insulin can no longer keep the levels in check 
and diabetes is diagnosed.  
Insulin resistance is also a factor; the body resists the normal functioning of the 
insulin because of chronic inflammation related to excess weight and inactivity. 
There then is an increased demand for more insulin since it is less effective. 
This is called impaired glucose tolerance. 
Hepatic glucose output—the liver, with its storage bank of glucose, begins to 
release more glucose than it needs to. The result is fasting blood glucose rises. 
With type I diabetes, there is an autoimmune disease action that destroys the 
beta cells of the pancreas. These cells make insulin, so that the body no longer 
has a mechanism to lower blood glucose effectively. People with type I diabetes 
must take exogenous insulin (from outside the body) to stay alive. 
In order to stay healthy by managing your diabetes well, you have a number of 
tools to help. Diet, exercise and medications are your arsenal of control. But 
first, you need to know your numbers by testing your blood sugar. 
Questions Newly Diagnosed Type II Diabetes Patients Might Ask 
Why Me?  
Genes and environment play a role in whether a person gets diabetes or not. 
Diabetes is not your fault. You have done nothing to cause it to happen; but 
what you can do now is learn how to take control of your health as best you 
can. At first, you may not really believe the diagnosis—and you may bargain 
with the doctor for a few more months so you can lose some weight or start 
exercising. Denial is common, but when reality sets in, you may feel the anger 
of being burdened with a disease. Anger may turn to feeling overwhelmed, or 
depressed. These feelings are natural coping mechanisms. You will come to a 
stable point, where you will be open to learning how to manage your health and 
diabetes. With knowledge and a positive attitude, you can lead a long, high-
quality life. 
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There Must Be Some Mistake? 
The lab results could be repeated, for your peace of mind. There are very 
definitive standards for the diagnosis; it is not a judgment call by your doctor. A 
fasting blood test of 126mg/dl or higher on two occasions, or  HgA1c test of 6.5 
percent or higher. 
What Went Wrong? 
You may have certain higher risks for developing type II diabetes, some of 
which are genetic. If you have a parent or sibling with diabetes, are over the 
age of 45, and of Arabic Libyan parents, you are at higher risk genetically. A 
female is at higher risk if she has had gestational diabetes or a baby over nine 
pounds at delivery. Additional risk factors are: being overweight, waist 
circumference higher than 35 inches in women, 40 inches in a man; high 
cholesterol; inactivity and if you smoke. 
How is Type II Diabetes Treated? 
By the time you are diagnosed with diabetes, your pancreas may have lost 50 
percent or more of its insulin-producing capability. This may slowly decline 
overtime. Changes happen over time that determines your treatment plan. The 
four major changes are: 
The body's cells become resistant to the action of insulin 
The pancreas first makes more insulin, but then less and less over time 
Less insulin is released with meals and blood glucose remains high 
The liver isn't releasing glucose correctly 
Your treatment plan is based on what changes are happening. You need to 
work on your food intake and physical activity, and may also need an oral 
medication. (The first medication that is typically prescribed is metformin for 
type II diabetes.) You may need additional oral medications as time passes. 
You may eventually need insulin injections or other injectable medications. You 
may have a different "mix" of diet and medications than another person with 
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diabetes; this depends on your unique body. You may also need blood pressure 
medication and blood fat medication as part of your prevention plan. 
What Can I Eat? 
A nutrition plan for a person with diabetes is a healthy diet that has less than 50 
percent of calories from carbohydrates. Carbohydrates should be selected from 
three major food groups: 
Starches: preferably high fiber, grains, cereals, breads, pasta, rice, legumes, 
starchy vegetables like potatoes, and peas 
Fruits 
Low fat diary such as milk and yogurt 
Added sugar is not recommended, but a person with diabetes who has well-
controlled blood glucose can work small amounts of sugar into their diet. The 
major selection of food needs to be lean proteins such as tuna and vegetables. 
The diet should be low in saturated fats, to prevent heart disease. Use of olive 
oil is preferred. Eat three balanced meals a day at regular times, select the 
healthiest foods, and achieve or maintain your healthiest possible weight. 
Do I Have to Give Up Sugar? 
A simple directive you may have heard is: "people with diabetes can't have 
sugar." But this is not true! What is true is that many people do consume too 
much simple sugar in sodas, sweetened teas, fruit juice, other sweetened 
beverages, candy, and desserts. These foods do not have a regular place in a 
diabetes friendly diet, especially if this person needs to lose weight. Simple 
sugars raise blood glucose levels quickly and quite high, so are not helpful to 
controlling blood glucose. A small amount of sugar however, when eaten with a 
meal, will have a lesser impact on blood glucose. The total amount of 
carbohydrates eaten at a meal, and for the entire day, is more important in 
managing blood glucose levels. 
Can Diabetes Be Cured? 
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To date, there is no cure for type II diabetes. However, when some people lose 
weight, exercise more often, and improve their nutrition, their blood glucose 
returns to normal without the need for medication. Some persons with diabetes 
who have had bariatric surgery eliminate their need for medication to manage 
blood glucose. However, even with lower blood glucose and diminished 
symptoms, the disease is still present. 
Do I Have to Test My Blood? 
Self-monitoring blood glucose is an important tool in controlling your diabetes. 
Your doctor will instruct you how often and when to test your blood glucose, as 
well as your target goals pre and post meals. You may need to improve your 
dietary or exercise habits to manage your numbers to an optimum range. 
What Should My Blood Glucose Numbers be? 
Your fasting blood glucose, as well as before a meal, should be 80mg/dl to 
130mg/dl. Two hours after a meal, no higher than 180mg/dl. Before bed, blood 
glucose targets range from 110-150 mg/dl. 
What is A1c? 
A1c is short for Hemoglobin A1c which is a measure of blood glucose that 
reflects the average blood glucose for the past 60-90 days. A1C is also used to 
diagnose diabetes. An A1C of 6.5 percent or higher is an indication of diabetes. 
Can I Just Take a Pill? 
Oral medications are usually an important part of your treatment plan, but first 
lifestyle changes may be recommended. Weight loss if necessary, increased 
exercise and controlling carbohydrate intake are important ways to manage 
your diabetes without medication. These recommendations may be the first 
prescribed step by your doctor. Lifestyle changes may reduce the need for oral 
medication, and provide better blood glucose control with medication. 
Do I Have to Take Insulin? 
Diabetes is a progressive disease, and there may be a point in time when 
lifestyle changes and oral medications aren't enough to give good glycemic 
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control. Trust your doctor's clinical judgment in making the right decision for 
your diabetes treatment. Many people who feared using insulin find they feel 
better and have better control over their disease. People with type I diabetes 
must take insulin because their pancreas produces none. 
What Happens if My Blood Sugar Goes Too Low? 
Low blood sugar or hypoglycemia is a blood glucose below 70 mg/dl which 
occurs when someone takes blood sugar lowering medicine and doesn't eat, or 
exercises too much, or delays or skips a meal. Symptoms are light-
headedness, shakiness, sweating, blurred vision and labored speech, confusion 
and could lead to unconsciousness. 
What happens if My Blood Sugar stays too high? 
Hyperglycemia is before meal blood glucose over 130 mg/dl and over 180 mg/dl 
2 hours after meals. If blood glucose is occasionally high but not over 250 
mg/dl, you may not have any symptoms. Symptoms to watch for are extreme 
thirst, frequent urination and hunger. Even without symptoms, the elevated 
concentration of glucose in your blood is damaging tissues. Unchecked high 
blood sugars will eventually lead to serious conditions including seizures, 
unconsciousness and coma. If your blood glucose levels are high, be sure to 
avoid dehydration by drinking adequate fluids. 
Do I Have To Exercise? 
Think of it as increasing your physical activity. Moving more will lower your 
blood sugar, help you control your weight and improve your fitness level. It is a 
part of the recommended treatment plan for nearly every person, especially 
those with diabetes. 
Who Can Help Me With This? 
Expect to be more connected to your primary care physician, and maybe an 
endocrinologist who specializes in diabetes care.  
How Do I Prepare for Sudden Illness? 
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This is a good topic for your doctor to discuss with you. If you have been sick 
for 24 hours and your blood sugars are high, call your doctor. If you have 
ketones in your urine, call your doctor. Avoid dehydration by drinking plenty of 
fluids, and keep track of the medications you take. You will want to review 
which cold relief medications are safe for you to take when you are under the 
weather. Keep a record of your blood glucose to show the doctor. 
Section two: newly diagnosed person with type 2 diabetes  
11 Essential Things You Must Do (As a Newly Diagnosed Person with Type II 
Diabetes) 
1. Test Your Blood Glucose 
Your doctor will give you a glucometer and test strips and have a nurse show 
you what to do, so you can demonstrate enough knowledge to test blood 
glucose yourself. The strips and meters should not be left in any places where 
extreme hot or cold temperatures could occur, like a car. Be sure the test strips 
are coded with the meter and not expired. 
2. Control Your Carbohydrates 
Carbohydrates are converted to glucose by digestion. Insulin carries the blood 
glucose into the cells to provide energy for living. If the insulin is lacking or 
ineffective, the glucose piles up in the blood, causing problems for the body. 
Limiting carbohydrates to a level that the insulin can manage is one treatment 
of diabetes. Carbohydrates are sugar, fruit, lactose in milk and yogurt, and 
starches such as grains, bread, salted biscuits, macaroni or spaghetti, rice, 
legumes such as humus and beans, and starchy vegetables such as potatoes, 
potatoes, zucchini, peas and corn. Your dietitian or certified diabetes educator 
can plan an individualized carbohydrate plan for you. Typically, women 
consume 45 grams of carbs per meal, and men 60 grams per meal. Keep 
snacks to 25-30 grams of carbohydrate. 
3. Get Moving 
Exercise lowers blood glucose. This is a second treatment for high blood 
glucose. Physical activity is important for everyone, even those without 
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diabetes. It will improve your mood, help with weight loss, build muscle, 
strengthen bones, and improve your sleep. Try to get 30 minutes of exercise 
most days. Be sure to check your blood glucose before you exercise. If it is 
lower than 90 mg/dl, eat a light snack, and if higher than 250 mg/dl, do not 
exercise until within a more normal range. 
4. Become Educated and Know Your Numbers 
What are your target blood glucose goals? Your doctor may give you individual 
instruction, but these are the American Diabetes Association recommendations: 
Fasting and before meals: 70-130 mg/dl 
2 hours after start of a meal: 180 mg/dl 
A1C: <7%( tested every 3 months or more) 
5. Build Your Support Team 
Your team should consist of your doctor or an endocrinologist, a certified 
diabetes educator, a registered dietitian, a foot doctor (podiatrist), a dentist, an 
eye doctor and an exercise professional. 
6. Take Your Medicine as Directed (and know how it works) 
Diabetes is a progressive disease and there may come a point where diet and 
exercise, called lifestyle changes, aren't enough to keep your glucose under 
control. There are quite a few oral medications that help lower blood glucose in 
different ways. Be sure you understand how to take the medication, what side 
effects to watch for, and how the medications work. There are also injectable 
medicines, and insulin by injection that are very effective in managing blood 
glucose.  
7. Know How to Treat Low Blood Sugar 
The signs of hypoglycemia are shakiness, sweating, weakness, blurred vision, 
hunger. A quick ingestion of simple carbohydrate is necessary to bring your 
blood sugar back up. 
8. Lose Weight 
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Most people with type II diabetes start out overweight-above their ideal body 
weight. Weight loss, of even just 10 percent, can make a huge difference in 
blood glucose levels. Some people see their blood glucose go back to normal 
with lifestyle changes alone. 
9. Get an Annual Physical with Blood Work to Prevent Complications 
There are large and small vessel problems that might occur over time, so make 
it a habit to get a good check-up annually. Your eyes, kidneys, nervous system, 
heart, skin, teeth and feet are all susceptible to injury from diabetes and high 
blood glucose. 
10. Know What to Do If You are Sick? 
Talk with your doctor about sick day plans. Call your doctor If you have been 
having vomiting or diarrhea for 6 hours, your blood sugars are over 240 mg/dl 
for 24 hours even with medicine, and if you show ketones in your urine. 
Remember to stay well hydrated. 
11. Watch Your Blood Pressure and Cholesterol 
Diabetes is closely related to heart disease. You need to control your blood 
pressure within 120/80 mmHg to reduce stress on blood vessels and kidneys. 
Protect your heart by lowering your LDL cholesterol <100mg/dl, and 
triglycerides <150 mg/dl and HDL cholesterol men >40 mg/dl and women >50 
mg/dl. You may be prescribed prophylactic statins and blood pressure medicine 
to reduce your risk of complications. 
The Rule of 15 
Hypoglycemia, or low blood sugar, is when blood glucose levels drop below 70 
mg/dl. Symptoms are shakiness or trembling, sweating, weakness, fatigue, 
dizzy or light headedness, headache, hunger, blurred vision or altered speech, 
nausea, rapid heartbeat. Severe symptoms may progress to confusion, 
seizures or unconsciousness. 
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Why does this happen? Taking too much diabetes medication, delaying or 
skipping a meal, too few carbohydrates at a meal, increased exercise can all 
cause hypoglycemia. 
How to treat Using the Rule of 15 
Take your blood glucose. If it is 70 mg/dl or below, consume 15 grams of easy 
to digest carbohydrate such as: 1/2 cup fruit juice; 1/2 cup regular soda; five-six 
hard candies; or three sugar packets 
Wait 15 minutes to feel better 
Check your blood glucose again, and if still low, take 15 grams of carbohydrate 
When your blood glucose starts to go up, wait about an hour and recheck. Eat a 
hearty snack or your next meal 
Special Note 
Resist the urge to over-treat. Don't drink unlimited amounts of sugared drinks to 
get your blood glucose up, it may go too high and may take days to get it 
regulated. 
Alert 
If three attempts don't work to bring your blood glucose up, call for emergency  
Section three: Your Diabetes Emergency Plan 
Prepare diabetes emergency kit in which you can keep critical information and 
supplies in case of an emergency. A kit you can grab in a hurry with all you 
need to take care of your medical health. Choose a container that is insulated, 
waterproof and portable. 
Information for Your Kit: 
Your type of diabetes 
List of all your medications 
Contact information of your doctors and Certified Diabetes Educator, as well as 
family members 
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Most recent lab results 
Letter from your healthcare providers describing your medication and food 
regimen. If you are on insulin, your current insulin to carbohydrate ratio and 
correction factor, or typical dosing routine. 
Kit Supplies: 
A supply of all your oral and injectable medications 
If on insulin, a glycogen kit, as well as glucose tablets or gels to treat low blood 
glucose. Also, some juice boxes, candy or sugar packets 
Blood glucose testing supplies and extra batteries 
Empty plastic bottle for safe disposal of sharps 
Non-perishable food supply such as, raisins, nuts such as almonds, dates and 
unsalted biscuits.  
Bottled water 
First aid kit with bandages, band-aides, cotton swabs, antibiotic ointments 
Money for unexpected cash-only needs 
Extra set of clothes and undergarments, socks; mini bottles of toothpaste, 
shampoo, etc. 
Prepaid cell phone and important numbers 
Section four: The Diabetic Diet - Your Choice 
Diabetic Plate Diet 
The Food Pyramid has been replaced with the Plate Method Diet by the UDSA 
and Department of Health and Human Services to describe a healthy diet for 
Americans (www.choosemyplate.gov). The Plate Method can be adapted for 
people with diabetes who want a simple, easy guideline on how to eat. With this 
visual tool, you can control your food portions and spread the carbohydrate 
evenly within each meal and throughout the day. 
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Using a 9 inch plate, divide it into 4 quarters for both lunch and dinner. Fill the 
plate like this: 
1/2 plate with non-starchy vegetables (cauliflower, green bean, leafy greens, 
salad, carrots, etc) 
1/4 plate with starches (bread, rice, spaghetti, legumes, grains, cereal, cuscus, 
starchy vegetables like potatoes, pumpkin, zucchini, , peas and legumes) 
1/4 plate with meat (lean beef, lamb, camel, fish, ricotta, eggs, cheese) 
one cup low fat milk (on the side) 
One serving of fruit. (on the side) (one piece fresh, 1/2 cup unsweetened 
canned) 
The breakfast plate will be arranged a little differently: 
1/4 to 1/2 plate with starch 
1/4 plate with protein 
One serving of milk and one serving of fruit. 
Although a simplistic tool to plan your meals, be careful about preparation 
methods and added condiments like butter and salad dressings, which can add 
extra calories. 
Exchange List for Diabetic Meal Planning 
The Exchange List was created by the American Dietetic Association and the 
American Diabetic Association to provide a consistent approach to calculating a 
diabetic meal plan. Foods are divided into six groups (each group has common 
nutrient composition): Milk, Meats, Starch, Fruit, Vegetables, and Fats. A meal 
plan is created by defining a set number of servings from each group. The 
advantage of this approach is better calorie control, and manipulation of the 
nutritional quality of the diet. 
Sample 1,500 Calorie Diet Using Food Exchanges 
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Meal  Exchange  Food& amount  Carb count 
(grams) 
Breakfast 1 meat 1 scrambled egg 0 
 1 starch 1 slice toast 15 
 1 milk 1 cup skim milk 12 (round - up to 
15) 
 1fruit  1 peach  15 
 1 fat 1 tsp. margarine on toast 0 
  Total 45 grams 
Lunch  2 meats  2 oz. chicken  0 
 2 starch 2 slices whole wheat bread 30 
 1 milk low fat yogurt (no sugar 
added) 
15 
Carbohydrate Counting 
Carbohydrate counting is a third option for better management of diabetes. The 
focus is to eat a prescribed number of carbohydrates at meals and snacks. A 
typical plan might be 45 grams of carbs at each meal, and one snack with 15 
grams of carbs. This totals 150 grams of carbohydrates per day. For people 
with type II diabetes, the carb counting can be learned from the exchange lists. 
A serving, or choice, of starch, fruit, or milk group provides 15 grams of carbs. 
Once someone learns portion sizes, carbohydate counting makes estimating a 
meal's carbohydrate content quick and simple. People with type I diabetes, who 
are on insulin, or even the insulin pump, must be exact about their carbohydrate 
counting since their insulin dose is based on the amount they eat at a meal. 
Advanced carbohydrate counting calculates for the smaller amounts of 
carbohydrate throughout all food choices, and may use such tools as 
carbohydrate listing booklets or online apps that track food intake. The 
disadvantage with only using the carbohydrate counting method is that other 
nutrients aren’t monitored and calorie intake is not controlled 
Section five: What You Need to Know about Diabetes and Medications? 
Insulin shots used to be the only treatment for diabetes for years. Insulin is a 
protein, and if swallowed would be digested. Therefore, it must be administered 
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by injection. Scientists have been working to find oral medications to help 
control diabetes. There are many to choose from today, and each category of 
medication does something different to help manage the blood glucose. If you 
are on a medication, learn about how it works, be sure you take it when and 
how you should, and be alert to side effects. 
Each drug belongs to a class, and each class of drugs works in specific ways. 
Some work on the pancreas, increasing its output of insulin. Another class 
works on the liver, decreasing the amount of sugar it releases. Another class 
works on the muscle, making it more sensitive to insulin. Even the GI tract 
(gastrointestinal) can be altered to decrease the absorption of carbohydrates 
and increase helpful hormones called GLP-1. 
Some people may be on several oral medications, or oral and injectable. Some 
medications are also in combination pills. Injectable and insulin are now 
available in easy to use pens, with extremely tiny needles. Insulin is also used 
in insulin pumps. You need to check your blood glucose regularly to know how 
effective your medication, exercise and diet are keeping your blood glucose in 
range. You can make corrections if you know what is happening to your blood 
glucose. 
The charts below give you an overview of all the types of medications that can 
be of help. 
Medications for Type II Diabetes 
Classification Medication Route How it Works 
Sulfonylureas Glimepiride 
(Amaryl) 
Glipizide 
(Glucotrol) 
Glyburide 
Oral Increases insulin 
production by the 
pancreas 
Biguanides Metformin Oral Lowers glucose 
released by the liver 
Alpha-Glucosidases 
Inhibitors 
Miglitol 
(Glyset) 
Oral Slows digestion, slows 
glucose production 
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Acarbose 
(Precose) 
Thiazolodinediones Pioglitizone 
(Actos) 
Oral Reduces insulin 
resitance, works in 
muscles and liver 
Meglitinides Repaglinide 
(Prandin) 
Nateglinide 
(Starlix) 
Oral Increases insulin 
production by pancreas 
DPP-4 Inhibitors Stagliptin 
(Januvia) 
Saxagliptin 
(Onglyza) 
Lingliptin 
(Tradjenta) 
Oral Lowers glucose by 
blocking an enzyme in 
the intestine 
GLP-1 Incretin 
Mimetics 
Liraglutide 
(Victoza) 
Extenatide 
(Byetta) 
Bydureon 
Injectable Helps the pancreas 
make insulin. 
Decreases glucagon to 
reduce glucose 
Amylin Analog Pramlintide 
(Symlin) 
Injectable Controls after meal 
blood glucose; used 
with insulin 
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Commonly Used Insulin 
Types of Insulin Onset of 
Action 
Peak Duration 
Fast-Acting:    
Regular 1/2-1 hour 2-4 hours 6-8 hours 
Humolog, Novolog, 
Apidra 
<15 minutes 1-2 hours 4-6 hours 
Intermediate-Acting:    
NPH 1-2 hours 6-10 hours 12+ hours 
U-500 Regular 30 minutes 2-4 hours 5-7 hours 
Lantus 1.5 hours Flat, maximun effect 5 
hours 
24-hour 
Levemir 1-hour Flat, maximum effect 5 
hours 
12-24 
hours 
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Appendix 13:   Diabetes Knowledge Test 
 
How Much Do You Know About Diabetes Care? 
1. The correct method for granting a glucometer is to:  
e) use small drop of blood to tell how much glucose is in your blood at 
that moment 
f) use lots of drops of blood to tell how much glucose is in your blood at 
that moment 
g) use large drop of blood to tell how much glucose is in your blood at 
that moment 
h) use three drops of blood to tell how much glucose is in your blood at 
that moment 
2. The  normal range of blood glucose pre-prandial in a Type II diabetic 
patient should be: 
e) 70- 130mg/dl 
f) 100-150 mg/dl 
g) 40-80 mg/dl 
h) 185-200 mg/dl 
3. The normal level of blood glucose 2 hours after eating in a Type II 
diabetic patient should be: 
i) >200mg/dl 
j) <180mg/dl 
k) <70mg/dl 
l) <400mg/dl 
4. What should patients do with their blood glucose measurements? 
e) Note them all in a daily diabetes record, and report exceptional values 
f) Note and report the day and time of exceptional values only 
5. The good diabetic diet is: 
d) The way most Libyan people eat  b) A healthy diet for most 
people 
419 
 
 
f) Too high in carbohydrate for most people d) Too high in protein for 
most people 
6. Which of the following is highest in carbohydrate? 
d) Baked chicken     b) Edam chess  
f) Couscous     d) Almond  
7. Which of the following food is a major carbohydrate source? 
• A. Spinach 
• B. Apple 
• C. Egg 
• D. Cheese 
8. Which of the following is highest in fat? 
a) Low fat milk     b) Orange juice 
c) Sweet Corn     d) Honey 
9. Which of the following is a sugar free food? 
m) Any unsweetened food 
n) Any dietetic food (specially made for people with diabetes) 
o) Any food that says “sugar free” on the label 
p) Any food that has less than 20 calories per serving 
10. What is the best meal plan for people with diabetes? 
• A. Balanced diet--like the Plate Diet 
• B. Low in carbohydrate choices only 
• C. High protein diet 
• D. Not sure 
11.   Glycosylated hemoglobin (hemoglobin Al) is a test that is a measure of 
your average blood glucose level for the past: 
i) Day  
j) Week 
k) 6-10 weeks 
l) 6 months 
12. Which is the reliable and accurate method for testing blood glucose? 
g) Urine testing 
h) Blood testing 
i) Both are equally good 
13.  What effect does unsweetened fruit juice have on blood glucose? 
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j) Lowers it 
k) Raises it 
l) Has no effect 
14. Which should not be used to treat low blood glucose? 
m) 3 hard candies 
n) 1/2 cup orange juice 
o) 1 cup diet coca cola 
p)  1 cup skim milk 
15. For a person in good glycaemic control, what effect does exercise have 
on blood glucose? 
j) Lowers it 
k) Raises it 
l) Has no effect 
16. Infection is likely to cause: 
g) An increase in blood glucose 
h) A decrease in blood glucose  
i) No change in blood glucose 
17.  The best way to take care of your feet is to: 
i) Look at and wash them each day 
j) Massage them with alcohol each day 
k) Soak them for one hour each day 
l) Buy shoes a size larger than usual 
18. Eating foods lower in fat decreases your risk for: 
m) Nerve disease 
n) Kidney disease 
o) Heart disease  
p) Eye disease 
19. Numbness and tingling may be symptoms of: 
i) Kidney disease 
j) Nerve disease 
k) Eye disease 
l) Liver disease 
20. Which of the following is usually not associated with diabetes? 
i) Vision problems 
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j) Kidney problems 
k) Nerve problems 
l) Lung problems 
21. Diabetes is a condition that: 
Please circle ONE answer only 
f) Can be cured by adopting a healthy lifestyle 
g) Can be cured with tablets and/or insulin 
h) Is currently not curable 
i) Is always life threatening when first diagnosed 
j) Unsure 
22. Which of the following statements about diabetes and diet is true?  
Please circle ONE answer only 
k) People with diabetes should eat a sugar free diet 
l)  It is OK to eat fried take away food three times a  week  
m)  Red meat is a carbohydrate food 
n)  A diet which is low in fat, high in fibre, low in added sugar is 
recommended for everyone with diabetes 
o) Unsure 
23. Why are people with diabetes advised to test their own blood glucose 
(BG)? 
Please circle ONE option only 
e) To alert them to changes in BG level patterns 
f) To help make decisions in relation to exercise, treating ‘hypos’ (low 
BG) or sick-day management. 
g) It can make people more confident in looking after their diabetes 
h) All of the above 
24. What should a person with diabetes do if s/he becomes ill (e.g. flu, 
gastric upset, infection)? 
Please circle AS MANY as apply, or circle ‘Unsure’. 
g) Check blood glucose level more frequently (every 2 to 4 hours) 
h) Stop taking all diabetes tablets and/or insulin. 
i) Drink lots of non-sweet fluid if blood glucose levels are over 
15mmol/L 
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j)  Seek medical attention if very unwell and unable to check blood 
glucose 
k) Try to do as much exercise as possible to lower blood glucose levels 
l)  Unsure 
25. What foot problems are people with diabetes most at risk of? 
 Please circle AS MANY as apply, or circle ‘Unsure’ 
f) Poor circulation 
g)  Loss of feeling in the feet 
h) Foot ulcers 
i)  Hammer toes 
j)  Infections 
k) Unsure 
26. How often should people with diabetes exercise or be physically active?  
Please circle ONE answer only 
k) Most days of the week for at least 30 minutes 
l) Once a week for at least 30 minutes 
m) Once a month for one hour 
n) At least every fortnight for two hours 
o)  Unsure 
27. Why is doing regular exercise or being physically active good for your 
health?  
Please circle AS MANY as apply, or circle ‘Unsure’ 
m) It can help to control blood glucose levels 
n) It can lower blood pressure 
o) It can help to regulate a person’s mood 
p)  It can reduce the risk of skin cancer 
q)  It can lower cholesterol levels 
r)  Unsure 
28. If a person with diabetes has a hypo (low blood glucose level) reaction, 
s/he should: Please circle ONE answer only 
k)  Immediately take some insulin or diabetes tablets 
l)  Rest and wait until s/he feels better 
m)  Immediately have some sugary food or drink (e.g. jelly beans, soft 
drink) 
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n)  Drink some diet soft drink 
o)  Unsure 
29. Well-managed diabetes decreases the risk of:  
Please circle AS MANY as apply, or circle ‘Unsure’ 
g) Kidney damage 
h) Blindness 
i)  Melanoma 
j)  Heart disease 
k)  Foot ulcers 
l) Unsure 
30. People with diabetes need a medical check-up of their eyes, nerve and 
kidney function at least: Please circle ONE answer only 
f) Every month 
g) Six monthly 
h)  Once a year 
i) Every two to three years 
j)  Unsure 
31. Which of the following statements about diabetes medication is true?  
Please circle ONE answer only 
f) If blood glucose levels are normal for two months, diabetes 
medication can be stopped.  
g) Tablets for diabetes work by increasing blood glucose levels 
h)  Regular medical check-ups are necessary to assess the need for 
adjustments to diabetes medication. 
i) People taking diabetes medication do not need to worry about 
healthy eating. 
j) Unsure. 
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Appendix 14: Protocol of study 
Medicine management for type II diabetic patients in Tripoli 
The prevalence of diabetes is growing dramatically these days due to different 
reasons such as ageing and increasing of obese people. To void long term 
complication diabetes requires more medical care and on-going patient self -
management education. The American Diabetes Association stated (2012, p.1) 
‘Diabetes care is complex and requires that many issues, beyond glycemic 
control, be addressed’. Diabetes care requires diabetes team means there are 
many people engaging to help diabetic persons to live and manage the disease 
effectively. It is very important that health care provider do not impose on the 
person but negotiate with them, so they can fit their diabetes management into 
their everyday life (Living with diabetes, 2006). The effectiveness of community 
pharmacist intervention in the management of type II diabetes has been 
supported and studied (Mehuys et al., 2011; Almazroui et al., 2009; Lidenmeyer 
et al., 2006; Wermeille et al., 2004). 
The current study focuses on two aspects of diabetes management: self-
management (i.e. how people manage everyday life in terms of diet, exercise, 
feet care, eye care) and medicine management (i.e. oral hypoglycaemic 
adherence). In the long term, diabetes cannot be managed by medicine or diet 
alone when first diagnosed type II diabetes can be managed by diet and 
exercise. However, older people have to take oral hypoglycaemic tablets to 
control blood glucose levels, and may progress to management with insulin. 
To manage diabetes successfully, patients must be able to set goals and make 
frequent daily decisions that are both effective and fit their values and lifestyles, 
while taking into account multiple physiological and personal psychosocial 
factors. Intervention strategies that enable patients to make decisions about 
goals, therapeutic options, and self-care behaviours and to assume 
responsibility for daily diabetes care are effective in helping patients care for 
themselves (Funnel& Anderson, 2004).There are some identified essential 
elements of diabetes self-management that people with diabetes need to be 
able to access, and a minimum service level that needs to be in place to ensure 
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that people are supported to self-manage. The necessary elements of diabetes 
self-management are highlighted in Figure 2.1(Diabetes UK, 2009). 
 
Figure 1.1: Essential elements of diabetes self-management 
Source: Diabetes UK (2009) 
There are a number of potential barriers to self-management. Physical barriers 
include the nature of their medical condition(s) where people have different 
needs. System barriers include conflicting advice, or a lack of collaborative 
working, between healthcare and social care professionals in providing services 
and on-going support for self-management. The structure of ‘once a year only’ 
reviews also works against self-management, as people can benefit from 
seeing their healthcare professionals on a more regular basis. This barrier is 
considered one of the most common. Financial barriers include physical 
limitations of access to services, time and locations, financial cost, local 
availability of services and on-going support once people have had self-
management training or guidance. Another potential barrier is resistance to 
change on the part of healthcare professionals, many of whom have been 
traditionally trained to deliver care to their patients; different skills are needed to 
effectively support people living with long-term conditions such as diabetes. 
Research Aim and Objectives 
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The main aim of this research is centred on improving diabetes medicine 
management amongst Type II diabetic Libyan patients through the use of self-
completion questionnaires and semi-structured interviews, and finally 
randomised controlled trials. The study will take six months in order to assess 
glycaemic control. In order to achieve this aim, the following objectives have 
been set: 
1. To assess pharmacists’ knowledge, attitudes and practices towards 
diabetes care in community pharmacies within Libya. 
2. To assess Type II diabetic patients’ awareness and attitudes. 
3.  To determine the barriers of diabetes medicine management amongst 
pharmacists and Type II diabetic patients in Tripoli, Libya 
4.  To provide patients with the diabetic information required, and to revise 
health checks by community pharmacist. 
Methodology:  
The research is divided into four stages. The first stage aims to explore 
community pharmacists’ knowledge, attitudes and practices towards Type II 
diabetes care. The reason for completing an audit for pharmacists’ diabetes 
knowledge and practices is to gain understanding into the weaknesses and 
strengths. Stage One is recognised as a descriptive stage; therefore, the study 
can be seen as using combined methods: a literature review and self-
completion questionnaire  in order to generate the relevant data that can both 
inform and provide a clear picture regarding the current situation of the study 
problem. The second stage will investigate Type II medicine management 
barriers of diabetes care amongst patients. During this stage, I sought to 
understand the barriers amongst community pharmacists and Type II diabetic 
patients in regard to implementing medicines management. The second stage 
will utilise a semi-structured interview and literature review. The third stage 
explores Type II diabetes knowledge, attitudes and practices toward diabetes 
care through the use of a self-completion questionnaire. The reason for doing 
this is in order to investigate the various elements of weak diabetes knowledge. 
The fourth stage will adopt a randomised controlled trial or non-randomised 
control trial to improve Type II diabetes disease and medicine management. 
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Once understanding has been gained in regard to Type II diabetes knowledge 
and practices, as well as the barriers facing community pharmacists and 
patients from implementing medicine management, the decision will be made 
as to which study should be used in order to complete such an intervention so 
as to improve diabetes medicine management. 
Cluster randomisation: 
It may be preferable, for reasons of cost or feasibility, to randomise the clusters 
containing individuals rather than individuals themselves.  
Reasons for Adopting Cluster Randomization: 
 Administrative convenience 
 To obtain cooperation of investigators 
 Ethical considerations  
 To enhance subject compliance 
 To avoid treatment group contamination 
 Intervention naturally applied at the cluster level. 
The opinion is widely held that RCTs provide high-evidence grade whilst 
observational studies are considered less valid due to reported overestimate 
treatment effects. This view ignores the disadvantages of randomised controlled 
trials. There are many limitations of RCTs, such as they are somewhat 
pointless, unsuitable and impossible or insufficient. Furthermore, it is 
sometimes difficult to implement because of professional resistance, and there 
is also difficulty in terms of gaining ethical consent, as well as political and legal 
obstacles (Black, 1996).  
 
The effectiveness of community pharmacists’ intervention on the medicine and 
disease management of Type II diabetes has been studied in Belgium by 
Mehuyset al. (2008, 2011). Accordingly, I aim to replicate the Belgium study 
and to compare the outcomes in the two locations. It is also expected that the 
differences in lifestyle and culture will have a significant impact. Accordingly, the 
question is posed as to whether or not the randomised controlled trails are 
effective on Type II diabetes management in Libya? Using RCTs in the future 
study is not done in order to test new medicines but simply to reorganise patient 
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care by asking them about various factors, namely medicine adherence and 
lifestyle, management, reviewing foot and eye checks the patients requires, and 
asking them to gather readings of fasting plasma glucose. The aim of using 
RCTs in the final stage is to assess the level of effectiveness of community 
pharmacists compared with Belgium study. Importantly, this provides a rationale 
for why an intervention study cannot be carried out before an audit for Type II 
diabetes knowledge and practices, and understanding of the barriers, is 
conducted. 
 
Protocol of patient study: there are two stages in this study.  
First stage: Type II Diabetic Patients’ Recruitment 
The patients are going to be recruited through community pharmacies. 
Community pharmacists are going to provide eligible patients with a patient 
questionnaire, including personnel information, knowledge, and attitudes 
towards diabetes, beliefs, and self-management. 
 Aim and Objectives 
The aim is to explore patients’ diabetes knowledge and self-management; this 
will be achieved through setting the following objectives: 
1. To assess patients’ diabetes knowledge and practices through the use of the 
Australian Diabetes Knowledge Test (Eigenmann et al (2011). 
2. To assess patient diabetes self-management through the adoption of the 
Summary of Diabetes Self-Care (Toobert et al., 2000). 
 
Second stage: Intervention by Community Pharmacists 
This phase is referred to as intervention by community pharmacists in order to 
improve Type II diabetic patient management, as well as to improve 
cooperation between pharmacists and patients on the basis that community 
pharmacists are easily accessible. Customers visit community pharmacies 
without any appointment, and so the pharmacist needs to be able to help and 
work together with the patient in order to achieve improvement. Before the start 
of the study, the intervention pharmacists will be provided with educational 
materials about the pathophysiology of Type II diabetes and its non-
pharmacological and pharmacological management according to current 
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treatment guidelines, as well as the study protocol. The control pharmacists 
only received training on the study protocol. 
  
Aims and Objectives 
The aim is to improve Type II diabetes management by measuring blood 
glucose control and to enhance pharmacists’ knowledge and practices towards 
diabetes care. In order to achieve the aim, the following objectives need to be 
completed: 
1. To provide patients with a diabetes record on which their fasting plasma 
glucose can be detailed. 
 
Methods 
1. A comparison between two groups (control and intervention) 
2. The provision of usual pharmacist care to patients in the control group 
3. Patients in the intervention group are to receive a protocol-defined 
intervention at the start of the study and at each prescription-refill visit (for 
hypoglycaemic medication) during the course of the study 
4. The intervention design was based on Stage One of the Belgium study 
(Mehuys et al., 2008), and comprised several elements, namely: 
 Education about Type 2 diabetes and its complications; 
 Education about the correct use of oral hypoglycaemic agents (timing in 
relation to food); 
  The facilitation of medication adherence (by counselling); 
 Healthy lifestyle education (diet, physical exercise and smoking 
cessation); and 
  Reminders about annual eye and foot examinations. 
 
Factors Influencing Loss of Precision Cluster Randomization Trials 
 Interventions often applied on a group basis with little or no attention given 
to individual study participants. 
 Some studies permit the immigration of new subjects after baseline. 
 Entire clusters, rather than just individuals, may be lost to follow-up 
 Presence of experimental contamination. 
 Over-optimistic expectations regarding effect size 
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 Difficulties associated with prevention trials (low event rates, compliance 
problems, and incomplete exposure to intervention).  
 
How the cluster randomisation to be done? 
To improve the precision of data collected the pharmacies going to divide into 
two groups control and intervention.  So, the researcher just knows which 
pharmacies are control and intervention to avoid study bias. Then each group 
provide with three types of questionnaire attached in the appendix I, II, III and 
glucometer record sheet of FBG. In addition to other materials such as meeting 
sheet, some diabetes education materials, and diabetes patient leaflet.  
What about ethical consideration? 
Nothing without ethics, each patient participates in the study going to provide 
him/her by patient information sheet (Appendix IV) and consent form (Appendix 
V).  
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Appendix 15: Type II diabetes awareness questionnaire English version 
 
Type II Diabetes Awareness Questionnaire 
Dear Participant  
I am a PhD student studying at University of Bradford in UK. I am doing 
research about diabetes care in Tripoli/Libya. The aim of the study is to improve 
glucose control in type II diabetes by understanding your knowledge, attitudes 
and self-management.  
 I am delighted if you participate in this study. Your response will be treated in 
complete confidence. If you wish it can also be anonymous. You will not be 
identified in any reports based on the data collected. All responses will be 
aggregated as part of the analysis. This questionnaire has been assessed and 
approved by the research ethics committee at the University of Bradford. 
It should take about 10 minutes to complete this questionnaire. Your answers 
will help us to suggest ways to improve your care. Participation is voluntary. 
Please return your questionnaire (whether completed or not) by hand to the 
pharmacist who gave it to you. Please do not hesitate to contact me if you have 
any questions or you would like a summary of the results. 
Telephone number: 0044-7414896689 
Email address: nmaelhat@student.bradford.ac.uk 
 
 
We truly appreciate your help!  Thank you! 
Section One: Demographic Data 
1. Could you please tell me your date of birth? 
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…………/……………………/…………………………… 
2. Are you    
           Male                                                                         Female  
3. How long have you had diabetes? 
……..................years                     ..............months         or              
…........days. 
4. What type of diabetes do you have? 
     Type I                                               Type II                           or              
Unsure  
5. How would you describe the amount of verbal information you receive about 
your diabetes when you were first diagnosed? (please tick one box only) 
I did not receive any verbal information 
I received too little verbal information 
I received about the right amount of verbal information 
I received too much verbal information 
I did not want any verbal information 
I do not know, a career was given verbal information 
I cannot remember  
6. How would you describe the amount of written information you received 
about your diabetes when you were first diagnosed? (please tick one box 
only) 
I did not receive any written information 
 
I received too little written information  
 
I received about the right amount of written information 
I received too much written information 
I did not want any written information 
I do not know, a career was given written information for me 
I cannot remember 
 
 
7. Do you take diabetes medication?                  Yes                         No 
If  yes…………………….  glucose lowering tablets 
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And/or …………………… Dietary and exercise control  
 
8. If ticked glucose lowering tablets, how many different tablets? 
         1                                 2                                     3 
Other, please specify ……………………………………… 
9. Have you ever seen a diabetes educator? 
     Yes                                           No 
10. Have you ever seen a dietician?   
    Yes                                         No   
Optional participation: 
11. If you would like to volunteer to help with further research, then please give 
your contact details: 
Name  
E-mail address  
Telephone number  
 
Section Two: Diabetes Knowledge Test 
This section assesses your knowledge and experience of diabetes (please 
circle responses). 
1. Diabetes is a condition that: 
Please circle ONE answer only 
a. Can be cured by adopting a healthy lifestyle 
b. Can be cured with tablets and/or insulin 
c. Is currently not curable 
d. Is always life threatening when first diagnosed 
e. Unsure 
2. Which of the following statements about diabetes and diet is true?  
Please circle ONE answer only 
a. People with diabetes should eat a sugar free diet 
b.  It is OK to eat fried take away food three times a  week  
c.  Red meat is a carbohydrate food 
d.  A diet which is low in fat, high in fibre, low in added sugar is recommended 
for everyone with diabetes 
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e.  Unsure 
3. Why are people with diabetes advised to test their own blood glucose (BG)? 
Please circle ONE option only 
a. To alert them to changes in BG level patterns 
b. To help make decisions in relation to exercise, treating ‘hypos’ (low BG) or 
sick-day management. 
c. It can make people more confident in looking after their diabetes 
d. All of the above 
4. The correct method for granting a glucometer is to:  
e. use small drop of blood to tell how much glucose is in your blood at that 
moment 
f. use lots of drops of blood to tell how much glucose is in your blood at that 
moment 
g. use large drop of blood to tell how much glucose is in your blood at that 
moment 
h. use three drops of blood to tell how much glucose is in your blood at that 
moment 
5. The  normal range of blood glucose pre-prandial in a Type II diabetic patient 
should be: 
e. 70- 130mg/dl 
f. 100-150 mg/dl 
g. 40-80 mg/dl 
h. 185-200 mg/dl 
6. The normal level of blood glucose 2 hours after eating in a Type II diabetic 
patient should be: 
m) >200mg/dl 
n) <180mg/dl 
o) <70mg/dl 
p) <400mg/dl 
7. What should patients do with their blood glucose measurements? 
g) Note them all in a daily diabetes record, and report exceptional 
valuesNote and report the day and time of exceptional values only 
8. What should a person with diabetes do if s/he becomes ill (e.g. flu, gastric 
upset, infection)? 
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Please circle AS MANY as apply, or circle ‘Unsure’. 
a. Check blood glucose level more frequently (every2 to 4 hours) 
b. Stop taking all diabetes tablets and/or insulin. 
c.  Drink lots of non-sweet fluid if blood glucose levels are over 15mmol/L 
d.  Seek medical attention if very unwell and unable to check blood glucose 
e. Try to do as much exercise as possible to lower blood glucose levels 
f.  Unsure 
9. What foot problems are people with diabetes most at risk of? 
 Please circle AS MANY as apply, or circle ‘Unsure’ 
a.  Poor circulation 
b.  Loss of feeling in the feet 
c. Foot ulcers 
d.  Hammer to 
e.  Infections 
f.  Unsure 
10. How often should people with diabetes exercise or be physically active?  
Please circle ONE answer only 
a.  Most days of the week for at least 30 minutes 
b. Once a week for at least 30 minutes 
c. Once a month for one hour 
d. At least every fortnight for two hours 
e.  Unsure 
11. Why is doing regular exercise or being physically active good for your 
health?  
Please circle AS MANY as apply, or circle ‘Unsure’ 
s) It can help to control blood glucose levels 
t) It can lower blood pressure 
u) It can help to regulate a person’s mood 
v)  It can reduce the risk of skin cancer 
w)  It can lower cholesterol levels 
x)  Unsure 
12. If a person with diabetes has a hypo (low blood glucose level) reaction, s/he 
should: Please circle ONE answer only 
p)  Immediately take some insulin or diabetes tablets 
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q)  Rest and wait until s/he feels better 
r)  Immediately have some sugary food or drink (e.g. jelly beans, soft drink) 
s)  Drink some diet soft drink 
t)  Unsure 
13. Well-managed diabetes decreases the risk of:  
Please circle AS MANY as apply, or circle ‘Unsure’ 
m) Kidney damage 
n) Blindness 
o)  Melanoma 
p)  Heart disease 
q)  Foot ulcers 
r) Unsure 
14. People with diabetes need a medical check-up of their eyes, nerve and 
kidney function at least: Please circle ONE answer only 
k) Every month 
l) Six monthly 
m)  Once a year 
n) Every two to three years 
o)  Unsure 
15. Which of the following statements about diabetes medication is true?  
Please circle ONE answer only 
k) If blood glucose levels are normal for two months, diabetes 
medication can be stopped.  
l) Tablets for diabetes work by increasing blood glucose levels 
m)  Regular medical check-ups are necessary to assess the need for 
adjustments to diabetes medication 
n) People taking diabetes medication do not need to worry about 
healthy eating 
o) Unsure 
Comments 
 
Thank you for your cooperation and help   
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Appendix 16: Diabetes self-management questionnaire English version 
 
 
 
Diabetes Self-Management Questionnaire  
The questions below ask about your diabetes self-care activities during the past 
seven days. If you were sick during the past seven days please think back to 
the last seven days when you were not sick. 
Q1: diet  
Diet  Number of days 
On how many of the last seven days have you 
followed a healthful eating plan? 
0 1 2 3 4 5 6 7 
On average, over the past month, how many days 
per week have you followed you’re eating plan? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you eat five 
or more servings of fruits and vegetables? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you eat high 
fat foods such as red meat or full-fat dairy products? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you space 
carbohydrates evenly through the day? 
0 1 2 3 4 5 6 7 
 
 
 
Q2:  Exercise 
Exercise  Number of days 
On how many of the last seven days did you 
participate in at least 30 minutes of physical activity? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you 0 1 2 3 4 5 6 7 
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participate in a specific exercise session (such as 
such swimming, walking, biking) other than what you 
do around the house or as part of your work? 
Continue…………… 
Q3: blood sugar testing 
Blood Sugar Testing Number of days 
On how many of the last seven days did you test 
your blood sugar? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you test 
your blood sugar the number of times recommended 
by your health care provider? 
        
 
Q4: foot care  
Foot Care Number of days 
On how many of the last seven days did you check 
your feet? 
0 1 2 3 4 5 6 7 
On how many of the last seven days did you inspect 
the inside of your shoes? 
        
 
Q5: Smoking  
a. Have you smoked a cigarette-even one puff-during the past seven days? 
         No 
        Yes. If yes, how many cigarettes did you smoke on an average day?  
Number of cigarettes ……………..… 
b. At your last doctor’s visit, did anyone ask about your smoking status? 
No 
Yes 
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c. If you smoke. At your last doctor’s visit, did anyone counsel you about 
stopping smoking or offer to refer you to stop-smoking program? 
No 
Yes 
Do not smoke 
d. When did you last smoke a cigarette? 
More than two years ago, or never smoked 
One to two years ago 
Four to twelve months ago 
One to three months ago 
Within the last month 
Today 
Q6: Self Care Recommendations 
a. Which of the following has your health care team (doctor, nurse, dietician, or 
diabetes educator, pharmacist) advised you to do? 
Please check all that apply: 
Follow a low-fat eating plan 
Follow a complex carbohydrate diet 
Reduce the number of calories you eat to lose weight 
Eat lots of food high in dietary fiber 
Eat lots (at least 5 servings per day) of fruits and vegetables 
Eat very few sweets (for example: desserts, non-diet sodas, candy bars) 
Other (specify): 
I have not been given any advice about my diet by my health care team. 
 
b. Which of the following has your health care team (doctor, nurse, dietitian or 
diabetes educator) advised you to do? Please check all that apply: 
  Get low level exercise (such as walking) on a daily basis. 
Exercise continuously for a least 20 minutes at least 3 times a week. 
 Fit exercise into your daily routine (for example, take stairs instead of 
elevators, park a block away and walk, etc.) 
Engage in a specific amount, type, duration and level of exercise. 
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Other (specify): 
…………………………………………………………………………... 
I have not been given any advice about exercise by my health care team. 
 
c. Which of the following has your health care team (doctor, nurse, dietitian, or 
diabetes educator) advised you to do? Please check all that apply: 
 Test your blood sugar using a drop of blood from your finger and a color 
chart. 
Test your blood sugar using a machine to read the results. 
Test your urine for sugar. 
Other (specify): 
 I have not been given any advice either about testing my blood or urine 
sugar level by my health care team 
 
d. Which of the following medications for your diabetes has your doctor 
prescribed? 
Please check all that apply. 
 Insulin shot 1 or 2 times a day. 
Insulin shot 3 or more times a day. 
 Diabetes pills to control my blood sugar level. 
Other (specify): 
I have not been prescribed either insulin or pills for my diabetes. 
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Appendix 17: Type II diabetes attitudes questionnaire English version 
 
 
 
 
Type II diabetic attitudes questionnaire toward diabetes care 
Dear participant  
I am a PhD student studying at University of Bradford in the UK. I am doing 
research about diabetes care in Tripoli/Libya. The aim of the study is to improve 
glucose control in type II diabetes by understanding your knowledge, attitudes 
and self-management.   
I am doing this research to understand your attitudes toward type II diabetes 
care. I would be delighted if you took part in the study by kindly completing this 
questionnaire.  Some people ask these questions: How long will this take?   
This questionnaire only takes about 5 to 10 minutes to complete 
OK, what do I do?   
Fill in the questionnaire as quickly and honestly as you can.  Hand it back to the 
pharmacist who gave it to you. 
Do I have to take part? 
No, of course not.  Your participation is completely voluntary.  Your answers will 
help us to suggest ways to improve your care.  
Your response will be treated in complete confidence. If you wish it can also be 
anonymous. You will not be identified in any reports based on the data 
collected. All responses will be aggregated as part of the analysis. This 
questionnaire has been assessed and approved by the research ethics 
committee at the University of Bradford. 
We truly appreciate your help!  Thank you! 
Mrs Nesrin Elhatab 
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Email address: nmaelhat@student.bradford.ac.uk   
Mohamed.nesrin@yahoo.com 
Telephone no: 0044-07735095109 
 
Section one: personnel information: 
1. What are your personal qualifications 
 
2. Your gender (please circle) 
c) Male    b) Female 
3. How old are you? 
 
4. How many years have you had diabetes? 
 
5. Do you have type II diabetes  
  Yes                            No 
If yes please continue, if not please stops 
6. How often does your diabetes prevent you from doing your normal daily 
activities (for example: working or studying)? Circle one number. 
1 2 3 4 5 6 7 8 9 10 
 
7. Have you ever attended a diabetes patient education program (a series 
of classes)? 
  Yes                        No            (If yes “Yes”, how many years ago?  
…………..…)  
 
8. How would you rate your understanding of diabetes and its treatment? 
Circle one number 
1 2 3 4 5 6 7 8 9 10 
 
9. Are you now taking diabetes pills?      Yes                  No  
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10. Please circle the number that indicates how able you are to fit diabetes 
into your life in a positive manner. 
1 2 3 4 5 6 7 8 9 10 
 
Optional participation 
11. If you would like to volunteer to help with further research, then please 
give your contact details: 
Name  
E-mail address  
Telephone number  
 
Section two: attitudes response 
For each statement, please put across in the box that most closely matches 
your level of agreement   
Attitude items  Strongly 
Agree  
Agree  Neutral  Disagree  Strongly 
Disagree  
In general, I believe that 
older people with Type II 
diabetes do not usually get 
complications. 
     
In general, I believe that 
Type II diabetes is a very 
serious disease. 
     
In general I believe that 
people who have Type II 
diabetes will probably not 
get much payoff from tight 
control of their blood 
sugars. 
     
In general I believe that 
blood sugar testing is not 
needed for people with 
Type II diabetes. 
     
In general I believe that 
diabetes is hard because 
you never get a break from 
it. 
     
In general I believe that 
people with diabetes should 
learn a lot about the 
disease so that they can be 
in charge of their own 
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diabetes care. 
In general I believe that 
tight control is too much 
work. 
     
In general I believe that it is 
frustrating for people with 
diabetes to take care of 
their disease. 
     
In general I believe that 
people with diabetes have 
a right to decide how hard 
they will work to control 
their blood sugar. 
     
 
Continue……………… 
Attitude items  Strongly 
Agree  
Agree  Neutral  Disagree  Strongly 
Disagree  
In general I believe that 
people who take diabetes 
pills should be as 
concerned about their 
blood sugar as people who 
take insulin. 
     
In general I believe that 
people with diabetes have 
the  right not to take good 
care of their diabetes 
     
In general I believe that 
support from family and 
friends are important in 
dealing with diabetes. 
     
In general I believe that 
having diabetes changes a 
person’s outlook on life. 
     
In general I believe that low 
blood sugar reactions make 
tight control too risky for 
most people. 
     
In general I believe that 
people with diabetes should 
have the final say in setting 
their blood glucose goals 
     
In general I believe that the 
emotional effects of 
diabetes are pretty small. 
     
In general I believe that 
almost everyone with 
diabetes should do 
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whatever it takes to keep 
their blood sugar close to 
normal. 
In general I believe that 
people whose diabetes is 
treated by just a diet do not 
have to worry about getting 
many long-term 
complications 
     
In general I believe that 
keeping the blood sugar 
close to normal can help to 
prevent the complications 
of diabetes. 
     
In general I believe that the 
important decisions 
regarding daily diabetes 
care should be made by the 
person with diabetes. 
     
 
Continue………………… 
Attitude Items  Strongly 
Agree  
Agree  Neutral  Disagree  Strongly 
Disagree  
In general I believe that 
diabetes affects almost 
every part of a diabetic 
person’s life. 
     
In general I believe that 
there is not much use in 
trying to have good blood 
sugar control because the 
complications of diabetes 
will happen anyway. 
     
In general I believe that 
people who do not need to 
take insulin to treat their 
diabetes have a pretty mild 
disease. 
     
In general I believe that 
health care professionals 
should help patients make 
informed choices about 
their care plans. 
     
 
Any comments please: (Space provided) 
Thank you very much for your cooperation  
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 إستبيان لمعرفة مدى وعيك بمرض السكري النوع الثاني
 الجزء الاول: معلومات شخصية عنك 
 ما تاريخ الولادة:
 ............./.................../...............
 هل أنَت/أنت  
 ا) ذكر  (     )                              ب)أنثى (    )
  السكر؟منذ متى أصبت بمرض 
 ...................سنوات   او.......................شهور   او ......................ايام
 ما نوع السكري الذي أنت مصاب به
 ا)النوع الاول                  ب)النوع الثاني                ج)غير متاكد
ض السكري لأول مرة تم كيف يمكنك وصف كمية المعلومات الشفوية التي تلقيتها حول مر
  على واحد من الصناديق الاّتية:)× تشخيص لديَك/لديك  (ضع علامة 
  أنا لم اتلق اي معلومات شفوية  
  أنا تلقيت القليل جدا ًمن المعلومات الشفوية   
  أنا تلقيت الكم الجيد من المعلومات الشفوية   
  أنا تلقيت الكم الوفير من المعلومات الشفوية     
  أنا لا اريد أن اتلقى أي معلومات شفوية   
  أنا لا أعلم المسؤل علي و الذي قد تلقى معلومات شفوية عني   
  أنا لا استطيع أن أتذكر أو لا أتذكر    
   
كيف يمكنك وصف كمية المعلومات الكتابية التي تلقيتها حول مرض السكري لأول مرة تم 
  ى صند وق واحد فقط)عل× تشخيصه لديَك/لديك  (ضع علامة 
  أنا لم اتلق أي معلومات كتابية        
  أنا تلقيت القليل جدا ًمن المعلومات الكتابية        
  أنا تلقيت الكم الجيد من المعلومات الكتابية         
  أنا تلقيتالمعلومات الكتابية بشكل وأخر وزيادة           
  أنا لا اريد أن اتلقى أي معلومات كتابية         
  أنا لا أعلم المسؤل علي و الذي قد تلقى معلومات شفوية عني        
  أنا لا استطيع ان أتذكر او لا أتذكر         
 هل تتناول أدوية السكر؟
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 ا)نعم                                    او ب)لا 
 لو نعم 
  المخفضة لسكرا)تأخذ الحبوب 
 ب)حمية غدائية وممارسة الرياضة 
 لو انت تاخد الحبوب المخفضة للسكر،كم حبة مختلفة تتناولها؟
  حبات    3حبة واحدة                         حبتان                           
 
  ........ادا كنت تاخد حبوبا ًأخرى، لو سمحت وضح لي ..................................
 هل سبق لك ان قابلت شخصا ًيعطي  دورات تعليمية عن مرض السكري
 ا)نعم                                              ب)لا 
 هل سبق لك ان قابلت اخصائي تغدية
 ا)نعم                                              ب)لا
 مشاركة اختيارية:
ة والاستمرار الرجاء قم بتعبئة الصندوق الذي امامك بالمعلومات لو أردت المشاركة في الدراس
 الشخصية للاتصال بك:
 الاسم  
 البريد الالكتروني 
 رقم الهاتف 
 
 الجزء الثاني: اختبار الوعي بمرض السكري
هذا الجزء يقيم مدى وعيك وتجربتك الشخصية لمرض السكري (اختر الاجابة الصحيحة 
  إ جابة سؤال)بوضع دائرة حول كل 
  )مرض السكري هو حالة مرضية التي:    1
 (الرجاء ضع دائرة حول إجابة واحدة فقط)
 ا) يمكن علاجها بتبني نمط أو اسلوب حياة صحي 
 ب) يمكن علاجها بالحبوب أو الأنسولين
 ج) حاليا ًلايمكن علاجها
 د) باستمرار تهدد حياة الشخص المصاب عند تشخيصيه لأول مرة 
  متاكده) غير 
  )أي من هذه التعبيرات حول مرض السكري والحمية الغذائية يكون صحيحاً 2
 (الرجاء ضع دائرة حول اجابة واحدة فقط)
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 ا)الاشخاص المصابين يجب أن يتناولوا الأطعمة الخالية من السكر 
 ب)  لابأس بأن تأكل ثلاث وجبات مقلية ثلاث مرات بالأسبوع
  لكربوهيدرات ج) اللحم الأحمر هو طعام ملئ با
د) الاكل الذي ينصح بأكله لأي مريض سكري يجب أن يكون قليل الدهون وغنيا ًبالألياف وبه القليل من 
 السكريات 
 ه) غير متأكد
  ) لماذا الأشخاص المصابين بمرض السكري ينصحون بأن يقيسوا سكر الدم  بحهازقياسالسكر بالدم3
 (الرجاء ضع دائرة حول إجابة واحدة فقط)
 ا)لتنبههم الى التغيرات التي تحدث في مستوى سكر الجلوكوز بالدم 
ب) لتساعدهم على صنع قرارات صائبة عند ممارسة الرياضة وعلاج هبوط السكر بالدم 
 أو حتى المرض باالأنفلونزا أو نزلة برد 
 ج) تجعل مريض السكري أكثر ثقة للعناية بمرض السكري لديه 
  علاهد) كل الاجابات المذكورة ا
  )الطريقة الصحيحة لاستعمال جهاز قياس السكري بالدم هي:4
ا)استخدام قطرة صغيرة من الدم لتدلك على معرفة كمية سكر الجلوكوز بالدم عند تلك 
 اللحظة 
ب)استعمال قطرات كبيرة من الدم لتدلك على معرفة كمية سكر الجلوكوز بالدم عند تلك 
 اللحظة
الدم لتدلك على معرفة كمية سكر الجلوكوز بالدم عند تلك ج) استعمال قطرة كبيرة من 
 اللحظة
د) استعمال ثلاث قطرات من الدم لتدلك على معرفة كمية سكر الجلوكوز بالدم عند تلك 
 اللحظة
)المعدل الطبيعي لمستوى سكر الجلوكوز بالدم قبل الاكل لدى المصابين بالنوع الثاني 5
 من السكري هو:
  /ديسم لتر ميليجرام 031-07ا)
  ميليجرام/ديسم لتر 051-001ب) 
  ميليجرام/ديسم لتر 08-04ج) 
  ميليجرام/ديسم لتر 002-581د) 
  )المعدل الطبيعي لمستوى سكر الجلوكوز بالدم بعد ساعتين من الاكل هو:6
  ميليجرام/ديسم لتر 002ا)>
  ميليجرام/ديسم لتر 081ب) <
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  ميليجرام/ديسم لتر 07ج) >
  ديسم لترميليجرام/ 004د) >
  )ماالذي يجب أن يفعله المريض بقراءة جهاز السكري بالدم7
 ا)يدون جميع القراءات في السجل اليومي بالسكري ويضع علامة على النتائج الاستثنائية
 ب) يدون اليوم والتاريخ للقراءات الاستثنائية فقط
 -لمثال:)ماالذي يفعله الشخص المصاب بالسكري عندما يصاب بالمرض (على سبيل ا8
 انفلونزا، اضرابات في المعدة، التهابات)
 (الرجاء اختر اكثر من إجابة صحيحة بوضع دائرة حولها او اختر غير متاكد)
 ا)التحقق من نسبة سكر الجلوكوز بالدم (كل ساعتين إلى أربع ساعات)
 ب) التوقف عن تناول حبوب السكر او الانسولين 
 تحتوي على سكريات لو مستوى سكر الجلوكوز ج) الاكثار من شرب السوائل التي لا 
  ملي مول/لتر 51بالدم اكثر من 
 د) ابحث عن عناية طبية لو شعرت بانك مريض جدا ًوغير قادر على قباس السكر بالدم
 ه) حاول أن تمارس الكثير من الرياضة قدر المستطاع لتقلل من نسبة السكر بالدم 
 و) غير متأكد 
  ) ما مشاكل القدمين التي أغلب مرضى السكري خطر لها 9
  (الرجاء اختر أكثر من إجابة صحيحة بوضع دائرة حولها أو اختر غير متأكد) 
 ا)ضعف الدورة الدموية
 ب) فقدان الإحساس بالقدمين
 ج) مسمار القدم
 د) الالتهابات
 ه) غير متأكد
  الرياضة ) كم عدد المرات التي يجب مرضى السكري ممارسة 01
 (الرجاء ضع دائرة حول اجابة واحدة فقط)
  دقيقة 03ا)أغلب أيام الاسبوع على الأقل 
 ب) مرة واحدة في الاسبوع لمدة ساعة كاملة
 ج) على الأقل كل خمسة عشر يوما لمدة ساعتين
 د) غير متاكد
  ) لماذا ممارسة الرياضة بانتظام شيء مفيد لصحتك11
  صحيحة بوضع دائرة حولها او اختر غير متاكد)(الرجاء اختر أكثر من إجابة 
 ا)لأنها يمكن أن تساعد في السيطرة على مستوى سكر الجلوكوز بالدم
 ب) لأنها يمكن أن تخفض ضغط الدم
 ج) لأنها يمكن أن تساعد على تنظيم مزاج الشخص
 د) لأنها يمكن أن تساعد في التقليل من الخطر الاصابة بمرض سرطان الجلد
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  يمكن أن تخفض من مستوى الكوليسترول ه)  لأنها
 و) غير متاكد
  ) لو أن شخصا ًأُصيب بهبوط السكر بالدم ماالذي يجب عليه فعله21
 (الرجاء ضع دائرة حول اجابة صحيحة واحدة فقط)
 ا)على الفور ان يتناول  حبوب السكر أو الانسولين
 ب) أرتاح حتى أشعر بالتحسن
طعام سكري (على سبيل المثال المشروبات ج) على الفورأشرب عصير سكري أو 
 الغازية أو الحلوى)
 د) اشرب عصيرا ًللحمية الغذائية
 ه) غير متأكد
  ) العناية الجيدة بمرض السكري تقلل ىمن التعرض للمخاطر التالية 31
 (الرجاء اختر اكثر من اجابة صحيحة بوضع دائرة حولها او اختر غير متاكد)
 ا)الفشل الكلوي
 ب) العمى
 ج) سرطان الجلد
 د) أمراض القلب
 ه) تقرحات القدم
 و) غير متأكد
) مريض السكري بحاجة الى فحص طبي للعيون والاعصاب ووظائف الكلى على 41
 الاقل كل:
 (الرجاء ضع دائرة حول اجابة صحيحة واحدة فقط)
 ا)كل شهر
 ب) كل ستة اشهر
 ج) مرة واحدة في السنة
 د) غير متأكد
  بيرات التالية حول الدواء لعلاج السكري صحيحة) ايا ًمن التع51
 (الرجاء ضع دائرة حول اجابة صحيحة واحدة فقط)
 ا)اذا كان مستوى السكر بالدم طبيعي لمدة شهرين، يمكن ايقاف تناول دواء السكر
ب) الحبوب أو الأقراص التي تستعمل لعلاج السكر تعمل على رفع مستوى سكر 
 الجلوكوز بالدم
طبي المنتظم ضروري لتقييم مااذا كان المريض بحاجة الى ضبط أدوية ج) الفحص ال
 السكر
 د) الأشخاص الذين يتناولون أدوية السكر لا يحتاجون أن يقلقوا بشأن تناول الأكل الصحي
 ه) غير متاكد
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 أي تعليقات
 
 
 
 
 شكرا ًلتعاونكم ومساعدتك
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 استبيان حول الادارة الذاتية لمرض السكري النوع الثاني 
الأَسلئة التي في الأسفل تسأل عن الرعاية الذاتية لمرض السكري التي قمت أنَت/أنت  بها في سبعة أيام مضت. لو 
  تفكر في السبعة الأيام الماضية عندما لم تكن مريضا ً  كنت مريضا ًخلال السبعة الايام الماضية الرجاء أن 
  )على رقم واحد من الأرقام الموجودة أمامك)× (الرجاء ضع علامة ( 
  -)الحمية الغذائية:1
 الحمية الغذائية  عدد الأيام
  1 2 3 4 5 6 7
        
في المتوسط، خلال الشهر الماضي كم يوما ًفي 
الطعام الخاصة الاسبوع كنت تتبع خطة تناول 
 بك
كم مرة في السبعة الايام الماضية اكلت خمسة        
 حصص أو أكثر من الفواكه والخضروات
كم مرة في السبعة الايام الماضية اكلت أطعمة        
مليئة بالدهون او غنية بالدهون على سبيل المثال: 
 اللحوم الحمراء أو منتجات الألبان كاملة الدسم
مرة في السبعة الايام الماضية اكلت الأطعمة كم        
التي تحتوي على الكربوهيدرات على فترات 
 متباعدة خلال اليوم
كم مرة في السبعة الايام الماضية اتبعت نظاما ً       
 غذائيا ًصحيا ً 
 
 
  -) ممارسة التمارين الرياضية:2
 ممارسة التمارين الرياضية  عدد الأيام
  1 2 3 4 5 6 7
كم مرة في السبعة الأيام الماضية مارست        
  دقيقة 03الرياضة على الاقل 
 
كم مرة في السبعة الأيام الماضية شاركت في        
دورات خاصة بالرياضة على سبيل المثال: 
رياضة السباحة، المشي، رياضة الدراجات غير 
الرياضة التي تمارسها حول المنزل أو تعتبر  
 جزءا ًمن شغلك
 
  -) قياس سكر الدم:3
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 قياس سكر الدم عدد الأيام
  1 2 3 4 5 6 7
كم مرة في السبعة الأيام الماضية قمت بقياس        
 سكر الدم
كم مرة في السبعة الأيام الماضية قمت بقياس        
سكر الدم وإتبعت عدد المرات المنصوح بها من 
 قبل الدكتور المختص
 
  -) العناية بالقدمين:4
  العناية بالقدمين  عدد الأيام
  1 2 3 4 5 6 7
كم مرة في السبعة الأيام الماضية قمت بفحص        
 قدميك
 
كم مرة قي السبعة الأيام الماضية قمت بالفحص        
 داخل حذائك
 
  -) التدخين:5
 ا)هل قمت بتدخين سيجارة واحدة في السبعة الأيام الماضية  
  نعم                                    لا      
  .................................................................... -عدد السيجارات:
 ب) عندما قمت بزيارة الطبيب، هل  سألك عن حالة التدخين
  نعم                       أو              لا     
خنا،ً عند زيارتك السابقة للطبيب، هل استشارك الطبيب بأن توقف التدخين اوأ حالك لأي جهة ج) فيما لو كنت مد
 أو جمعية تقوم ببرنامج إيقاف التدخين
  نعم                               لا                                 لا أدخن    
 د) متى أخر مرة أخذت فيها سيجارة
  ين ماضيتين أو إطلاقا لم أتعاطى التدخينأكثر من سنت        
  من سنة إلى سنتين ماضيتين        
  من أربعة إلى إثنتى عشرا ًشهرا ًمضى         
  من شهر إلى ثلاثة أشهر ماضية       
  اليوم       
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  -) نصائح الرعاية الذاتية:6
او الصيدلي) نصحك بان تقوم بفعله: ا)أي من فرق الرعاية الصحية (الطبيب، الممرض/ة، اخصائي التغذية 
 الرجاء التاكد من انك تقوم بهذه الافعال: 
  إتباع نظام غذائي يحتوي على القليل من الدسم       
  إتباع حمية غذائية تحتوي على كربوهيدرات معقدة       
  الخفض من عدد السعرات الحرارية التي تأكلها حتى تخفض من وزنك       
  تناول الطعام الغني والملئ بالالياف       
  تناول الكثير من الفواكه والخضروات (على الأقل خمسة حصص في كل يوم)        
  تناول القليل جدا ًمن الحلويات (على سبيل المثال: الحلويات، بترا صودا محلاة، قطع من الحلوى)         
  أشياء أخرى (حدد): ............................................................................         
  أنا لم اتلق أي نصيحة حول الحمية الغذائية من فرق الرعاية الصحية         
بأن تقوم بفعله: ب) أي من فرق الرعاية الصحية (الطبيب، الممرض/ة، اخصائي التغذية او الصيدلي) نصحك 
 الرجاء التأكد من أنك تقوم بهذه الأفعال: 
  المشي) على أساس يومي -القيام بممارسة الرياضة الخفيفة (مثل:         
  دقيقة ثلاث مرات بالإسبوع  02القيام بممارسة الرياضة بإستمرار على الأقل           
بارها روتين يومي (مثلا:ً الصعود بالدرج بدل السلم، إيقاف القيام بممارسة الرياضة يوميا ًعلى إعت          
 سيارتك بمكان بعيد والذهاب على قدميك ماشيا ًإلخ .....)
  المشاركة في كمية محددة ونوع ومدة معينة من ممارسة الرياضة        
  .........................أشياء أُخرى (حدد): ...................................................         
  أنا لم أتلق أي نصيحة حول ممارسة الرياضة من فرق الرعاية الصحية         
ج) ) أي من فرق الرعاية الصحية (الطبيب، الممرض/ة، اخصائي التغذية او الصيدلي) نصحك بأن تقوم بفعله: 
 الرجاء التأكد من أنك تقوم بهذه الأفعال:
  السكر بالدم بإستعمال قطرة من الدم من إصبعك  إختبار نسبة         
  إختبار نسبة السكر بالدم بإستعمال جهاز لقراءة نتائج السكر بالدم         
  إختبار البول إذا كان به سكر           
  أشياء أُخرى (حدد): .....................................................          
  لم اتلق أي نصيحة حول إختبار نسبة السكر بالدم او البول من فرق الرعاية الصحيةأنا           
 د) أي من هذه الأدوية لعلاج مرض السكر طبيبك وصفها لك؟
 ( الرجاء التأكد من أنك تقوم بهذه الأفعال)
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  إستعمال إبرة الأنسولين مرة أو مرتين باليوم      
  ثة مرات أو اكثر باليوم إستعمال إبرة الأنسولين ثلا        
  تناول أقراص لعلاج مرض السكر للتحكم في نسية السكر بالدم        
  أشياء أُخرى (حدد): ...............................................          
  أنا لم يوصف لي الأنسولين ولا الحبوب المخفضة للسكر      
 
 
 شكرا ًجزيلا ًعلى تعاونكم معنا 
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 sedutittA setebaid II epyT fo noisrev cibarA detalsnarT ehT :02 xidneppA
  stneitap rof
إستبيان لمعرفة اّراء ووجهات نظر مريض السكري النوع الثاني تجاه الرعاية الصحية لمرض السكر في 
 طرابلس 
 الجزء الاول: معلومات شخصية 
  )ماهو مستواك التعليمي؟ 1
             ا)مستوى ابتدائي
 ب) مستوى متوسط (تعليم اعدادي او معهد متوسط او ثانوي)
 ج) مستوى عالي (تعليم جامعي او معهد عالي)
   
  ) هل انت 2
 ا)ذكر(     )                                                       ب) أُنثى (    )
  ) كم عمرك؟3
 
  ) كم مضى على اصابتك بمرض السكري؟4
 
  )هل انت مصاب بالنوع الثاني من السكري؟5
 ا) نعم                                               ب) لا 
 لو أجبت بنعم الرجاء استمر، اما لو اجبت بلا الرجاء التوقف
العمل او الدراسة) الرجاء ضع  -)مااللأنشطة اليومية التي يمنعك مرض السكر من أدائها (على سبيل المثال:6
 دائرة على رقم واحد من اللأرقام الموجودة امامك
  7           6            5               4          3              2          1
 يمنعني اكثر من القيام بالنشاطات اليومية
  ) هل حضرت من قبل برنامجا ًتعليميا ًلمرض السكري  (سلسلة من الحصص)7
ب) لا    ( لو نعم، كم مرة في السنوات الماضية                    ا)نعم                  
 ....................................................................................................)
  ) كيف تقييم فهمك لمرض السكري وعلاجه؟ (ضع دائرة على رقٍم واحد من الارقام الموجودة امامك)8
  7            6        5      4        3          2         1
 أكثر فهماً 
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  ) هل تتناول الحبوب المخفضة لنسبة الجلوكوز بالدم لعلاج السكري؟9
 ا)نعم                                                  ب) لا 
ك مع مرض السكر في حياتك اليومية بشكل ) الرجاء ضع دائرة حول الرقم الذي يدل على مدى مقدرتك لتكيف01
 ايجابي
  7          6             5         4                 3              2                   1
 أكثر مقدرة على التكيف
 مشاركة إختيارية:
 لو أردت المشاركة في الدراسة والاستمرار الرجاء قم بتعبئة الصندوق الذي امامك
 بالمعلومات الشخصية للاتصال بك:
 الاسم  
 البريد الالكتروني 
 رقم الهاتف 
 
 
 الجزء الثاني: الاستجابة السلوكية
غير موافق 
 بشدة 
موافق  موافق محايد غير موافق
 بشدة 
 بند السلوك 
بشكل عام، أنا أعتقد أن كبار السن المصابين      
بالنوع الثاني من مرض السكري لا يتعرضون 
 لأي مضاعفات 
بشكل عام، أنا أعتقد أن النوع الثاني من السكر      
 هو مرض خطير جداً 
 يتبع....................
غير موافق 
 بشدة 
موافق  موافق محايد غير موافق
 بشدة 
 بند السلوك 
بشكل عام، أنا أعتقد أن الاشخاص الذين لديهم      
مرض السكري النوع الثاني ربما لا يحصلون 
على الكثير من مردود الرقابة المشددة على نسبة 
 السكر بالدم
بشكل عام، أنا أعتقد أنَّ الحاجة لفحص السكر      
بالدم ليست ضرورية لمرضى السكري النوع 
 الثاني
اعتقد بان مرض السكري مرض بشكل عام، انا      
 صعب لاني لاأستطيع أن أخذ راحة منه
بشكل عام، أنا أعتقد بأنَّ الأَشخاص المصابين      
بمرض السكر يجب ان يتعلموا الكثير حول 
المرض ليساعدهم على أن يصبحوا مسؤليين 
 على انفسهم للعناية بمرض السكري
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على العناية  بشكل عام، اعتقد أنَّ الرقابة المشددة     
 بمرض السكري هو عمل اكثر من الللازم
بشكل عام، أنا أعتقد بأنه أمر محبط لمرضى      
 السكرحين يقومون بالعناية بمرضهم 
بشكل عام، أنا أعتقد أن مريض السكري له      
الحق بأْن يقرر مدى صعوبة العمل على 
 السيطرة للتحكم في نسبة السكر بالدم
أنا اعتقد أن الاشخاص الذين  بشكل عام،     
يتناولون الأقراص المخفضة للجلوكوز بالدم 
ينبغي أن يقلقوا بشان السكر بالدم مثل الاشخاص 
 الذين يعالجون بواسطة الأنسولين
بشكل عام، انا اعتقد بأنَّ الأشخاص المصابين      
بمرض السكري لديهم الحق في عدم الرعاية 
 الصحية الجيدة بمرض السكري
 
 يتبع.............
غير موافق 
 بشدة 
موافق  موافق محايد غير موافق
 بشدة 
 بند السلوك 
بشكل عام، أنا اعتقد بأن الدعم من الاسرة      
 والاصدقاء مهم في التعامل مع مرض السكري
بشكل عام، انا اعتقد بأن الشخص المصاب      
 بالسكري يغير من فلسفته للحياة
بشكل عام، انا اعتقد بأن الهبوط في السكر يجعل      
مريض السكري في خطر لأنه من الصعب 
 السيطرة عليه 
بشكل عام، أنا اعتقد بأن الاشخاص المصابين      
بالسكر يجب أن يكون لديهم القول النهائي في 
 تحديد أهدافهم  
بشكل عام، أنا اعتقد بأن الأثار العاطفية لمرض      
  صغيرة جداً  السكر هي
بشكل عام، أنا أعتقد أن أي شخص مصاب      
بمرض السكري يجب ان يفعل أي شئ ليحافظ 
 على نسبة السكر بالدم قريبة للمعدل الطبيعي
بشكل عام، انا اعتقد أن الحفاظ على نسبة السكر      
بالدم قريبة إلى وضعها الطبيعي يمكن أن يساعد 
 على منع مضاعفات مرض السكر
بشكل عام، انا اعتقد أن القرارات الهامة بشان      
رعاية مرض السكر اليومية ينبغي ان تصدر من 
 الشخص المصاب بمرض السكر
بشكل عام، أنا اعتقد أن مرض السكري يؤثر      
على كل جزء تقريبا ًمن حياة الشخص المصاب 
 بالسكري
بشكل عام، انا اعتقد أنَّه ُليس هناك أي فائدة      
كبيرة من المحافظة على السكر بالدم للمعدل 
الطبيعي لأن مضاعفات المرض تحدث على أي 
 حال
 يتبع............................................
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غير موافق 
 بشدة 
موافق  موافق محايد غير موافق
 بشدة 
 بند السلوك 
بشكل عام، أنا أعتقد أن الاشخاص الذين لا      
الانسولين لعلاج مرض  يحتاجون الى اخذ
 السكري يعتبر مرض السكري لديهم خفيفاً 
بشكل عام، انا اعتقد ان المتخصصين في      
الرعاية الصحية من شأنه أن يساعد المرضى 
على اتخاذ قرارات مستنيرة بشأن مخطط 
  الرعاية الصحية بمرض السكري
بشكل عام، أنا أعتقد أن المتخصصين في      
الصحية يجب ان يتعلموا كيفية وضع الرعاية 
أهداف مع المرضى، وليس أن تقول لهم ماالذي 
 يجب فعله فقط
بشكل عام، أنا أعتقد أن الشخص المصاب      
بمرض السكري هو الشخص الأكثر أهمية أو 
هو العضو الأكثر أهمية في فريق الرعاية 
 الصحية بمرض السكري
 
 
 
 
 
 الرجاء أي ملاحظات
 
 
 
 
 
 
 شكرا ًجزيلا ًعلى تعاونكم معنا 
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Appendix 21: Patient Information Sheet 
Patient information sheet 
Medicine management for type II diabetic patients in Tripoli 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with friends, relatives and your physician if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
What is the purpose of the study?  
The general aim of this study is to improving the control of your diabetes. You 
will complete some questionnaires and we will interview you. We will help you 
to look after yourself and control your diabetes. We will collect records of your 
blood sugar levels for 6 months. 
Why have I been chosen?  
Your community pharmacist has approached you because you are a regular 
customer, you have diabetes and you are at least 40 years old. We will recruit 
about 300 patients. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason. This will not affect the standard of care you receive. 
What will happen to me if I take part?  
First you would fill in three questionnaires about: awareness of diabetes, 
attitudes and self-management. The pharmacist will give you these 
questionnaires and a glucose meter. We will ask you to keep records of your 
glucose levels. You will need to visit the pharmacy once a month for 6 months. 
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We will also ask you to get a HbA1c test (long term glucose measure) at the 
start and the end of the study. 
 
This study is a controlled trial. Half the participants will receive normal care and 
have some extra glucose monitoring (control group). Half the participants will 
receive extra help from us to control their diabetes (intervention group).  
What do I have to do?  
If you complete the questionnaires, then we will give you a score.  If you are in 
the intervention group, we will discuss the best answers to the questions and 
agree a list of things for you to do. These actions should help you to control 
your glucose levels. We will ask all participants (control and intervention) to 
monitor their glucose regularly. 
What are the possible disadvantages and risks of taking part?  
In this study we want to help you to control your own diabetes. The things we 
suggest you do will be based on the based current evidence. We will not 
change the medicines your doctor has prescribed. We will try to improve your 
knowledge and skills. There are no medical risks to taking part. Thinking more 
about your diabetes may make you worried or anxious. So please tell us if this 
happens. If you feel unwell at any point please discuss it with your doctor or 
pharmacists as normal. 
What are the possible benefits of taking part?  
You will learn more about diabetes and how to manage the condition. Many 
people find that setting goals and learning to help themselves is rewarding. We 
hope that the control of your diabetes will get better. We cannot promise this will 
happen. The results of the study will help us to design better services for other 
people. 
Will my taking part in this study be kept confidential? 
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All information collected about you during this research study will be kept 
private. Any information about you will have your name and address removed 
so that you cannot be recognised from it. 
The results of the study will be analysed by the University of Bradford and a 
report will be written. You will not be able to be identified in the report. 
What will happen to the results of the research study?  
We hope the study results will be published in medical journals. We will send 
you and your pharmacist a short summary. 
Who has reviewed the study?  
The study has been given ethical approval by the University of Bradford’s ethics 
committee. 
Contacts for Further Information 
Should you require any further information then please contact PhD student: 
Nesrin Mohamed Elhatab, school of Pharmacy, University of Bradford, BD7 
1DP, Tel no: 0044-7735095109, email address: 
nmaelhat@student.bradford.ac.uk& Dr Jonthan Silcock Senior Lecturer in 
Pharmacy Practice, Bradford School of Pharmacy, University of Bradford, 
Bradford, West Yorkshire, BD7 1DP, Telephone: 44(0)1274 236624, email 
address: j.silcock@bradford.ac.uk, if you speak English.  
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Appendix 22: Consent form for patients 
 CONSENT FORM 
Title of Project: Medicine management for type II diabetic patients in Tripoli 
Name of Researcher: Nesrin Mohgamed Elhatab& Dr Jonathan Silcock& Dr 
Anne Graham  
Please initial all boxes  
1. I confirm that I have read and understand the information sheet for the 
above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
University of Bradford, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my 
records. 
 
4. I agree to my GP being informed of my participation in the study.    
 
5. I agree to take part in the above study.    
 
            
Name of Participant   Date    Signature 
                                
            
Name of Person   Date    Signature  
Taking consent 
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Appendix 23: Randomisation of community pharmacies 
Table  10.1: Cluster randomisation for 40 community pharmacy in Tripoli/ Libya  
Name of street or area 
Number of 
Geographic areas 
that participated in 
the study  
Cluster 
sampling  Type of area 
Abou Meshmasha 1 
 
Residential 
Abou Meshmasha 1 
 
Commercial 
Abu seta 2 
 
Residential 
Abu seta 2 
 
Residential 
Abu seta 2 
 
Commercial 
Abusalim 3 
 
Commercial 
Abusalim 3 
 
Commercial 
Ain Zara 4 1 Commercial 
Alhadba Alkhadra 5 1 Commercial 
Alhadba Alkhadra 5 1 Commercial 
Almaanshea 6 
 
Residential 
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Almaanshea 6 
 
Commercial 
Almadena 7 
 
Commercial 
Almadeena 7 
 
Commercial 
Alnaser street 8 1 Residential 
Al-Noflyeen Street 9 1 Commercial 
Al-Noflyeen Street 9 1 Residential 
Al-Noflyeen Street 9 1 Commercial 
Alrashed street 10 1 Commercial 
Alsaha Alkhadra 11 
 
Residential 
Alsharaa Al-Gharbi 12 1 Commercial 
Alsharqia 13 
 
Residential 
Alsharqia 13 
 
Residential 
Alsyahia 14 
 
Commercial 
Assreem Street 15 
 
Residential 
Bab Alazezeya 16 
 
Commercial 
Bab Alazezeya 16 
 
Commercial 
Bab Alazezeya 16 
 
Commercial 
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Bab Alazezeya 16 
 
Commercial 
Bab Alazezeya 16 
 
Commercial 
Bab Alazezeya 16 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Residential 
Bab Ben Ashur street 17 
 
Residential 
Bab Ben Ashur street 17 
 
Residential 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Residential 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab Ben Ashur street 17 
 
Commercial 
Bab ben Gashir 18 
 
Commercial 
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Bab Ben Ghashir 18 
 
Commercial 
Bab Ben Ghashir 18 
 
Residential 
Bab ben Gashir 18 
 
Commercial 
Bab Ben Ghashir 18 
 
Residential 
Bab ben Gashir 18 
 
Residential 
Bab ben Gashir 18 
 
Commercial 
Bohrida Street 19 
 
Commercial 
Duriby 20 1 Commercial 
Duriby 20 1 Residential 
Duriby 20 1 Commercial 
Fashlum 21 
 
Commercial 
Fashlum 21 
 
Commercial 
Fashlum 21 
 
Commercial 
Gaser Ben Ghashir 22 
 
Residential 
Gaser Ben Ghashir 22 
 
Commercial 
Gorji Street  23 
 
Residential 
Gorji Street  23 
 
Residential 
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Gorji Street 23 
 
Residential 
Got Alshaal 24 1 Residential 
Got Alshaal 24 1 Commercial 
Got Alshaal 24 1 Residential 
Heshan 25 
 
Commercial 
Hi alzuhur 26 
 
Residential 
Hi Damascus 27 1 Commercial 
Hialandules 28 
 
Residential 
Janzur 29 
 
Residential 
Janzur 29 
 
Commercial 
Janzur 29 
 
Residential 
Midan Aljazear 30 1 Commercial 
Omar Almoukhtar Street 31 1 Commercial 
Raashasan 32 
 
Commercial 
Salah Alden 33 
 
Commercial 
Salah Alden 33 
 
Residential 
Salah Alden 33 
 
Residential 
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Salah Alden 33 
 
Commercial 
Salah Alden 33 
 
Commercial 
Salah Alden 33 
 
Commercial 
Salah Alden 33 
 
Residential 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Commercial 
Sharaa Azzawya 34 1 Commercial 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Commercial 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Residential 
Sharaa Azzawya 34 1 Residential 
Shreea Aldel 35 
 
Commercial 
Sidi Almasri 36 1 Residential 
Sooq Al-Gomaa 37 1 Commercial 
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Sooq Al-Gomaa 37 1 Residential 
Sooq Al-Gomaa 37 1 Commercial 
Sooq Al-Gomaa 37 1 Commercial 
Sooq Al-Gomaa 37 1 Residential 
Sooq Al-Gomaa 37 1 Commercial 
Sooq Al-Gomaa 37 1 Residential 
Sooq Al-Gomaa 37 1 Residential 
Sooq Al-Gomaa 37 1 Commercial 
Soug Al Sabt 38 1 Commercial 
Souk Elthoulatha 39 1 Commercial 
Zawiat Aldehmany 40 
 
Residential 
Zawiat Aldehmany 40 
 
Residential 
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Appendix 24: Geographical location of community pharmacies  
 
Figure  10.1: Geographical areas for community pharmacies participating in 
clinical trial (blue stars intervention pharmacies and yellow triangles control 
pharmacies) 
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Figure  10.2: Geographical areas for community pharmacies participating in 
clinical trial 
 
Figure  10.3: Geographical areas for community pharmacies participating in 
clinical trial 
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Appendix 25: Arabic leaflet about diet choices for diabetic people  
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Appendix 26: Arabic leaflets for patients with diabetes 
 
 
 
  
475 
 
 
476 
 
 
477 
 
 
478 
 
 
479 
 
 
Appendix 27: Ethical approval 
 
 
APPLICANT’S ETHICS CHECKLIST 
 
This checklist is designed to help you to decide whether or not ethics 
approval is required and, if required, to decide on the appropriate ethics 
review procedure –  
please read Annex 1 on page 5 before you complete this form 
 
 
Please Note: 
 
a) This Checklist should be completed for all research projects involving human 
participation. 
 
b) All questions on this checklist should be completed. 
 
c) Contact details (email address) should be given for PI or PS and student (if 
applicable). 
 
d) In the case of Student projects, Supervisors should read and sign this checklist 
(in the correct box – EITHER/OR – not both boxes) BEFORE it is submitted to 
the Ethics Administrator for sign off by the Chair of the Research Ethics Panel. 
 
e) Guidance on the 2 different ethics review procedures that together make up the 
University’s Ethics Review System (i.e. ‘University’ and ‘NHS’) is available on 
the University Ethics website. 
 
f) If your project will involve human tissue/biological fluids you should contact the 
UoB Designated Individual for the HTA licence, Dr Sue Boyce for advice 
(s.g.boyce@bradford.ac.uk or on 01274 235879) 
g) If this Checklist is NOT correctly completed, it will be returned to you 
unauthorised. 
 
_______________________________________________________________
_______ 
 
 
Project Title:    Medicine management of type II diabetes 
 
 
Name of Principal Investigator / Principal Supervisor: - Dr Jon Silcock  
 
 
Contact Details – email address: j.silcock@bradford.ac.uk 
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Department/School:- PhD Pharmacy&  Pharmaceutical Innovation  
 
 
Name of Student (if applicable):- Nesrin Mohamed Elhatab  
 
 
Contact Details – email address:- nmaelhat@student.bradford.ac.uk  
 
 
Has student attended appropriate ethics training: Yes  No  
 
 
 
Please give summary of project (max 150 words): 
 
The main aim of this research is centred on improving diabetes medicine 
management amongst Type II diabetic Libyan patients through the use of self-
completion questionnaires and semi-structured interviews, and finally 
randomised controlled trials. 
The research is divided into four stages. The first stage aims to explore 
community pharmacists’ knowledge, attitudes and practices towards Type II 
diabetes care. The reason for completing an audit for pharmacists’ diabetes 
knowledge and practices is to gain understanding into the weaknesses and 
strengths. Stage One is recognised as a descriptive stage; therefore, the study 
can be seen as using combined methods: a literature review and self-completion 
questionnaire  in order to generate the relevant data that can both inform and 
provide a clear picture regarding the current situation of the study problem.  
The second stage will investigate Type II medicine management barriers of 
diabetes care amongst patients. During this stage, I sought to understand the 
barriers amongst community pharmacists and Type II diabetic patients in regard 
to implementing medicines management. The second stage will utilise a semi-
structured interview (appendix I) and literature review. 
 The third stage explores Type II diabetes knowledge, attitudes and practices 
toward diabetes care through the use of a self-completion questionnaire. The 
reason for doing this is in order to investigate the various elements of weak 
diabetes knowledge.  
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The fourth stage will adopt a randomised controlled trial to improve Type II 
diabetes disease and medicine management. Once understanding has been 
gained in regard to Type II diabetes knowledge and practices, as well as the 
barriers facing community pharmacists and patients from implementing medicine 
management, the decision will be made as to which study should be used in 
order to complete such an intervention so as to improve diabetes medicine 
management 
 
 
 
Q1 
 
Is the proposed project an empirical research project 
involving people?    
 will the project include primary data collection from 
human subjects, their data or their tissue?   
 Will it constitute an ‘investigation undertaken in order 
to gain knowledge and understanding’?   (this includes 
work of educational value designed to improve 
understanding of the research process)   
 
 
If you answer ‘Yes’ to Q1 ethical approval may be required, 
move to Q2. 
 
If you answer ‘No’ to Q1 then a research ethics review is not 
required and you are not required to fill in this checklist. 
 
Note:  there may be occasions where a project is not defined 
as research but still raises ethical issues – please submit for 
review if you think this is the case. 
 
 
Yes  No  
 
Yes  No  
 
Yes  No  
 
Q1a 
 
Is the proposed project an audit involving humans? 
 
A more detailed definition of Research, Audit and Service 
Evaluation is available on the University Ethics website.   
 
If you answered ‘Yes’ to Q.1a then ethical review is required. 
 
Yes  No  
 
Q2 
 
Will the research project involve the NHS?   
See See Research Ethics and Governance in NHS and Social 
Care page of the website 
 
If you answer ‘No’ to Q2 move on to Q3 
 
If you answer ‘Yes’ to Q2 ethical approval will be required by 
NHS Research Ethics Committee (REC) 
 
Yes  No  
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Q3 
 
Will the research project involve any of the following in 
the UK: 
Testing a medicinal product  
Investigating a medical device 
Taking samples of human biological material (e.g. blood, 
tissue) 
Prisoners or others in custodial care (e.g. young 
offenders) as participants 
Adults with mental incapacity as participants 
Other vulnerable groups (e.g. vulnerable children) as 
participants 
 
If you answer ‘Yes’ to Q3 ethical approval will usually be 
required through  
Ethical Tissue or NHS Research Ethics Committee (REC) or 
where the project includes participants which need approval 
under the Mental Capacity Act approval will be required by 
the Social Care REC.  
 
If you wish to source material from Ethical Tissue at the 
University, they can be contacted on 01274 235897 or visit 
www.ethicaltissue.org  
 
See information specific to research in Social Care on the 
University Ethics website 
 
If you answer ‘No’ to Q3 move on to Q4 
 
 
Yes  No  
 
Q4 
 
Will the research project involve human participants 
and/or human data (but not accessed through the NHS)?   
 
If you ticked ‘Yes’ please give details of: 
 
1. Interviews (how many, how long will they last),  
Number of interviewer 20 and it will take 15-
30minutes. 
2. who you intend to interview,  
I intend to interview community pharmacist  
3. where interviews will take place and  
In Tripoli/Libya. In the work place of community 
pharmacist  
4. attach interview guidelines or the questions you intend 
to ask: 
See appendix I page: 3-4 in the document of ethical 
amendment.  
 
 
 
Yes  No  
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Q5 
 
 
 
 
 
 
 
 
 
 
Q5a 
 
Will the research project involve human tissue (but not 
requiring NHS approval – see Q3)? 
 
If you answer ‘Yes’ to Q5 University ethical approval is 
required 
 
If you require advice on human biological material please 
contact Human Tissue Act (HTA) Designated Individual: Dr 
Sue Boyce [s.g.boyce@bradford.ac.uk] 
on ext 5897 or visit www.ethicaltissue.org 
 
If you answered ‘Yes’ to Q5, is the human material over 100 
years old and archaeological? 
 
If ‘YES’ please refer to the Biological Anthropology Research 
Centre (BARC) guidelines at 
http://www.barc.brad.ac.uk/BARC_human_remains_policy.pdf 
 
 
Yes  No  
 
 
 
 
 
 
 
 
 
Yes  No  
 
If you answer ‘No’ to Q5 and have answered ‘No’ to Q2, Q3 and Q4 ethical 
approval is not required. 
 
 
 
 
 
 
 
PLEASE COMPLETE and SIGN ONE of the two boxes below  
(in the case of a student project, we do require a Supervisor’s signature in 
whichever box is relevant,  before we can have the checklist signed off by the 
Research Ethics Panel): 
 
 
1. I have discussed this project with my student AND/OR 
2. I confirm that there are no ethical issues requiring further consideration. 
 
(Any subsequent changes to the nature of the project will require that the Panel 
are informed of all changes) 
 
Signed by (Principal Investigator or Principal Supervisor (in case of student 
project)): 
 
Signature: ……………………………………………. ……. Date: 
…………………………. 
 
PLEASE PRINT NAME 
………………………………………………………………………… 
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OR 
 
 
 
 
I confirm that there are ethical issues requiring further consideration and will either: 
1.  refer the proposal  to Ethical Tissue,  or,  
2.  fill in and submit a full ethics application to be considered by the appropriate 
Research Ethics Panel. 
 
Name (Principal Investigator/Principal Supervisor): 
 
Signature: …………………………………………………………..     Date: 
……………………………. 
 
PLEASE PRINT NAME 
…………………………………………………………………………………….. 
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Annex 1 
 
Ethical Scrutiny by a University Research Ethics Panel is not required if: 
 
 The project is NOT a research project.  There may be occasions 
where a project is not defined as research but still raises ethical 
issues – please submit for review if you think this is the case. 
 
 The research project will only involve unlinked or aggregated 
human data which was collected and which was, at the time, 
subject to relevant research ethics panel approval. 
However, where this is the case the researcher should at least confirm this 
in an email to the Research Support Unit’s Ethics Administrator so that the 
Ethics Administrator has a record and can inform the Chair of the 
appropriate Research Ethics Panel that the researcher plans to go ahead 
without ethics approval. The email should confirm that the research project 
does not require ethics approval because it only involves unlinked or 
aggregated data, which when originally obtained from people was obtained 
in accordance with the protocol as approved at the time by an appropriate 
research ethics panel. The email should also briefly explain how the 
researcher now plans to use the unlinked or aggregated data.  
 
 The research is Public Domain Data: 
 The Economic and Social Research Council’s (ESRC) Research Ethics 
Framework states that ethics approval may not be required for data sets that 
exist in the public domain (e.g. datasets that are available from the Office for 
National Statistics or from the ESRC’s Data Archive) so long as the 
appropriate permissions from individuals have already been obtained (i.e. 
informed consent) and where it is not possible to identify the individuals from 
the information provided.  It must be remembered that public domain data is 
still covered by the laws of copyright.  
 
 The research involves Simple Uncontentious Questionnaires: 
If a research project’s only involvement with human subjects is a simple brief 
questionnaire with uncontroversial content it may not require ethical 
approval.  It is the Principal Investigator or Principal Supervisor’s 
responsibility to decide whether a project comes under this category and 
must indicate this at Q.4 on the checklist and attach the questionnaire 
document for information. 
 
Guidance on supervisor and principal investigator sign off of 
uncontentious research 
 
Audit and service evaluation are usually uncontentious, and guidance on how to 
differentiate between research, audit and service evaluation is given at: 
University Ethics website.  
 
Even where a project is clearly research, as a supervisor or principal 
investigator, you can sign off simple, ethically uncontentious projects as not 
needing further ethical scrutiny.  To do this, you should consider the level of risk 
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to participants and researchers, the level of effort required by participants, the 
level of intrusion into participants’ lives and the level of sensitivity of both the 
general subject matter and the information requested of participants. Basically, 
the lower these levels, the more likely the research is to be uncontentious and 
the more confident you should feel about signing off. 
 
The following examples may help.   
 
These studies can almost always be signed off by the supervisor or principal 
investigator: 
 
 Brief questionnaires asking opinions about matters which are clearly not 
sensitive (attitudes to a product, beliefs about the usefulness of a course).   
 Brief interviews about such topic. 
 Observational studies about everyday behaviour in public places which 
involve no risk to subjects or the researcher. 
 
But the following studies almost always need further scrutiny by a University 
Ethics Panel: 
 
 Long questionnaires (these require considerable potential inconvenience to 
subjects). 
 Long interviews 
 Any questionnaires which ask subjects about intimate behaviours or issue 
likely to cause distress or would in other ways normally be regarded as 
contentious or sensitive (e.g. illegal activities, attitudes to abortion, capital 
punishment, immigration, euthanasia). 
 Any interviews which examine these matters. 
 Observational studies which involve intimate behaviours, behaviours which 
are not normally public or which might normally be considered contentious 
or sensitive (Activities of ethics committees, appointment committees, etc; 
professional consultations). 
 
Naturally, this list is for illustration only, and should not be considered in any 
way exhaustive, permissive or prescriptive.  For example, there are many 
categories of research not mentioned here which would definitely require ethics 
approval (e.g. treatment research).  Rather the list demonstrates the issue of 
proportionality.  Thus, even though the method may be the same for activities 
requiring and not requiring further scrutiny, the content in some way 
distinguishes between the two categories. 
 
At the same time, there is obviously some middle ground.  Are ethics 
committees not public?  Is what is discussed so sensitive that the proposal 
needs further scrutiny?  What about asking people about their views on the 
actions of senior members of staff in their organisation?  Probably, it is in these 
middle ground areas that further advice should be sought from a Panel Chair 
about whether the project can be signed off by the supervisor or principal 
investigator alone.  Given that, in so doing, the supervisor or PI is attesting to 
the ethical probity of the study, it is usually best to err on the side of caution 
where there is uncertainty.  Panel chairs are very happy to advise. 
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(Dr Martin Brinkworth, Chair, Biomedical, Natural, Physical and Health 
Sciences Research Ethics Panel, m.h.brinkworth@bradford.ac.uk, ext. 3584 
 
Dr Clare Beckett,  Chair, Humanities, Social and Health Sciences Research 
Ethics Panel, c.beckett@bradford.ac.uk, ext. 3521) 
 
 
 
Please submit this checklist to: 
 
Mr Omar Ali, Ethics Administrator,  
RKTS, in hard copy  
or by email to ethics@bradford.ac.uk  
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Appendix 28: FPG recording sheet (Arabic translation) 
 
 
